0001437749-24-004149.txt : 20240214 0001437749-24-004149.hdr.sgml : 20240214 20240214160558 ACCESSION NUMBER: 0001437749-24-004149 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AYTU BIOPHARMA, INC CENTRAL INDEX KEY: 0001385818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 470883144 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38247 FILM NUMBER: 24637843 BUSINESS ADDRESS: STREET 1: 7900 E. UNION AVENUE STREET 2: SUITE 920 CITY: DENVER STATE: CO ZIP: 80237 BUSINESS PHONE: (720) 437-6580 MAIL ADDRESS: STREET 1: 7900 E. UNION AVENUE STREET 2: SUITE 920 CITY: DENVER STATE: CO ZIP: 80237 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC. DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: Rosewind CORP DATE OF NAME CHANGE: 20070110 10-Q 1 aytu20231231_10q.htm FORM 10-Q aytu20231231_10q.htm
0001385818 false --06-30 Q2 2024 0.0001 0.0001 50,000,000 50,000,000 0 0 0 0 0.0001 0.0001 200,000,000 200,000,000 5,567,347 5,567,347 5,517,174 5,517,174 2 20 0.3 0 0.1 5.5 0.7 70,000 1 5 1 5 1 5 1 5 2 false false false false Includes $0.2 million from the Consumer Health Segment as of December 31, 2023 and June 30, 2023. 00013858182023-07-012023-12-31 xbrli:shares 00013858182024-02-01 thunderdome:item iso4217:USD 00013858182023-12-31 00013858182023-06-30 iso4217:USDxbrli:shares 00013858182023-10-012023-12-31 00013858182022-10-012022-12-31 00013858182022-07-012022-12-31 0001385818us-gaap:CommonStockMember2023-06-30 0001385818us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001385818us-gaap:RetainedEarningsMember2023-06-30 0001385818us-gaap:CommonStockMember2023-07-012023-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0001385818us-gaap:RetainedEarningsMember2023-07-012023-09-30 00013858182023-07-012023-09-30 0001385818us-gaap:CommonStockMember2023-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001385818us-gaap:RetainedEarningsMember2023-09-30 00013858182023-09-30 0001385818us-gaap:CommonStockMember2023-10-012023-12-31 0001385818us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-31 0001385818us-gaap:RetainedEarningsMember2023-10-012023-12-31 0001385818us-gaap:CommonStockMember2023-12-31 0001385818us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001385818us-gaap:RetainedEarningsMember2023-12-31 0001385818us-gaap:CommonStockMember2022-06-30 0001385818us-gaap:AdditionalPaidInCapitalMember2022-06-30 0001385818us-gaap:RetainedEarningsMember2022-06-30 00013858182022-06-30 0001385818us-gaap:CommonStockMember2022-07-012022-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-30 0001385818us-gaap:RetainedEarningsMember2022-07-012022-09-30 00013858182022-07-012022-09-30 0001385818us-gaap:CommonStockMember2022-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2022-09-30 0001385818us-gaap:RetainedEarningsMember2022-09-30 00013858182022-09-30 0001385818us-gaap:CommonStockMember2022-10-012022-12-31 0001385818us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-31 0001385818us-gaap:RetainedEarningsMember2022-10-012022-12-31 0001385818us-gaap:CommonStockMember2022-12-31 0001385818us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001385818us-gaap:RetainedEarningsMember2022-12-31 00013858182022-12-31 xbrli:pure 0001385818aytu:ReverseStockSplitMember2023-01-062023-01-06 0001385818aytu:AvenueNoteMember2023-12-31 0001385818aytu:RxSegmentMember2023-10-012023-12-31 0001385818aytu:RxSegmentMember2022-10-012022-12-31 0001385818aytu:RxSegmentMember2023-07-012023-12-31 0001385818aytu:RxSegmentMember2022-07-012022-12-31 0001385818aytu:ConsumerHealthMember2023-10-012023-12-31 0001385818aytu:ConsumerHealthMember2022-10-012022-12-31 0001385818aytu:ConsumerHealthMember2023-07-012023-12-31 0001385818aytu:ConsumerHealthMember2022-07-012022-12-31 0001385818aytu:AdhdPortfolioMemberaytu:RxSegmentMember2023-10-012023-12-31 0001385818aytu:AdhdPortfolioMemberaytu:RxSegmentMember2022-10-012022-12-31 0001385818aytu:AdhdPortfolioMemberaytu:RxSegmentMember2023-07-012023-12-31 0001385818aytu:AdhdPortfolioMemberaytu:RxSegmentMember2022-07-012022-12-31 0001385818aytu:ThePediatricPortfolioMemberaytu:RxSegmentMember2023-10-012023-12-31 0001385818aytu:ThePediatricPortfolioMemberaytu:RxSegmentMember2022-10-012022-12-31 0001385818aytu:ThePediatricPortfolioMemberaytu:RxSegmentMember2023-07-012023-12-31 0001385818aytu:ThePediatricPortfolioMemberaytu:RxSegmentMember2022-07-012022-12-31 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2023-10-012023-12-31 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2022-10-012022-12-31 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2023-07-012023-12-31 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2022-07-012022-12-31 0001385818aytu:ManufacturingEquipmentMember2023-12-31 0001385818aytu:ManufacturingEquipmentMember2023-06-30 0001385818aytu:OfficeEquipmentFurnitureAndOtherMember2023-12-31 0001385818aytu:OfficeEquipmentFurnitureAndOtherMember2023-06-30 0001385818us-gaap:LeaseholdImprovementsMember2023-12-31 0001385818us-gaap:LeaseholdImprovementsMember2023-06-30 0001385818aytu:LabEquipmentMember2023-12-31 0001385818aytu:LabEquipmentMember2023-06-30 0001385818us-gaap:AssetUnderConstructionMember2023-12-31 0001385818us-gaap:AssetUnderConstructionMember2023-06-30 utr:Y 0001385818aytu:LeaseForPrincipalOfficeMember2023-09-30 0001385818us-gaap:OperatingExpenseMember2023-10-012023-12-31 0001385818us-gaap:OperatingExpenseMember2022-10-012022-12-31 0001385818us-gaap:OperatingExpenseMember2023-07-012023-12-31 0001385818us-gaap:OperatingExpenseMember2022-07-012022-12-31 0001385818us-gaap:CostOfSalesMember2023-10-012023-12-31 0001385818us-gaap:CostOfSalesMember2022-10-012022-12-31 0001385818us-gaap:CostOfSalesMember2023-07-012023-12-31 0001385818us-gaap:CostOfSalesMember2022-07-012022-12-31 0001385818us-gaap:OtherExpenseMember2023-10-012023-12-31 0001385818us-gaap:OtherExpenseMember2022-10-012022-12-31 0001385818us-gaap:OtherExpenseMember2023-07-012023-12-31 0001385818us-gaap:OtherExpenseMember2022-07-012022-12-31 0001385818aytu:PropertyAndEquipmentNetMember2023-12-31 0001385818aytu:PropertyAndEquipmentNetMember2023-06-30 0001385818us-gaap:OtherCurrentLiabilitiesMember2023-12-31 0001385818us-gaap:OtherCurrentLiabilitiesMember2023-06-30 0001385818aytu:CurrentPortionOfDebtMember2023-12-31 0001385818aytu:CurrentPortionOfDebtMember2023-06-30 0001385818us-gaap:OtherNoncurrentLiabilitiesMember2023-12-31 0001385818us-gaap:OtherNoncurrentLiabilitiesMember2023-06-30 0001385818us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-31 0001385818us-gaap:DevelopedTechnologyRightsMember2023-12-31 0001385818us-gaap:DistributionRightsMember2023-12-31 0001385818us-gaap:TechnologyBasedIntangibleAssetsMember2023-06-30 0001385818us-gaap:DevelopedTechnologyRightsMember2023-06-30 0001385818us-gaap:DistributionRightsMember2023-06-30 0001385818aytu:TrisKarbinalAgreementMember2023-07-012023-12-31 0001385818us-gaap:PatentedTechnologyMemberaytu:AdhdPortfolioMember2023-12-31 0001385818us-gaap:DistributionRightsMemberaytu:ConsumerHealthMember2023-04-012023-06-30 0001385818aytu:NeosTherapeuticsIncMemberus-gaap:InProcessResearchAndDevelopmentMemberaytu:RxSegmentMember2022-10-012022-12-31 0001385818srt:MinimumMember2023-07-012023-12-31 0001385818srt:MaximumMember2023-07-012023-12-31 0001385818aytu:TrisKarbinalAgreementMember2023-07-012023-12-31 0001385818aytu:TrisKarbinalAgreementMember2023-12-31 0001385818us-gaap:OtherCurrentLiabilitiesMemberaytu:TrisKarbinalAgreementMember2023-12-31 0001385818us-gaap:OtherNoncurrentLiabilitiesMemberaytu:TrisKarbinalAgreementMember2023-12-31 0001385818aytu:TrisLicenseAgreementMember2022-05-12 0001385818aytu:TrisLicenseAgreementMember2022-05-122022-05-12 0001385818us-gaap:OtherCurrentLiabilitiesMemberaytu:TrisLicenseAgreementMember2023-12-31 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2021-03-31 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2021-03-012021-03-31 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2021-03-012021-03-31 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMemberaytu:AfterJanuary262023ButBeforeJanuary262024Member2023-03-24 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMemberaytu:AfterJanuary262024ButBeforeJanuary262025Member2023-03-24 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2023-10-012023-12-31 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2022-10-012022-12-31 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2023-07-012023-12-31 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2022-07-012022-12-31 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2023-12-31 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2023-06-30 0001385818aytu:AvenueCapitalLoanMember2022-01-26 0001385818aytu:AvenueCapitalLoanMemberus-gaap:PrimeRateMember2022-01-262022-01-26 0001385818aytu:AvenueCapitalLoanMemberaytu:AfterJanuary262023ButBeforeJanuary262024Member2022-01-26 0001385818aytu:AvenueCapitalLoanMemberaytu:AfterJanuary262024ButBeforeJanuary262025Member2022-01-26 0001385818aytu:AvenueCapitalWarrantsMember2022-01-26 0001385818aytu:AvenueCapitalIssuanceMember2022-03-07 0001385818aytu:AvenueCapitalWarrantsMember2022-03-07 0001385818aytu:AvenueCapitalWarrantsMember2022-10-25 0001385818aytu:AvenueCapitalLoanMember2022-01-262022-01-26 0001385818aytu:AvenueCapitalLoanMember2023-12-31 0001385818aytu:AvenueCapitalLoanMember2023-10-012023-12-31 0001385818aytu:AvenueCapitalLoanMember2022-10-012022-12-31 0001385818aytu:AvenueCapitalLoanMember2023-07-012023-12-31 0001385818aytu:AvenueCapitalLoanMember2022-07-012022-12-31 0001385818us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-12-31 0001385818us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-12-31 0001385818us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-12-31 0001385818us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-12-31 0001385818us-gaap:FairValueInputsLevel1Member2023-12-31 0001385818us-gaap:FairValueInputsLevel2Member2023-12-31 0001385818us-gaap:FairValueInputsLevel3Member2023-12-31 0001385818us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-06-30 0001385818us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-06-30 0001385818us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-06-30 0001385818us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-06-30 0001385818us-gaap:FairValueInputsLevel1Member2023-06-30 0001385818us-gaap:FairValueInputsLevel2Member2023-06-30 0001385818us-gaap:FairValueInputsLevel3Member2023-06-30 0001385818us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-07-012023-12-31 0001385818aytu:June2023WarrantsTrancheABMemberus-gaap:MeasurementInputExpectedTermMember2023-12-31 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2023-12-31 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2023-12-31 0001385818aytu:June2023WarrantsTrancheABMemberus-gaap:MeasurementInputPriceVolatilityMember2023-12-31 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2023-12-31 0001385818aytu:June2023WarrantsTrancheABMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-31 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2023-12-31 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2023-12-31 0001385818aytu:June2023WarrantsTrancheABMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-12-31 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-12-31 0001385818aytu:RumpusAcquisitionMemberaytu:EarnOutPaymentsMember2021-04-12 0001385818aytu:RumpusAcquisitionMemberaytu:EarnOutPaymentsMember2022-04-012022-04-30 0001385818aytu:RumpusAcquisitionMemberaytu:RoyaltiesMember2021-04-12 0001385818aytu:RumpusAcquisitionMemberaytu:MilestonePaymentsMember2021-04-12 0001385818aytu:SabbyLitigationWarrantsMemberaytu:SabbyVolatilityWarrantMasterFundLtdMemberaytu:SabbyLitigationMember2023-02-22 0001385818aytu:SabbyVolatilityWarrantMasterFundLtdMemberaytu:SabbyLitigationMember2023-02-22 0001385818aytu:SabbyLitigationWarrantsMemberaytu:WalleyeOpportunitiesMasterFundLtdMemberaytu:SabbyLitigationMember2023-02-22 0001385818aytu:WalleyeOpportunitiesMasterFundLtdMemberaytu:SabbyLitigationMember2023-02-22 0001385818us-gaap:RestrictedStockMember2023-12-31 0001385818aytu:The2020ShelfMember2020-06-08 0001385818aytu:AtthemarketOfferingMember2021-06-04 0001385818aytu:AtthemarketOfferingMember2022-07-012023-06-30 0001385818aytu:The2021ShelfMember2021-09-28 0001385818aytu:The2021ShelfMember2023-12-31 0001385818aytu:TheAugust2022OfferingMember2022-08-112022-08-11 0001385818aytu:August2022PrefundedWarrantsMember2022-08-11 0001385818aytu:August2022CommonWarrantsMember2022-08-11 0001385818aytu:August2022CommonAndPrefundedWarrantsMember2022-08-11 0001385818aytu:TheAugust2022OfferingMember2022-08-11 0001385818aytu:SecuritiesPurchaseAgreementMember2023-06-082023-06-08 0001385818aytu:PrefundedWarrantsMember2023-06-08 0001385818aytu:TrancheACommonWarrantsMember2023-06-08 0001385818aytu:TrancheBCommonWarrantsMember2023-06-08 0001385818aytu:CommonWarrantsMember2023-06-08 0001385818aytu:CommonWarrantsExchangedForPrefundedWarrantsMember2023-06-08 0001385818aytu:TrancheACommonWarrantsAtDoubleExercisePriceMember2023-06-08 0001385818aytu:SecuritiesPurchaseAgreementMember2023-06-08 0001385818aytu:SecuritiesPurchaseAgreementWarrantsMember2023-06-08 0001385818aytu:SecuritiesPurchaseAgreementWarrantsMember2023-06-082023-06-08 0001385818aytu:The2023EquityIncentivePlanMember2023-05-182023-05-18 0001385818aytu:The2023EquityIncentivePlanMember2023-05-18 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMember2023-05-182023-05-18 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMembersrt:MinimumMember2023-05-182023-05-18 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMembersrt:MaximumMember2023-05-182023-05-18 0001385818aytu:RestrictedStockAndRestrictedStockUnitsRsusMemberaytu:The2023EquityIncentivePlanMembersrt:MinimumMember2023-05-182023-05-18 0001385818aytu:RestrictedStockAndRestrictedStockUnitsRsusMemberaytu:The2023EquityIncentivePlanMembersrt:MaximumMember2023-05-182023-05-18 0001385818aytu:The2015PlanMember2023-12-31 0001385818aytu:The2015PlanMember2015-06-01 0001385818aytu:The2015PlanMember2020-02-13 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2015PlanMember2015-06-012015-06-01 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2015PlanMembersrt:MinimumMember2015-06-012015-06-01 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2015PlanMembersrt:MaximumMember2015-06-012015-06-01 0001385818us-gaap:RestrictedStockMemberaytu:The2015PlanMembersrt:MinimumMember2015-06-012015-06-01 0001385818us-gaap:RestrictedStockMemberaytu:The2015PlanMembersrt:MaximumMember2015-06-012015-06-01 0001385818us-gaap:RestrictedStockUnitsRSUMemberaytu:The2015PlanMember2015-06-012015-06-01 0001385818aytu:Neos2015PlanMember2021-04-19 0001385818us-gaap:RestrictedStockUnitsRSUMemberaytu:Neos2015PlanMember2021-04-19 0001385818us-gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMember2021-04-192021-04-19 0001385818us-gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMembersrt:MinimumMember2021-04-192021-04-19 0001385818us-gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMembersrt:MaximumMember2021-04-192021-04-19 00013858182022-07-012023-06-30 0001385818us-gaap:EmployeeStockOptionMember2023-12-31 0001385818us-gaap:EmployeeStockOptionMember2023-07-012023-12-31 0001385818us-gaap:RestrictedStockMember2023-06-30 0001385818us-gaap:RestrictedStockMember2023-07-012023-12-31 0001385818us-gaap:RestrictedStockMemberaytu:The2023EquityIncentivePlanMember2023-12-31 0001385818us-gaap:RestrictedStockMemberaytu:The2023EquityIncentivePlanMember2023-07-012023-12-31 0001385818us-gaap:RestrictedStockMemberaytu:OutsideEquityIncentivePlanMember2023-12-31 0001385818us-gaap:RestrictedStockMemberaytu:OutsideEquityIncentivePlanMember2023-07-012023-12-31 0001385818us-gaap:RestrictedStockUnitsRSUMember2023-06-30 0001385818us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-12-31 0001385818us-gaap:RestrictedStockUnitsRSUMember2023-12-31 0001385818us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-31 0001385818us-gaap:ResearchAndDevelopmentExpenseMember2023-10-012023-12-31 0001385818us-gaap:ResearchAndDevelopmentExpenseMember2022-10-012022-12-31 0001385818us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-12-31 0001385818us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-12-31 0001385818us-gaap:SellingAndMarketingExpenseMember2023-10-012023-12-31 0001385818us-gaap:SellingAndMarketingExpenseMember2022-10-012022-12-31 0001385818us-gaap:SellingAndMarketingExpenseMember2023-07-012023-12-31 0001385818us-gaap:SellingAndMarketingExpenseMember2022-07-012022-12-31 0001385818us-gaap:GeneralAndAdministrativeExpenseMember2023-10-012023-12-31 0001385818us-gaap:GeneralAndAdministrativeExpenseMember2022-10-012022-12-31 0001385818us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-12-31 0001385818us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-12-31 0001385818aytu:August2022CommonWarrantsMembersrt:MinimumMember2022-08-11 0001385818aytu:August2022CommonWarrantsMembersrt:MaximumMember2022-08-11 0001385818aytu:August2022CommonWarrantsMember2022-12-31 0001385818aytu:August2022CommonWarrantsMember2023-06-30 0001385818srt:WeightedAverageMember2023-06-30 0001385818srt:WeightedAverageMember2023-07-012023-12-31 0001385818srt:WeightedAverageMember2023-12-31 0001385818aytu:LiabilityWarrantsMember2023-07-012023-12-31 0001385818aytu:LiabilityWarrantsMember2022-07-012022-12-31 0001385818aytu:EquityWarrantsMember2023-07-012023-12-31 0001385818aytu:EquityWarrantsMember2022-07-012022-12-31 0001385818us-gaap:EmployeeStockOptionMember2023-07-012023-12-31 0001385818us-gaap:EmployeeStockOptionMember2022-07-012022-12-31 0001385818us-gaap:RestrictedStockMember2023-07-012023-12-31 0001385818us-gaap:RestrictedStockMember2022-07-012022-12-31 0001385818us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-12-31 0001385818us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-12-31
 

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to ___________

 

Commission File No. 001-38247

 

aytu20231231_10qimg001.jpg

 

AYTU BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

47-0883144

(State or other jurisdiction of incorporation or organization)

 

(IRS Employer Identification No.)

 

7900 East Union Avenue, Suite 920, Denver, Colorado 80237

 (720) 437-6580
(Address of principal executive offices and zip code) (Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value

 

AYTU

 

The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

 

Large accelerated filer

  ☐

Accelerated filer

  ☐

Non-accelerated filer

  ☒

Smaller reporting company

 

  

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes  No ☒

 

As of February 1, 2024, the registrant had 5,567,597 shares of common stock outstanding.



 

 

 
 

TABLE OF CONTENTS

 

Item  

Page

  Cautionary Information Regarding Forward-Looking Statements 3
     
  PART I - FINANCIAL INFORMATION 4
     
Item 1.

Financial Statements

4
 

Unaudited Consolidated Balance Sheets

4

 

Unaudited Consolidated Statements of Operations

5

 

Unaudited Consolidated Statements of Stockholders’ Equity

6

 

Unaudited Consolidated Statements of Cash Flows

7

 

Notes to the Unaudited Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

30

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

35

Item 4.

Controls and Procedures

35

     
 

PART II - OTHER INFORMATION

37
     
Item 1.

Legal Proceedings

37

Item 1A.

Risk Factors

37

Item 5. Other Information 37
Item 6.

Exhibits

38

 

SIGNATURES

39

 

 

 

CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

 

This Report on Form 10‑Q (“Form 10-Q” or “this report”) includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). All statements other than statements of historical facts contained in this report, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation: our anticipated future cash position; the planned expanded commercialization of our products and the potential future commercialization of our product candidates; our anticipated future growth rates; anticipated sales increases; anticipated net revenue increases; amounts of certain future expenses and costs of goods sold; our plans to acquire additional assets or dispose of assets, anticipated increases or decreases to operating expenses, and selling, general, and administrative expenses; and future events under our current and potential future collaborations.

 

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation the risks described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10‑K for the year ended June 30, 2023 (“2023 Form 10-K”), and in the reports we file with the U.S. Securities and Exchange Commission (“SEC”). These risks are not exhaustive. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We can provide no assurance that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements, except as may be required under applicable law.

 

This Form 10-Q refers to trademarks, such as Aytu, Aytu BioPharma, Adzenys XR-ODT, Cotempla XR-ODT, Innovus Pharma, Neos, Neos Therapeutics, Poly-Vi-Flor, and Tri-Vi-Flor, which are protected under applicable intellectual property laws and are our property or the property of our subsidiaries. This Form 10-Q also contains trademarks, service marks, copyrights and trade names of other companies, which are the property of their respective owners. Solely for convenience, our trademarks and tradenames referred to in this Form 10-Q may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames.

 

 

PART 1 - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AYTU BIOPHARMA, INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 

ASSETS

        

Current assets:

        

Cash and cash equivalents

 $19,529  $22,985 

Accounts receivable, net

  29,403   28,937 

Inventories

  13,001   11,995 

Prepaid expenses

  8,105   8,047 

Other current assets

  1,333   868 

Total current assets

  71,371   72,832 

Non-current assets:

        

Property and equipment, net

  1,127   1,815 

Operating lease right-of-use assets

  2,133   2,054 

Intangible assets, net

  55,711   58,970 

Other non-current assets

  907   792 

Total non-current assets

  59,878   63,631 

Total assets

 $131,249  $136,463 
         

LIABILITIES AND STOCKHOLDERS' EQUITY

        

Current liabilities:

        

Accounts payable

 $10,473  $13,478 

Accrued liabilities

  43,413   46,799 

Short-term line of credit

  1,026   1,563 

Current portion of debt

  39   85 

Other current liabilities

  9,236   7,090 

Total current liabilities

  64,187   69,015 

Non-current liabilities:

        

Debt, net of current portion

  14,978   14,713 

Derivative warrant liabilities

  12,887   6,403 

Other non-current liabilities

  6,344   6,975 

Total non-current liabilities

  34,209   28,091 
         

Commitments and contingencies (note 13)

          
         

Stockholders’ equity:

        

Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding

      

Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,347 and 5,517,174 shares issued and outstanding, respectively

  1   1 

Additional paid-in capital

  345,321   343,485 

Accumulated deficit

  (312,469)  (304,129)

Total stockholders’ equity

  32,853   39,357 

Total liabilities and stockholders equity

 $131,249  $136,463 

 

The accompanying Notes to the Unaudited Consolidated Financial Statements are an integral part of this statement.

 

 

 

AYTU BIOPHARMA, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

 

   

Three Months Ended

   

Six Months Ended

 
   

December 31,

   

December 31,

 
   

2023

   

2022

   

2023

   

2022

 

Product revenue, net

  $ 22,934     $ 26,279     $ 45,033     $ 53,934  

Cost of sales

    6,731       8,986       14,046       18,609  

Gross profit

    16,203       17,293       30,987       35,325  
                                 

Operating expenses:

                               

Selling and marketing

    6,576       10,560       13,998       20,662  

General and administrative

    5,439       8,018       12,395       15,340  

Research and development

    524       1,710       1,128       2,774  

Amortization of intangible assets

    1,300       1,198       2,606       2,395  

Impairment expense

          2,600             2,600  

Loss from contingent consideration

          75             230  

Total operating expenses

    13,839       24,161       30,127       44,001  

Income (loss) from operations

    2,364       (6,868 )     860       (8,676 )

Other expense, net

    (1,179 )     (1,228 )     (1,888 )     (2,312 )

(Loss) gain on derivative warrant liabilities

    (577 )     1,403       (6,484 )     3,594  

Income (loss) before income tax

    608       (6,693 )     (7,512 )     (7,394 )

Income tax expense

    828             828        

Net loss

  $ (220 )   $ (6,693 )   $ (8,340 )   $ (7,394 )
                                 

Basic and diluted weighted-average common shares outstanding

    5,517,670       3,110,304       5,499,951       2,817,979  

Basic and diluted net loss per common share

  $ (0.04 )   $ (2.15 )   $ (1.52 )   $ (2.62 )

 

The accompanying Notes to the Unaudited Consolidated Financial Statements are an integral part of this statement.

 

 

 

AYTU BIOPHARMA, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

 

                   

Additional

           

Total

 
   

Common Stock

   

Paid-in

   

Accumulated

   

Stockholders’

 
   

Shares

   

Amount

   

Capital

   

Deficit

   

Equity

 

Balances, June 30, 2023

    5,517,174     $ 1     $ 343,485     $ (304,129 )   $ 39,357  

Stock-based compensation expense

    13,061             930             930  

Net loss

                      (8,120 )     (8,120 )

Balances, September 30, 2023

    5,530,235     $ 1     $ 344,415     $ (312,249 )   $ 32,167  

Stock-based compensation expense

    108             820             820  

Issuance of common stock with exercise of warrants

    37,004             86             86  

Net loss

                      (220 )     (220 )

Balances, December 31, 2023

    5,567,347     $ 1     $ 345,321     $ (312,469 )   $ 32,853  

 

 

                   

Additional

           

Total

 
   

Common Stock

   

Paid-in

   

Accumulated

   

Stockholders’

 
   

Shares

   

Amount

   

Capital

   

Deficit

   

Equity

 

Balances, June 30, 2022

    1,928,941     $     $ 331,386     $ (287,078 )   $ 44,308  

Stock-based compensation expense

    (1,666 )           1,177             1,177  

Issuance of common stock, net of issuance cost

    1,194,196             3,564             3,564  

Net loss

                      (701 )     (701 )

Balances, September 30, 2022

    3,121,471     $     $ 336,127     $ (287,779 )   $ 48,348  

Stock-based compensation expense

    (19,228 )           3,067             3,067  

Issuance of common stock, net of issuance cost

    280,902             1,095             1,095  

Net loss

                      (6,693 )     (6,693 )

Balances, December 31, 2022

    3,383,145     $     $ 340,289     $ (294,472 )   $ 45,817  

 

The accompanying Notes to the Unaudited Consolidated Financial Statements are an integral part of this statement.

 

 

 

AYTU BIOPHARMA, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

   

Six Months Ended

 
   

December 31,

 
   

2023

   

2022

 

Cash flows from operating activities:

               

Net loss

  $ (8,340 )   $ (7,394 )

Adjustments to reconcile net loss to cash used in operating activities:

               

Depreciation, amortization and accretion

    4,409       4,507  

Stock-based compensation expense

    1,750       4,244  

Loss (gain) on derivative warrant liabilities

    6,484       (3,594 )

Amortization of senior debt discount

    302       315  

Inventory write-down

    133       82  

Impairment expense

          2,600  

Loss from contingent consideration

          230  

Other noncash adjustments

    (50 )     (33 )

Changes in operating assets and liabilities:

               

Accounts receivable, net

    (466 )     (3,834 )

Inventories

    (1,140 )     (2,183 )

Prepaid expenses and other current assets

    (321 )     (4,606 )

Accounts payable

    (3,032 )     (838 )

Accrued liabilities

    (3,927 )     (1,008 )

Other operating assets and liabilities, net

    3,852       (76 )

Net cash used in operating activities

    (346 )     (11,588 )
                 

Cash flows from investing activities:

               

Contingent consideration payment

          (5 )

Other investing activities

    (250 )     42  

Net cash (used in) provided by investing activities

    (250 )     37  
                 

Cash flows from financing activities:

               

Proceeds from issuance of stock and warrants

    86       11,573  

Net (payments made on) proceeds received from, short-term line of credit

    (537 )     3,616  

Payment made to fixed payment arrangement

    (2,204 )     (2,433 )

Payment of stock issuance costs

    (160 )     (1,000 )

Payments made to borrowings

    (45 )      

Other financing activities

          (64 )

Net cash (used in) provided by financing activities

    (2,860 )     11,692  
                 

Net change in cash and cash equivalents

    (3,456 )     141  

Cash and cash equivalents at beginning of period

    22,985       19,360  

Cash and cash equivalents at end of period

  $ 19,529     $ 19,501  
                 

Supplemental disclosure of cash flow information:

               

Cash paid for interest

  $ 2,170     $ 2,021  

Cash paid for income taxes

  $ 432     $  

 

The accompanying Notes to the Unaudited Consolidated Financial Statements are an integral part of this statement.

 

 

AYTU BIOPHARMA, INC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

 

Note 1 - Nature of Business, Financial Condition, Basis of Presentation

 

Aytu BioPharma, Inc. (“Aytu”, or the “Company”), is a pharmaceutical company focused on commercializing novel therapeutics. The Company operates through two business segments (i) the Rx Segment, consisting of prescription pharmaceutical products sold primarily through third party wholesalers and (ii) the Consumer Health Segment, which consists of various consumer healthcare products sold directly to consumers (the “Consumer Health Portfolio”). The Company was originally incorporated as Rosewind Corporation on August 9, 2002, in the State of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021, (the “Neos Acquisition”) the Company changed its name to Aytu BioPharma, Inc.

 

On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every twenty shares held (the “Reverse Stock Split”). All share and per share amounts in this quarterly report have been adjusted to reflect the effect of the Reverse Stock Split.

 

The Rx Segment primarily consists of two product portfolios. First the ADHD Portfolio, which consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”). Second the Pediatric Portfolio, which consists of Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions.

 

The Consumer Health Segment consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health and general wellness, commercialized through direct mail and e-commerce marketing channels. To date, the Consumer Health Segment has generated negative cash flows. In fiscal 2023, the Company announced it would wind down the Consumer Health Segment in fiscal 2024.

 

The Company’s strategy is to continue building its portfolio of revenue-generating prescription pharmaceutical products, leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. As a result of focusing on building the portfolio of revenue-generating products and generating profitability, in fiscal 2023, the Company indefinitely suspended active development of its clinical development programs including AR101 (enzastaurin) and terminated the license agreements relating to Healight and NT0502 (N-desethyloxybutynin).

 

As of December 31, 2023, the Company had $19.5 million of cash and cash equivalents and $29.4 million of accounts receivable. The Company’s operations have historically consumed cash and may continue to consume cash in the future. The Company had a net loss of $0.2 million and $8.3 million during the three and six months ended December 31, 2023, respectively. The Company had an accumulated deficit of $312.5 million and $304.1 million as of December 31, 2023 and June 30, 2023, respectively. Cash used in operations was $0.4 million and $11.6 million during the six months ended December 31, 2023 and 2022, respectively.

 

In addition, the Company has non-operating liabilities that are scheduled to, or may become, current in the twelve months following the filing of this Form 10-Q, most notably the maturity of the $15 million Avenue Capital term note (the “Avenue Note”) as discussed further in Note 11 - Long-term Debt. The Company expects to refinance the Avenue Note, however, there are no assurances the Company will be able to refinance the Avenue Note. As a result of this, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern.

 

8

 

Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on (i) improving cash flows from operations, (ii) winding down the Consumer Health Segment, (iii) refinancing its $15 million Avenue Note to extend its maturity date, and, (iv), if necessary, raising additional capital through public or private equity offerings, debt offerings, or monetizing additional assets in order to meet its obligations. Management believes that the Company has adequate access to capital resources. However, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets, or obtain new financing on commercially acceptable terms. If the Company is unable to support its operations and obligations, it may be required to curtail its operations, or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern.

 

Basis of Presentation. The unaudited consolidated financial statements contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted pursuant to such rules and regulations. The unaudited consolidated financial statements should be read in conjunction with the Company’s 2023 Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of  June 30, 2023, was derived from the audited annual financial statements but does not contain all of the footnote disclosure from the annual financial statements. The results of operations for the period ended December 31, 2023 are not necessarily indicative of expected operating results for the full year or any future period.

 

Prior Period Reclassification. Certain prior year amounts in the consolidated statements of operations have been reclassified to conform to the current year presentation, including a reclassification of the fair value adjustment from contingent consideration. Net gain or loss from the fair value of contingent consideration was previously included in other expense, net, and is currently recorded in operating expenses on the consolidated statements of operations. This reclassification did not impact net loss or cash flows for the three or six months ended December 31, 2023 and 2022 or the Company’s financial position as of December 31, 2023 or June 30, 2023.

 

 

Note 2 - Significant Accounting Policies

 

Use of Estimates

 

Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for credit losses, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of warrants and derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.

 

Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC Topic 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable.

 

9

 

Income Taxes

 

The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three and six months ended December 31, 2023. The effective tax rate was 136.2% and negative 11.0% for the three and six months ended December 31, 2023, respectively, primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances. The effective tax rate was 0% for both the three and six months ended December 31, 2022, respectively, reflecting the full valuation allowance and no impact of Section 382 of the Internal Revenue Code.

 

An ownership change could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Company's ability to use the pre-acquisition net operating loss carryovers. The ownership changes could result in increased future tax liability and are a driver of the change from a zero percent effective tax rate.

 

Employee Retention Credit

 

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020 through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic.

 

As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). In accordance with IAS 20, when management determines reasonable assurance that the Company had substantially met all eligibility requirements of the ERC, the ERC benefit shall be recognized as other income in the consolidated statement of operations (see Note - 9 Other Liabilities).

 

Recently Adopted Accounting Pronouncements

 

Financial Instruments – Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (“ASU 2016-13”) requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU 2016-13 is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after December 15, 2019. However, in October 2019, the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after December 15, 2022. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company adopted ASU 2016-13 and ASU 2019-05 on July 1, 2023. The Company evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company’s consolidated financial statements.

 

Recent Accounting Pronouncements Not Yet Adopted

 

Debt - Debt with Conversion and Other Options. In August 2020, the FASB issued ASU No. 2020-06, DebtDebt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entitys Own Equity (Subtopic 815-40) Accounting for Convertible Instruments and Contracts in an Entitys Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2024 and does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.

 

10

 

Segment Reporting - Improvements to Reportable Segment Disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company’s consolidated financial statements and disclosures.

 

For a complete set of the Company’s significant accounting policies, refer to the Company's 2023 Form 10-K. Other than the application of IAS 20 for the ERC, there have been no significant changes to the Company’s significant accounting policies during the six months ended December 31, 2023

 

 

Note 3 - Revenues from Contracts with Customers

 

Net product revenue in the Rx Segment consists of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net product revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally “free-on-board” destination when shipped domestically within the United States, consistent with contractual terms.

 

The Company generates Consumer Health Segment revenue from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized “free-on-board” shipping point, consistent with contractual terms and aligning with the transfer of control of the products. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from customers are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost, and are included in cost of sales.

 

Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company’s periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate reporting and settlement of deductions. The Company continually monitors these provisions and does not believe variances between actual and estimated amounts have been or will be material.

 

Revenues by Segment. Net product revenue disaggregated by segment for the three and six months ended December 31, 2023 and 2022 were as follows:

 

 

  

Three Months Ended

  

Six Months Ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

  

2023

  

2022

 
  

(in thousands)

 

Consolidated net revenue:

                

Rx Segment

 $18,748  $18,029  $36,565  $36,681 

Consumer Health Segment

  4,186   8,250   8,468   17,253 

Total consolidated net revenue

 $22,934  $26,279  $45,033  $53,934 

 

11

 

Revenues by Product Portfolio. Net product revenue disaggregated by significant product portfolio in the Rx Segment for the three and six months ended December 31, 2023 and 2022 were as follows:

 

  

Three Months Ended

  

Six Months Ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

  

2023

  

2022

 
  

(in thousands)

 

Rx Segment net revenue:

                

ADHD Portfolio

 $16,572  $11,120  $31,700  $22,705 

Pediatric Portfolio

  2,145   6,328   4,710   12,886 

Other

  31   581   155   1,090 

Total Rx Segment net revenue

 $18,748  $18,029  $36,565  $36,681 

 

Other includes discontinued products in the Rx Segment. The Consumer Health Segment is comprised of one product portfolio, the Consumer Health Portfolio.

 

Revenues by Geographic location. The Company’s revenues are predominately within the United States, with insignificant sales internationally.

 

 

Note 4 - Inventories

 

Inventories consist of raw materials, work in process and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period first recognized. The Company incurred inventory write-downs of $0.1 million and zero for each of the three months ended December 31, 2023 and 2022, respectfully, and $0.1 million for each of the six months ended December 31, 2023 and 2022.

 

Inventory balances consist of the following:

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Raw materials

 $1,654  $1,301 

Work in process

  2,674   2,956 

Finished goods

  8,673   7,738 

Inventories

 $13,001  $11,995 

 

 

Note 5 - Property and Equipment

 

Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assets’ estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term.

 

12

 

Property and equipment consist of the following:

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Manufacturing equipment

 $1,183  $2,433 

Office equipment, furniture and other

  1,146   1,125 

Leasehold improvements

  999   999 

Lab equipment

  832   832 

Assets under construction

  45   107 

Property and equipment, gross

  4,205   5,496 

Less: accumulated depreciation and amortization

  (3,078)  (3,681)

Property and equipment, net

 $1,127  $1,815 

 

Depreciation and amortization expense from property and equipment was $0.3 million and $0.4 million for the three months ended December 31, 2023 and 2022, respectfully, and $0.6 million and $0.7 million for the six months ended December 31, 2023 and 2022, respectively.

 

 

Note 6 - Leases

 

The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between fiscal 2024 and fiscal 2029. Most leases include one or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain leases also include options to purchase the leased property. The Company’s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.

 

In May 2023, the Company entered into a lease agreement to relocate its principal office. The space was made available to the Company in September 2023 (lease commencement) with an initial term of five and a half years. The Company recorded an operating lease right-of-use (“ROU”) asset of $0.7 million and a lease liability of $0.7 million at lease commencement. The ROU asset and lease liability were recorded at present value using an incremental borrowing rate of 10.3%. The Company utilized the practical expedient to not separate lease and non-lease components upon recognition.

 

The components of lease expenses are as follows:

 

  

Three Months Ended

  

Six Months Ended

  
  

December 31,

  

December 31,

  
  

2023

  

2022

  

2023

  

2022

 

Statement of Operations Classification

  

(in thousands)

  

Lease cost:

                 

Operating lease cost

 $381  $359  $741  $716 

Operating expenses

Short-term lease cost

  21   19   44   44 

Operating expenses

Finance lease cost:

                 

Amortization of leased assets

  15   19   29   37 

Cost of sales

Interest on lease liabilities

  1   2   2   5 

Other expense, net

Total net lease cost

 $418  $399  $816  $802  

 

13

 

Supplemental balance sheet information related to leases is as follows:

 

  

December 31,

  

June 30,

  
  2023  2023 

Balance Sheet Classification

  

(in thousands)

  

Assets:

         

Operating lease assets

 $2,133  $2,054 

Operating lease right-of-use assets

Finance lease assets

     159 

Property and equipment, net

Total lease assets

 $2,133  $2,213  

Liabilities:

         

Current:

         

Operating leases

 $1,369  $1,258 

Other current liabilities

Finance leases

  39   85 

Current portion of debt

Non-current:

         

Operating leases

  845   832 

Other non-current liabilities

Total lease liabilities

 $2,253  $2,175  

 

Remaining lease term and discount rate used are as follows:

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 

Weighted-average remaining lease term (years):

        

Operating lease assets

  2.62   1.72 

Finance lease assets

  0.37   0.87 

Weighted-average discount rate:

        

Operating lease assets

  8.85%  7.78%

Finance lease assets

  6.54%  6.54%

 

Supplemental cash flow information related to lease is as follows:

 

  

Six Months Ended

 
  

December 31,

 
  

2023

  

2022

 
  

(in thousands)

 

Cash flow classification of lease payments:

        

Operating cash flows from operating leases

 $697  $716 

Operating cash flows from finance leases

 $2  $5 

Financing cash flows from finance leases

 $46  $52 

 

As of December 31, 2023, the maturities of the Company’s future minimum lease payments were as follows:

 

  

Operating

  

Finance

 
  

(in thousands)

 

2024 (remaining 6 months)

 $735  $40 

2025

  938    

2026

  282    

2027

  241    

2028

  199    

Thereafter

  151    

Total lease payments

  2,546   40 

Less: imputed interest

  (332)  (1)

Lease liabilities

 $2,214  $39 

 

14

 
 

Note 7 - Intangible Assets

 

The following table provides the summary of the Company’s intangible assets as of December 31, 2023 and June 30, 2023, respectively. Carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period.

 

  

December 31, 2023

 
              

Weighted-

 
          

Net

  

Average

 
  

Carrying

  

Accumulated

  

Carrying

  

Remaining

 
  

Amount

  

Amortization

  

Amount

  

Life (in years)

 
  

(in thousands)

 

Definite-lived intangibles:

                

Acquired product technology rights

 $41,467  $(11,777) $29,690   11.04 

Acquired technology right

  30,200   (4,943)  25,257   14.25 

Acquired product distribution rights

  6,207   (5,443)  764   0.50 

Total intangible assets

 $77,874  $(22,163) $55,711   12.35 

 

  

June 30, 2023

 
              

Weighted-

 
          

Net

  

Average

 
  

Carrying

  

Accumulated

  

Carrying

  

Remaining

 
  

Amount

  

Amortization

  

Amount

  

Life (in years)

 
  

(in thousands)

 

Definite-lived intangibles:

                

Acquired product technology rights

 $42,176  $(10,881) $31,295   11.49 

Acquired technology right

  30,200   (4,054)  26,146   14.75 

Acquired product distribution rights

  6,207   (4,678)  1,529   1.00 

Total intangible assets

 $78,583  $(19,613) $58,970   12.67 

 

The following table summarizes the estimated future amortization expense to be recognized over the next five fiscal years and periods thereafter:

 

  

December 31,

 
  

(in thousands)

 

2024 (remaining 6 months)

 $3,259 

2025

  4,989 

2026

  4,989 

2027

  4,989 

2028

  4,988 

Thereafter

  32,497 

Total future amortization expense

 $55,711 

 

Acquired Product Technology Rights

 

The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021.

 

15

 

Karbinal ER. The Company acquired and assumed all rights and obligations pursuant to the Supply and Distribution Agreement, as Amended, with Tris Pharma, Inc. (“Tris”) for the exclusive rights to commercialize Karbinal ER in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in August of 2033, with an optional additional 20-year extension.

 

Poly-Vi-Flor and Tri-Vi-Flor. The Company acquired and assumed all rights and obligations pursuant to a Supply and License Agreement and various assignment and release agreements, including a previously agreed to Settlement and License Agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.

 

ADHD Portfolio. As part of the Neos Acquisition, the Company acquired product technology for the production and sale of Adzenys XR-ODT and Cotempla XR-ODT. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 17 years.

 

Acquired Technology Right

 

TRRP Technology. As part of the Neos Acquisition, the Company acquired Time Release Resin Particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlies the ADHD portfolio and can potentially be used in future product development initiatives as well.

 

Acquired Product Distribution Rights (and customer list)

 

In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. During the fourth quarter of fiscal 2023, the acquired product distribution rights incurred an impairment charge of $3.0 million due to the discontinuation of products in the Consumer Health Segment.

 

Acquired In-Process R&D

 

IPR&D NT0502. As part of the Neos Acquisition, the Company acquired in-process research and development associated with NT0502, a new chemical entity being developed for the treatment of sialorrhea, which is excessive salivation or drooling. As this is an indefinite-lived intangible asset, this acquired asset remains an indefinite-lived asset until the completion or abandonment of the associated research and development efforts. If a product using this technology is eventually approved for commercial sale, at that time, the IPR&D will begin amortizing on a straight-line basis over the life of the product. During fiscal 2023, the Company terminated its development program of NT0502. As a result, the Company fully impaired the IPR&D of NT0502, recording impairment expense of $2.6 million to its Rx Segment during the three months ended December 31, 2022.

 

Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.6 million and $1.5 million for the three months ended December 31, 2023 and 2022, respectively, and $3.3 million and $3.0 million for the six months ended December 31, 2023 and 2022, respectively.

 

16

 
 

Note 8 - Accrued Liabilities

 

Accrued liabilities consist of the following:

 

   

December 31,

   

June 30,

 
   

2023

   

2023

 
   

(in thousands)

 

Accrued savings offers

  $ 14,852     $ 15,739  

Accrued program liabilities

    11,841       11,012  

Accrued customer and product related fees

    5,699       6,579  

Return reserve

    5,129       5,777  

Accrued employee compensation

    3,362       5,675  

Other accrued liabilities

    2,530       2,017  

Total accrued liabilities

  $ 43,413     $ 46,799  

 

Accrued savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. The return reserve represents the Company’s accrual for estimated product returns. Other accrued liabilities consist of various other accruals, none of which individually or in the aggregate represent greater than five percent of total liabilities.

 

Note 9 - Other Liabilities

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Fixed payment arrangements

 $9,043  $10,420 

Operating lease liabilities

  2,214   2,090 

Employee retention credit

  3,759    

Other

  564   1,555 

Total other liabilities

  15,580   14,065 

Less: current portion

  (9,236)  (7,090)

Total other liabilities, non-current

 $6,344  $6,975 

 

Fixed Payment Arrangements

 

Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments.

 

17

 

The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. As of December 31, 2023, the fixed payment arrangement balance was $1.8 million in other current liabilities, and $1.2 million in other non-current liabilities on the consolidated balance sheet.

 

On May 12, 2022, the Company entered into an agreement with Tris to terminate the Tuzistra XR License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $9.0 million, which reduced its total liability for minimum payments by approximately $8.0 million from the original License Agreement. As of December 31, 2023, the balance was $6.0 million in other current liabilities on the consolidated balance sheet.

 

Operating Lease Liabilities 

 

The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to Note 6 - Leases for further detail.

 

Employee Retention Credit 

 

The $3.8 million ERC accrual in other non-current liabilities as of December 31, 2023, represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. The ERC is a refundable payroll tax credit from the CARES Act enacted by the U.S. government to provide certain relief from the COVID-19 pandemic. The refundable payroll tax credit shall be recognized in the consolidated statement of operations following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Service (see Note 2 – Significant Accounting Policies). The associated vendor fee of $0.4 million was expensed as incurred in the first quarter of fiscal 2024.

 

Other

 

Other consists of taxes payable and deferred cost related to the Company’s technology transfer.

 

 

Note 10 - Line of Credit

 

The Company has entered into a secured credit agreement, as amended, with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $14.0 million, less a $3.5 million availability block, in secured revolving loans (the “Revolving Loans”), against 85% of eligible accounts receivable. The Revolving Loans thereunder, accrue at variable interest through maturity at the one-month Secure Overnight Financing Rate (“SOFR”), plus 4.50%. The Eclipse Loan Agreement includes an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The maturity date under the Eclipse Loan Agreement is January 26, 2025.

 

In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (ii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement at any time with at least five business days prior notice to Eclipse.

 

The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of December 31, 2023, the Company was in compliance with the covenants under the Eclipse Loan Agreement.

 

18

 

The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement.

 

Total interest expense on the Revolving Loans, including amortization of deferred financing costs, was $23.2 thousand and $176.7 thousand for the three months ended December 31, 2023 and 2022, respectively and $50.1 thousand and $274.0 thousand for the six months ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and June 30, 2023, the outstanding Revolving Loans under the Eclipse Loan Agreement, as amended, were $1.0 million and $1.6 million, respectively.

 

 

Note 11 - Long-term Debt

 

Avenue Capital Loan

 

On January 26, 2022 (“Closing Date”), the Company entered into a Loan and Security Agreement (the “Avenue Capital Agreement”) with Avenue Venture Opportunities Fund, L.P. (“Avenue”) and Avenue Venture Opportunities Fund II, L.P. (Avenue 2”) as lenders (the “Avenue Capital Lenders”), and Avenue Capital Management II, L.P. as administrative agent (the “Avenue Capital Agent”, and collectively with the Avenue Capital Lenders, “Avenue Capital”), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan is the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used to repay the senior secured term credit facility with Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P., which the Company assumed through the Neos Acquisition.

 

Pursuant to the Avenue Capital Agreement, the Company made interest only payments for the first 18 months following the Closing Date (“Interest-only Period”). In June 2023, the Company achieved certain defined milestones extending the Interest-Only Period through the maturity date.

 

In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (ii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount.

 

The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement.

 

The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of December 31, 2023, the Company was in compliance with the covenants under the Avenue Capital Agreement.

 

On January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering, and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants are immediately exercisable and expire on January 31, 2027. The Company accounted for the Avenue Capital Warrants as a liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million.

 

19

 

On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants at an offering price of $25.00 per share. As the Avenue Capital Agreement precluded the Company from pursuing any equity financing prior to July 7, 2022, and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the number of shares of common stock issuable upon exercise of the Avenue Capital Warrants were set to 43,388 at an exercise price of $24.20.

 

On October 25, 2022, the Company entered into an agreement with Avenue to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company’s August 2022 equity financing.

 

In addition to the debt discount discussed above, the Company incurred $0.4 million in loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 19.6%. Total interest expense, including debt discount amortization, was $0.7 million for both the three months ended December 31, 2023 and 2022, and $1.5 million and $1.3 million for the six months ended December 31, 2023 and 2022, respectively.

 

Long-term debt consists of the following:

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Long-term debt, due on January 26, 2025

 $15,000  $15,000 

Long-term, final payment fee

  638   638 

Unamortized discount and issuance costs

  (660)  (925)

Financing leases, maturing through May 2024

  39   85 

Total debt

  15,017   14,798 

Less: current portion

  (39)  (85)

Non-current portion of debt

 $14,978  $14,713 

 

Future principal payments of long-term debt, including financing leases, are as follows:

 

  

December 31,

 
  

(in thousands)

 

2024 (remaining 6 months)

 $39 

2025

  15,638 

Future principal payments

  15,677 

Less: unamortized discount and issuance costs

  (660)

Less: current portion

  (39)

Non-current portion of debt

 $14,978 

 

 

Note 12 - Fair Value Considerations

 

The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to determine fair value as follows:

 

 

Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;

 

 

Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and

 

 

Level 3: Unobservable inputs that are supported by little or no market activity.

 

20

 

The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, fixed payment arrangements, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on the unaudited consolidated balance sheets. The remaining financial instruments and derivative warrant liabilities are reported on the unaudited consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2, and Level 3 in the periods presented.

 

Recurring Fair Value Measurements

 

The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of  December 31, 2023 and June 30, 2023, by level within the fair value hierarchy.

 

      

Fair Value Measurements at December 31, 2023

 
  

Fair Value at December 31,

             
  

2023

  

(Level 1)

  

(Level 2)

  

(Level 3)

 
  

(in thousands)

 

Liabilities:

                

Derivative warrant liabilities

  12,887         12,887 

Total

 $12,887  $  $  $12,887 

 

 

      

Fair Value Measurements at June 30, 2023

 
  

Fair Value at June 30,

             
  

2023

  

(Level 1)

  

(Level 2)

  

(Level 3)

 
  

(in thousands)

 

Liabilities:

                

Derivative warrant liabilities

  6,403         6,403 

Total

 $6,403  $  $  $6,403 

 

Summary of Level 3 Input Changes

 

The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the six months ended December 31, 2023.

 

  

Derivative

 
  

Warrant Liabilities

 
  

(in thousands)

 

Balance as of June 30, 2023

 $6,403 

Included in earnings

  6,484 

Balance as of December 31, 2023

 $12,887 

 

21

 

Significant Assumptions

 

The following table presents the valuation methodologies and key assumptions used for the marked to market fair value measurements of derivative warrant liabilities as of December 31, 2023.

 

  

June 2023 Warrants

  

Warrants

 
  

Tranche A & B

  

Other *

 
  

Monte Carlo Simulation

    
  

& Black-Scholes

  

Black-Scholes

 

Equivalent term (years)

 4.44  3.09-3.69 

Expected volatility

 

96.15%

  

96.15%

 

Risk-free rate

 

3.88%

  

3.95-4.01%

 

Dividend yield

 

0.00%

  

0.00%

 

 

* Includes August 2022 Warrants, March 2022 Warrants, and Avenue Capital Warrants.

 

The Black-Scholes option pricing model is used to value all warrants with significant Level 3 inputs. The Monte Carlo Simulation is used to simulate the exit price and EBITDA forecast; average warrant value per share is from 100,000 Monte Carlo simulations. The Monte Carlo is based on significant inputs including financial projections provided by the Company’s management used primarily to forecast future results not observable in the market, and thus, represents a Level 3 measure.

 

 

Note 13 - Commitments and Contingencies

 

Pediatric Portfolio Fixed Payments and Product Milestone

 

The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell Karbinal ER in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales.

 

The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000‑unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of product net revenues.

 

Rumpus Earn Out Payments

 

On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, the Company made a payment of $0.6 million for a license fee in April 2022. In addition, upon the achievement of regulatory and commercial milestones, the Company may be required to pay up to $101.7 million and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for royalties of 3.0% of net product sales, with a minimum of $20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. In October 2022, the Company announced the indefinite suspension of its development of AR101.

 

22

 

Legal Matters

 

Witmer Class-Action Securities Litigation. A stockholder derivative suit filed on September 12, 2022, in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, and later amended, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice’s Chief Investment Officer and Managing Partner, and a former director of Aytu) (collectively “Armistice”), and certain other current and former directors of Aytu, Joshua Disbrow, Gary Cantrell, John Donofrio, Jr, Carl Dockery and Ketan B. Mehta. The amended complaint alleges that (i) Armistice facilitated the sale of assets of Cerecor, Inc., in 2019 and Innovus Pharmaceuticals, Inc., in 2020 to Aytu in exchange for convertible securities, which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants’ breaches of fiduciary duties, in connection with these acquisitions. The amended complaint seeks unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys’ fees. While the Company believes that this lawsuit is without merit and has vigorously defended against it, the Company has agreed to settle the matter, as against it and the director defendants other than Mr. Boyd, for various corporate governance modifications and the payment of plaintiff’s attorneys’ fees. That settlement is subject to court approval, the hearing on which has not yet been scheduled.

 

Sabby Litigation. A complaint was filed on February 22, 2023, in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund Ltd (“Sabby”) and Walleye Opportunities Master Fund Ltd (“Walleye”), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrant holders may receive, and that the Company failed to provide prompt notice to the warrant holders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. In October 2023, the Company entered into a settlement agreement and general release with Sabby and Walleye.

 

Stein Litigation. Cielo Stein (“Stein”), a former sales specialist, filed a complaint on February 1, 2023, in Jefferson County Circuit Court in Kentucky against the Company and its wholly owned subsidiary Neos Therapeutics. The complaint alleges that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleges that the Company’s response to Stein’s subsequent complaint to human resources was inadequate. The complaint seeks an award of unspecified compensatory damages, emotional-distress damages, and attorneys’ fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky and filed a motion to dismiss the complaint, which was denied. The case has been referred to a magistrate judge for, among other things, the entry of a scheduling order and to conduct a settlement conference. Due to the early stage of litigation, and while the Company believes that this lawsuit is without merit, the Company is not able to predict at this time whether this proceeding will have a material impact on its financial condition or results of operations and intend to vigorously defend this case in the event it is not dismissed.

 

 

Note 14 - Capital Structure

 

The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. Included in the common stock outstanding are 40,017 shares of unvested restricted stock issued to executives, directors and employees.

 

On June 8, 2020, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on June 17, 2020. This shelf registration statement covered the offering, issuance, and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2020 Shelf”). On June 4, 2021, the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the 2020 Shelf (the “ATM Sales Agreement”). During the year ended June 30, 2023, the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of approximately $2.9 million. The 2020 Shelf expired in June 2023.

 

23

 

On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2021 Shelf”). As of December 31, 2023, approximately $82.4 million remained available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitation to the Form S-3.

 

On August 11, 2022, the Company closed on an underwritten public offering (the “August 2022 Offering”) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock, and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants have a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders’ equity in the Company’s consolidated financial statements (See Note 16 – Warrants).

 

On June 8, 2023, using a placement agency, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the “Pre-Funded Warrants”), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the “Common Warrants”). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the “Exchange Warrants”). Each Pre-Funded Warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company’s common stock equaling 200% of the exercise price ($3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company’s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million. The Company raised $4.0 million in gross proceeds and net proceeds were approximately $3.4 million after deducting offering expenses. The warrants have a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in other expense along with the issuance costs of $0.6 million in the consolidated financial statement of operations (See Note 16 – Warrants).

 

24

 
 

Note 15 - Equity Incentive Plans

 

2023 Equity Incentive Plan. On May 18, 2023, the Company’s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the “2023 Equity Incentive Plan”). Prior to the Company’s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (the “Aytu 2015 Plan”) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (the “Neos 2015 Plan”, and collectively with the Aytu 2015 Plan, the “2015 Plans”). For the 2023 Equity Incentive Plan, the stockholders approved (a) 200,000 new shares, (b) 87,129 shares available for grant under the 2015 Plans be “rolled over” to the 2023 Equity Incentive Plan and (c) any shares that are returned to the company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional awards will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the 2023 Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of December 31, 2023, the Company had 179,732 shares that are available for grant under the 2023 Equity Incentive Plan.

 

Aytu 2015 Plan. On June 1, 2015, the Company’s stockholders approved the Aytu 2015 Plan, which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 150,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. On February 13, 2020, the Company’s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, whereas the restricted stock units have a vesting period of 4 years.

 

Neos 2015 Plan. Pursuant to the Neos Merger, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos 2015 Plan. Accordingly, on April 19, 2021, the Company registered 5,272 shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos 2015 Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years.

 

Stock Options

 

Stock option activity is as follows:

 

          

Weighted

 
          

Average

 
      

Weighted

  

Remaining

 
  

Number of

  

Average

  

Contractual

 
  

Options

  

Exercise Price

  

Life in Years

 

Outstanding June 30, 2023

  52,762  $18.37   9.06 

Granted

  112,000  $1.73   9.61 

Forfeited/cancelled

  (15,060) $2.94    

Expired

  (615) $184.80    

Outstanding at December 31, 2023

  149,087  $6.43   9.17 
             

Exercisable at December 31, 2023

  20,470  $30.18   8.02 

 

25

 

The weighted-average grant date fair value of options granted during the six months ended December 31, 2023 was $1.73. As of December 31, 2023, there was $0.4 million total unrecognized compensation costs related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.85 years.

 

Restricted Stock

 

Restricted stock activity is as follows:

 

      

Weighted

 
      

Average Grant

 
  

Number of

  

Date Fair

 
  

Shares

  

Value

 

Unvested at June 30, 2023

  38,075  $142.20 

Granted

  12,500  $1.77 

Vested

  (12,189) $130.45 

Forfeited/cancelled

  (457) $136.80 

Unvested at December 31, 2023

  37,929  $99.75 

 

As of December 31, 2023, there was $2.0 million total unrecognized compensation costs related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.9 years.

 

As of December 31, 2023, there was $0.3 million total unrecognized costs related to non-vested restricted stock outside of the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.1 years. As of December 31, 2023, 2,088 shares of restricted stock remain unvested.

 

Restricted Stock Units

 

Restricted stock units (“RSU” or “RSUs”) activity is as follows:

 

      

Weighted

 
      

Average Grant

 
  

Number of

  

Date Fair

 
  

Shares

  

Value

 

Unvested at June 30, 2023

  4,963  $25.62 

Vested

  (1,126) $24.28 

Forfeited

  (939) $31.60 

Unvested at December 31, 2023

  2,898  $24.19 

 

As of December 31, 2023, there was $0.1 million total unrecognized compensation costs related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.2 years.

 

26

 

Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table:

 

  

Three Months Ended

  

Six Months Ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

  

2023

  

2022

 
  

(in thousands)

 

Cost of sales

 $1  $3  $1  $8 

Research and development

  2   14   3   23 

Selling and marketing

     3      6 

General and administrative

  817   3,047   1,746   4,207 

Total stock-based compensation expense

 $820  $3,067  $1,750  $4,244 

 

 

Note 16 - Warrants

 

Liability Classified Warrants

 

On June 8, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock, (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering. The Tranche A Warrants and Tranche B Warrants may be exercised for either shares of common stock or pre-funded exchange warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the pre-funded warrant. Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The Tranche A Warrants and Tranche B Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per pre-funded exchange warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company’s common stock equaling 200% of the exercise price ($3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company’s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million (see Note 14 – Capital Structure).

 

On August 11, 2022, the Company closed an offering (the “August 2022 Offering”), pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant was sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The common warrants provide that if there occurs any stock split, stock dividend stock recapitalization, or similar event (a “Stock Combination Event”), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the common stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by (y) five; or $2.32, and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see Note 14 – Capital Structure).

 

In November 2022 and throughout the quarter ended December 31, 2022, the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022 Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $8.60. As a result, the common warrants exercise price was adjusted to $3.30. On January 6, 2023, the Company consummated a 20 to 1 reverse stock split. Pursuant to the warrant agreement described above, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest five trading days during the twenty-day consecutive trading day period beginning on December 30, 2022. Subsequently, as a result of the Securities Purchase Agreement in June 2023, the common warrants from the August 2022 Offering had an adjusted exercise price of $2.32.

 

27

 

Certain outstanding warrants are classified as derivative warrant liabilities in the consolidated balance sheets and are marked to market at each reporting period (see Note 12 – Fair Value Considerations).

 

A summary of warrants is as follows:

 

          

Weighted

 
          

Average

 
      

Weighted

  

Remaining

 
  

Number of

  

Average

  

Contractual

 
  

Warrants

  

Exercise Price

  

Life in Years

 

Outstanding June 30, 2023

  6,538,052  $4.42   4.71 

Warrants exercised

  (37,004) $2.32    

Warrants expired

  (20,958) $300.00    

Outstanding December 31, 2023

  6,480,090  $3.48   4.22 

 

 

Note 17 - Earnings Per Share

 

Basic loss per common share is calculated by dividing the net loss available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company.

 

The following table sets forth securities that are considered anti-dilutive, and therefore excluded from the calculation of diluted earnings per share.

 

  

December 31,

 
  

2023

  

2022

 

Warrants to purchase common stock - liability classified

  6,498,980   1,642,235 

Warrant to purchase common stock - equity classified

  39,072   56,486 

Employee stock options

  149,087   52,861 

Employee unvested restricted stock

  40,017   48,280 

Employee unvested restricted stock units

  2,898   8,167 

Total

  6,730,054   1,808,029 

 

 

Note 18 - License Agreements

 

Teva

 

On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances.

 

Actavis

 

On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis (now Teva, following Teva’s acquisition of Actavis’ generic products) has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances.

 

28

 
 

Note 19 - Segment Reporting

 

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on the Company’s financial information. The CODM reviews financial information presented for each reportable segment for the purpose of making operating decisions and assessing financial performance.

 

The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company’s prescription products. The Consumer Health Segment contains the Company’s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment.

 

Select financial information for these segments is as follows:

 

  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Three Months Ended December 31, 2023

            
             

Product revenue, net

 $18,748  $4,186  $22,934 

Income (loss) from operations

 $3,146  $(782) $2,364 
             

Depreciation and amortization

 $1,510  $389  $1,899 

Stock-based compensation expense

 $707  $113  $820 
             

Three Months Ended December 31, 2022

            
             

Product revenue, net

 $18,029  $8,250  $26,279 

Loss from operations

 $(5,464) $(1,404) $(6,868)
             

Depreciation and amortization

 $1,572  $281  $1,853 

Impairment expense

 $2,600  $  $2,600 

Stock-based compensation expense

 $2,987  $80  $3,067 

 

  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Six Months Ended December 31, 2023

            
             

Product revenue, net

 $36,565  $8,468  $45,033 

Income (loss) from operations

 $2,280  $(1,420) $860 
             

Depreciation and amortization

 $3,064  $776  $3,840 

Stock-based compensation expense

 $1,432  $318  $1,750 
             

Six Months Ended December 31, 2022

            
             

Product revenue, net

 $36,681  $17,253  $53,934 

Loss from operations

 $(6,457) $(2,219) $(8,676)
             

Depreciation and amortization

 $3,146  $562  $3,708 

Impairment expense

 $2,600  $  $2,600 

Stock-based compensation expense

 $4,149  $95  $4,244 

 

29

 
 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

This discussion should be read in conjunction with the Company2023 Form 10-K. The following discussion and analysis contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. For additional information regarding these risks and uncertainties, please see the risk factors included in the Company2023 Form 10-K, and in Part II Item 1A of this Form 10-Q.

 

Objective

 

The purpose of the Management’s Discussion and Analysis (the “MD&A”) is to present information that management believes is relevant to an assessment and understanding of our results of operations and cash flows for the three and six months ended December 31, 2023, and our financial condition as of December 31, 2023. The MD&A is provided as a supplement to, and should be read in conjunction with, our Unaudited Consolidated Financial Statements and Notes to the Unaudited Consolidated Financial Statements.

 

Overview

 

We are a pharmaceutical company focused on commercializing novel therapeutics. We operate through two business segments (i) the Rx Segment, consisting of prescription pharmaceutical products sold primarily through third party wholesalers and (ii) the Consumer Health Segment, which consists of various consumer health products sold directly to consumers. We currently manufacture our products for the treatment of attention deficit hyperactivity disorder (“ADHD”) at our manufacturing facility and use third party manufacturers for our other prescription and consumer health products. We are in the process of moving production of our ADHD products to a third-party manufacturer to improve the profitability of these products.

 

We have incurred significant losses in each year since inception. Our net loss was $0.2 million and $8.3 million for the three and six months ended December 31, 2023, respectively. As of December 31, 2023, and June 30, 2023, we had accumulated deficits of $312.5 million and $304.1 million, respectively. As of December 31, 2023, and largely as a result of the January 2025 maturity of the Avenue Note, there is significant uncertainty about our ability to fund planned operations for the twelve months following the filing date of this Form 10-Q, which raises substantial doubt about our ability to continue as a going concern.

 

Company Strategy

 

In the first quarter of fiscal 2023, we announced that we will focus our efforts on accelerating the growth of our Rx business and achieving operating cash flows. To achieve these goals, we indefinitely suspended active development of our clinical development programs. The suspension of these programs is expected to save over $20 million in projected future study costs over the next three fiscal years. In addition, we announced that we would wind down our Consumer Health Segment in fiscal 2024, which has not generated cash flows since we acquired the business in February 2020, to allow us to focus our efforts on improving the performance of our Rx Segment.

 

Business Environment

 

We have continued to experience significant inflationary pressure and have experienced supply chain disruptions related to the sourcing of raw materials, energy, logistics and labor during fiscal 2023 and 2024. While we do not have sales or operations in Russia, Ukraine, or the Middle East, it is possible that the conflict or actions taken in response, could adversely affect some of our markets and suppliers, economic and financial markets, costs and availability of energy and materials, or cause further supply chain disruptions. We continue to closely monitor the impact of, and responses to, COVID-19 variants, including government-imposed lockdowns, on demand conditions and our supply chain. We expect that inflationary pressures and supply chain disruptions could continue to be significant across the business throughout fiscal 2024. The Company has not experienced stock outages for its ADHD products since the launch of those products, and the pediatric product supply has remained adequate to satisfy demand for the preceding three years.

 

 

Results of Operations

 

The results of operations for the three and six months ended December 31, 2023, compared to the three and six months ended December 31, 2022 is as follows:

 

   

Three Months Ended

   

Six Months Ended

 
   

December 31,

   

December 31,

 
   

2023

   

2022

   

Change

   

2023

   

2022

   

Change

 
   

(in thousands)

 

Product revenue, net

  $ 22,934     $ 26,279     $ (3,345 )   $ 45,033     $ 53,934     $ (8,901 )

Cost of sales

    6,731       8,986       (2,255 )     14,046       18,609       (4,563 )

Gross profit

    16,203       17,293       (1,090 )     30,987       35,325       (4,338 )
                                                 

Operating expenses:

                                               

Advertising and direct marketing

    1,358       4,595       (3,237 )     2,689       9,047       (6,358 )

Other selling and marketing

    5,218       5,965       (747 )     11,309       11,615       (306 )

General and administrative

    5,439       8,018       (2,579 )     12,395       15,340       (2,945 )

Research and development

    524       1,710       (1,186 )     1,128       2,774       (1,646 )

Amortization of intangible assets

    1,300       1,198       102       2,606       2,395       211  

Impairment expense

          2,600       (2,600 )           2,600       (2,600 )

Loss from contingent consideration

          75       (75 )           230       (230 )

Total operating expenses

    13,839       24,161       (10,322 )     30,127       44,001       (13,874 )

Income (loss) from operations

    2,364       (6,868 )     9,232       860       (8,676 )     9,536  

Other expense, net

    (1,179 )     (1,228 )     49       (1,888 )     (2,312 )     424  

(Loss) gain on derivative warrant liabilities

    (577 )     1,403       (1,980 )     (6,484 )     3,594       (10,078 )

Income (loss) before income tax

    608       (6,693 )     7,301       (7,512 )     (7,394 )     (118 )

Income tax expense

    828             828       828             828  

Net loss

  $ (220 )   $ (6,693 )   $ 6,473     $ (8,340 )   $ (7,394 )   $ (946 )

 

Product revenue, net

 

During the three and six months ended December 31, 2023, net product revenue decreased by $3.3 million, or 13% and decreased by $8.9 million, or 17%, compared to the same period ended December 31, 2022. The decrease during the three and six months ended December 31, 2023 was primarily due to the decrease in revenue from the Consumer Health Segment, with some of the decrease in revenue attributed to a decline in revenue from the Pediatric Portfolio in the Rx Segment. These declines were partially offset by an increase in revenue from the ADHD Portfolio in the Rx Segment.

 

Gross margin

 

During the three and six months ended December 31, 2023, gross profit decreased by 6% and by 12%, respectfully, compared to the same period ended December 31, 2022. Gross margin percentage was 71% and 69% for the three and six months ended December 31, 2023, respectfully, compared to 66% and 65% for the same period ended December 31, 2022. The improvements were primarily due to higher net revenues and cost saving efficiencies in the Pediatric Portfolio and a decline in the lower-margin Consumer Health Segment. Gross margin improvements in the ADHD Portfolio were due to efficiencies in production related to higher demand for Adzenys XR-ODT and Cotempla XR-ODT.

 

Advertising and direct marketing

 

During the three and six months ended December 31, 2023, advertising and direct marketing expense decreased $3.2 million, or 70% and $6.4 million or 70%, compared to the same periods ended December 31, 2022. Advertising and direct marketing expense include direct-to-consumer marketing, advertising, sales, and customer support and processing fees related to our Consumer Health Segment and have decreased as we continue to wind down our Consumer Health Segment.

 

 

Other selling and marketing

 

During the three and six months ended December 31, 2023, other selling and marketing expense decreased by $0.7 million, or 13% and $0.3 million, or 3%, compared to the same periods ended December 31, 2022. The decreases were primarily driven by commission expense based on prescriptions generated by our sale force and commercial marketing program fees that decrease as product sales decrease.

 

General and administrative

 

During the three and six months ended December 31, 2023, general and administrative expense decreased by $2.6 million, or 32% and $2.9 million, or 19% compared to the same periods ended December 31, 2022. The decrease is primarily a result of ongoing cost-cutting initiatives and operational improvements.

 

Research and development

 

During the three and six months ended December 31, 2023, research and development expense decreased by $1.2 million, or 69% and $1.6 million, or 59%, compared to the same periods ended December 31, 2022. Our research and development costs were primarily associated with AR101 and to a lesser extent, the development of Healight and support for our commercialized products. In October 2022, we announced the suspension of the development of AR101 and Healight to focus on our commercial operations. As a result, research and development spending has significantly declined. We expect our research and development expenses to decrease from historical levels as a result of our focus on commercial operations.

 

Amortization of intangible assets

 

In the three and six months ended December 31, 2023, amortization expense of intangible assets, excluding amounts included in cost of sales, were relatively consistent compared to the same periods ended December 31, 2022.

 

Impairment expense

 

In the three and six months ended December 31, 2023, no impairment expense was recorded.

 

Due to increased focus on our Rx business efforts, we ceased active development of our NT0502 product candidate. As a result, we returned the intellectual property and terminated the Exclusive License Agreement with NeuRx Pharmaceuticals entered in October 2018. In the three and six months ended December 31, 2022, we incurred an impairment charge of $2.6 million related to these decisions.

 

Other expense, net

 

In the three and six months ended December 31, 2023, other expense, net, decreased by $49.0 thousand, or 4% and $0.4 million, or 18% compared to the same periods ended December 31, 2022, primarily due to $0.5 million in other income from insurance proceeds for damage of inventory in the first quarter of fiscal 2024. Other expense, net, include interest expense, accretion from fixed payment arrangements, and other income.

 

(Loss) gain on derivative warrant liabilities

 

The fair value of derivative warrant liabilities is calculated using either the Black-Scholes option model or the Monte Carlo simulation model and is revalued at each reporting period. For the three and six months ended December 31, 2023, we recognized unrealized losses of $0.6 million and $6.5 million, respectively, from the fair value adjustments.

 

Income tax expense

 

For both the three and six months ended December 31, 2023, income tax expense was $0.8 million with an effective tax rate of 136.2% and negative 11.0% for the three and six months ended December 31, 2023, respectively. This income tax expense was primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances.

 

For both the six months ended December 31, 2023 and 2022, income tax expense was zero with an effective tax rate of zero percent for both the six months ended December 31, 2023 and 2022, reflecting the full valuation allowance and no impact of Section 382 of the Internal Revenue Code.

 

 

Liquidity and Capital Resources

 

Sources of Liquidity

 

We have obligations related to our loan agreements, and in the form of contingent consideration related to our acquisitions, milestone payments for licensed products, and manufacturing purchase commitments.

 

We finance our operations through a combination of sales of our common stock and warrants, borrowings under our line of credit facility, and from cash generated from operations.

 

Shelf Registrations

 

On September 28, 2021, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2021 Shelf”). As of December 31, 2023, approximately $82.4 million remains available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitations of Form S-3.

 

Eclipse Loan Agreement

 

The Eclipse Loan Agreement, as amended, provides us with up to $14.5 million, less a $3.5 million availability block, in Revolving Loans, against 85% of eligible accounts receivable. The Revolving Loans bore interest at LIBOR, plus 4.50% through April 2022. Beginning in May 2022 through maturity, the Revolving Loans bear interest at the Secured Overnight Financing Rate (“SOFR”) plus 4.50%. In addition, we are required to pay an unused line fee of 0.50% of the average unused portion of the maximum Revolving Loans amount during the immediately preceding month. Interest is payable monthly in arrears. The maturity date under the Eclipse Loan Agreement, as amended, is January 26, 2025.

 

Cash Flows

 

The following table shows cash flows for the six months ended December 31, 2023 and 2022:

 

   

Six Months Ended December 31,

 
   

2023

   

2022

   

Change

 
   

(in thousands)

 

Net cash used in operating activities

  $ (346 )   $ (11,588 )   $ 11,242  

Net cash (used in) provided by investing activities

  $ (250 )   $ 37     $ (287 )

Net cash (used in) provided by financing activities

  $ (2,860 )   $ 11,692     $ (14,552 )

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities during these periods primarily reflected our net losses, partially offset by changes in working capital and non-cash charges including impairment, stock-based compensation expense, gain or loss on derivative warrant liabilities, depreciation, amortization and accretion, and other charges.

 

During the six months ended December 31, 2023, net cash used in operating activities totaled $0.4 million. The use of cash was primarily the result of the decrease in accrued liabilities, partially offset by funds from the Employee Retention Credit program recorded in other operating liabilities (see Note 9 - Other Liabilities). Additionally, these were partially offset by positive cash earnings (net loss offset by non-cash depreciation, amortization and accretion, derivative warrant liabilities adjustment, and stock compensation expense).

 

 

During the six months ended December 31, 2022, net cash used in operating activities totaled $11.6 million. The use of cash was primarily the result of the decrease in inventory, prepaid expenses, and accrued liabilities. These were partially offset by positive cash earnings (net loss offset by non-cash depreciation, amortization and accretion, in addition to stock compensation expense and impairment charges).

 

Net Cash (Used in) Provided by Investing Activities

 

Net cash flows from investing activities were nominal during each of the six months ended December 31, 2023 and 2022.

 

Net Cash (Used in) Provided by Financing Activities

 

Net cash used in financing activities of $2.7 million during the six months ended December 31, 2023, was primarily from payments made to fixed payment arrangements.

 

Net cash provided by financing activities of $11.7 million during the six months ended December 31, 2022, was primarily from $9.1 million of proceeds from our August 2022 equity raise, $3.6 million of additional net borrowing made under our short-term line of credit, and $1.5 million from our sales under our ATM Sales Agreement.

 

Inflation

 

Inflation has resulted in increased costs for our suppliers and our customers. In addition, the U.S. Government has responded to inflation by raising interest rates, which has increased the cost of capital. We believe this has resulted in some of our customers making decisions to reduce their costs as well as increased costs of our operations, which has negatively impacted the results of our operations during the three and six months ended December 31, 2023. We maintain strategies to mitigate the impact of higher material, energy and commodity costs, including cost reduction, alternative sourcing strategies, and passing along cost increases to customers, which may offset only a portion of the adverse impact.

 

Contractual Obligations, Commitments and Contingencies

 

As a result of our acquisitions and licensing agreements, we are contractually and contingently obliged to pay, when due, various fixed and contingent milestone payments. See Note 13 – Commitments and Contingencies in the accompanying Notes to the Unaudited Consolidated Financial Statements for further information.

 

On May 12, 2022, we entered into an agreement with Tris Pharma Inc. (“Tris”) to terminate the Tuzistra License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “Tuzistra License Agreement”). Pursuant to such termination, we agreed to pay Tris a total of $6 million to $9 million, which reduced our total liability for minimum payments by approximately $8 million from the original Tuzistra License Agreement. As of December 31, 2023, the total remaining liability for minimum payments was $6.0 million. Pursuant to the settlement agreement, if the Company does not make timely payments, it is required to pay interest on any outstanding balances at a rate equal to the greater of (i) 2.5% per month and (ii) the maximum interest rate permitted by applicable law.

 

Upon closing of the acquisition of a line of prescription pediatric products from Cerecor, Inc. in October 2019, we assumed payment obligations that require us to make fixed and product milestone payments based on sales. As of December 31, 2023, up to $3.0 million of fixed and product milestone payments based on net sales remain.

 

In connection with our acquisition of the assets from Rumpus VEDS, LLC, Rumpus Therapeutics, LLC, Rumpus Vascular, LLC (collectively, “Rumpus”), and only if we resume and ultimately complete clinical development of AR101, we may be required to pay up to $67.5 million in regulatory and commercial-based earn-out payments to Rumpus, which are primarily paid against commercial milestone achievements. Under the licensing agreement with Denovo Biopharma LLC (“Denovo”), we made a payment of $0.6 million for a license fee in April 2022. In addition, upon the achievement of regulatory and commercial milestones, we may be required to pay up to $101.7 million. Under the licensing agreement with Johns Hopkins University (“JHU”), upon achievement of regulatory and commercial milestone, we may be required to pay up to $1.6 million to JHU. In fiscal 2022, two milestones payable to Rumpus were achieved totaling $4.0 million, which were paid in 109,447 shares of common stock and $2.6 million in cash. The Company also assumed the responsibility for royalties of 3.0% of net product sales, with a minimum of $20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. With clinical development currently suspended, only if we resume and ultimately complete clinical development of AR101, are substantially all milestones payable to these parties.

 

 

Critical Accounting Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a detailed discussion about the Company’s significant accounting policies, refer to our 2023 Form 10-K.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2023. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective, due to the material weakness in our internal control over financial reporting related to the Company’s accounting for complex financial instruments with regards to warrants, and the valuation of inventory. As a result, we performed additional analysis as described below to ensure that our financial statements were prepared in accordance with U.S. GAAP. Accordingly, management believes that the financial statements present fairly in all material respects our financial position, results of operations and cash flows for the period presented.

 

Changes in Internal Control over Financial Reporting

 

Previous Disclosure of Material Weakness in Internal Controls Over Financial Reporting

 

Warrants. As disclosed in our September 30, 2022 Form 10-Q/A, we identified a material weakness in controls over the accounting for complex warrant issuances and the classification of these issued warrants. This material weakness resulted in the failure to prevent material adjustments in accounting for the warrants as equity classification when the warrants should have been classified as liabilities and marked to market each reporting period. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements, other literature, and consultation with third-party experts, we did not classify the warrants correctly.

 

 

Inventory. In connection with the preparation of our financial statements for the period ended June 30, 2023 in our 2023 Form 10-K, we concluded that we had a material weakness in internal control over financial reporting related to our analysis for the accounting for valuation of our inventory. At fiscal year end, it was determined that the analysis of over/under absorbed manufacturing costs was not performed, which could have led to material misstatement of our financial statement. If not addressed, the deficiency could result in a material misstatement in the future. In response, we have incorporated the process for quantifying any over or under absorbed manufacturing costs, and having the appropriate level of management evaluate the analysis and materiality of any over or under absorption.

 

Remediation Plan

 

Our Audit Committee is conducting an internal investigation to identify and determine a plan to remediate the material weaknesses described above and to enhance our overall control environment. We will not consider the material weakness remediated until our enhanced controls are operational for a sufficient period of time and tested, enabling management to conclude that the enhanced controls are operating effectively. Our remediation plan includes the implementation of controls over the process of reviewing significant and complex contracts and agreements, and the valuation of inventory.

 

Inherent Limitations

 

Our management team, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple errors or mistakes. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.

 

Changes in Internal Control Over Financial Reporting

 

Except for the material weaknesses noted above, there have been no changes in the Company’s internal control over financial reporting that occurred during the three months ended December 31, 2023 that have a material effect, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEDINGS

 

Sabby Litigation. A complaint was filed on February 22, 2023 in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund Ltd (“Sabby”) and Walleye Opportunities Master Fund Ltd (“Walleye”), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrant holders may receive, and that the Company failed to provide prompt notice to the warrant holders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. In October 2023, we entered into a settlement agreement and general release with Sabby and Walleye.

 

ITEM 1A. RISK FACTORS

 

Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business prospects, financial condition, and results of operations, and you should carefully consider them. There have not been any material changes to our risk factors from those reported in our 2023 Form 10-K.

 

 

ITEM 5. OTHER INFORMATION

 

Rule 10b5-1 Trading Plans

 

During the fiscal quarter ended  December 31, 2023, none of our directors or executive officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).

 

37

 
 

ITEM 6. EXHIBITS

 

Exhibit No.

 

Description

10.1*,†   Commercial Manufacturing Services Agreement, dated November 13, 2023, by and between Aytu BioPharma, Inc. and Halo Pharmaceutical, Inc.

31.1*

 

Certificate of the Chief Executive Officer of Aytu BioPharma, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

 

Certificate of the Chief Financial Officer of Aytu BioPharma, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

 

Certificate of the Chief Executive Officer and the Chief Financial Officer of Aytu BioPharma, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

  Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*   Inline XBRL Taxonomy Extension Schema.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase.
101.DEF*   Inline XBRL Taxonomy Extension Definition Document.
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase.

104

 

Cover Page Interactive Data File - formatted as Inline XBRL and contained in Exhibit 101.

 


*    Filed herewith.

**  Furnished herewith.

†    Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that (1) the omitted information is not material and (2) the omitted information would likely cause competitive harm to the registrant if publicly disclosed.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

AYTU BIOPHARMA, INC.

     

Date:  February 14, 2024

By:

/s/ Joshua R. Disbrow

   

Joshua R. Disbrow

    Chairman and Chief Executive Officer
    (Principal Executive Officer)
     
Date:  February 14, 2024 By: /s/ Mark K. Oki
    Mark K. Oki
    Chief Financial Officer
    (Principal Financial Officer)
   

(Principal Accounting Officer)

 

39
EX-10.1 2 ex_626088.htm EXHIBIT 10.1 ex_626088.htm

Exhibit 10.1

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS

DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH

(I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS

AS PRIVATE AND CONFIDENTIAL.

 

COMMERCIAL MANUFACTURING SERVICES AGREEMENT

 

This Commercial Manufacturing Services Agreement (this “Agreement”) is effective as of November 13, 2023 (the “Effective Date”) by and between Halo Pharmaceutical, Inc., a Delaware corporation (“Halo”), and Aytu BioPharma, Inc., a Delaware corporation (“Client”). Each of Halo and Client may be referred to herein individually as a “Party” or collectively as the “Parties.”

 

RECITALS

 

A.         Client develops, markets, and sells pharmaceutical products.

 

B.         Halo provides commercial manufacturing and related analytical services to the pharmaceutical industry on a contract basis.

 

C.         Client desires to engage Halo to provide certain services to Client, and Halo desires to provide such services, on the terms and subject to the conditions set out below.

 

ARTICLE 1

DEFINITIONS

 

1.1.    Glossary. The following capitalized terms have the indicated meanings, with grammatical variations having corresponding meanings:

 

Affiliate” means, with respect to a Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person. For the purposes of this definition only, "control" and, the terms "controlled by" and "under common control with", shall mean (a) the possession, directly or indirectly, of the power to direct the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise; or (b) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of a Person.

 

API” means the active pharmaceutical ingredient(s), whether chemical or biologic in nature, listed on Schedule E (as updated from time to time pursuant to the terms hereof) and provided by Client in accordance with Section 3.3 (API) for inclusion in Product.

 

API Cost” means Client’s cost to purchase and deliver API to Halo in accordance with Section 3.3 (API). In lieu of determining an actual cost on a case-by-case basis, the Parties will use the cost set forth on Schedule E (as updated from time to time pursuant to the terms hereof) as the API Cost for purposes of this Agreement; provided, that upon Halo’s reasonable request from time to time, Client shall provide Halo with reasonable documentary evidence substantiating the validity of the API Cost.

 

 

 

Applicable Law” means all laws, statutes, ordinances, regulations, rules, judgments, decrees or orders, as amended from time to time during the Term, of any Authority: (a) with respect to Halo, in the United States and in any other jurisdiction in which Halo performs a given Service; and (b) with respect to Client, in any jurisdiction in which Client operates or performs activities in respect of this Agreement and/or in any jurisdiction in which API or Product is produced, marketed, distributed, made available, used or sold by or for Client. The term “Applicable Law” includes cGMPs unless the Parties agree in writing to the contrary on a case-by-case basis.

 

Authority” means any governmental authority, department, body or agency or any court, tribunal, bureau, commission, or other similar body, whether international, supranational, federal, state, provincial, county, or municipal.

 

Aytu Facility” means that certain facility owned and operated by Aytu which is located at 2940 North Highway 360, Suite 100 Grand Prairie, TX 75050 with FDA registration number 3019769579.

 

Batch” means a defined quantity of Product as set forth in the Specifications.

 

Business Day” means any day except Saturday, Sunday, or any other day on which commercial banks located in New York, New York, USA are authorized or required by Applicable Law to be closed for business.

 

cGMPs” means current good manufacturing practices promulgated by Regulatory Authorities: (a) with respect to Halo, in the United States and in any other jurisdiction in which Halo performs a given Service; and (b) with respect to Client, in any jurisdiction in which Client operates or performs activities in respect of this Agreement and/or in any jurisdiction in which API or Product is produced, marketed, distributed, made available, used or sold; in each case as amended from time to time during the Term. In the United States, cGMPs include, but are not limited to, 21 C.F.R. Parts 210 and 211; outside of the United States cGMPs include, but are not limited to, the International Council for Harmonization (ICH) guide Q7A “ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.

 

Components” means, collectively, all raw materials and ingredients, other than API, that are incorporated into or used to produce Product in accordance with the Specifications. The term Components includes Exclusive Components.

 

DEA” means the United States Drug Enforcement Administration or any successor thereto performing similar functions.

 

Exclusive Components” means any Components that are unique to any Product (i.e., that Halo does not procure for any other customer or drug product).

 

Facility” means the facility operated by Halo located at 30 North Jefferson Road, Whippany, New Jersey, 07981, USA.

 

 

 

Fault” means a Party’s recklessness, gross negligence, willful misconduct, fraud, material violation of Applicable Law or material breach of the Quality Agreement.

 

FDA” means the United States Food and Drug Administration or any successor thereto performing similar functions.

 

Intellectual Property” means all intellectual property and embodiments thereof, including patents, patent applications, trademarks, trademark applications, tradenames, copyrights, industrial designs, trade secrets, and know-how, as well as all industrial and other intellectual property rights, and all rights, interests, and protections that are associated with, equivalent or similar to, or required for the exercise of, any of the foregoing, however arising, in each case whether registered or unregistered and including all registrations and applications for, and renewals or extensions of, these rights or forms of protection under the Applicable Laws of any jurisdiction throughout in any part of the world.

 

Invention” means any innovation, improvement, development, discovery, method, know-how, process, technique, work of authorship, or similar invention, whether or not written or otherwise fixed in any form or medium and whether or not patentable or copyrightable, that is generated, conceived, or reduced to practice by either Party (or any of its employees, independent contractors, subcontractors or agents), or jointly by the Parties, in connection with this Agreement and all Intellectual Property rights therein.

 

Inventory” means all stocks and inventories of Exclusive Components and Product-Specific Items purchased, produced, held, or maintained by Halo in accordance with this Agreement, including any excess material purchased by reason of a vendor’s minimum purchase requirements and any long lead time material. The term Inventory does not include any API.

 

Latent Defect” means any non-conformity that causes Product to be Non-Conforming Product and that could not reasonably be detected by visual inspection or the analytical methods used to characterize the Product at the time of release.

 

Non-Conforming Product” means Product resulting from Services hereunder that has been delivered by Halo hereunder and that fails to meet the warranty set forth in Section 9.3(d) (Product Warranty) due to Halo’s Fault.

 

Person” means any individual, corporation, company, partnership, association, joint-stock corporation, trust, unincorporated organization, or Authority.

 

Product” means that certain pharmaceutical product identified on Schedule A, as more specifically described in the Specifications.

 

Recall” means any action (a) by Client to recover title to or possession of, or to issue a field alert or field correction with respect to, quantities of Product sold or shipped to Third Parties, including any voluntary withdrawal of Product from the market; or (b) by any Regulatory Authority to recall, withdraw from the market, order any corrective action, or otherwise detain or destroy any Product.

 

 

 

Regulatory Authority” means any Authority responsible for granting marketing, distribution, and related approvals for pharmaceutical, medicinal, or therapeutic device products intended for human use in the Territory and/or in the jurisdictions in which the Facility is located. The term Regulatory Authority includes the FDA and DEA, as applicable.

 

Representatives” means a Party’s Affiliates and its and their respective directors, officers, employees, independent contractors, accountants, attorneys, professional consultants and agents.

 

Services” means the manufacturing (including processing, preparation, fill, finish, pressing, coating, etc. as applicable), quality control and assurance, testing, and storage that Halo shall perform under this Agreement to produce Products from API and Components. The term Services excludes Additional Services.

 

Specifications” means, with respect to a Product, the written specifications for such Product in its final configuration for purposes of this Agreement, comprised of a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other objective criteria for the tests described, as agreed in writing by the Parties and appended to the Quality Agreement.

 

Split” means, with respect to a Batch, the division of the bulk blend into different presentations of the applicable Product, to the extent permitted by cGMPs. (For example only, 50% of one Batch of bulk blend could be compressed into [***] strength Product, and the remaining 50% could be compressed into [***]strength Product.) Splitting of Batches, outside of the standard batch size detailed in Schedule A or as agreed upon in writing by both Parties, is done at Client’s request only and is subject to an additional fee as set forth on Schedule A.

 

Territory” means the United States of America (including its territories, military bases, possessions and protectorates, such as Puerto Rico).

 

Third Party” means any Person that is not a Party or an Affiliate of a Party.

 

Year” means, (a) with respect to the first year of this Agreement, the period from the Effective Date up to and including December 31 of the same calendar year; (b) with respect to the last year of this Agreement, the period from January 1 of such last calendar year up to and including the date of termination or expiration of this Agreement; and (c) for all periods in between, a calendar year.

 

 

 

1.2.    Index. The following capitalized terms are defined in the section of this Agreement indicated below, with grammatical variations having corresponding meanings:

 

Term

Section

Additional Services

2.2(b)

Agreement

Introductory paragraph

Client

Introductory paragraph

Client Indemnitees

10.2(a)

Client Inventions

12.2(a)

Commitment

3.1

Confidential Information

11.1(a)

Deficiency Notice

6.1(a)

Discloser

11.1(a)

Dispute

13.1

Effective Date

Introductory paragraph

Exclusive Components Purchasing Summary

4.3(b)

Facilitator

13.1

Firm Order

4.1(b)

First Production Year

5.1(a)

Forecast

3.1

Halo

Introductory paragraph

Halo Indemnitees

10.2(b)

Halo Inventions

12.2(b)

Losses

10.2(a)

Price

5.1(a)

Product-Specific Items

2.1(b)(iii)

Proprietary IP

12.1

Purchase Order

4.1(a)

Quality Agreement

7.8

Recipient

11.1(a)

Records

7.3

Rejected Product

6.1(c)

Supply Committee

7.2(a)

Term

8.1

Third Party Claim

10.2(a)

 

 

 

ARTICLE 2

SERVICES

 

2.1.    Manufacturing Services.

 

(a)    Arrangement. In consideration of Client’s payment of the fees due under, and the other terms and conditions of, this Agreement, Halo shall perform the manufacturing Services at the Facility in order to supply Product to Client. Client shall purchase one hundred percent (100%) of its requirements for Product from Halo except (i) for Products produced in the Aytu Facility as determined by Client in its sole discretion; or (ii) to the extent otherwise expressly permitted in this Agreement.

 

(b)    Conversion of API and Components. Subject to the terms of this Agreement, Halo shall convert API and Components into Products in accordance with this Agreement. To this end:

 

(i)    API. Subject to the terms of this Agreement, Client will deliver, or cause the delivery of, all API to Halo in accordance with Section 3.3 (API). Halo shall (A) upon receipt of API, compare shipping documents against labeling to verify identity and quantity received; (B) perform conformance testing of the API to the extent required by the Quality Agreement; (C) promptly, and in any event within [***] days after receipt of API at the Facility (or such other period as may be specified in the Quality Agreement), notify Client if it detects a defect in API and follow Client’s reasonable written instructions in respect of return or disposal of defective API, at Client’s cost; (D) store API in a manner designed to avoid adulteration or loss of efficacy, and in accordance with the specifications therefor and Applicable Law; (E) turn over inventory of API in accordance with cGMP to optimize its shelf life; (F) maintain the API free and clear of any encumbrances imposed as a result of any act or omission of Halo; (G) use API only to provide the Services; and (H) notify Client if it anticipates that additional amounts of API will be needed for Halo to meet the first [***]months of Client’s then-current Forecast. If any API is a controlled substance within the meaning of Applicable Law, Halo, at its sole cost, shall request appropriate quota allowances for such API from the DEA based on the most recent Forecast submitted by Client at the time requests for quota are due.

 

(ii)    Components. Subject to the terms of this Agreement, Halo shall purchase all Components as required by the Specifications and as further described in Section 4.3 (Procurement) from vendors identified in the Quality Agreement or otherwise agreed to in writing by the Parties. Halo shall test all Components after receipt at the Facility as required by the Quality Agreement. Halo shall turn over Component inventory in accordance with cGMP to optimize the shelf life of such items.

 

(iii)    Product-Specific Items. Subject to the terms of this Agreement, Halo shall purchase all tooling, consumables, and any other Product-specific items pre-approved in writing by Client reasonably necessary for Halo to perform the Services (“Product-Specific Items”). Halo shall charge through to Client all Third-Party vendor fees for such purchases at Halo’s actual cost plus a [***] administrative fee.

 

 

 

(iv)    Equipment. Halo shall provide at its sole cost all equipment needed to perform the Services, subject to the terms of this Section 2.1(b)(iv). If, following the Effective Date, (1) the volume of Client’s requirements for Product hereunder make it reasonably necessary for Halo to purchase additional equipment for exclusive use in providing the Services hereunder to Client (i.e., to use a given item solely to provide Services to Client) or (2) an amendment to this Agreement (e.g., the addition of a new Product) or a change to the Specifications (as contemplated by Section 5.1(e) (Technical Changes)) requires the use of equipment necessary to provide the revised Services that Halo does not then own, then Halo will so inform Client of the need and cost of such new equipment, whereupon such equipment, subject to Client’s reasonable approval, may be either (A) purchased by Halo and charged through to Client at Halo’s actual cost plus a [***] administrative fee; or (B) purchased directly by Client and supplied to Halo DDP (Incoterms 2020) the Facility at Client’s sole cost.

 

(c)    Batch Number. Halo shall assign each Batch a unique batch number using Halo’s batch numbering system. This batch number will appear on all documents relating to the particular Batch.

 

(d)    Quality Control. Halo shall perform Product quality control and quality assurance testing as and to the extent required by the Quality Agreement. Batch review and release to Client shall be the responsibility of Halo’s quality assurance group. Halo shall perform such Batch review and release responsibilities in accordance with Halo’s standard operating procedures. Client shall review and respond to any Batch investigational report provided by Halo within ten (10) Business Days of receipt of such report. Each time Halo delivers a Batch to Client, Halo shall provide Client with a certificate of compliance and any other certificates required under the Quality Agreement, which shall include, if Halo is responsible for Product testing, a certificate of analysis. At Client’s reasonable request, Halo will provide copies of additional Batch documentation, such as Batch manufacturing records, equipment data printouts, raw material data, and laboratory notebooks.

 

2.2.    Expanded Services.

 

(a)    Additional Products and Territories. Additional products and countries may be added to this Agreement upon the Parties’ written agreement in accordance with Section 14.6 (Entire Agreement; Amendments; Waivers). Subject to the terms hereof, the Parties shall amend or supplement this Agreement (including the Schedules) as necessary to reflect their agreement on modifications to Product-specific or Territory-specific terms, including Price.

 

(b)    Product Related Services. In addition to the Services, Halo shall perform any services in connection with Product as the Parties may agree in writing from time to time (“Additional Services”). The Parties’ written agreement shall specify the scope, timing, parameters (including protocols, if applicable), fees payable by Client, and other matters pertinent to the Additional Services. To the extent the Parties have agreed to any such matters as of the Effective Date, they are set forth on Schedule B. The terms and conditions of this Agreement shall govern the provision and receipt of any Additional Services.

 

 

 

(c)    Post Marketing Stability Testing. At Client’s request, as an Additional Service and in consideration of the fees set forth on Schedule B, Halo shall conduct post marketing stability testing on Product in accordance with such commercial and Product stability protocols as the Parties may agree in writing.

 

2.3.    API Yield. The following shall apply solely in respect of API provided and paid for by Client. Within sixty (60) days after the end of each Year:

 

(a)    Inventory Reports. Halo shall provide Client with an inventory report, as of the end of each calendar month, for each API held at the Facility. Each inventory report shall be in substantially the form set forth on Schedule C, shall be based on data from Halo’s manufacturing resource planning (MRP) system or Batch manufacturing records.

 

(b)    Annual Yield Calculation. Halo shall perform the annual yield calculation and reconciliation procedures set forth on Schedule C and notify Client of the results thereof.

 

2.4.    Storage. If Client fails to take possession of Product upon tender of delivery under Section 4.4 (Shipment), Halo will move Product into storage at the Facility. Such storage shall comply with cGMP. Storage shall be free of charge for the first three (3) months following Product release by Halo’s quality group. Client shall thereafter pay Halo the monthly storage fee set forth in Schedule B for storing such Product. Upon two (2) weeks’ written notice to Client, Halo shall have the option to ship to Client, at Client’s cost, (a) any released Product that is or contains a controlled substance, (b) any released Product that has been held by Halo in storage longer than twelve (12) months or (c) any Exclusive Components or API that have been held by Halo in inventory longer than six (6) months and that are not reasonably expected to be needed for Halo to manufacture Product based on Client’s then-current Forecast.

 

ARTICLE 3

CLIENT OBLIGATIONS

 

3.1.    Rolling Forecasts. Concurrently with the signing of this Agreement, Client shall provide Halo with a written [***] month forecast of the volume of each Product that Client anticipates it will require Halo to supply during each month of that [***] -month period (the “Forecast”). Client shall provide Halo with an updated Forecast in writing (a) on or before the tenth (10th) day of each calendar month on a rolling [***] -month basis; and (b) promptly, and within three (3) Business Days, following any determination by Client that the volumes set forth in the Forecast most recently provided to Halo have changed [***] percent ([***]) or more. Subject to the terms of this Agreement, the first [***] months of each Forecast shall be binding on Client with respect to the quantities of Product specified therein (the “Commitment”), and the balance shall be a non-binding, good faith estimate. Client shall place orders for Services against the Forecast as specified in Article 4 (Orders & Shipment). Except as provided herein, the Forecast shall not be binding on Client.

 

3.2.    Specifications. Prior to the Effective Date, Client has provided Halo with a preliminary copy of the Specifications pertaining to Product, which are attached to Schedule A. Prior to Client placing its first Purchase Order, Client shall provide Halo with originally executed copies of final Specifications and any other Product-related information reasonably requested by Halo in connection with the Services. If such final Specifications are different from the preliminary Specifications attached to Schedule A, Section 5.1(e) (Technical Changes) shall apply. Thereafter, Client may revise the Specifications from time to time, subject to Section 5.1(e) (Technical Changes).

 

 

 

3.3.    API. Client shall, at its sole cost and expense, deliver the API to Halo DDP (Incoterms 2020) the Facility in such quantities and at such times as the Parties may agree so as to enable Halo to timely provide the Services on a non-rush basis, but in any event (a) in quantities (subject to DEA quotas) sufficient to satisfy Client’s Product requirements set forth in the first [***] months of Client’s most recent Forecast; and (b) at least [***] prior to the scheduled compounding date of the Batch in which such API will be used; provided, that, should the delivery timeframes in either or both of the foregoing clauses (a) and (b) cause Halo difficulties in testing and releasing API on a timely basis in advance of scheduled manufacturing (without expediting), the Parties will discuss a resolution in good faith. Client shall be responsible at its expense for securing any necessary export or import, or similar clearances or governmental permits required in respect of the provision of API to Halo. Title to and risk of loss of the API shall at all times remain with Client, and Client will insure the API at Client’s cost; provided, that Halo will be responsible for loss of API to the extent caused by Halo’s Fault. If Client refuses or fails to timely supply API, or the parties are unable, despite good faith discussions, to resolve any problems caused by the delivery timeframes in either or both of the foregoing clauses (a) and (b), Halo reserves the right to treat such delay as a cancellation of the applicable Firm Order by Client under Section 4.1(b) (Firm Orders). Halo will promptly, and within three (3) Business Days, notify Client in writing of any such election.

 

3.4.    Quality Control; Safety. Client shall have sole responsibility for the release of Product to the market and for handling customer matters as contemplated by Section 6.4 (Customer Inquiries). Prior to the Effective Date (or the effective date of the applicable amendment to this Agreement, in the case of Products added to this Agreement after the Effective Date), Client shall have provided Halo with all environmental, health and safety information relating to API and Product, including material safety data sheets; provided, that Halo acknowledges that Client does not draft, and is not responsible for, any information on the API, which is provided to Client by the API manufacturer. Client shall promptly, and within ten (10) Business Days, provide Halo any updates to such documentation that become available.

 

3.5.    Product Discontinuation. Client shall use commercially reasonable efforts to provide at least [***] months’ advance notice to Halo if it intends to no longer order Services for a Product.

 

ARTICLE 4

ORDERS & SHIPMENT

 

4.1.    Orders.

 

(a)    Purchase Orders. From time to time as provided in this Section 4.1(a), Client shall submit to Halo a binding, non-cancellable purchase order for Services identifying an order number, the Product to be manufactured (including the strength), the number of Batches, the Batch size (to the extent the Specifications permit Batches of different sizes), Client’s requested delivery date for each Batch, and any other elements necessary to ensure the timely production and delivery of Product (each, a “Purchase Order”). For Product strengths that utilize less than 100% of an ODT blend batch (as indicated on Schedule A, in the columns titled “Product”), any Purchase Order that includes quantities of such strength must also specify other Product strengths and quantities (in any combination) that result in the use of 100% of an ODT blend batch. (For example only, if Client orders a Batch of Adzenys XR ODT Bulk in [***] strength, which utilizes [***] of an ODT blend batch, Client must also order one or more Products that collectively utilize the remaining [***] of the ODT blend batch, such as: [***] of Adzenys XR ODT Bulk in [***] strength; or [***] of Adzenys XR ODT Bulk in [***] strength; or [***] of [***] of Adzenys XR ODT Bulk in [***] strength). Client shall submit Purchase Orders at least [***] months in advance of the delivery date requested in the Purchase Order.

 

 

 

(b)    Firm Orders. Halo will confirm in writing each Purchase Order, including the Product, quantity and expected delivery date, within [***] Business Days of receipt. If Halo is unable to meet the delivery date requested by Client in its Purchase Order, Halo shall so notify Client in Halo’s confirmation of such Purchase Order and provide to Client an alternative delivery date, which shall not be more than [***] days earlier or later than the initial delivery date requested by Client in its Purchase Order. Only upon Halo’s confirmation of Client-issued Purchase Orders will such orders become firm (each, a “Firm Order”). Halo may change the expected delivery date of any Firm Order within a +/- [***] day window upon written notice to Client.

 

(c)    Cancellation or Modification of Firm Orders by Client. Except as expressly provided herein, Client may not cancel or modify any Firm Order without Halo’s prior written consent, which consent shall not be unreasonably withheld, delayed, or conditioned; provided, that

 

(i)    if Client requests a cancellation of a Firm Order, Halo reserves the right to condition its consent to such request on Client’s payment of the “conversion cost” portion of the Price of the cancelled Batches; and

 

(ii)    Halo shall use its best efforts to accommodate any Client request to:

 

(A)    Split any Batch that was not already Split in the Firm Order, subject to payment of both a Split Batch fee and a change fee as set forth on Schedule B;

 

(B)    Revise the Split of a Batch in any manner (e.g. strengths, quantities; including to remove a Split) where the Firm Order already included a Split, subject to payment of a change fee as set forth on Schedule B;

 

(C)    Substitute one [***] ODT blend batch strength under a Firm Order for a different [***] ODT blend batch strength, subject to payment of a change fee as set forth on Schedule B; or

 

(D)    designate the priority of Products to be delivered in a Firm Order (i.e., where a Firm Order is for multiple Batches (whether or not Split) compressed into multiple Product Presentations, or for one Split Batch, to designate which Product presentation(s) specified in such Firm Order should be manufactured before the others in such Firm Order; or where multiple Firm Orders have similar delivery dates, to designate which of such Firm Orders should be fulfilled before the others; but

 

 

 

(iii)    so long as, in each and every case set forth above ((i), (ii)(A), (ii)(B), (ii)(C), and (ii)(D)), Client’s request for cancellation, Splitting, modification or prioritization, as applicable, is submitted to Halo in writing at least [***] prior to the scheduled delivery date for the applicable Firm Order (or, where more than one Firm Order is involved, the earliest scheduled delivery date as among the applicable Firm Orders) but in any event at least [***] prior to the commencement of Batch manufacture (or, where more than one Batch is involved, prior to the commencement of manufacturing of any of the applicable Batches). The commencement of Batch manufacturing shall be deemed to occur on the date Halo weighs and dispenses the first material (whether API or any Component) necessary to manufacture such Batch.

 

For the avoidance of doubt, Halo may withhold its consent, in its sole discretion, to any Client request to cancel or modify any Firm Order if such request is not in accordance with the foregoing clauses (i), (ii) and (iii).

 

(d)    Rejection; Excess Volume. Subject to the following sentence, Halo may reject any Purchase Order without penalty or liability to Client (i) for Product quantities in excess of the Commitment; (ii) if Halo has an insufficient DEA procurement quota in respect of the applicable API; or (iii) the Purchase Order is not given in accordance with this Agreement. Halo shall use commercially reasonable efforts to supply Client with quantities of Product that are up to [***] of Commitment quantities and to accommodate the delivery date requested by Client in its Purchase Order. Without breaching the terms of this Agreement or incurring any additional cost or expense hereunder, Client may purchase from Third Parties or manufacture internally any quantities of Product requested in Purchase Orders that Halo rejects based on clause (i) or (ii) above.

 

4.2.    Minimum Order Quantity. Subject to any greater or lesser minimum order quantities provided for in Schedule A, each Purchase Order submitted by Client shall be for at least [***]; however, [***] may be Split.

 

4.3.    Procurement.

 

(a)    Reliance on Forecast. Subject to the terms of this Agreement, Client understands and acknowledges that Halo will rely on the Forecast, Commitment and Firm Orders to procure the Components necessary for Halo to fulfill its obligations to supply Product under this Agreement. Accordingly, Client authorizes and instructs Halo to purchase Components sufficient to satisfy Client’s Product requirements set forth in the [***] of Client’s most recent Forecast (or any longer period the Parties may agree in writing from time to time), plus, for each Exclusive Component, any additional amounts necessary to satisfy the applicable vendor’s minimum order quantity requirements, if any (as set forth in the Exclusive Component Purchasing Summary, discussed below). Client acknowledges that the foregoing authorization enables and requires Halo to purchase quantities of Components beyond those needed to satisfy the Commitment, and that such excess quantities are intended to comprise safety stock hereunder. In the event that any Component becomes subject to purchase lead time beyond [***], the Parties will negotiate in good faith an appropriate amendment to this Section 4.3(a) (Reliance on Forecast).

 

 

 

(b)    Exclusive Components.

 

(i)    List of Exclusive Components. Set forth on Schedule D (as amended from time to time) is a list of Exclusive Components that Halo expects to be required to purchase pursuant to Section 2.1(b)(ii) (Components) in connection with its provision of the Services hereunder. From time to time as set forth herein, Halo shall provide Client with a written purchasing summary of all Exclusive Components that reflects and updates the information set forth on Schedule D (the “Exclusive Components Purchasing Summary”), in keeping with the Product volumes set forth in the then-current Forecast, Commitment and Firm Orders. Halo shall provide a preliminary Exclusive Components Purchasing Summary within [***] of the Effective Date, a revised version following receipt of final Specifications, and thereafter an updated version on a [***] basis. The list set forth on Schedule D and each Exclusive Components Purchasing Summary shall indicate those Exclusive Components that have a long lead time or limited shelf life and/or that are subject to minimum order quantities as specified by the Third-Party vendor.

 

(ii)    Obsolete Exclusive Components. Client shall reimburse Halo its documented costs for procuring and testing any Exclusive Components that become obsolete for manufacturing of the Products hereunder. An Exclusive Component shall be deemed obsolete as follows: (A) for items that do not have an expiration or re-test date, the item will be obsolete on the last day of the month that is [***] after the Forecasted month in respect of which such purchase were made; and (B) for items that have an expiration or re-test date, the item will be obsolete on such date, so long as (and to the extent) Halo procured such Exclusive Components for use under this Agreement in the quantities and at the times specified in Section 4.3(a) (Reliance on Forecast) and the then-applicable Exclusive Components Purchasing Summary. Notwithstanding the foregoing, for Exclusive Components that have a re-test date, at Client’s request and cost, Halo will re-test any such Exclusive Component for efficacy and if, based on such test results, such Exclusive Component can still be used by Halo to provide Services, then Halo shall retain such Exclusive Component in inventory and [***]; however, this Section 4.3(b)(ii) shall apply anew to such re-tested Exclusive Component retained by Halo, with the new re-test date being substituted for the most recent re-test date. Any reimbursement due under this Section 4.3(b)(ii) shall be invoiced in accordance with Section 5.3(d) (Other Amounts) and payable in accordance with Section 5.4 (Payment Terms).

 

(iii)    Audit of Exclusive Component Vendors. Client shall be responsible for auditing and qualifying all Exclusive Component vendors; however, at Client’s written request, Halo will perform any such vendor audit on Client’s behalf at the applicable fee set forth on Schedule B.

 

(c)    Delays. Halo shall not be liable for any delay in delivery of Product if Halo is unable to obtain any Component in a timely manner so long as Halo placed orders for such Component in keeping with this Section 4.3 and in the quantity and subject to the lead time imposed by the applicable vendor and [***]. In addition, for any API or Component that is a controlled substance, Halo shall not be liable for any delay in delivery of Product where Halo does not receive the necessary DEA quota or other approvals even though Halo filed for such quota or other approvals in accordance with Applicable Law and in quantities consistent with Client’s most recent Forecast available at the time such filings are due under Applicable Law. In the event of any such delay (actual or anticipated), Halo shall notify Client, whereupon the Parties shall discuss in good faith the cause, the anticipated duration and effect thereof, and projected cost, as well as ways to mitigate such effects, which may include Client negotiating directly with the applicable vendor to secure an adequate and timely supply of the applicable Component.

 

 

 

4.4.    Shipment. Halo shall deliver Product and other deliverables to Client or its designee FCA (Incoterms 2020) at the Facility. [***]. Halo shall pack and label shipping containers in accordance with Applicable Law and transport guidelines, the Specifications, and Client’s written instructions (to the extent not inconsistent with any of the foregoing). Client shall arrange for insurance and shall select the freight carrier to be used to ship Products.

 

ARTICLE 5

PRICING & PAYMENT

 

5.1.    Price for Manufacturing Services.

 

(a)    Consideration. Subject to the terms of this Agreement, Client shall pay Halo the total per-unit sale price for Product set forth on Schedule A, as the same may be adjusted in accordance with the terms and conditions of this Agreement (the “Price”).

 

(b)    Initial Price. Each Price set forth on Schedule A as of the Effective Date (or the effective date of any amendment adding a new Product to the scope of this Agreement) is valid through the first full Year of commercial production of the relevant Product under this Agreement (i.e., excluding Product manufactured under any development agreement, such as validation batches) (the “First Production Year”); provided, that Halo reserves the right to revise the Price (i) if such commercial manufacturing under this Agreement has not commenced within [***] of the Effective Date and (ii) to the extent otherwise permitted by this Agreement. (For example only, and subject to the foregoing proviso, if such commercial production of a Product included on Schedule A as of the Effective Date begins on November 15, 2023, then the Price set forth on Schedule A as of the Effective Date for such Product shall be valid through December 31, 2024).

 

(c)    Subsequent Year Price Adjustments. Effective on January 1 of each Year following the First Production Year, the Price shall be adjusted to reflect (i) inflation, which adjustment shall be based on the increase in the Producer Price Index (PPI) for Pharmaceutical Preparations PCU325412325412 published by the U.S. Department of Labor, Bureau of Labor Statistics, in September of the then-current Year compared to the same month of the preceding Year; and (ii) documented changes in Component costs so as to pass on to Client the actual amount of any increase or decrease in such costs. Halo shall provide in writing to Client by November 1 of each Year the updated Price for the subsequent Year, with appropriate supporting documentation; provided, that Halo may redact confidential portions of any supporting documents subject to obligations of confidentiality between Halo and its vendors. Such revised Price shall be effective with respect to any Product [***].

 

 

 

(d)    Current Year Price Adjustments. During any Year of this Agreement, the Price shall be adjusted in accordance with this Section 5.1(d) to reflect material changes in Component costs (whether individually or in the aggregate) due to market conditions [***]. To the extent that a Price has been previously adjusted pursuant to Section 5.1(c) (Subsequent Year Price Adjustments) or this Section 5.1(d) to reflect an increase or decrease in the cost of one or more Components, the adjustments provided for herein shall operate based on the costs attributed to such Component(s) at the time the last such adjustment was made. Halo shall provide in writing to Client the revised Price, with documentation to support both Halo’s normal forecasted cost and new materially changed cost; provided, that Halo may redact confidential portions of any supporting documents subject to obligations of confidentiality between Halo and its vendors. Such revised Price shall be effective with respect to any Product delivered by Halo [***] after Client’s receipt of Halo’s notice.

 

(e)    Technical Changes. Amendments to a Product’s master batch record, Specifications or the applicable Quality Agreement requested by either Party will be implemented only following a technical and cost review by the Parties and are subject to Client and Halo reaching agreement on appropriate revisions to the Price and any other impacted fees under this Agreement, other relevant terms of this Agreement, and on a timeframe for implementation by Halo. If the Parties proceed with such amendment and Client accepts a proposed fee revision, the Parties shall memorialize the amendment in writing (and where the amendment is to Specifications, Client shall provide Halo with originally executed copies of such revised Specifications), Halo shall implement the proposed amendment on the agreed timeframe, and the revised fee shall apply only to Products that are manufactured under the amended master batch record, Specifications or Quality Agreement, as applicable. Client shall either, at its election, (i) purchase from Halo any Inventory, Product and work-in-process rendered obsolete as a result of such amendment or (ii) reimburse Halo for such items together with the costs of its destruction thereof.

 

5.2.    Supplemental Charges.

 

(a)    Taxes. All taxes, duties and other amounts assessed by any Authority (excluding tax based on net income or real property and franchise taxes) on API, Product, Services, Additional Services or other amounts due hereunder are the responsibility of Client, and Client shall reimburse Halo for all such taxes, duties and amounts required to be paid by Halo to any Authority (or such sums will be added to invoices directed at Client, where applicable). Halo shall reasonably cooperate with Client to utilize any legally available reductions or exemptions from any such taxes, duties, or assessments.

 

(b)    Annual Product Review. Halo shall have the right to charge Client the annual product review fee set forth on Schedule B for the services provided pursuant to Section 7.4 (Reports).

 

(c)    Retesting. Halo reserves the right to charge Client for retesting and required investigational studies performed that are not directly due to Halo’s Fault. Any tests or investigations requested by Client that are not required pursuant to the Quality Agreement will be charged to Client at Halo’s then-current standard rates.

 

 

 

5.3.    Invoicing.

 

(a)    Recipient. Halo shall send invoices by fax or email to such fax number or email address as Client may provide to Halo in writing from time to time.

 

(b)    Product Invoices. If Halo is responsible for Product release testing under the Quality Agreement, Halo shall invoice Client for Product on the date on which Halo notifies Client that Product is released by Halo’s quality assurance department and is ready for shipment. If Halo is not responsible for Product release testing under the Quality Agreement, Halo shall invoice Client for Product upon completion of manufacturing and issuance of certificate of manufacture. Each Product invoice shall identify Client’s Purchase Order number, Batch numbers, Product names and quantities, Price, freight charges and the total amount to be remitted by Client. Halo shall also submit to Client with each shipment of Product an invoice covering such shipment.

 

(c)    Component Reimbursement. Halo shall invoice Client for any reimbursement to which Halo is entitled under Section 4.3(b) (Exclusive Components) when the applicable Component has not been used within the required time period or has expired. Halo shall deliver to Client documentation reasonably sufficient to support the amount of such reimbursement; provided, that Halo shall not be obligated to provide specific pricing information regarding any Component that is subject to confidentiality obligations between Halo and its vendor. In respect of any unused, but unexpired, Components reimbursed by Client hereunder, to the extent such Components are incorporated into or used in connection with Product subsequent to such reimbursement, Halo will credit Client for the amount reimbursed to Halo.

 

(d)    Other Amounts. Halo shall invoice Client for all other fees due under this Agreement (such as in connection with Additional Services or permitted cancellations of Firm Orders pursuant to Section 4.1(b) (Firm Orders)) as and when earned or accrued. Any fees assessed on an annual basis will be invoiced as of the first day of each Year. Each such invoice shall reference this Agreement and identify in reasonable detail the nature of the charges therein.

 

5.4.    Payment Terms. Client shall pay all invoiced amounts that are not subject to a good faith dispute by Client in full within [***] days following the invoice date. Client shall make payment in (and all prices, fees and charges set forth in this Agreement are quoted in) U.S. dollars to the account indicated in the applicable invoice. If any payment is not received by Halo by its due date, Halo shall have the right, in addition to any other remedies available at law or in equity, to take one or more of the following actions: (a) terminate for breach in accordance with Section 8.2(a) (Breach); (b) suspend performance until all overdue amounts are paid in full; (c) charge to Client interest on the outstanding sum from the due date (both before and after any judgment) at [***] per month (or, if less, the maximum amount permitted by Applicable Law) until paid in full, plus all reasonable costs of collection of late payments, including reasonable attorneys’ fees and court costs, incurred through the date of actual payment; (d) require Client to pre-pay for Components to be procured by Halo; and/or (e) change the payment terms under this Agreement upon written notice to Client, including to require all or a portion of payment in advance of shipment of Product. For the avoidance of doubt, Halo’s delivery obligations under this Agreement shall be tolled during any period in which the foregoing clause (b) is invoked.

 

 

 

5.5.    Pre-Validation Batches. Client shall be responsible for the cost of each Batch produced under this Agreement (including Batches necessary to support the validation portion of Client’s submissions for Product approvals by Regulatory Authorities and any Batch manufactured following (a) a change in Specifications or (b) a scale-up in the manufacturing process to produce greater quantities of Product), even if the Batch fails to meet the Specifications, until all manufacturing, testing and storage methods and processes have been validated in accordance with industry standards (including production of at least [***] Batches of each strength that meet the then-applicable Specifications); provided, that the foregoing shall not apply to the extent Halo was grossly negligent, engaged in willful misconduct, or violated cGMPs (to the extent applicable) in the manufacturing of the out-of-Specification Batch. In cases where Halo is responsible for an out-of-Specification Batch pursuant to the foregoing proviso, Halo will also be responsible for the cost of destroying the out-of-Specification Batch and its components. In all other cases, Client will be responsible for the cost of destroying the out-of-Specification Batch and its components. Halo and Client shall cooperate in good faith to determine and resolve any problems causing the out-of-Specification Batch.

 

ARTICLE 6

PRODUCT CLAIMS AND RECALLS

 

6.1.    Product Claims.

 

(a)    Non-Conforming Product. Client has the right to reject any portion of any shipment of Product that is alleged to be Non-Conforming Product without invalidating any remainder of such shipment. Upon receipt of each Product shipment under this Agreement, Client shall visually inspect each Batch and perform any testing that the Quality Agreement requires Client to perform. Client shall give Halo written notice of any claim that a Batch is Non-Conforming Product and a sample of the allegedly Non-Conforming Product (together, a “Deficiency Notice”) within [***] after Client’s receipt of such Batch or, in the case of a Latent Defect, within [***] after Client’s discovery of the Latent Defect, but in no event after the expiration date of the Batch in question. If Client fails to timely provide Halo with a Deficiency Notice hereunder the Batch shall be deemed accepted by Client.

 

(b)    Evaluation. If Halo disagrees with a Deficiency Notice, Halo shall give Client written notice of such disagreement within [***] after receiving the Deficiency Notice. If, within [***] after Client’s receipt of Halo's disagreement notice, Client and Halo fail to agree as to whether each Batch identified in the Deficiency Notice is Non-Conforming Product, the Parties shall mutually select an independent laboratory or qualified person, as appropriate, to evaluate whether such Products are Non-Conforming Product and the cause of any non-conformity. Such evaluation shall be binding on the Parties. If the evaluation confirms that a Batch is Non-Conforming Product (or if Halo does not timely disagree with a Deficiency Notice), then (i) the applicable Batch(es) shall be deemed properly rejected under this Agreement, (ii) Halo shall bear the cost of the evaluation, and (iii) Section 6.1(c) (Remedies) shall apply. If the evaluation determines that a Batch is not Non-Conforming Product, then (A) the applicable Batch(es) shall be deemed accepted by Client; and (B) Client shall bear the cost of the evaluation.

 

 

 

(c)    Remedies. In respect of any Batch properly rejected under this Section 6.1 as Non-Conforming Product (“Rejected Product”), Halo will replace the Rejected Product [***], so long as Client provides the necessary API [***], calculated as the volume of API necessary to replace the Rejected Product [***]) and pay for the destruction or return shipping of the Rejected Product (so long as Client destroys or returns the Rejected Product at Halo’s direction).

 

(d)    Validated Testing. Any tests conducted by Client under Section 6.1(a) (Non-Conforming Product) or by a Third Party under Section 6.1(b) (Evaluation) shall employ only the validated methods and procedures required to be used by Client or Halo, as applicable, under the Specifications or Quality Agreement.

 

6.2.    Product Recalls. Each Party shall promptly, and within [***], notify the other Party by telephone (confirmed by written notice) of any information of which it becomes aware that might affect the safety, efficacy, or marketability of any Product and/or that could reasonably be expected to result in a Recall. The conduct of and regulatory filings for any Recall shall be controlled, implemented, and made by Client, and Halo will co-operate in such Recall as reasonably requested by Client, having regard to all Applicable Law. Client shall provide Halo with an advance copy of any proposed submission to a Regulatory Authority in respect of any Recall and shall consider in good faith any comments from Halo. Client shall bear the cost of any Recall and reimburse Halo for the expenses incurred by Halo in connection with any Recall, unless such Recall is caused solely by Halo’s gross negligence or willful misconduct, in which case Halo will reimburse Client for Client’s reasonable, actual, and documented out-of-pocket expenses of conducting such Recall and bear the expenses incurred by Halo in connection with such Recall (subject, for the avoidance of doubt, to Section 10.1 (Limitation of Liability). For clarity, to the extent that a Recall involves Product that is alleged to be Non-Conforming Product, the Parties’ respective rights and remedies with respect to such Product shall be governed by Section 6.1 (Product Claims).

 

6.3.    Disposition of Product. Client shall not use or sell any Product that does not, or that Client has reason to believe does not, meet the Specifications or comply with Applicable Law. Client shall not, without Halo’s prior written consent (which consent shall not be unreasonably withheld, delayed, or conditioned), return, destroy, or otherwise dispose of any Non-Conforming Products or Recalled Products in relation to which it intends to assert a claim against Halo. Halo shall bear the cost of destroying Rejected Products and Recalled Products to the extent it is deemed liable for such products under Section 6.1 (Product Claims) or 6.2 (Product Recalls), respectively. In all other circumstances, Client shall bear the cost of such destruction.

 

6.4.    Customer Inquiries. Client shall have the sole responsibility for responding to questions and complaints from Client’s customers, for handling customer returns of Product and for all other pharmacovigilance activities. Halo will promptly, and within [***], refer to Client in writing any questions or complaints that it receives from Client’s customers. At Client’s request and cost, Halo shall reasonably co-operate with Client to allow Client to determine the cause of, respond to, and resolve any customer questions and complaints.

 

6.5.    Limitations. For the avoidance of doubt, Halo shall have no obligation for Product or Services if any deficiencies in, or other liabilities associated with, such Product or Services (a) are caused by incorrect, unlawful or deficient Specifications (including artwork and labeling), by problems relating to the safety, efficacy or marketability of Product that occur even when the Product conforms with the Specifications, or by Product distribution and commercialization activities (including off-label marketing), (b) result from any defect in API or other materials supplied by Client that Halo could not reasonably discover by visual inspection or testing as required under Section 2.1(b)(i) (API), (c) are caused by actions of Client or Third Parties occurring after Product is tendered for delivery by Halo pursuant to Section 4.4 (Shipment), or (d) are caused by any breach of Client’s obligations, representations, warranties or covenants under this Agreement.

 

 

 

6.6.    Sole Remedy. The remedies described in this Article 6 shall be Halos sole liability and Clients sole remedy for any Non-Conforming Product.

 

ARTICLE 7

COOPERATION

 

7.1.    Liaisons; Quarterly Review. Promptly, and within [***], following the signing of this Agreement, each Party shall appoint one of its employees to be a relationship manager responsible for liaising between the Parties with respect to the Products. The relationship managers shall meet quarterly to review the current status of the business relationship and manage any issues that have arisen. The Parties shall cooperate in good faith to ensure a stable supply of Product to Client within the terms of this Agreement by timely providing relevant information to one another through the relationship managers.

 

7.2.    Supply Committee.

 

(a)    Formation. Promptly following the Effective Date, the Parties shall establish a supply committee which shall be comprised of at least [***] from each of Client and Halo representing technical, operations and quality functions having the appropriate credentials, knowledge and experience (the "Supply Committee"). The Supply Committee may agree on reasonable written guidelines and procedures to facilitate regular and efficient communications and to keep appropriate records of the interactions and decisions.

 

(b)    General Remit. The Supply Committee shall serve as the coordinating body for the manufacture and supply of Product under this Agreement and shall regularly review the status of the Parties’ respective performance of this Agreement. Without derogating from Article 6 (Product Claims and Recalls) or Article 13 (Dispute Resolution), the Supply Committee shall also work to resolve any disagreements between the Parties relating to the Services.

 

(c)    Meetings. The Supply Committee shall meet (in person, by telephone or as otherwise agreed by the Parties) on a regular basis, but not less frequently than [***] until the first Product’s commercial launch, and thereafter not less frequently than [***] during the Term, unless otherwise agreed by the Supply Committee. Meeting agendas shall include as appropriate information on (i) anticipated market demand for Product, including any changes, (ii) the Parties’ inventory positions of API and Halo’s inventory position on Raw Materials, (iii) any capacity concerns, unusual production situations, or prioritization issues, including changes to delivery or sourcing, (iv) any quality related issues, (v) any proposed changes to the manufacturing process or Specifications, and (vi) any other matters which may impact or influence the Product supply chain.

 

 

 

(d)    Costs. Each Party shall be responsible for its own costs arising out of participation in the Supply Committee, including in respect of travel and accommodations for personnel attending in person meetings.

 

7.3.    Records and Retain Samples. Halo shall keep materially complete and accurate records of the manufacture, testing, storage, and shipping of Product, including master batch records, completed Batch records, quality control documentation and results for all acceptance tests performed (collectively, “Records”) and retain samples of Product in accordance with its standard operating procedures and as necessary to comply with Applicable Law. Copies of Records and all retain samples shall be retained for a period of [***] following the date of Product expiry, or longer if required by Applicable Law. Before destroying Records, Halo will contact Client to offer Client the opportunity to take delivery and possession of such Records at Client’s cost.

 

7.4.    Reports. [***], Halo will provide Client with a copy of all Product data in its control (including release test results, complaint test results, and all investigations in manufacturing, testing and storage) that Client reasonably requires in order to complete any filing required by any Regulatory Authority, including an annual report within the meaning of 21CFR314.81(b)(2). At Client’s request, Halo will provide Client with a copy of the annual product review report within the meaning of 21CFR211.180(e). Any additional reports requested by Client beyond the scope of cGMPs and requirements of Regulatory Authorities shall be subject to an additional fee to be agreed upon between Halo and Client.

 

7.5.    Client Inspections. [***] period during the Term (or, if for cause, more frequently as reasonably agreed by the Parties), upon at least [***] prior written notice, Halo shall grant Client access, during normal business hours, to areas of the Facility in which API or Product is manufactured, handled, stored or shipped in order to verify that Halo is performing the Services in accordance with the Specifications and cGMPs. During any such inspection, Halo shall also permit Client to inspect Records, samples, and reports relating to this Agreement. The Parties’ relationship managers shall arrange such inspections. Inspections shall be designed to minimize disruption of operations at the Facility and shall be limited to [***] for up to [***]. A Halo representative shall be present at all times during each inspection. Client’s representatives shall comply with the Facility’s rules. Client shall indemnify and hold harmless Halo for any act or omission of Client’s representatives while on Halo’s premises.

 

7.6.    Regulatory Inspections.

 

(a)    Information Sharing. Each Party shall promptly, and [***], notify the other Party of any planned or actual Facility inspection by any Regulatory Authority specifically involving a Product. Client acknowledges that it may not direct the manner in which Halo fulfills its obligations to permit inspection by and to communicate with Regulatory Authorities related to such inspection. Halo shall notify Client within [***] of receipt of any Form 483s, warning letters or other significant regulatory action that could reasonably be expected to impact the regulatory status of the Products or Halo’s ability to perform the Services in accordance with the terms of this Agreement. Halo shall provide Client with copies of the sections of all Form 483s or comparable regulatory notices that are specific to any Product, redacted as necessary to preserve the confidentiality of Halo’s other information. Likewise, Client shall provide Halo [***] with any material correspondence with any Regulatory Authority, including any FDA refusal to file, rejection, or warning letters, that could reasonably be expected to impact the timing and volume of Client’s Product purchases under this Agreement.

 

 

 

(b)    Costs. If an inspection by a Regulatory Authority is [***] related to a Product (such as a pre-approval inspection or in connection with adding a jurisdiction pursuant to Section 2.2(a)), Client shall pay Halo at the hourly rate set forth on Schedule B for time spent, and reimburse Halo for all reasonable and documented costs incurred, in connection with such inspection. [***]. If an inspection by a Regulatory Authority pertains to the Facility generally, Halo shall bear the costs of such inspection.

 

7.7.    Regulatory Filings.

 

(a)    Approvals & Permits. Client shall have the sole responsibility for filing, and shall file, all Product-specific documents with all Regulatory Authorities and for taking, and shall take, any other actions that may be required for the receipt and/or maintenance of Regulatory Authority approval for the commercial manufacture and sale of the Products. Halo shall assist Client, to the extent consistent with Halo’s obligations under this Agreement, to obtain Regulatory Authority approval for the commercial manufacture of all Products as quickly as reasonably possible. Halo shall have the sole responsibility for filing, and shall file, all documents with Regulatory Authorities and for taking, and shall take, any other actions that may be required for the receipt and/or maintenance of Regulatory Authority licensure of the Facility.

 

(b)    Verification of Data & CMC. From time to time during the Term, Client may desire to file documents with a Regulatory Authority in connection with obtaining regulatory approval of a Product, including a document that is, or is equivalent to, the FDA’s Chemistry and Manufacturing Controls (CMC). If any such document incorporates or relies on data generated by Halo, Client shall provide Halo with a copy of the document at least [***] prior to its filing so as to permit Halo to verify the accuracy of such document solely as it relates to the Halo-generated data, including that the CMC accurately describes the Services that Halo has performed and the manufacturing processes that Halo will perform pursuant to this Agreement. Thereafter, Client shall provide Halo at the time of submission a final copy of any portion of any filing with a Regulatory Authority that contains chemistry, manufacturing or controls information that is derived from data regarding the Product generated by Halo.

 

(c)    Deficiencies. If, acting reasonably, Halo determines that any of the information provided by Client in accordance with clause (b) above is inaccurate or deficient, Halo shall notify Client in writing of such matter within [***] of receipt of documents from Client. The Parties shall work together to have such matters resolved prior to Client’s submission of such information to the Regulatory Authority.

 

7.8.    Quality Agreement. The Parties acknowledge that, prior to the Effective Date, they signed an agreement setting out the quality assurance standards and protocols applicable to the Services and the Parties’ responsibilities in respect thereof (“Quality Agreement”). The Parties acknowledge and agree that the Quality Agreement is required by Applicable Law and is intended only to operationalize quality-based activities relating to the Services. As such, (i) the Quality Agreement shall not determine a Party’s financial responsibility for the performance or non-performance of the responsibilities set forth therein, (ii) any breach of the Quality Agreement by a Party shall be deemed a breach of this Agreement and shall be subject to the terms and conditions of this Agreement, including Section 8.2(a) ([Termination for] Breach) and Article 10 (Indemnities & Insurance), and (iii) neither Party shall have a cause of action for breach of the Quality Agreement except as a cause of action for breach of this Agreement. In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement with respect to quality-based activities, the provisions of the Quality Agreement shall govern. In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement with respect to any commercial matters, including allocation of risk, liability and financial responsibility, the provisions of this Agreement shall govern.

 

 

 

ARTICLE 8

TERM & TERMINATION

 

8.1.    Term. This Agreement shall commence as of the Effective Date and shall expire on the fifth (5th) anniversary of the date on which Client placed its first Firm Order, unless terminated earlier in accordance with Section 8.2 (Termination). This Agreement shall automatically extend for successive [***] unless and until either Party gives the other Party at least [***] written notice of its desire to terminate this Agreement as of the end of the then-current term. The period of effectiveness of this Agreement, as extended in accordance with this Section 8.1 and/or terminated in accordance with Section 8.2 (Termination), is referred to as the “Term”.

 

8.2.    Termination.

 

(a)    Breach. Either Party may terminate this Agreement upon written notice to the other Party if the other Party has failed to remedy a material breach of this Agreement within [***] following receipt of a written notice that describes the breach in reasonable detail and expressly states that it is a notice under this Section 8.2(a).

 

(b)    Bankruptcy. Either Party may terminate this Agreement immediately without further action in the event that (i) ) in the case of Client, if Halo is declared insolvent or bankrupt by a court of competent jurisdiction, and such declaration or order remains in effect for a period of [***] or if Halo files a voluntary petition of bankruptcy in any court of competent jurisdiction; (ii) in the case of Halo, if Client is liquidated in connection with a bankruptcy filing; or (iii) this Agreement is assigned by such other Party for the benefit of creditors.

 

(c)    Regulatory Considerations. In the event that (i) any Authority takes any action that prevents Client from importing, exporting, purchasing or selling a Product in all or part of the Territory or (ii) subject to Section 3.5 (Product Discontinuation), Client elects to discontinue selling a Product or otherwise withdraws a Product from the market in all or part of the Territory, Client may terminate this Agreement as to any Product and applicable portion of the Territory upon [***] prior written notice to Halo.

 

 

 

8.3.    Obligations on Termination. Expiration or termination of this Agreement shall be without prejudice to any rights or obligations that accrued to either Party prior to such expiration or termination. Upon expiration or termination of this Agreement:

 

(a)    Work In Process. At Client’s election, Halo shall either (i) complete any Product that is a work in process, which Product shall be subject to Section 8.3(b) (Product), or (ii) cease such work and transfer such work in process into storage containers, and Client shall be obligated to pay Halo a pro rata amount of all work to date; it being understood that if Client fails to timely make such an election or if termination is by Halo under Section 8.2(a) (Breach) or 8.2(b) (Bankruptcy), clause (ii) above shall automatically apply;

 

(b)    Product. Client shall take delivery of and pay for, at the Price in effect at the time, all completed, undelivered Product that Halo has produced pursuant to a Firm Order;

 

(c)    Inventory. Client shall purchase, at Halo’s cost (to the extent not already paid for by Client in accordance with Section 2.1(b)(iii) (Product Specific Items)), all Inventory then in stock or that is later delivered by a Third Party vendor pursuant to non-cancellable orders, and shall reimburse Halo for any cancellation fees assessed by Third Party vendors for Inventory orders that are cancellable;

 

(d)    Client-Owned Materials. Halo shall return to Client all unused API and deliver to Client all Inventory paid for by Client pursuant to clause (c) above;

 

(e)    Records & Samples. Halo shall maintain reserve samples and Batch production records in accordance with Applicable Law and this Agreement; and

 

(f)    Stability. At Client’s election, Halo shall either (i) continue to perform any ongoing stability testing or (ii) ship the stability samples to Client; it being understood that if Client fails to timely make such an election or if termination is by Halo under Section 8.2(a) (Breach) or 8.2(b) (Bankruptcy), clause (ii) above shall automatically apply.

 

Any costs incurred by Halo to comply with the foregoing obligations, including shipping and related expenses, shall be borne by Client, except in the event of termination of this Agreement by Client for Halo’s uncured material breach under Section 8.2(a) (Breach), in which case Halo shall bear all such expenses (excluding fees under clause (f)(i), which shall be borne by Client in all events). In lieu of taking possession of any of the materials described in this Section 8.3, Client may direct Halo to destroy such items, which Halo shall cause to be done at Client’s cost.

 

8.4.    Survival. Notwithstanding any expiration or termination of this Agreement for any reason, the Parties’ rights and obligations under the following provisions shall survive and continue in effect in accordance with their respective terms: Sections 2.4 (Storage), 4.4 (Shipment), 5.2 (Supplemental Charges), 5.3 (Invoicing), 5.4 (Payment Terms), 7.3 (Records), 7.8 (Quality Agreement), 8.3 (Obligations on Termination), 8.4 (Survival) and 9.3(f) (Limited Warranty), and Articles 6 (Product Claims & Recalls), 10 (Indemnities & Insurance), 11 (Confidentiality), 12 (Intellectual Property), 13 (Dispute Resolution) and 14 (Miscellaneous).

 

 

 

ARTICLE 9

REPRESENTATIONS & WARRANTIES

 

9.1.    Authority. Each Party represents and warrants to the other that (a) it has the full right and authority to enter into this Agreement, (b) it is in good standing in its jurisdiction of organization and all jurisdictions in which it operates, (c) the execution and delivery of this Agreement and the performance of such its obligations hereunder do not conflict with, or constitute a default or require any consent under, any contractual obligation of such Party, and (d) it will comply with all Applicable Law in performing its obligations under this Agreement.

 

9.2.    Client Warranties. Client covenants, represents, and warrants to Halo that:

 

(a)    Rights to Specifications. Client owns or has a valid right and license to use all Specifications for each Product and Client may lawfully disclose all Specifications to Halo for Halo’s use in connection with providing Services;

 

(b)    Rights to Intellectual Property. All Intellectual Property (other than Halo’s Intellectual Property) provided by Client to Halo for use in connection with providing Services (i) may lawfully be used by Halo in connection with providing Services and (ii) so long as Halo uses such Intellectual Property solely as contemplated by this Agreement, such use does not and will not infringe, violate, or misuse any rights held by Third Parties;

 

(c)    Third Party Intellectual Property. There are no rights held by Third Parties related to Client’s Intellectual Property that would be infringed, violated, or misused by Client’s performance of this Agreement and, as of the Effective Date, Client has no knowledge of any claims of infringement that have been made by Third Parties against Client in connection with the Product; and

 

(d)    API Warranty. All API provided to Halo hereunder have been manufactured in accordance with Applicable Law, including cGMPs, and shall at the time of receipt by Halo meet all relevant Specifications and not be adulterated, misbranded, or mislabeled within the meaning of Applicable Law;

 

(e)    API Cost. The API Cost fairly and accurately reflects Client’s actual, out-of-pocket cost to procure the API from its Third-Party vendors and provide it to Halo;

 

(f)    Use of Product. All Product delivered to Client by Halo hereunder shall be held, stored, used, distributed, sold, and otherwise disposed of by or on behalf of Client in accordance with all Applicable Law; and

 

(g)    Not Generic. No Product is a “generic” drug product (e.g., filed for marketing approval in the United States under an Abbreviated New Drug Application).

 

 

 

9.3.    Halo Warranties. Halo covenants, represents, and warrants to Client that:

 

(a)    Third Party Intellectual Property. To the best of Halo’s knowledge, there are no rights held by Third Parties related to Halo’s Intellectual Property that would be infringed, violated, or misused by Halo’s performance of this Agreement;

 

(b)    Claims. As of the Effective Date, it has no knowledge of any claims, actions or other actual or threatened legal proceedings by any Regulatory Authority or other Third Party, the subject of which is the infringement, violation, or misuse of any rights in Intellectual Property held by Third Parties related to any Halo’s Intellectual Property;

 

(c)    Debarment. It does not and will not use in the performance of its obligations under this Agreement the services of any Person debarred or suspended under 21 U.S.C. §335(a) or (b); and it does not have and will not hire as an officer or employee any Person who has been convicted of a felony under the laws of the United States for conduct relating to the regulation of any drug product under the U.S. Federal Food, Drug, and Cosmetic Act, as amended;

 

(d)    Product Warranty. It shall have performed the manufacturing of all Products provided to Client hereunder in accordance with Applicable Law (including cGMPs), and all Products provided to Client hereunder shall, at the time of delivery under Section 4.4 (Shipment), meet all Specifications and not be adulterated, misbranded or mislabeled within the meaning of Applicable Law; provided, that a Product will not fail to comply with the foregoing representation and warranty to the extent such failure results solely from (and Halo shall not be liable for any defect in Product attributable to) matters not caused by Halo’s Fault; provided further, that Halo makes no representation or warranty with respect to any Product or circumstance that is expressly excluded from liability under Section 6.5 (Limitations);

 

(e)    No Liens. Upon delivery of Products to Client, Halo shall convey, and Client shall have, good and marketable title to such Products, free and clear of any encumbrances imposed as a result of any act or omission of Halo; and

 

(f)    Facility. The Facility has, and during the Term will maintain, a current FDA establishment registration and, as of the Effective Date, it has no knowledge of any claims, actions or other actual or threatened legal proceedings by the FDA or DEA, the subject of which is its violation of any Applicable Law that is within the jurisdiction of such Regulatory Authority. [***].

 

9.4.    Limited Warranty. NEITHER PARTY MAKES ANY REPRESENTATION, WARRANTY OR GUARANTEE OF ANY KIND, EITHER EXPRESS OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS ARTICLE 9. HALO EXPRESSLY DISCLAIMS THE IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE AND ANY WARRANTY OF MERCHANTABILITY WITH RESPECT TO THE PRODUCTS AND SERVICES.

 

 

 

ARTICLE 10

INDEMNITIES & INSURANCE

 

10.1.    Limitation of Liability.

 

(a)    No Consequential Damages. Under no circumstances whatsoever shall either Party be liable to the other Party in contract, tort, negligence, breach of statutory duty or otherwise for (i) any direct or indirect loss of profits, revenues, production, anticipated savings, data, business or goodwill or (ii) any other liability, damage, cost or expense of any kind incurred by the other Party of an indirect, incidental, consequential, punitive or special nature, regardless of any notice of the possibility of such damages.

 

(b)    API. Subject to 2.3(b) (Annual Reconciliation), and Section 3.3 (API), under no circumstances whatsoever shall Halo be responsible for any loss or damage to API.

 

(c)    Maximum Liability. Halo’s maximum liability under this Agreement for any reason whatsoever (in the aggregate and including any amounts payable pursuant to clause (b) above) shall not exceed the greater of (i) [***].

 

(d)    Exclusions. The foregoing clauses (a), (b) and (c) shall not limit (i) damages arising from a Party’s gross negligence or willful misconduct or (ii) damages arising from a Party’s breach of Article 11 (Confidentiality).

 

10.2.    Indemnification.

 

(a)    By Halo. Halo shall defend, indemnify, and hold harmless Client, its Affiliates, and their respective directors, officers and employees (“Client Indemnitees”) from and against any and all losses, damages, costs, expenses (including reasonable attorneys’ fees and reasonable investigative costs), judgments and liabilities (“Losses”) in connection with any suit, demand, claim or action by any Third Party (“Third Party Claim”) arising or resulting from (i) a material breach by Halo of any of its obligations, warranties, or representations under this Agreement, including Section 9.1(d); (ii) Halo’s gross negligence or willful misconduct; or (iii) [***]; in each case, except to the extent that such Losses arise or result from the breach of this Agreement by Client or the gross negligence or willful misconduct of any Client Indemnitee.

 

(b)    By Client. Client shall defend, indemnify and hold harmless Halo, its Affiliates, and their respective directors, officers and employees (“Halo Indemnitees”) from and against any and all Losses in connection with any Third Party Claim arising or resulting from (i) a material breach by Client of any of its obligations, warranties, or representations under this Agreement, (ii) Client’s gross negligence or willful misconduct, (iii) any actual or alleged infringement, violation or misuse of any rights held by Third Parties in respect of any aspect of any Product (other than solely by reason of Halo’s practice of Halo’s Intellectual Property), or (iv) any distribution, sale or use of or exposure to any API or Product; in each case, except to the extent that such Losses arise or result from the gross negligence or willful misconduct of any Halo Indemnitee.

 

 

 

(c)    Procedure. In the event a Party seeks indemnity under this Section 10.2, it shall: (i) promptly, and within [***], notify the indemnifying Party of the Third Party Claim subject to indemnification (provided, that any delay in providing such notice shall not relieve the indemnifying Party from any of its indemnification obligations hereunder except to the extent it is actually prejudiced in the defense of the Third Party Claim due to such delay); (ii) use commercially reasonable efforts to mitigate the effects of such Third Party Claim; (iii) reasonably cooperate with the indemnifying Party in the defense of such Third Party Claim; (iv) not settle or compromise such Third Party Claim or make any admission relating thereto; and (v) permit the indemnifying Party to control the defense and settlement of such Third Party Claim using counsel reasonably satisfactory to the indemnified Party, all at the indemnifying Party’s cost and expense. The indemnified Party may be represented by its own counsel in connection with such Third-Party Claim, and such representation shall be at the indemnified Party’s own expense unless the indemnifying Party fails to assume the defense of such Third Party Claim as required hereunder. The indemnifying Party shall have the right to settle any such Third-Party Claim without the consent of any indemnitee so long as such settlement does not admit to any wrongdoing by any indemnitee, does not impose any liability or obligation (whether financial or otherwise) on any indemnitee and fully releases the indemnitees from liability in connection with such Third-Party Claim. The indemnified Party’s consent to any other settlement shall be required.

 

10.3.    Insurance. During the Term and for at least [***] thereafter, each Party shall obtain from and maintain, with reputable and financially secure insurance carriers, prudent insurance coverage appropriate to cover its activities related to and obligations under this Agreement. Each Party shall provide to the other Party a certificate evidencing such insurance upon the other Party’s request.

 

10.4.    Reasonable Allocation of Risk. The Parties agree that (a) the provisions of this Agreement (including this Article 10) are reasonable and create a reasonable allocation of risk having regard to the relative profits the Parties respectively expect to derive from the Products; (b) Halo, in its fees for the provision of the Services, has not accepted a greater degree of the risks arising from the manufacture, distribution, sale and use of the Products based on the fact that Client has developed the Products and requires Halo to manufacture and label the Products strictly in accordance with the Specifications; and (c) Client and not Halo is in a position to inform and advise potential users of the Products as to the circumstances and manner of use of the Products.

 

ARTICLE 11

CONFIDENTIALITY

 

11.1.    Confidential Information.

 

(a)    Definition. In this Agreement, “Confidential Information” means any and all information disclosed by or on behalf of one Party (“Discloser”) to the other Party (“Recipient”) or any of its Representatives, (i) whether before, on, or after the Effective Date, (ii) whether tangible or intangible, (iii) whether written, electronic, oral, visual (e.g., obtained by observation at a site visit), or in any other form or medium, and (iv) whether or not marked with a legend such as “Confidential” or “Proprietary”. For the avoidance of doubt, the term Confidential Information shall be construed as “Discloser’s Confidential Information.”

 

 

 

(b)    Inclusions. Confidential Information includes but is not limited to (i) research and development activities; marketing plans, business strategies, and business opportunities; pricing, costs, and financial information; data, specifications, formulae, models, and processes; customers and vendors; regulatory strategies and information; and non-public intellectual property (e.g., knowhow and trade secrets), (ii) information of Affiliates and Third Parties, (iii) any copies, extracts, summaries and other analyses of other Confidential Information prepared by or for Recipient or any of its Representatives (collectively, “Notes”), and (iv) the existence and terms of this Agreement.

 

(c)    Exclusions. Confidential Information excludes any information that, as proven by competent evidence, (i) is or, other than by a breach of confidentiality owed to Discloser, becomes available to the general public, (ii) was known to Recipient or any of its Representatives without any limitation on use or disclosure prior to its receipt from or on behalf of Discloser, as shown by Recipient’s records, (iii) is received by Recipient or any of its Representatives from a Third Party without any obligation of confidentiality owed to Discloser, as shown by Recipient’s records, or (iv) is independently developed by or for Recipient or any of its Representatives without reference to or reliance on any Confidential Information, as shown by Recipient’s records. For the avoidance of doubt, Confidential Information shall not be deemed to be in the public domain or in the prior possession of a Person where it is merely embraced by or contained in more general information that is in the public domain or such Person’s possession.

 

11.2.    Confidentiality and Non-Use. In consideration of receiving Confidential Information, Recipient shall use Confidential Information only for performing its obligations and exercising its rights under this Agreement and shall not disclose Confidential Information to any Person other than as expressly permitted by this Agreement or as authorized in writing by Discloser. Recipient may disclose Confidential Information to those of its Representatives who (a) have a need to know such information in connection with Recipient’s performance of its obligations and the exercise of its rights under this Agreement, (b) have been advised of Recipient’s obligations under this Agreement, and (c) are bound to Recipient by obligations of confidentiality and non-use at least as stringent as those contained in this Article 11 (Confidentiality). Recipient shall be liable to Discloser for any breach of this Article 11 (Confidentiality) caused by Recipient’s Representatives.

 

11.3.    Standard of Care. Recipient shall (a) protect Confidential Information with the same degree of care that it uses to protect its own confidential information, but no less than a reasonable degree of care, (b) comply with all Applicable Law relating to Confidential Information, including in respect of data privacy and the export of information outside of national borders, (c) not remove or obscure any copyright or trademark notice, proprietary legend, indication of confidentiality, or other restrictive notation on any Confidential Information, and (d) promptly notify Discloser of any actual or suspected disclosure, use, or loss of Confidential Information in contravention of this Article 11 (Confidentiality), including a description of the circumstances, Persons involved, steps taken to mitigate resulting damage, and steps taken to prevent any further such disclosure, use, or loss.

 

11.4.    Compelled Disclosure. Recipient may disclose Confidential Information to the extent required by Applicable Law or by the listing standards, rules, or agreements of any public exchange on which any securities of Recipient or its Affiliates are listed, so long as Recipient (a) uses reasonable efforts to give Discloser as much prior notice of such required disclosure as circumstances permit, (b) allows Discloser to contest such disclosure or to seek a protective order or similar remedy, and reasonably cooperates with Discloser in any such efforts, at Discloser’s request and expense, and (c) limits the disclosure to only the information required to be disclosed.

 

 

 

11.5.    Ownership. As between the Parties, Confidential Information is the property of Discloser, and Discloser shall retain all right, title and interest in and to its Confidential Information. The disclosure of Confidential Information to Recipient or any of its Representatives does not, in itself, grant or imply to Recipient or any such Representative any right or license to use or practice any Intellectual Property of Discloser. Any such right or license shall be solely as set forth in Article 12 (Intellectual Property).

 

11.6.    Return of Information. Upon termination of this Agreement or Discloser’s earlier written request, Recipient shall immediately cease using all Confidential Information and promptly either, as directed by Discloser, return it to Discloser or destroy it (and certify as to such destruction), including all Notes; provided, that Recipient may destroy, and need not deliver to Discloser, such Notes. Notwithstanding the foregoing, (a) Recipient may retain a single copy of Confidential Information in the secure files of its legal counsel or a senior executive for the sole purpose of proving what was disclosed, (b) Recipient is not required to return or destroy any Confidential Information if doing so would violate (or result in the violation of) any Applicable Law, (c) Recipient is not required to expunge any minutes or written consents of its board of directors (or equivalent governance body), and (iv) to the extent that Recipient’s computer back-up or archiving procedures create copies of Confidential Information, Recipient may retain such copies for the period it normally archives backed-up computer records, so long as such copies are not readily accessible and are not used or consulted for any purpose other than disaster recovery. Any Confidential Information retained pursuant to the foregoing sentence shall remain subject to this Agreement until destroyed or no longer deemed Confidential Information based on Section 11.1(c) (Exclusions).

 

11.7.    Securities Law Compliance. Halo acknowledges that it understands that: (a) Client’s Confidential Information or other information disclosed by Client hereunder may contain or constitute material non-public information concerning the Client; and (b) trading in the Client’s securities while in possession of material nonpublic information or communicating that information to any other Person who trades in such securities could subject Halo and its Representatives to liability under the U.S. federal and state securities laws, and the rules and regulations promulgated thereunder, including Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder. Halo agrees that it and its Representatives will not trade in the Client’s securities while in possession of material nonpublic information or at all until Halo and its Representatives can do so in compliance with all applicable laws and without breach of this Agreement.

 

11.8.    Injunctive Relief. The Parties acknowledge and agree that, due to the unique nature of the Confidential Information, the breach of this Article 11 (Confidentiality) by Recipient may cause irreparable damage to Discloser for which monetary damages would be inadequate. Accordingly, Discloser shall be entitled to seek injunctive relief or other remedies in connection with a threatened or actual breach of any of Recipient’s obligations under this Article 11 (Confidentiality), and the Parties waive the requirement of any bond being posted as security in any application for such relief.

 

11.9.    Publicity. Subject to Section 11.4 (Compelled Disclosure), neither Party will use the other Party’s name in any public context or make any press release or other public disclosure regarding this Agreement or the transactions contemplated hereby, including identifying the other Party as a business partner or in connection with any scholarly or industry publications or presentations, without the other Party’s express prior written consent, which consent shall not be unreasonably withheld, conditioned, or delayed, except to the extent such use or disclosure is required by Applicable Law, by any Authority, or by the rules of any public exchange on which the securities of such Party are listed, in which case such Party shall use commercially reasonable efforts to obtain the approval of the other Party as to the form, nature and extent of the press release or public disclosure prior to issuing or making the disclosure.

 

 

 

11.10.    Survival. This Article 11 (Confidentiality) shall survive the expiration or termination of this Agreement for [***]; provided, that Confidential Information that is otherwise protected by law or regulation (e.g., trade secret and data privacy) shall remain protected as, and for as long as, such law or regulation permits or requires (unless and until such information loses such protection other than due to a breach of this Article 11 (Confidentiality) by Recipient.

 

ARTICLE 12

INTELLECTUAL PROPERTY

 

12.1.    Proprietary Intellectual Property. For purposes of this Agreement: (a) all Intellectual Property owned by a Party or any of its Affiliates as of the Effective Date shall be deemed owned by such Party; (b) all Intellectual Property licensed to a Party or any of its Affiliates by a Third Party at any time shall be deemed, solely as between the Parties, owned by such Party; and (c) all Intellectual Property generated, conceived or reduced to practice by or for a Party or any of its Affiliates outside the scope of activities under this Agreement shall be deemed owned by such Party (collectively, such Party’s “Proprietary IP”).

 

12.2.    Inventions.

 

(a)    Client Inventions. As between the Parties, all Inventions to the extent (i) specific to the development, manufacture, use or sale of Client’s Product or (ii) dependent on Client’s Proprietary IP, shall be the exclusive property of Client (“Client Inventions”).

 

(b)    Halo Inventions. As between the Parties, all Inventions that (i) do not comprise Client Inventions and (ii) either (A) have application to manufacturing processes for drug products or drug delivery systems generally or (B) are dependent on Halo’s Proprietary IP shall be the exclusive property of Halo (“Halo Inventions”).

 

(c)    Disclosure. Halo shall submit to Client a written description of all Inventions of which it becomes aware during the Term. Client may, in its sole discretion, disclose Halo Inventions in any patent application claiming Client’s Inventions, as Client may reasonably require to support the claimed subject matter of such patent application, subject to Halo’s prior written approval, which shall not be unreasonably withheld.

 

(d)    Cooperation; Costs. The Parties shall cooperate to achieve the allocation of rights to Inventions anticipated herein. Each Party shall be solely responsible for the costs of filing, prosecution and maintenance of patents and patent applications on, and otherwise protecting, its Inventions.

 

 

 

12.3.    Licenses.

 

(a)    To Halo. Client hereby grants to Halo and its Affiliates a non-exclusive, paid-up, royalty-free, non-transferable, sublicensable (solely to Halo’s subcontractors) right and license during the Term to use Client’s Intellectual Property (including Client Inventions) solely in connection with the Services.

 

(b)    To Client. Halo hereby grants to Client a non-exclusive, non-transferable, sublicensable (solely to Client’s subcontractors) right and license to use Halo Inventions solely to develop and manufacture Client’s Product.

 

(c)    No Other Rights. Neither Party has, nor shall it acquire, any interest in any Intellectual Property of the other Party, and neither Party shall use any Intellectual Property of the other Party, except to the extent expressly permitted by this Section 12.3.

 

12.4.    Ownership of Data. Except as set forth in Section 12.2(b) (Halo Inventions), all data and information resulting from the conduct of the Services shall be the sole property of Client and shall be subject to Client’s exclusive use, commercial or otherwise.

 

ARTICLE 13

DISPUTE RESOLUTION

 

13.1.    Escalation. The Parties shall try to resolve any dispute arising out of or in connection with this Agreement other than a dispute determined in accordance with Section 6.1(b) (Evaluation) (a “Dispute”) amicably between themselves before resorting to any formal dispute resolution proceeding. To this end, either Party may send a notice of Dispute to the other. Within [***] following the date of the Dispute notice, each Party shall appoint a single, senior representative with the full power and authority to resolve the Dispute (a “Facilitator”). The Facilitators shall meet and discuss as necessary to try to resolve the Dispute as quickly as practicable. If a Dispute relates exclusively to technical aspects of the Services, the Facilitators shall be competent to address the technical nature of the issues in question and may elect to engage an independent laboratory or expert to assist them in their discussions; however, the input of such laboratory or expert shall not be binding on either Party. If a Party fails to timely appoint a Facilitator or if, despite their reasonable efforts, the Facilitators have not resolved a Dispute within [***] from the date of the Dispute notice, either Party may resort to a court of competent jurisdiction, subject to Section 13.3 (Jurisdiction), or any other method of binding dispute resolution on which the Parties may agree.

 

13.2.    Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of New York and the laws of the United States applicable therein, without regard to any conflicts of law principles. The UN Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.

 

13.3.    Jurisdiction. The Parties irrevocably agree that the state and federal courts sitting in the State of New York shall have exclusive jurisdiction to deal with any Dispute and that venue is proper in such courts. Each Party hereby expressly consents and submits to the personal jurisdiction of such courts, waives any objection to the laying of venue in such courts, and waives any claim that such courts constitute an inconvenient forum. Each Party, to the extent permitted by law, knowingly, voluntarily, and intentionally waives its right to a trial by jury in any Dispute, regardless of the legal theory of the claims asserted in such Dispute. All documents and proceedings in connection with any Dispute shall be in the English language.

 

 

 

13.4.    [Intentionally Omitted.]

 

ARTICLE 14

MISCELLANEOUS

 

14.1.    Further Assurances. The Parties agree to execute, acknowledge, and deliver such further instruments and to take all such other incidental acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.

 

14.2.    Right to Dispose and Settle. If Halo requests in writing Client’s direction with respect to disposal of any Inventory, Product, work-in-process, API, equipment, Records, samples or other items belonging to Client and is unable to obtain a response from Client within [***] of providing written notice to Client, Halo shall have the right to dispose of such items at Client’s expense (which may be by set off against any credit on Client’s account).

 

14.3.    Force Majeure. Neither Party shall be liable for the failure to perform its obligations under this Agreement if such failure is occasioned by a cause or contingency beyond such Party's reasonable control, whether or not foreseeable, including strikes or other labor disturbances, lockouts, riots, quarantines, communicable disease outbreaks (including pandemics and epidemics), wars, acts of terrorism, fires, floods, storms, interruption of or delay in transportation, lack of or inability to obtain fuel, power, materials or components, or compliance with any order or regulation of any Authority acting within color of right. A Party claiming a right to excused performance under this Section 14.3 shall promptly, and within [***], notify the other Party in writing of the extent of its inability to perform and the nature of the force majeure event. Such excuse shall continue as long as the force majeure event continues. Upon cessation of such force majeure event, the affected Party shall promptly, and within [***], resume performance under this Agreement. Neither Party shall be entitled to rely on a force majeure event to relieve it from an obligation to pay money (including any interest for delayed payment) that would otherwise be due and payable under this Agreement. In the event a force majeure event continues for [***], and such force majeure event is solely related to Halo (e.g., is not a circumstance that is generally impacting global trade, the pharmaceutical industry, the U.S. economy, etc.), [***].

 

 

 

14.4.    Notices. Any notice or other communication required or permitted by this Agreement shall be in writing and deemed given to the other Party (a) upon receipt if delivered personally, (b) upon receipt or refusal if sent by reputable overnight courier service or registered/certified mail with tracking capability, postage prepaid, or (c) on the next Business Day if sent by email with electronic verification of delivery, in each case to the mailing address or email address set forth below (or to such other contact information provided to the other Party in accordance with the terms of this Section 14.4):

 

To Client:

Aytu BioPharma, Inc.

7900 East Union Avenue, Suite 920

Denver, CO 80237

Attention: Legal Department

Email: legal@aytubio.com

   
To Halo:

Halo Whippany

30 North Jefferson Rd.

Whippany NJ 07981 USA

Attention: VP, GM

   
With copy to:

Noramco

500 Swedes Landing Road

Wilmington, DE 19801 USA

Attention: General Counsel

 

14.5.    Assignment; No Third-Party Beneficiaries. This Agreement shall be binding upon and inure to the benefit of the Parties, their successors and permitted assigns. Neither Party may assign this Agreement, in whole or in part, without the prior written consent of the other Party, which consent may be withheld in the other Party’s sole discretion except that either Party may, without the other Party’s consent (but subject to prior written notice), assign this Agreement in its entirety to an Affiliate or to a successor to all or substantially all of the business or assets of the assigning Party or the assigning Party’s business unit responsible for performance under this Agreement. This Agreement shall not confer any rights or remedies upon any Person other than the Parties named herein and their respective successors and permitted assigns.

 

14.6.    Entire Agreement; Amendments; Waivers. This Agreement, together with the Quality Agreement and the Confidentiality Agreement, constitutes the entire and integrated agreement between the Parties relating to the subject matter hereof and supersedes all previous written or oral negotiations, commitments, agreements, transactions, or understandings with respect to the subject matter hereof. Any modification, amendment or supplement to this Agreement must be in writing and signed by both Parties to be effective, except to the extent otherwise expressly provided in this Agreement. Either Party’s failure to require the other Party to comply with any provision of this Agreement shall not be deemed a waiver of such provision or any other provision of this Agreement, or of any other breach of such provision.

 

14.7.    Conflicts. No terms, provisions or conditions of any purchase order, order acknowledgement, quote, proposal, invoice, or other business form or written authorization used by Client or Halo will have any effect on the rights, duties or obligations of the Parties under, or otherwise modify, this Agreement, regardless of any failure of Client or Halo to object to such terms, provisions, or conditions, except to the extent such document specifically refers to this Agreement, sets forth an express intent to override it, and is signed by both Parties.

 

 

 

14.8.    Construction.

 

(a)    Independent Contractors. The Parties are independent contractors to one another, and this Agreement shall not be construed to create between Halo and Client any other relationship such as, by way of example only, that of employer-employee, principal-agent, joint-venturers, partners or any similar relationship, the existence of which is expressly denied by the Parties. Neither Party shall have the power or authority to bind the other Party or to assume or create any obligation, express or implied, on the other Party’s behalf or in the other Party’s name, and it will not represent to any Person that it has such power or authority.

 

(b)    Drafting Party. The language in this Agreement is to be construed in all cases according to its fair meaning. Halo and Client acknowledge that each Party and its counsel have reviewed and revised this Agreement and that any rule of construction, to the effect that any ambiguities are to be resolved against the drafting Party, is not to be employed in the interpretation of this Agreement.

 

(c)    Severability. If any provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, such determination shall not impair or affect the validity, legality, or enforceability of the remaining provisions hereof, and each provision is hereby declared to be separate, severable, and distinct.

 

(d)    Divisions. The division of this Agreement into Articles, Sections, subsections, clauses and Schedules and the insertion of headings are for convenience of reference only and shall not affect the interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement to an Article, Section, subsection, clause, or Schedule refers to the specified Article, Section subsection, clause, or Schedule to this Agreement. In this Agreement, the terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar expressions refer to this Agreement as a whole (including any Schedules hereto) and not to any particular Article, Section, subsection, clause, Schedule or other provision hereof.

 

(e)    Conventions. Whenever used in this Agreement, unless otherwise specified: (a) all monetary amounts are expressed in, and all references to “$” or “dollars” mean, the lawful currency of the United States; (b) the word “including” (with its grammatical variations) means “including without limitation,” “including but not limited to”, or words of similar import; (c) the words “agree” or “written agreement” will not impose any obligation on either Party to agree to any terms or to engage in discussions relating to such terms, except as such Party may elect in such Party’s sole discretion; (d) the word “Client” includes its Affiliates whenever the context requires or to the extent applicable; (e) the word “days” means calendar days unless otherwise specified as Business Days; (f) the words “copy” and “copies” include, to the extent available, electronic copies, files or databases containing the information, files, items, documents or materials to which such words apply; and (g) all references to the singular shall include the plural and vice versa.

 

14.9.    Counterparts. This Agreement may be executed in counterparts, by original, electronic, or facsimile signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be delivered electronically by email of a signed PDF copy.

 

 

Signature page follows

 

 

 

 

 

IN WITNESS WHEREOF, the duly authorized representatives of the Parties have executed this Agreement as of the Effective Date.

 

HALO PHARMACEUTICAL, INC.

 

 

By          /s/ Adam Hopper                          

 

Name:    Adam Hopper

 

Title:      President

 

 

AYTU BIOPHARMA, INC.

 

 

By          /s/ Joshua R. Disbrow                   

 

Name:     Joshua R. Disbrow

 

Title:       Chief Executive Officer

 

 

SCHEDULES

[***]

 

 
EX-31.1 3 ex_612117.htm EXHIBIT 31.1 ex_612117.htm

Exhibit 31.1

 

AYTU BIOPHARMA, INC.

Certification by Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Joshua R. Disbrow, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of Aytu BioPharma, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a—15(e) and 15d—15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a—15(f) and 15d—15(f)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities particularly during the period in which this report is being prepared;

 

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 14, 2024

   
     
     
 

By:

/s/ Joshua R. Disbrow

   

Joshua R. Disbrow

    Chairman and Chief Executive Officer
    (Principal Executive Officer)

 

 
EX-31.2 4 ex_612118.htm EXHIBIT 31.2 ex_612118.htm

Exhibit 31.2

 

AYTU BIOPHARMA, INC.

Certification by Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Mark K. Oki, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of Aytu BioPharma, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a—15(e) and 15d—15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a—15(f) and 15d—15(f)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities particularly during the period in which this report is being prepared;

 

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 14, 2024

   
     
     
 

By:

/s/ Mark K. Oki

   

Mark K. Oki

    Chief Financial Officer
    (Principal Financial Officer)
   

(Principal Accounting Officer)

 

 
EX-32.1 5 ex_612119.htm EXHIBIT 32.1 ex_612119.htm

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S. C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I Joshua R. Disbrow, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10‑Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2023, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10‑Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc.

 

 

Date: February 14, 2024

   
     
     
 

By:

/s/ Joshua R. Disbrow

   

Joshua R. Disbrow

    Chairman and Chief Executive Officer
   

(Principal Executive Officer)

 

 

 

I Mark K. Oki, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10‑Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2023, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10‑Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc.

 

 

Date: February 14, 2024

   
     
     
 

By:

/s/ Mark K. Oki

   

Mark K. Oki

    Chief Financial Officer
    (Principal Financial Officer)
   

(Principal Accounting Officer)

 

 
EX-101.SCH 6 aytu-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Business, Financial Condition, Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Revenues From Contracts with Customers link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Inventories link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Leases link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Accrued Liabilities link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Other Liabilities link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Line of Credit link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Long-term Debt link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Fair Value Considerations link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Capital Structure link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 15 - Equity Incentive Plans link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 16 - Warrants link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 17 - Earnings Per Share link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 18 - License Agreements link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 19 - Segment Reporting link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 3 - Revenues From Contracts with Customers (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 4 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 5 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 6 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 7 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 8 - Accrued Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 9 - Other Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 11 - Long-term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 12 - Fair Value Considerations (Tables) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 15 - Equity Incentive Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 16 - Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 17 - Earnings Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 19 - Segment Reporting (Tables) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 1 - Nature of Business, Financial Condition, Basis of Presentation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 3 - Revenues From Contract With Customers - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 4 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 5 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 6 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 6 - Leases - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 7 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 9 - Other Liabilities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 10 - Line of Credit (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 11 - Long-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) link:calculationLink link:definitionLink link:presentationLink 995505 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995506 - Disclosure - Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details) link:calculationLink link:definitionLink link:presentationLink 995507 - Disclosure - Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) link:calculationLink link:definitionLink link:presentationLink 995508 - Disclosure - Note 12 - Fair Value Considerations - Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995509 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995510 - Disclosure - Note 14 - Capital Structure (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995511 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995512 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995513 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995514 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995515 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995516 - Disclosure - Note 16 - Warrants (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995517 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 995518 - Disclosure - Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995519 - Disclosure - Note 19 - Segment Reporting (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995520 - Disclosure - Note 19 - Segment Reporting - Schedule of Segment Information (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 aytu-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 aytu-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 aytu-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Neos Therapeutics, Inc. [Member] Related to Neos Therapeutics, Inc. Note To Financial Statement Details Textual (Loss) gain on derivative warrant liabilities Loss (gain) on derivative warrant liabilities Significant Accounting Policies Note 3 - Revenues From Contracts with Customers Note 4 - Inventories Note 5 - Property and Equipment Note 6 - Leases Note 7 - Intangible Assets Note 8 - Accrued Liabilities Non-current liabilities: Note 9 - Other Liabilities Note 11 - Long-term Debt Note 12 - Fair Value Considerations Note 15 - Equity Incentive Plans Note 16 - Warrants Note 17 - Earnings Per Share Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Note 19 - Segment Reporting us-gaap_LiabilitiesCurrent Total current liabilities Schedule of Maturities of Long-Term Debt [Table Text Block] Note 3 - Revenues From Contract With Customers - Disaggregation of Revenue (Details) Note 4 - Inventories - Schedule of Inventories (Details) Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) Other current liabilities Less: current portion Note 6 - Leases - Lease Cost (Details) Note 6 - Leases - Lease Balance Sheet Information (Details) Note 6 - Leases - Schedule of Lease Liability Maturity (Details) Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) Note 7 - Intangible Assets - Future Amortization Expense (Details) Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) Note 11 - Long-term Debt - Future Principal Payments (Details) Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details) Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 12 - Fair Value Considerations - Valuation Assumptions (Details) Note 15 - Equity Incentive Plans - Stock Option Activity (Details) Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) Granted, weighted average grant date fair value (in dollars per share) Vested, weighted average grant date fair value (in dollars per share) Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) Forfeited/cancelled, weighted average grant date fair value (in dollars per share) Forfeited, weighted average grant date fair value (in dollars per share) Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Unvested, weighted average grant date fair value (in dollars per share) Unvested, weighted average grant date fair value (in dollars per share) Note 16 - Warrants - Schedule of Warrants Outstanding (Details) Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, shares (in shares) Forfeited/cancelled, shares (in shares) Note 19 - Segment Reporting - Schedule of Segment Information (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Unvested, shares (in shares) Unvested, shares (in shares) Notes To Financial Statements Notes To Financial Statements [Abstract] us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Less: current portion Granted, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested, shares (in shares) Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Current portion of debt Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] aytu_SupplyAndDistributionAgreementExtensionTerm Supply and Distribution Agreement, Extension Term (Year) Represents the extension term of a supply and distribution agreement. Exercisable, options, weighted average exercise price (in dollars per share) Exercisable, options, weighted average remaining contractual life (Year) Exercisable, options (in shares) Outstanding, options, weighted average remaining contractual life (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, options, weighted average exercise price (in dollars per share) Outstanding, options, weighted average exercise price (in dollars per share) Forfeited/Cancelled, options, weighted average exercise price (in dollars per share) Expired, options, weighted average exercise price (in dollars per share) Granted, options, weighted average exercise price (in dollars per share) Accrued liabilities Total accrued liabilities Accrued employee compensation Accounts payable Secured Debt [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) Outstanding, options (in shares) Outstanding, options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired, options (in shares) Other accrued liabilities us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) The Pediatric Portfolio [Member] Represents the Pediatric Portfolio. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Cash paid for income taxes Tris Karbinal Agreement [Member] Relating to Tris Karbinal Agreement. Product and Service, Other [Member] aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year) Represents the renewable period for a finite-lived intangible asset. Employee retention credit Employee Retention Credit Represents the amount of employee retention credit. Current liabilities: Return reserve Represents the amount of return reserve classified as current. Developed Technology Rights [Member] Patented Technology [Member] Accrued customer and product related fees Represents the amount of accrued customer and product related fees classified as current. Fixed payment arrangements Fixed Payment Arrangements Represents the amount of fixed payment arrangements. us-gaap_Assets Total assets Supplemental disclosure of cash flow information: Equity Warrants [Member] Relating to Equity Warrants. Plan Name [Axis] Technology-Based Intangible Assets [Member] Plan Name [Domain] In Process Research and Development [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Consumer Health [Member] Represents consumer health. Distribution Rights [Member] Manufacturing Equipment [Member] Represents manufacturing equipment. Finite-Lived Intangible Assets by Major Class [Axis] Share-Based Payment Arrangement [Text Block] Lab Equipment [Member] Represents lab equipment. Finite-Lived Intangible Assets, Major Class Name [Domain] Office Equipment, Furniture and Other [Member] Represents office equipment, furniture and other. Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Award Type [Domain] Net loss Net Income (Loss) Attributable to Parent Net loss Award Type [Axis] us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-lived intangible assets, amortization Finite-lived intangible assets, net Total future amortization expense Intangible assets, net Restricted Stock Units (RSUs) [Member] Finite-lived intangible assets, gross Restricted Stock [Member] Accrued program liabilities Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities. At-the-market Offering [Member] Represents the at-the-market offering. Share-Based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrants or Rights Disclosure [Text Block] The entire disclosure for warrants or rights. Commitments and Contingencies Disclosure [Text Block] The 2015 Plan [Member] Represents the Aytu BioScience 2015 Stock Option and Incentive Plan (the “2015 Plan”). us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: accumulated depreciation and amortization Property and equipment, net Property and equipment, net Property and equipment, gross Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] aytu_FixedPaymentArrangementsLiabilityReduction Fixed Payment Arrangements, Liability, Reduction Represents the amount of reduction of a fixed payment arrangement liability. aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Eligible Accounts Receivable Represents the percentage of eligible accounts receivable on a line of credit facility. aytu_EmployeeRetentionCreditVendorFee Employee Retention Credit, Vendor Fee Represents the amount of vendor fee from employee retention credit during the period. aytu_ClassOfWarrantOrRightExercisedDuringPeriod Warrants exercised (in shares) The number of warrants or rights exercised during period. aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment Line of Credit Facility, Termination, Fee, Percentage of Commitment Represents the percentage of commitment used as a termination fee of a line of credit facility. Cash flows from investing activities: Eclipse Business Capital LLC Loan Agreement [Member] Relating to Eclipse Business Capital LLC Loan Agreement. Warrants, weighted average remaining contractual life (Year) The weighted average period of remaining contractual life of warrants or rights. Liability Warrants [Member] Represents liability warrants. us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Other operating assets and liabilities, net Earnings Per Share [Text Block] Tris License Agreement [Member] Represents the Tris License Agreement. After January 26, 2024 But Before January 26, 2025 [Member] Relating to after January 26, 2024 but before January 26, 2025. After January 26, 2023 But Before January 26, 2024 [Member] Relating to after January 26, 2023 but before January 26, 2024. Other Warrants [Member] Relating to other warrants. June 2023 Warrants Tranche A & B [Member] Relating to the June 2023 Warrants Tranche A & B. Long-term, final payment fee Debt Instrument, Final Payment Represents the final payment of a debt instrument. aytu_DebtInstrumentPrepaymentFeePercentage Debt Instrument, Prepayment Fee, Percentage Represents the percentage of loan that is payable as a prepayment fee. Avenue Capital Warrants [Member] Relating to the Avenue Capital Warrants. Avenue Capital Loan [Member] Relating to the Avenue Capital Loan. Accrued liabilities us-gaap_IncreaseDecreaseInAccruedLiabilities Income tax expense The 2020 Shelf [Member] Relating to the 2020 Shelf. aytu_SaleOfStockRemainingAmountAvailable Sale of Stock, Remaining Amount Available Represents the remaining amount of equity issuable. aytu_SupplyAndDistributionCommitmentPeriod Supply and Distribution Commitment, Period (Year) Period covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. The 2021 Shelf [Member] Relating to the 2021 Shelf. Avenue Capital Issuance [Member] Relating to Avenue Capital Issuance. aytu_SaleOfStockMaximumAmountOfEquityIssuable Sale of Stock, Maximum Amount of Equity Issuable Represents the maximum monetary amount of equity issuable. Securities Purchase Agreement [Member] Relating to the Securities Purchase Agreement. Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment Supply and Distribution Agreement, Maximum Yearly Make-whole Payment The maximum amount of make-whole payment per year under supply and distribution agreement. August 2022 Common and Prefunded Warrants [Member] Relating to the August 2022 Common and Prefunded Warrants. aytu_SupplyAndDistributionAgreementMinimumSalesPerYear Supply and Distribution Agreement, Minimum Sales Per Year Th minimum amount of units to be sold per year under supply and distribution agreement. Tranche A Common Warrants [Member] Relating to Tranche A Common Warrants. aytu_SupplyAndDistributionAgreementMakewholePaymentPerUnitForSalesUnderMinimum Supply and Distribution Agreement, Make-whole Payment Per Unit for Sales Under Minimum The amount of make-whole payment per unit for sales under the minimum units for the supply and distribution agreement. Pre-Funded Warrants [Member] Relating to the Pre-Funded Warrants. The August 2022 Offering [Member] Relating to the August 2022 Offering. aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales Supply and Distribution Commitment, Royalty, Percentage of Net Sales The percentage of net sales to be paid for royalties under supply and distribution agreement. August 2022 Common Warrants [Member] Relating to the August 2022 Common Warrants. August 2022 Prefunded Warrants [Member] Relating to August 2022 prefunded warrants. Tranche A Common Warrants at Double Exercise Price [Member] Relating to Tranche A Common Warrants at double exercise price. aytu_ClassOfWarrantOrRightCovenantAdjustedEbitda Class of Warrant or Right, Covenant, Adjusted EBITDA Represents the amount of Earnings Before Income Tax, Depreciation, and Amortization needed satisfy a warrant or right covenant. aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations Supply and Distribution Agreement, Maximum Milestone Obligations The maximum amount of milestone obligations of the supply and distribution agreement. Common Warrants [Member] Relating to the Common Warrants. Tranche B Common Warrants [Member] Relating to the Tranche B Common Warrants. us-gaap_OperatingExpenses Total operating expenses Securities Purchase Agreement Warrants [Member] Relating to the Securities Purchase Agreement Warrants. aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues Supply and Distribution Agreement, First Milestone, Minimum Net Revenues The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement. Common Warrants Exchanged for PreFunded Warrants [Member] Relating to Common Warrants exchanged for Pre-Funded Warrants. Restricted Stock and Restricted Stock Units (RSUs) [Member] Share instruments in which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met. Outside Equity Incentive Plan [Member] Relating to outside the equity incentive plan. General and administrative The 2023 Equity Incentive Plan [Member] Relating to the 2023 Equity Incentive Plan. Cash and cash equivalents Total stock-based compensation expense Included in earnings Amendment Flag City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] aytu_LicenseAgreementMinimumAnnualRoyaltyPayment License Agreement, Minimum Annual Royalty Payment Represents the minimum annual royalty payment as part of a license agreement. Rumpus Acquisition [Member] Relating to the Rumpus Acquisition. us-gaap_SharesOutstanding Balances (in shares) Balances (in shares) Common stock, outstanding (in shares) Common Stock, Shares, Outstanding (in shares) Preferred stock, outstanding (in shares) aytu_LicenseAgreementRoyaltyPercentage License Agreement, Royalty Percentage Represents the percentage of net sales that is paid as a royalty. Walleye Opportunities Master Fund Ltd. [Member] Relating to Walleye Opportunities Master Fund Ltd. Sabby Volatility Warrant Master Fund Ltd. [Member] Relating to Sabby Volatility Warrant master Fund Ltd. Sabby Litigation [Member] Relating to the Sabby Litigation. Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Royalties [Member] Relating to royalties. Earn Out Payments [Member] Relating to earn out payments. us-gaap_LeaseCost Total net lease cost us-gaap_DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage Milestone Payments [Member] Relating to milestone payments. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Operating lease assets Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Short-term lease cost Lease, Cost [Table Text Block] Sabby Litigation Warrants [Member] Relating to warrants calculated by the claimant in the Sabby Litigation. Document Period End Date Operating lease assets (Year) Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Impairment expense Entity Small Business Entity Shell Company Schedule of Warrant or Right Activity Tabular disclosure of warrant or right activity. Document Information [Line Items] Document Information [Table] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_ImpairmentOfIntangibleAssetsFinitelived Impairment of Intangible Assets, Finite-Lived Variable Rate [Domain] Prime Rate [Member] Schedule of Long-Term Debt Instruments [Table Text Block] Variable Rate [Axis] us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable, net Entity Tax Identification Number Entity Central Index Key Depreciation and amortization Entity Registrant Name Liability Class [Axis] Fair Value by Liability Class [Domain] Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Amortization of intangible assets Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Material Terms of Trading Arrangement [Text Block] Entity Common Stock, Shares Outstanding Long-Term Debt [Text Block] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number us-gaap_TableTextBlock Notes Tables us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Stock-based compensation expense (in shares) Stock-based compensation expense Granted, options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited/Cancelled, options (in shares) us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term (Year) Selling and marketing Line of Credit Facility, Lender [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Issuance of common stock with exercise of warrants (in shares) Stock Issued During Period, Shares, New Issues (in shares) Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Raw materials Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Finished goods Work in process Issuance of common stock with exercise of warrants Derivative liability, measurement input Accumulated deficit Retained Earnings (Accumulated Deficit) Research and development us-gaap_AssetsNoncurrent Total non-current assets Short-Term Debt [Text Block] us-gaap_InterestExpenseDebt Interest Expense, Debt Measurement Input, Price Volatility [Member] Changes in operating assets and liabilities: Measurement Input, Risk Free Interest Rate [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_OtherNoncashIncomeExpense Other noncash adjustments Inventory Disclosure [Text Block] Measurement Input, Expected Dividend Rate [Member] us-gaap_OperatingLeaseLiabilityNoncurrent Operating leases Schedule of Inventory, Current [Table Text Block] Measurement Input, Expected Term [Member] Operating lease liabilities Operating Lease, Liability Operating leases Finance leases Operating lease right-of-use assets Operating Lease, Right-of-Use Asset us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total operating lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Operating lease, less: Imputed interest Finance lease liabilities Financing cash flows from finance leases Operating lease, 2027 Thereafter Measurement Input Type [Axis] Operating lease, 2028 2024 (remaining 6 months) Measurement Input Type [Domain] Finance lease assets 2026 2027 Operating lease, 2025 2028 Operating lease, 2026 Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] 2025 Other non-current assets Stock-based compensation expense us-gaap_ShareBasedCompensation Operating lease, 2024 (remaining 6 months) Finite-lived intangible assets, remaining life (Year) us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) Amortization of senior debt discount Operating expenses: Income Tax, Policy [Policy Text Block] Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract (Year) us-gaap_Depreciation Depreciation us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Depreciation, amortization and accretion Intangible Assets Disclosure [Text Block] Financial liabilities, fair value us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) us-gaap_AssetsCurrent Total current assets Non-current assets: Equity [Text Block] Loss from contingent consideration Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,347 and 5,517,174 shares issued and outstanding, respectively Adjustments to reconcile net loss to cash used in operating activities: Common stock, authorized (in shares) Common Stock, Shares Authorized (in shares) us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities Payment for Contingent Consideration Liability, Operating Activities Common stock, issued (in shares) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Statistical Measurement [Domain] Operating cash flows from operating leases Maximum [Member] Minimum [Member] Weighted Average [Member] Other current assets Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] Operating cash flows from finance leases Litigation Case [Axis] Litigation Case [Domain] Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding Preferred stock, issued (in shares) Cash paid for interest Prepaid expenses Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Preferred stock, authorizzed (in shares) Preferred Stock, Shares Authorized (in shares) Inventories Inventories Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Cash flows from operating activities: Schedule of Segment Reporting Information, by Segment [Table Text Block] us-gaap_WarrantsAndRightsOutstanding Warrants and Rights Outstanding Asset under Construction [Member] Statement [Line Items] us-gaap_NumberOfOperatingSegments Number of Operating Segments Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current us-gaap_NumberOfReportableSegments Number of Reportable Segments Additional paid-in capital Stockholders’ equity: Leasehold Improvements [Member] Other expense, net Long-Lived Tangible Asset [Axis] Segment Reporting Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Current assets: us-gaap_SaleOfStockPricePerShare Sale of Stock, Price Per Share (in dollars per share) Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash (used in) provided by financing activities Commitments and contingencies (note 13) Sale of Stock [Axis] Sale of Stock [Domain] Income (loss) from operations Income (loss) from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) provided by investing activities us-gaap_OtherLiabilities Total other liabilities us-gaap_GrossProfit Gross profit Cost of sales Counterparty Name [Axis] Counterparty Name [Domain] Inventory write-down Inventory Write-down Other Liabilities [Table Text Block] Other financing activities Other us-gaap_PaymentOfFinancingAndStockIssuanceCosts Payment of Financing and Stock Issuance Costs us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs Payment of stock issuance costs Other Liabilities Disclosure [Text Block] Proceeds from issuance of stock and warrants Proceeds from Issuance or Sale of Equity Scenario [Domain] us-gaap_LoanProcessingFee Loan Processing Fee Retained Earnings [Member] Revenue Product revenue, net Scenario [Axis] Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Warrants, weighted average exercise price (in dollars per share) Warrants, weighted average exercise price (in dollars per share) Other Current Liabilities [Member] Class of Warrant or Right [Axis] Other Noncurrent Liabilities [Member] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) us-gaap_ClassOfWarrantOrRightOutstanding Warrants outstanding (in shares) Warrants outstanding (in shares) us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (loss) before income tax us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_LineOfCredit Long-Term Line of Credit us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Less: unamortized discount and issuance costs Disaggregation of Revenue [Table Text Block] us-gaap_RepaymentsOfLongTermDebt Payments made to borrowings Revenue from Contract with Customer [Text Block] us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet Unamortized discount and issuance costs Balance Sheet Location [Axis] Balance Sheet Location [Domain] Document Quarterly Report Entity Incorporation, State or Country Code Long-term debt, due on January 26, 2025 General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset Total lease assets Represents right-of-use asset for operating lease and finance lease. Short-term line of credit Entity Interactive Data Current Selling and Marketing Expense [Member] Accrued savings offers Represents information related to accrued saving offers. aytu_OperatingLeaseAndFinanceLeaseLiability Total lease liabilities Represents operating and finance lease liability. Security Exchange Name Operating Expense [Member] Other Expense [Member] Title of 12(b) Security Non-current portion of debt us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities Total debt Cost of Sales [Member] Research and Development Expense [Member] Income Statement Location [Axis] Income Statement Location [Domain] Nonmonetary Transaction Type [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Nonmonetary Transaction Type [Axis] Licensing Agreements [Text Block] The entire disclosure for licensing agreements. Warrants exercised, weighted average exercise price (in dollars per share) Represents the exercise price of warrants or rights exercised during the period. Granted, options, weighted average remaining contractual life (Year) Weighted average remaining contractual term for option awards granted during the periof, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Segments [Axis] Segments [Domain] Neos 2015 Plan [Member] Represents Neos 2015 plan. Warrants expired (in dollars per share) Represents the exercise price of warrants or rights expired during the period. aytu_ClassOfWarrantOrRightExpiredDuringPeriod Warrants expired, weighted average exercise price (in shares) Represents the number of warrants or rights expired during the period. Antidilutive securities (in shares) Statement [Table] Statement of Financial Position [Abstract] Basic and diluted weighted-average common shares outstanding (in shares) us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent Business Acquisition [Axis] Basic and diluted net loss per common share (in dollars per share) Business Acquisition, Acquiree [Domain] aytu_LineOfCreditFacilityMaximumBorrowingCapacityPortionAvailableForShortTermSwinglineLoans Line of Credit Facility, Maximum Borrowing Capacity, Portion Available for Short-term Swingline Loans With regard to the maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility, this element represents the portion available for short-term swingline loans. Net (payments made on) proceeds received from, short-term line of credit Statement of Cash Flows [Abstract] aytu_LongTermDebtAndCapitalLeaseObligationsGross Future principal payments Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations. us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear 2024 (remaining 6 months) Lease Contractual Term [Domain] us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Axis] Income Statement [Abstract] Schedule of Accrued Liabilities [Table Text Block] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2025 aytu_PaymentsOfFixedPaymentArrangements Payment made to fixed payment arrangement The cash outflow for fixed payments arrangements. Interest on lease liabilities us-gaap_FinanceLeaseLiabilityPaymentsDue Total finance lease payments Amortization of leased assets us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Finance lease, less: Imputed interest Finance lease,2025 Finance lease,2026 Finance lease,2027 Current Portion of Debt [Member] Represents current portion of debt. Finance lease,2028 Finance lease assets us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Finance lease, 2024 (remaining 6 months) us-gaap_LiabilitiesNoncurrent Total non-current liabilities us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Finance lease assets (Year) us-gaap_PaymentsForProceedsFromOtherInvestingActivities Other investing activities Cash flows from financing activities: Warrants [Policy Text Block] Disclosure of the company's accounting policy regarding warrants. Avenue Note [Member] Relating to the Avenue Note. Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total other liabilities, non-current Other non-current liabilities us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities Contingent consideration payment Derivative warrant liabilities Rx Segment [Member] Relating to the Rx Segment. ADHD Portfolio [Member] Relating to the ADHS Portfolio. Lease for Principal Office [Member] Relating to the lease for principal office. Leases Disclosure [Text Block] The entire disclosure for leases. us-gaap_StockholdersEquity Total stockholders’ equity Balances Balances Property and Equipment, Net [Member] Relating to Property and Equipment, Net. Schedule of Lease by Balance Sheet Information [Table Text Block] Tabular disclosure of leases by balance sheet information. Class of Stock [Axis] Debt, net of current portion Operating lease, thereafter Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee, Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position. Accrued Liabilities [Text Block] The entire disclosure regarding accrued liabilities. Derivative Financial Instruments, Liabilities [Member] aytu_AmortizationExpenseOfIntangibleAssets Amortization Expense of Intangible Assets The value of amortization expense of intangible assets. Finance lease, thereafter Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). EX-101.PRE 10 aytu-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 aytu20231231_10qimg001.jpg begin 644 aytu20231231_10qimg001.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information - shares
6 Months Ended
Dec. 31, 2023
Feb. 01, 2024
Document Information [Line Items]    
Entity Central Index Key 0001385818  
Entity Registrant Name AYTU BIOPHARMA, INC.  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2024  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Dec. 31, 2023  
Document Transition Report false  
Entity File Number 001-38247  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 47-0883144  
Entity Address, Address Line One 7900 East Union Avenue, Suite 920  
Entity Address, City or Town Denver  
Entity Address, State or Province CO  
Entity Address, Postal Zip Code 80237  
City Area Code 720  
Local Phone Number 437-6580  
Title of 12(b) Security Common Stock, $0.0001 par value  
Trading Symbol AYTU  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   5,567,597
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 19,529 $ 22,985
Accounts receivable, net 29,403 28,937
Inventories 13,001 11,995
Prepaid expenses 8,105 8,047
Other current assets 1,333 868
Total current assets 71,371 72,832
Non-current assets:    
Property and equipment, net 1,127 1,815
Operating lease right-of-use assets [1] 2,133 2,054
Intangible assets, net 55,711 58,970
Other non-current assets 907 792
Total non-current assets 59,878 63,631
Total assets 131,249 136,463
Current liabilities:    
Accounts payable 10,473 13,478
Accrued liabilities 43,413 46,799
Short-term line of credit 1,026 1,563
Current portion of debt 39 85
Other current liabilities 9,236 7,090
Total current liabilities 64,187 69,015
Non-current liabilities:    
Debt, net of current portion 14,978 14,713
Derivative warrant liabilities 12,887 6,403
Other non-current liabilities 6,344 6,975
Total non-current liabilities 34,209 28,091
Commitments and contingencies (note 13)
Stockholders’ equity:    
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding 0 0
Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,347 and 5,517,174 shares issued and outstanding, respectively 1 1
Additional paid-in capital 345,321 343,485
Accumulated deficit (312,469) (304,129)
Total stockholders’ equity 32,853 39,357
Total liabilities and stockholders’ equity $ 131,249 $ 136,463
[1] Includes $0.2 million from the Consumer Health Segment as of December 31, 2023 and June 30, 2023.
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
Dec. 31, 2023
Jun. 30, 2023
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, authorizzed (in shares) 50,000,000 50,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 200,000,000 200,000,000
Common stock, issued (in shares) 5,567,347 5,517,174
Common stock, outstanding (in shares) 5,567,347 5,517,174
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Product revenue, net $ 22,934 $ 26,279 $ 45,033 $ 53,934
Cost of sales 6,731 8,986 14,046 18,609
Gross profit 16,203 17,293 30,987 35,325
Operating expenses:        
Selling and marketing 6,576 10,560 13,998 20,662
General and administrative 5,439 8,018 12,395 15,340
Research and development 524 1,710 1,128 2,774
Amortization of intangible assets 1,300 1,198 2,606 2,395
Impairment expense 0 2,600 0 2,600
Loss from contingent consideration 0 75 0 230
Total operating expenses 13,839 24,161 30,127 44,001
Income (loss) from operations 2,364 (6,868) 860 (8,676)
Other expense, net (1,179) (1,228) (1,888) (2,312)
(Loss) gain on derivative warrant liabilities (577) 1,403 (6,484) 3,594
Income (loss) before income tax 608 (6,693) (7,512) (7,394)
Income tax expense 828 0 828 0
Net loss $ (220) $ (6,693) $ (8,340) $ (7,394)
Basic and diluted weighted-average common shares outstanding (in shares) 5,517,670 3,110,304 5,499,951 2,817,979
Basic and diluted net loss per common share (in dollars per share) $ (0.04) $ (2.15) $ (1.52) $ (2.62)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balances (in shares) at Jun. 30, 2022 1,928,941      
Balances at Jun. 30, 2022 $ 0 $ 331,386 $ (287,078) $ 44,308
Stock-based compensation expense (in shares) (1,666)      
Stock-based compensation expense $ 0 1,177 0 1,177
Net loss $ 0   (701) (701)
Issuance of common stock with exercise of warrants (in shares) 1,194,196      
Issuance of common stock with exercise of warrants $ 0 3,564 0 3,564
Balances (in shares) at Sep. 30, 2022 3,121,471      
Balances at Sep. 30, 2022 $ 0 336,127 (287,779) 48,348
Balances (in shares) at Jun. 30, 2022 1,928,941      
Balances at Jun. 30, 2022 $ 0 331,386 (287,078) 44,308
Net loss       (7,394)
Balances (in shares) at Dec. 31, 2022 3,383,145      
Balances at Dec. 31, 2022 $ 0 340,289 (294,472) 45,817
Balances (in shares) at Jun. 30, 2022 1,928,941      
Balances at Jun. 30, 2022 $ 0 331,386 (287,078) 44,308
Balances (in shares) at Jun. 30, 2023 5,517,174      
Balances at Jun. 30, 2023 $ 1 343,485 (304,129) 39,357
Balances (in shares) at Sep. 30, 2022 3,121,471      
Balances at Sep. 30, 2022 $ 0 336,127 (287,779) 48,348
Stock-based compensation expense (in shares) (19,228)      
Stock-based compensation expense $ 0 3,067 0 3,067
Net loss $ 0   (6,693) (6,693)
Issuance of common stock with exercise of warrants (in shares) 280,902      
Issuance of common stock with exercise of warrants $ 0 1,095 0 1,095
Balances (in shares) at Dec. 31, 2022 3,383,145      
Balances at Dec. 31, 2022 $ 0 340,289 (294,472) 45,817
Balances (in shares) at Jun. 30, 2023 5,517,174      
Balances at Jun. 30, 2023 $ 1 343,485 (304,129) 39,357
Stock-based compensation expense (in shares) 13,061      
Stock-based compensation expense $ 0 930 0 930
Net loss $ 0   (8,120) (8,120)
Balances (in shares) at Sep. 30, 2023 5,530,235      
Balances at Sep. 30, 2023 $ 1 344,415 (312,249) 32,167
Balances (in shares) at Jun. 30, 2023 5,517,174      
Balances at Jun. 30, 2023 $ 1 343,485 (304,129) 39,357
Net loss       (8,340)
Balances (in shares) at Dec. 31, 2023 5,567,347      
Balances at Dec. 31, 2023 $ 1 345,321 (312,469) 32,853
Balances (in shares) at Sep. 30, 2023 5,530,235      
Balances at Sep. 30, 2023 $ 1 344,415 (312,249) 32,167
Stock-based compensation expense (in shares) 108      
Stock-based compensation expense $ 0 820 0 820
Net loss $ 0   (220) (220)
Issuance of common stock with exercise of warrants (in shares) 37,004      
Issuance of common stock with exercise of warrants $ 0 86 0 86
Balances (in shares) at Dec. 31, 2023 5,567,347      
Balances at Dec. 31, 2023 $ 1 $ 345,321 $ (312,469) $ 32,853
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Cash flows from operating activities:              
Net loss $ (220) $ (8,120) $ (6,693) $ (701) $ (8,340) $ (7,394)  
Adjustments to reconcile net loss to cash used in operating activities:              
Depreciation, amortization and accretion         4,409 4,507  
Stock-based compensation expense 820   3,067   1,750 4,244  
Loss (gain) on derivative warrant liabilities 577   (1,403)   6,484 (3,594)  
Amortization of senior debt discount         302 315  
Inventory write-down 100   0   133 82  
Impairment expense 0   2,600   0 2,600  
Loss from contingent consideration 0   75   0 230  
Other noncash adjustments         (50) (33)  
Changes in operating assets and liabilities:              
Accounts receivable, net         (466) (3,834)  
Inventories         (1,140) (2,183)  
Prepaid expenses and other current assets         (321) (4,606)  
Accounts payable         (3,032) (838)  
Accrued liabilities         (3,927) (1,008)  
Other operating assets and liabilities, net         3,852 (76)  
Net cash used in operating activities         (346) (11,588)  
Cash flows from investing activities:              
Contingent consideration payment         0 (5)  
Other investing activities         (250) 42  
Net cash (used in) provided by investing activities         (250) 37  
Cash flows from financing activities:              
Proceeds from issuance of stock and warrants         86 11,573  
Net (payments made on) proceeds received from, short-term line of credit         (537) 3,616  
Payment made to fixed payment arrangement         (2,204) (2,433)  
Payment of stock issuance costs         (160) (1,000)  
Payments made to borrowings         (45) 0  
Other financing activities         0 (64)  
Net cash (used in) provided by financing activities         (2,860) 11,692  
Net change in cash and cash equivalents         (3,456) 141  
Cash and cash equivalents at beginning of period   $ 22,985   $ 19,360 22,985 19,360 $ 19,360
Cash and cash equivalents at end of period $ 19,529   $ 19,501   19,529 19,501 $ 22,985
Supplemental disclosure of cash flow information:              
Cash paid for interest         2,170 2,021  
Cash paid for income taxes         $ 432 $ 0  
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 1 - Nature of Business, Financial Condition, Basis of Presentation
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 - Nature of Business, Financial Condition, Basis of Presentation

 

Aytu BioPharma, Inc. (“Aytu”, or the “Company”), is a pharmaceutical company focused on commercializing novel therapeutics. The Company operates through two business segments (i) the Rx Segment, consisting of prescription pharmaceutical products sold primarily through third party wholesalers and (ii) the Consumer Health Segment, which consists of various consumer healthcare products sold directly to consumers (the “Consumer Health Portfolio”). The Company was originally incorporated as Rosewind Corporation on August 9, 2002, in the State of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021, (the “Neos Acquisition”) the Company changed its name to Aytu BioPharma, Inc.

 

On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every twenty shares held (the “Reverse Stock Split”). All share and per share amounts in this quarterly report have been adjusted to reflect the effect of the Reverse Stock Split.

 

The Rx Segment primarily consists of two product portfolios. First the ADHD Portfolio, which consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”). Second the Pediatric Portfolio, which consists of Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions.

 

The Consumer Health Segment consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health and general wellness, commercialized through direct mail and e-commerce marketing channels. To date, the Consumer Health Segment has generated negative cash flows. In fiscal 2023, the Company announced it would wind down the Consumer Health Segment in fiscal 2024.

 

The Company’s strategy is to continue building its portfolio of revenue-generating prescription pharmaceutical products, leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. As a result of focusing on building the portfolio of revenue-generating products and generating profitability, in fiscal 2023, the Company indefinitely suspended active development of its clinical development programs including AR101 (enzastaurin) and terminated the license agreements relating to Healight and NT0502 (N-desethyloxybutynin).

 

As of December 31, 2023, the Company had $19.5 million of cash and cash equivalents and $29.4 million of accounts receivable. The Company’s operations have historically consumed cash and may continue to consume cash in the future. The Company had a net loss of $0.2 million and $8.3 million during the three and six months ended December 31, 2023, respectively. The Company had an accumulated deficit of $312.5 million and $304.1 million as of December 31, 2023 and June 30, 2023, respectively. Cash used in operations was $0.4 million and $11.6 million during the six months ended December 31, 2023 and 2022, respectively.

 

In addition, the Company has non-operating liabilities that are scheduled to, or may become, current in the twelve months following the filing of this Form 10-Q, most notably the maturity of the $15 million Avenue Capital term note (the “Avenue Note”) as discussed further in Note 11 - Long-term Debt. The Company expects to refinance the Avenue Note, however, there are no assurances the Company will be able to refinance the Avenue Note. As a result of this, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on (i) improving cash flows from operations, (ii) winding down the Consumer Health Segment, (iii) refinancing its $15 million Avenue Note to extend its maturity date, and, (iv), if necessary, raising additional capital through public or private equity offerings, debt offerings, or monetizing additional assets in order to meet its obligations. Management believes that the Company has adequate access to capital resources. However, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets, or obtain new financing on commercially acceptable terms. If the Company is unable to support its operations and obligations, it may be required to curtail its operations, or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern.

 

Basis of Presentation. The unaudited consolidated financial statements contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted pursuant to such rules and regulations. The unaudited consolidated financial statements should be read in conjunction with the Company’s 2023 Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of  June 30, 2023, was derived from the audited annual financial statements but does not contain all of the footnote disclosure from the annual financial statements. The results of operations for the period ended December 31, 2023 are not necessarily indicative of expected operating results for the full year or any future period.

 

Prior Period Reclassification. Certain prior year amounts in the consolidated statements of operations have been reclassified to conform to the current year presentation, including a reclassification of the fair value adjustment from contingent consideration. Net gain or loss from the fair value of contingent consideration was previously included in other expense, net, and is currently recorded in operating expenses on the consolidated statements of operations. This reclassification did not impact net loss or cash flows for the three or six months ended December 31, 2023 and 2022 or the Company’s financial position as of December 31, 2023 or June 30, 2023.

 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 2 - Significant Accounting Policies
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

Note 2 - Significant Accounting Policies

 

Use of Estimates

 

Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for credit losses, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of warrants and derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.

 

Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC Topic 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable.

 

Income Taxes

 

The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three and six months ended December 31, 2023. The effective tax rate was 136.2% and negative 11.0% for the three and six months ended December 31, 2023, respectively, primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances. The effective tax rate was 0% for both the three and six months ended December 31, 2022, respectively, reflecting the full valuation allowance and no impact of Section 382 of the Internal Revenue Code.

 

An ownership change could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Company's ability to use the pre-acquisition net operating loss carryovers. The ownership changes could result in increased future tax liability and are a driver of the change from a zero percent effective tax rate.

 

Employee Retention Credit

 

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020 through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic.

 

As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). In accordance with IAS 20, when management determines reasonable assurance that the Company had substantially met all eligibility requirements of the ERC, the ERC benefit shall be recognized as other income in the consolidated statement of operations (see Note - 9 Other Liabilities).

 

Recently Adopted Accounting Pronouncements

 

Financial Instruments – Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (“ASU 2016-13”) requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU 2016-13 is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after December 15, 2019. However, in October 2019, the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after December 15, 2022. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company adopted ASU 2016-13 and ASU 2019-05 on July 1, 2023. The Company evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company’s consolidated financial statements.

 

Recent Accounting Pronouncements Not Yet Adopted

 

Debt - Debt with Conversion and Other Options. In August 2020, the FASB issued ASU No. 2020-06, DebtDebt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entitys Own Equity (Subtopic 815-40) Accounting for Convertible Instruments and Contracts in an Entitys Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2024 and does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.

 

Segment Reporting - Improvements to Reportable Segment Disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company’s consolidated financial statements and disclosures.

 

For a complete set of the Company’s significant accounting policies, refer to the Company's 2023 Form 10-K. Other than the application of IAS 20 for the ERC, there have been no significant changes to the Company’s significant accounting policies during the six months ended December 31, 2023

 

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 3 - Revenues From Contracts with Customers
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

Note 3 - Revenues from Contracts with Customers

 

Net product revenue in the Rx Segment consists of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net product revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally “free-on-board” destination when shipped domestically within the United States, consistent with contractual terms.

 

The Company generates Consumer Health Segment revenue from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized “free-on-board” shipping point, consistent with contractual terms and aligning with the transfer of control of the products. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from customers are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost, and are included in cost of sales.

 

Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company’s periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate reporting and settlement of deductions. The Company continually monitors these provisions and does not believe variances between actual and estimated amounts have been or will be material.

 

Revenues by Segment. Net product revenue disaggregated by segment for the three and six months ended December 31, 2023 and 2022 were as follows:

 

 

  

Three Months Ended

  

Six Months Ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

  

2023

  

2022

 
  

(in thousands)

 

Consolidated net revenue:

                

Rx Segment

 $18,748  $18,029  $36,565  $36,681 

Consumer Health Segment

  4,186   8,250   8,468   17,253 

Total consolidated net revenue

 $22,934  $26,279  $45,033  $53,934 

 

Revenues by Product Portfolio. Net product revenue disaggregated by significant product portfolio in the Rx Segment for the three and six months ended December 31, 2023 and 2022 were as follows:

 

  

Three Months Ended

  

Six Months Ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

  

2023

  

2022

 
  

(in thousands)

 

Rx Segment net revenue:

                

ADHD Portfolio

 $16,572  $11,120  $31,700  $22,705 

Pediatric Portfolio

  2,145   6,328   4,710   12,886 

Other

  31   581   155   1,090 

Total Rx Segment net revenue

 $18,748  $18,029  $36,565  $36,681 

 

Other includes discontinued products in the Rx Segment. The Consumer Health Segment is comprised of one product portfolio, the Consumer Health Portfolio.

 

Revenues by Geographic location. The Company’s revenues are predominately within the United States, with insignificant sales internationally.

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Inventories
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Inventory Disclosure [Text Block]

Note 4 - Inventories

 

Inventories consist of raw materials, work in process and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period first recognized. The Company incurred inventory write-downs of $0.1 million and zero for each of the three months ended December 31, 2023 and 2022, respectfully, and $0.1 million for each of the six months ended December 31, 2023 and 2022.

 

Inventory balances consist of the following:

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Raw materials

 $1,654  $1,301 

Work in process

  2,674   2,956 

Finished goods

  8,673   7,738 

Inventories

 $13,001  $11,995 

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Property and Equipment
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

Note 5 - Property and Equipment

 

Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assets’ estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term.

 

Property and equipment consist of the following:

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Manufacturing equipment

 $1,183  $2,433 

Office equipment, furniture and other

  1,146   1,125 

Leasehold improvements

  999   999 

Lab equipment

  832   832 

Assets under construction

  45   107 

Property and equipment, gross

  4,205   5,496 

Less: accumulated depreciation and amortization

  (3,078)  (3,681)

Property and equipment, net

 $1,127  $1,815 

 

Depreciation and amortization expense from property and equipment was $0.3 million and $0.4 million for the three months ended December 31, 2023 and 2022, respectfully, and $0.6 million and $0.7 million for the six months ended December 31, 2023 and 2022, respectively.

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Leases
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Leases Disclosure [Text Block]

Note 6 - Leases

 

The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between fiscal 2024 and fiscal 2029. Most leases include one or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain leases also include options to purchase the leased property. The Company’s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.

 

In May 2023, the Company entered into a lease agreement to relocate its principal office. The space was made available to the Company in September 2023 (lease commencement) with an initial term of five and a half years. The Company recorded an operating lease right-of-use (“ROU”) asset of $0.7 million and a lease liability of $0.7 million at lease commencement. The ROU asset and lease liability were recorded at present value using an incremental borrowing rate of 10.3%. The Company utilized the practical expedient to not separate lease and non-lease components upon recognition.

 

The components of lease expenses are as follows:

 

  

Three Months Ended

  

Six Months Ended

  
  

December 31,

  

December 31,

  
  

2023

  

2022

  

2023

  

2022

 

Statement of Operations Classification

  

(in thousands)

  

Lease cost:

                 

Operating lease cost

 $381  $359  $741  $716 

Operating expenses

Short-term lease cost

  21   19   44   44 

Operating expenses

Finance lease cost:

                 

Amortization of leased assets

  15   19   29   37 

Cost of sales

Interest on lease liabilities

  1   2   2   5 

Other expense, net

Total net lease cost

 $418  $399  $816  $802  

 

Supplemental balance sheet information related to leases is as follows:

 

  

December 31,

  

June 30,

  
  2023  2023 

Balance Sheet Classification

  

(in thousands)

  

Assets:

         

Operating lease assets

 $2,133  $2,054 

Operating lease right-of-use assets

Finance lease assets

     159 

Property and equipment, net

Total lease assets

 $2,133  $2,213  

Liabilities:

         

Current:

         

Operating leases

 $1,369  $1,258 

Other current liabilities

Finance leases

  39   85 

Current portion of debt

Non-current:

         

Operating leases

  845   832 

Other non-current liabilities

Total lease liabilities

 $2,253  $2,175  

 

Remaining lease term and discount rate used are as follows:

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 

Weighted-average remaining lease term (years):

        

Operating lease assets

  2.62   1.72 

Finance lease assets

  0.37   0.87 

Weighted-average discount rate:

        

Operating lease assets

  8.85%  7.78%

Finance lease assets

  6.54%  6.54%

 

Supplemental cash flow information related to lease is as follows:

 

  

Six Months Ended

 
  

December 31,

 
  

2023

  

2022

 
  

(in thousands)

 

Cash flow classification of lease payments:

        

Operating cash flows from operating leases

 $697  $716 

Operating cash flows from finance leases

 $2  $5 

Financing cash flows from finance leases

 $46  $52 

 

As of December 31, 2023, the maturities of the Company’s future minimum lease payments were as follows:

 

  

Operating

  

Finance

 
  

(in thousands)

 

2024 (remaining 6 months)

 $735  $40 

2025

  938    

2026

  282    

2027

  241    

2028

  199    

Thereafter

  151    

Total lease payments

  2,546   40 

Less: imputed interest

  (332)  (1)

Lease liabilities

 $2,214  $39 

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Intangible Assets
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]

Note 7 - Intangible Assets

 

The following table provides the summary of the Company’s intangible assets as of December 31, 2023 and June 30, 2023, respectively. Carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period.

 

  

December 31, 2023

 
              

Weighted-

 
          

Net

  

Average

 
  

Carrying

  

Accumulated

  

Carrying

  

Remaining

 
  

Amount

  

Amortization

  

Amount

  

Life (in years)

 
  

(in thousands)

 

Definite-lived intangibles:

                

Acquired product technology rights

 $41,467  $(11,777) $29,690   11.04 

Acquired technology right

  30,200   (4,943)  25,257   14.25 

Acquired product distribution rights

  6,207   (5,443)  764   0.50 

Total intangible assets

 $77,874  $(22,163) $55,711   12.35 

 

  

June 30, 2023

 
              

Weighted-

 
          

Net

  

Average

 
  

Carrying

  

Accumulated

  

Carrying

  

Remaining

 
  

Amount

  

Amortization

  

Amount

  

Life (in years)

 
  

(in thousands)

 

Definite-lived intangibles:

                

Acquired product technology rights

 $42,176  $(10,881) $31,295   11.49 

Acquired technology right

  30,200   (4,054)  26,146   14.75 

Acquired product distribution rights

  6,207   (4,678)  1,529   1.00 

Total intangible assets

 $78,583  $(19,613) $58,970   12.67 

 

The following table summarizes the estimated future amortization expense to be recognized over the next five fiscal years and periods thereafter:

 

  

December 31,

 
  

(in thousands)

 

2024 (remaining 6 months)

 $3,259 

2025

  4,989 

2026

  4,989 

2027

  4,989 

2028

  4,988 

Thereafter

  32,497 

Total future amortization expense

 $55,711 

 

Acquired Product Technology Rights

 

The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021.

 

Karbinal ER. The Company acquired and assumed all rights and obligations pursuant to the Supply and Distribution Agreement, as Amended, with Tris Pharma, Inc. (“Tris”) for the exclusive rights to commercialize Karbinal ER in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in August of 2033, with an optional additional 20-year extension.

 

Poly-Vi-Flor and Tri-Vi-Flor. The Company acquired and assumed all rights and obligations pursuant to a Supply and License Agreement and various assignment and release agreements, including a previously agreed to Settlement and License Agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.

 

ADHD Portfolio. As part of the Neos Acquisition, the Company acquired product technology for the production and sale of Adzenys XR-ODT and Cotempla XR-ODT. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 17 years.

 

Acquired Technology Right

 

TRRP Technology. As part of the Neos Acquisition, the Company acquired Time Release Resin Particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlies the ADHD portfolio and can potentially be used in future product development initiatives as well.

 

Acquired Product Distribution Rights (and customer list)

 

In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. During the fourth quarter of fiscal 2023, the acquired product distribution rights incurred an impairment charge of $3.0 million due to the discontinuation of products in the Consumer Health Segment.

 

Acquired In-Process R&D

 

IPR&D NT0502. As part of the Neos Acquisition, the Company acquired in-process research and development associated with NT0502, a new chemical entity being developed for the treatment of sialorrhea, which is excessive salivation or drooling. As this is an indefinite-lived intangible asset, this acquired asset remains an indefinite-lived asset until the completion or abandonment of the associated research and development efforts. If a product using this technology is eventually approved for commercial sale, at that time, the IPR&D will begin amortizing on a straight-line basis over the life of the product. During fiscal 2023, the Company terminated its development program of NT0502. As a result, the Company fully impaired the IPR&D of NT0502, recording impairment expense of $2.6 million to its Rx Segment during the three months ended December 31, 2022.

 

Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.6 million and $1.5 million for the three months ended December 31, 2023 and 2022, respectively, and $3.3 million and $3.0 million for the six months ended December 31, 2023 and 2022, respectively.

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 8 - Accrued Liabilities
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Accrued Liabilities [Text Block]

Note 8 - Accrued Liabilities

 

Accrued liabilities consist of the following:

 

   

December 31,

   

June 30,

 
   

2023

   

2023

 
   

(in thousands)

 

Accrued savings offers

  $ 14,852     $ 15,739  

Accrued program liabilities

    11,841       11,012  

Accrued customer and product related fees

    5,699       6,579  

Return reserve

    5,129       5,777  

Accrued employee compensation

    3,362       5,675  

Other accrued liabilities

    2,530       2,017  

Total accrued liabilities

  $ 43,413     $ 46,799  

 

Accrued savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. The return reserve represents the Company’s accrual for estimated product returns. Other accrued liabilities consist of various other accruals, none of which individually or in the aggregate represent greater than five percent of total liabilities.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 9 - Other Liabilities
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Other Liabilities Disclosure [Text Block]

Note 9 - Other Liabilities

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Fixed payment arrangements

 $9,043  $10,420 

Operating lease liabilities

  2,214   2,090 

Employee retention credit

  3,759    

Other

  564   1,555 

Total other liabilities

  15,580   14,065 

Less: current portion

  (9,236)  (7,090)

Total other liabilities, non-current

 $6,344  $6,975 

 

Fixed Payment Arrangements

 

Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments.

 

The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. As of December 31, 2023, the fixed payment arrangement balance was $1.8 million in other current liabilities, and $1.2 million in other non-current liabilities on the consolidated balance sheet.

 

On May 12, 2022, the Company entered into an agreement with Tris to terminate the Tuzistra XR License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $9.0 million, which reduced its total liability for minimum payments by approximately $8.0 million from the original License Agreement. As of December 31, 2023, the balance was $6.0 million in other current liabilities on the consolidated balance sheet.

 

Operating Lease Liabilities 

 

The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to Note 6 - Leases for further detail.

 

Employee Retention Credit 

 

The $3.8 million ERC accrual in other non-current liabilities as of December 31, 2023, represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. The ERC is a refundable payroll tax credit from the CARES Act enacted by the U.S. government to provide certain relief from the COVID-19 pandemic. The refundable payroll tax credit shall be recognized in the consolidated statement of operations following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Service (see Note 2 – Significant Accounting Policies). The associated vendor fee of $0.4 million was expensed as incurred in the first quarter of fiscal 2024.

 

Other

 

Other consists of taxes payable and deferred cost related to the Company’s technology transfer.

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 10 - Line of Credit
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Short-Term Debt [Text Block]

Note 10 - Line of Credit

 

The Company has entered into a secured credit agreement, as amended, with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $14.0 million, less a $3.5 million availability block, in secured revolving loans (the “Revolving Loans”), against 85% of eligible accounts receivable. The Revolving Loans thereunder, accrue at variable interest through maturity at the one-month Secure Overnight Financing Rate (“SOFR”), plus 4.50%. The Eclipse Loan Agreement includes an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The maturity date under the Eclipse Loan Agreement is January 26, 2025.

 

In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (ii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement at any time with at least five business days prior notice to Eclipse.

 

The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of December 31, 2023, the Company was in compliance with the covenants under the Eclipse Loan Agreement.

 

The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement.

 

Total interest expense on the Revolving Loans, including amortization of deferred financing costs, was $23.2 thousand and $176.7 thousand for the three months ended December 31, 2023 and 2022, respectively and $50.1 thousand and $274.0 thousand for the six months ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and June 30, 2023, the outstanding Revolving Loans under the Eclipse Loan Agreement, as amended, were $1.0 million and $1.6 million, respectively.

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 11 - Long-term Debt
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Long-Term Debt [Text Block]

Note 11 - Long-term Debt

 

Avenue Capital Loan

 

On January 26, 2022 (“Closing Date”), the Company entered into a Loan and Security Agreement (the “Avenue Capital Agreement”) with Avenue Venture Opportunities Fund, L.P. (“Avenue”) and Avenue Venture Opportunities Fund II, L.P. (Avenue 2”) as lenders (the “Avenue Capital Lenders”), and Avenue Capital Management II, L.P. as administrative agent (the “Avenue Capital Agent”, and collectively with the Avenue Capital Lenders, “Avenue Capital”), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan is the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used to repay the senior secured term credit facility with Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P., which the Company assumed through the Neos Acquisition.

 

Pursuant to the Avenue Capital Agreement, the Company made interest only payments for the first 18 months following the Closing Date (“Interest-only Period”). In June 2023, the Company achieved certain defined milestones extending the Interest-Only Period through the maturity date.

 

In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (ii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount.

 

The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement.

 

The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of December 31, 2023, the Company was in compliance with the covenants under the Avenue Capital Agreement.

 

On January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering, and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants are immediately exercisable and expire on January 31, 2027. The Company accounted for the Avenue Capital Warrants as a liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million.

 

On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants at an offering price of $25.00 per share. As the Avenue Capital Agreement precluded the Company from pursuing any equity financing prior to July 7, 2022, and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the number of shares of common stock issuable upon exercise of the Avenue Capital Warrants were set to 43,388 at an exercise price of $24.20.

 

On October 25, 2022, the Company entered into an agreement with Avenue to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company’s August 2022 equity financing.

 

In addition to the debt discount discussed above, the Company incurred $0.4 million in loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 19.6%. Total interest expense, including debt discount amortization, was $0.7 million for both the three months ended December 31, 2023 and 2022, and $1.5 million and $1.3 million for the six months ended December 31, 2023 and 2022, respectively.

 

Long-term debt consists of the following:

 

  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Long-term debt, due on January 26, 2025

 $15,000  $15,000 

Long-term, final payment fee

  638   638 

Unamortized discount and issuance costs

  (660)  (925)

Financing leases, maturing through May 2024

  39   85 

Total debt

  15,017   14,798 

Less: current portion

  (39)  (85)

Non-current portion of debt

 $14,978  $14,713 

 

Future principal payments of long-term debt, including financing leases, are as follows:

 

  

December 31,

 
  

(in thousands)

 

2024 (remaining 6 months)

 $39 

2025

  15,638 

Future principal payments

  15,677 

Less: unamortized discount and issuance costs

  (660)

Less: current portion

  (39)

Non-current portion of debt

 $14,978 

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Fair Value Considerations
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

Note 12 - Fair Value Considerations

 

The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to determine fair value as follows:

 

 

Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;

 

 

Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and

 

 

Level 3: Unobservable inputs that are supported by little or no market activity.

 

The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, fixed payment arrangements, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on the unaudited consolidated balance sheets. The remaining financial instruments and derivative warrant liabilities are reported on the unaudited consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2, and Level 3 in the periods presented.

 

Recurring Fair Value Measurements

 

The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of  December 31, 2023 and June 30, 2023, by level within the fair value hierarchy.

 

      

Fair Value Measurements at December 31, 2023

 
  

Fair Value at December 31,

             
  

2023

  

(Level 1)

  

(Level 2)

  

(Level 3)

 
  

(in thousands)

 

Liabilities:

                

Derivative warrant liabilities

  12,887         12,887 

Total

 $12,887  $  $  $12,887 

 

 

      

Fair Value Measurements at June 30, 2023

 
  

Fair Value at June 30,

             
  

2023

  

(Level 1)

  

(Level 2)

  

(Level 3)

 
  

(in thousands)

 

Liabilities:

                

Derivative warrant liabilities

  6,403         6,403 

Total

 $6,403  $  $  $6,403 

 

Summary of Level 3 Input Changes

 

The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the six months ended December 31, 2023.

 

  

Derivative

 
  

Warrant Liabilities

 
  

(in thousands)

 

Balance as of June 30, 2023

 $6,403 

Included in earnings

  6,484 

Balance as of December 31, 2023

 $12,887 

 

Significant Assumptions

 

The following table presents the valuation methodologies and key assumptions used for the marked to market fair value measurements of derivative warrant liabilities as of December 31, 2023.

 

  

June 2023 Warrants

  

Warrants

 
  

Tranche A & B

  

Other *

 
  

Monte Carlo Simulation

    
  

& Black-Scholes

  

Black-Scholes

 

Equivalent term (years)

 4.44  3.09-3.69 

Expected volatility

 

96.15%

  

96.15%

 

Risk-free rate

 

3.88%

  

3.95-4.01%

 

Dividend yield

 

0.00%

  

0.00%

 

 

* Includes August 2022 Warrants, March 2022 Warrants, and Avenue Capital Warrants.

 

The Black-Scholes option pricing model is used to value all warrants with significant Level 3 inputs. The Monte Carlo Simulation is used to simulate the exit price and EBITDA forecast; average warrant value per share is from 100,000 Monte Carlo simulations. The Monte Carlo is based on significant inputs including financial projections provided by the Company’s management used primarily to forecast future results not observable in the market, and thus, represents a Level 3 measure.

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Commitments and Contingencies
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

Note 13 - Commitments and Contingencies

 

Pediatric Portfolio Fixed Payments and Product Milestone

 

The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell Karbinal ER in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales.

 

The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000‑unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of product net revenues.

 

Rumpus Earn Out Payments

 

On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, the Company made a payment of $0.6 million for a license fee in April 2022. In addition, upon the achievement of regulatory and commercial milestones, the Company may be required to pay up to $101.7 million and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for royalties of 3.0% of net product sales, with a minimum of $20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. In October 2022, the Company announced the indefinite suspension of its development of AR101.

 

Legal Matters

 

Witmer Class-Action Securities Litigation. A stockholder derivative suit filed on September 12, 2022, in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, and later amended, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice’s Chief Investment Officer and Managing Partner, and a former director of Aytu) (collectively “Armistice”), and certain other current and former directors of Aytu, Joshua Disbrow, Gary Cantrell, John Donofrio, Jr, Carl Dockery and Ketan B. Mehta. The amended complaint alleges that (i) Armistice facilitated the sale of assets of Cerecor, Inc., in 2019 and Innovus Pharmaceuticals, Inc., in 2020 to Aytu in exchange for convertible securities, which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants’ breaches of fiduciary duties, in connection with these acquisitions. The amended complaint seeks unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys’ fees. While the Company believes that this lawsuit is without merit and has vigorously defended against it, the Company has agreed to settle the matter, as against it and the director defendants other than Mr. Boyd, for various corporate governance modifications and the payment of plaintiff’s attorneys’ fees. That settlement is subject to court approval, the hearing on which has not yet been scheduled.

 

Sabby Litigation. A complaint was filed on February 22, 2023, in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund Ltd (“Sabby”) and Walleye Opportunities Master Fund Ltd (“Walleye”), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrant holders may receive, and that the Company failed to provide prompt notice to the warrant holders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. In October 2023, the Company entered into a settlement agreement and general release with Sabby and Walleye.

 

Stein Litigation. Cielo Stein (“Stein”), a former sales specialist, filed a complaint on February 1, 2023, in Jefferson County Circuit Court in Kentucky against the Company and its wholly owned subsidiary Neos Therapeutics. The complaint alleges that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleges that the Company’s response to Stein’s subsequent complaint to human resources was inadequate. The complaint seeks an award of unspecified compensatory damages, emotional-distress damages, and attorneys’ fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky and filed a motion to dismiss the complaint, which was denied. The case has been referred to a magistrate judge for, among other things, the entry of a scheduling order and to conduct a settlement conference. Due to the early stage of litigation, and while the Company believes that this lawsuit is without merit, the Company is not able to predict at this time whether this proceeding will have a material impact on its financial condition or results of operations and intend to vigorously defend this case in the event it is not dismissed.

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Capital Structure
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Equity [Text Block]

Note 14 - Capital Structure

 

The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. Included in the common stock outstanding are 40,017 shares of unvested restricted stock issued to executives, directors and employees.

 

On June 8, 2020, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on June 17, 2020. This shelf registration statement covered the offering, issuance, and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2020 Shelf”). On June 4, 2021, the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the 2020 Shelf (the “ATM Sales Agreement”). During the year ended June 30, 2023, the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of approximately $2.9 million. The 2020 Shelf expired in June 2023.

 

On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2021 Shelf”). As of December 31, 2023, approximately $82.4 million remained available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitation to the Form S-3.

 

On August 11, 2022, the Company closed on an underwritten public offering (the “August 2022 Offering”) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock, and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants have a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders’ equity in the Company’s consolidated financial statements (See Note 16 – Warrants).

 

On June 8, 2023, using a placement agency, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the “Pre-Funded Warrants”), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the “Common Warrants”). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the “Exchange Warrants”). Each Pre-Funded Warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company’s common stock equaling 200% of the exercise price ($3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company’s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million. The Company raised $4.0 million in gross proceeds and net proceeds were approximately $3.4 million after deducting offering expenses. The warrants have a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in other expense along with the issuance costs of $0.6 million in the consolidated financial statement of operations (See Note 16 – Warrants).

 

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 15 - Equity Incentive Plans
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

Note 15 - Equity Incentive Plans

 

2023 Equity Incentive Plan. On May 18, 2023, the Company’s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the “2023 Equity Incentive Plan”). Prior to the Company’s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (the “Aytu 2015 Plan”) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (the “Neos 2015 Plan”, and collectively with the Aytu 2015 Plan, the “2015 Plans”). For the 2023 Equity Incentive Plan, the stockholders approved (a) 200,000 new shares, (b) 87,129 shares available for grant under the 2015 Plans be “rolled over” to the 2023 Equity Incentive Plan and (c) any shares that are returned to the company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional awards will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the 2023 Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of December 31, 2023, the Company had 179,732 shares that are available for grant under the 2023 Equity Incentive Plan.

 

Aytu 2015 Plan. On June 1, 2015, the Company’s stockholders approved the Aytu 2015 Plan, which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 150,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. On February 13, 2020, the Company’s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, whereas the restricted stock units have a vesting period of 4 years.

 

Neos 2015 Plan. Pursuant to the Neos Merger, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos 2015 Plan. Accordingly, on April 19, 2021, the Company registered 5,272 shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos 2015 Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years.

 

Stock Options

 

Stock option activity is as follows:

 

          

Weighted

 
          

Average

 
      

Weighted

  

Remaining

 
  

Number of

  

Average

  

Contractual

 
  

Options

  

Exercise Price

  

Life in Years

 

Outstanding June 30, 2023

  52,762  $18.37   9.06 

Granted

  112,000  $1.73   9.61 

Forfeited/cancelled

  (15,060) $2.94    

Expired

  (615) $184.80    

Outstanding at December 31, 2023

  149,087  $6.43   9.17 
             

Exercisable at December 31, 2023

  20,470  $30.18   8.02 

 

The weighted-average grant date fair value of options granted during the six months ended December 31, 2023 was $1.73. As of December 31, 2023, there was $0.4 million total unrecognized compensation costs related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.85 years.

 

Restricted Stock

 

Restricted stock activity is as follows:

 

      

Weighted

 
      

Average Grant

 
  

Number of

  

Date Fair

 
  

Shares

  

Value

 

Unvested at June 30, 2023

  38,075  $142.20 

Granted

  12,500  $1.77 

Vested

  (12,189) $130.45 

Forfeited/cancelled

  (457) $136.80 

Unvested at December 31, 2023

  37,929  $99.75 

 

As of December 31, 2023, there was $2.0 million total unrecognized compensation costs related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.9 years.

 

As of December 31, 2023, there was $0.3 million total unrecognized costs related to non-vested restricted stock outside of the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.1 years. As of December 31, 2023, 2,088 shares of restricted stock remain unvested.

 

Restricted Stock Units

 

Restricted stock units (“RSU” or “RSUs”) activity is as follows:

 

      

Weighted

 
      

Average Grant

 
  

Number of

  

Date Fair

 
  

Shares

  

Value

 

Unvested at June 30, 2023

  4,963  $25.62 

Vested

  (1,126) $24.28 

Forfeited

  (939) $31.60 

Unvested at December 31, 2023

  2,898  $24.19 

 

As of December 31, 2023, there was $0.1 million total unrecognized compensation costs related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.2 years.

 

Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table:

 

  

Three Months Ended

  

Six Months Ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

  

2023

  

2022

 
  

(in thousands)

 

Cost of sales

 $1  $3  $1  $8 

Research and development

  2   14   3   23 

Selling and marketing

     3      6 

General and administrative

  817   3,047   1,746   4,207 

Total stock-based compensation expense

 $820  $3,067  $1,750  $4,244 

 

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 16 - Warrants
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Warrants or Rights Disclosure [Text Block]

Note 16 - Warrants

 

Liability Classified Warrants

 

On June 8, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock, (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering. The Tranche A Warrants and Tranche B Warrants may be exercised for either shares of common stock or pre-funded exchange warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the pre-funded warrant. Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The Tranche A Warrants and Tranche B Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per pre-funded exchange warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company’s common stock equaling 200% of the exercise price ($3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company’s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million (see Note 14 – Capital Structure).

 

On August 11, 2022, the Company closed an offering (the “August 2022 Offering”), pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant was sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The common warrants provide that if there occurs any stock split, stock dividend stock recapitalization, or similar event (a “Stock Combination Event”), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the common stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by (y) five; or $2.32, and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see Note 14 – Capital Structure).

 

In November 2022 and throughout the quarter ended December 31, 2022, the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022 Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $8.60. As a result, the common warrants exercise price was adjusted to $3.30. On January 6, 2023, the Company consummated a 20 to 1 reverse stock split. Pursuant to the warrant agreement described above, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest five trading days during the twenty-day consecutive trading day period beginning on December 30, 2022. Subsequently, as a result of the Securities Purchase Agreement in June 2023, the common warrants from the August 2022 Offering had an adjusted exercise price of $2.32.

 

Certain outstanding warrants are classified as derivative warrant liabilities in the consolidated balance sheets and are marked to market at each reporting period (see Note 12 – Fair Value Considerations).

 

A summary of warrants is as follows:

 

          

Weighted

 
          

Average

 
      

Weighted

  

Remaining

 
  

Number of

  

Average

  

Contractual

 
  

Warrants

  

Exercise Price

  

Life in Years

 

Outstanding June 30, 2023

  6,538,052  $4.42   4.71 

Warrants exercised

  (37,004) $2.32    

Warrants expired

  (20,958) $300.00    

Outstanding December 31, 2023

  6,480,090  $3.48   4.22 

 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 17 - Earnings Per Share
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Earnings Per Share [Text Block]

Note 17 - Earnings Per Share

 

Basic loss per common share is calculated by dividing the net loss available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company.

 

The following table sets forth securities that are considered anti-dilutive, and therefore excluded from the calculation of diluted earnings per share.

 

  

December 31,

 
  

2023

  

2022

 

Warrants to purchase common stock - liability classified

  6,498,980   1,642,235 

Warrant to purchase common stock - equity classified

  39,072   56,486 

Employee stock options

  149,087   52,861 

Employee unvested restricted stock

  40,017   48,280 

Employee unvested restricted stock units

  2,898   8,167 

Total

  6,730,054   1,808,029 

 

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 18 - License Agreements
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Licensing Agreements [Text Block]

Note 18 - License Agreements

 

Teva

 

On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances.

 

Actavis

 

On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis (now Teva, following Teva’s acquisition of Actavis’ generic products) has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances.

 

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 19 - Segment Reporting
6 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 19 - Segment Reporting

 

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on the Company’s financial information. The CODM reviews financial information presented for each reportable segment for the purpose of making operating decisions and assessing financial performance.

 

The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company’s prescription products. The Consumer Health Segment contains the Company’s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment.

 

Select financial information for these segments is as follows:

 

  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Three Months Ended December 31, 2023

            
             

Product revenue, net

 $18,748  $4,186  $22,934 

Income (loss) from operations

 $3,146  $(782) $2,364 
             

Depreciation and amortization

 $1,510  $389  $1,899 

Stock-based compensation expense

 $707  $113  $820 
             

Three Months Ended December 31, 2022

            
             

Product revenue, net

 $18,029  $8,250  $26,279 

Loss from operations

 $(5,464) $(1,404) $(6,868)
             

Depreciation and amortization

 $1,572  $281  $1,853 

Impairment expense

 $2,600  $  $2,600 

Stock-based compensation expense

 $2,987  $80  $3,067 

 

  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Six Months Ended December 31, 2023

            
             

Product revenue, net

 $36,565  $8,468  $45,033 

Income (loss) from operations

 $2,280  $(1,420) $860 
             

Depreciation and amortization

 $3,064  $776  $3,840 

Stock-based compensation expense

 $1,432  $318  $1,750 
             

Six Months Ended December 31, 2022

            
             

Product revenue, net

 $36,681  $17,253  $53,934 

Loss from operations

 $(6,457) $(2,219) $(8,676)
             

Depreciation and amortization

 $3,146  $562  $3,708 

Impairment expense

 $2,600  $  $2,600 

Stock-based compensation expense

 $4,149  $95  $4,244 

 

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
6 Months Ended
Dec. 31, 2023
Insider Trading Arr Line Items  
Material Terms of Trading Arrangement [Text Block]

ITEM 5. OTHER INFORMATION

 

Rule 10b5-1 Trading Plans

 

During the fiscal quarter ended  December 31, 2023, none of our directors or executive officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).

 

Rule 10b5-1 Arrangement Adopted [Flag] false
Non-Rule 10b5-1 Arrangement Adopted [Flag] false
Rule 10b5-1 Arrangement Terminated [Flag] false
Non-Rule 10b5-1 Arrangement Terminated [Flag] false
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Significant Accounting Policies (Policies)
6 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for credit losses, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of warrants and derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.

 

Warrants [Policy Text Block]

Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC Topic 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable.

 

Income Tax, Policy [Policy Text Block]

Income Taxes

 

The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three and six months ended December 31, 2023. The effective tax rate was 136.2% and negative 11.0% for the three and six months ended December 31, 2023, respectively, primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances. The effective tax rate was 0% for both the three and six months ended December 31, 2022, respectively, reflecting the full valuation allowance and no impact of Section 382 of the Internal Revenue Code.

 

An ownership change could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Company's ability to use the pre-acquisition net operating loss carryovers. The ownership changes could result in increased future tax liability and are a driver of the change from a zero percent effective tax rate.

 

Employee Retention Credit

 

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020 through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic.

 

As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). In accordance with IAS 20, when management determines reasonable assurance that the Company had substantially met all eligibility requirements of the ERC, the ERC benefit shall be recognized as other income in the consolidated statement of operations (see Note - 9 Other Liabilities).

 

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Pronouncements

 

Financial Instruments – Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (“ASU 2016-13”) requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU 2016-13 is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after December 15, 2019. However, in October 2019, the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after December 15, 2022. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company adopted ASU 2016-13 and ASU 2019-05 on July 1, 2023. The Company evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company’s consolidated financial statements.

 

Recent Accounting Pronouncements Not Yet Adopted

 

Debt - Debt with Conversion and Other Options. In August 2020, the FASB issued ASU No. 2020-06, DebtDebt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entitys Own Equity (Subtopic 815-40) Accounting for Convertible Instruments and Contracts in an Entitys Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2024 and does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.

 

Segment Reporting - Improvements to Reportable Segment Disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company’s consolidated financial statements and disclosures.

 

For a complete set of the Company’s significant accounting policies, refer to the Company's 2023 Form 10-K. Other than the application of IAS 20 for the ERC, there have been no significant changes to the Company’s significant accounting policies during the six months ended December 31, 2023

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 3 - Revenues From Contracts with Customers (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

Three Months Ended

  

Six Months Ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

  

2023

  

2022

 
  

(in thousands)

 

Consolidated net revenue:

                

Rx Segment

 $18,748  $18,029  $36,565  $36,681 

Consumer Health Segment

  4,186   8,250   8,468   17,253 

Total consolidated net revenue

 $22,934  $26,279  $45,033  $53,934 
  

Three Months Ended

  

Six Months Ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

  

2023

  

2022

 
  

(in thousands)

 

Rx Segment net revenue:

                

ADHD Portfolio

 $16,572  $11,120  $31,700  $22,705 

Pediatric Portfolio

  2,145   6,328   4,710   12,886 

Other

  31   581   155   1,090 

Total Rx Segment net revenue

 $18,748  $18,029  $36,565  $36,681 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Inventories (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Raw materials

 $1,654  $1,301 

Work in process

  2,674   2,956 

Finished goods

  8,673   7,738 

Inventories

 $13,001  $11,995 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Property and Equipment (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Property, Plant and Equipment [Table Text Block]
  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Manufacturing equipment

 $1,183  $2,433 

Office equipment, furniture and other

  1,146   1,125 

Leasehold improvements

  999   999 

Lab equipment

  832   832 

Assets under construction

  45   107 

Property and equipment, gross

  4,205   5,496 

Less: accumulated depreciation and amortization

  (3,078)  (3,681)

Property and equipment, net

 $1,127  $1,815 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Leases (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Lease, Cost [Table Text Block]
  

Three Months Ended

  

Six Months Ended

  
  

December 31,

  

December 31,

  
  

2023

  

2022

  

2023

  

2022

 

Statement of Operations Classification

  

(in thousands)

  

Lease cost:

                 

Operating lease cost

 $381  $359  $741  $716 

Operating expenses

Short-term lease cost

  21   19   44   44 

Operating expenses

Finance lease cost:

                 

Amortization of leased assets

  15   19   29   37 

Cost of sales

Interest on lease liabilities

  1   2   2   5 

Other expense, net

Total net lease cost

 $418  $399  $816  $802  
  

December 31,

  

June 30,

 
  

2023

  

2023

 

Weighted-average remaining lease term (years):

        

Operating lease assets

  2.62   1.72 

Finance lease assets

  0.37   0.87 

Weighted-average discount rate:

        

Operating lease assets

  8.85%  7.78%

Finance lease assets

  6.54%  6.54%
  

Six Months Ended

 
  

December 31,

 
  

2023

  

2022

 
  

(in thousands)

 

Cash flow classification of lease payments:

        

Operating cash flows from operating leases

 $697  $716 

Operating cash flows from finance leases

 $2  $5 

Financing cash flows from finance leases

 $46  $52 
Schedule of Lease by Balance Sheet Information [Table Text Block]
  

December 31,

  

June 30,

  
  2023  2023 

Balance Sheet Classification

  

(in thousands)

  

Assets:

         

Operating lease assets

 $2,133  $2,054 

Operating lease right-of-use assets

Finance lease assets

     159 

Property and equipment, net

Total lease assets

 $2,133  $2,213  

Liabilities:

         

Current:

         

Operating leases

 $1,369  $1,258 

Other current liabilities

Finance leases

  39   85 

Current portion of debt

Non-current:

         

Operating leases

  845   832 

Other non-current liabilities

Total lease liabilities

 $2,253  $2,175  
Lessee, Liability, Maturity [Table Text Block]
  

Operating

  

Finance

 
  

(in thousands)

 

2024 (remaining 6 months)

 $735  $40 

2025

  938    

2026

  282    

2027

  241    

2028

  199    

Thereafter

  151    

Total lease payments

  2,546   40 

Less: imputed interest

  (332)  (1)

Lease liabilities

 $2,214  $39 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Intangible Assets (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
  

December 31, 2023

 
              

Weighted-

 
          

Net

  

Average

 
  

Carrying

  

Accumulated

  

Carrying

  

Remaining

 
  

Amount

  

Amortization

  

Amount

  

Life (in years)

 
  

(in thousands)

 

Definite-lived intangibles:

                

Acquired product technology rights

 $41,467  $(11,777) $29,690   11.04 

Acquired technology right

  30,200   (4,943)  25,257   14.25 

Acquired product distribution rights

  6,207   (5,443)  764   0.50 

Total intangible assets

 $77,874  $(22,163) $55,711   12.35 
  

June 30, 2023

 
              

Weighted-

 
          

Net

  

Average

 
  

Carrying

  

Accumulated

  

Carrying

  

Remaining

 
  

Amount

  

Amortization

  

Amount

  

Life (in years)

 
  

(in thousands)

 

Definite-lived intangibles:

                

Acquired product technology rights

 $42,176  $(10,881) $31,295   11.49 

Acquired technology right

  30,200   (4,054)  26,146   14.75 

Acquired product distribution rights

  6,207   (4,678)  1,529   1.00 

Total intangible assets

 $78,583  $(19,613) $58,970   12.67 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
  

December 31,

 
  

(in thousands)

 

2024 (remaining 6 months)

 $3,259 

2025

  4,989 

2026

  4,989 

2027

  4,989 

2028

  4,988 

Thereafter

  32,497 

Total future amortization expense

 $55,711 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 8 - Accrued Liabilities (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   

December 31,

   

June 30,

 
   

2023

   

2023

 
   

(in thousands)

 

Accrued savings offers

  $ 14,852     $ 15,739  

Accrued program liabilities

    11,841       11,012  

Accrued customer and product related fees

    5,699       6,579  

Return reserve

    5,129       5,777  

Accrued employee compensation

    3,362       5,675  

Other accrued liabilities

    2,530       2,017  

Total accrued liabilities

  $ 43,413     $ 46,799  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 9 - Other Liabilities (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Other Liabilities [Table Text Block]
  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Fixed payment arrangements

 $9,043  $10,420 

Operating lease liabilities

  2,214   2,090 

Employee retention credit

  3,759    

Other

  564   1,555 

Total other liabilities

  15,580   14,065 

Less: current portion

  (9,236)  (7,090)

Total other liabilities, non-current

 $6,344  $6,975 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 11 - Long-term Debt (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Long-Term Debt Instruments [Table Text Block]
  

December 31,

  

June 30,

 
  

2023

  

2023

 
  

(in thousands)

 

Long-term debt, due on January 26, 2025

 $15,000  $15,000 

Long-term, final payment fee

  638   638 

Unamortized discount and issuance costs

  (660)  (925)

Financing leases, maturing through May 2024

  39   85 

Total debt

  15,017   14,798 

Less: current portion

  (39)  (85)

Non-current portion of debt

 $14,978  $14,713 
Schedule of Maturities of Long-Term Debt [Table Text Block]
  

December 31,

 
  

(in thousands)

 

2024 (remaining 6 months)

 $39 

2025

  15,638 

Future principal payments

  15,677 

Less: unamortized discount and issuance costs

  (660)

Less: current portion

  (39)

Non-current portion of debt

 $14,978 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Fair Value Considerations (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
      

Fair Value Measurements at December 31, 2023

 
  

Fair Value at December 31,

             
  

2023

  

(Level 1)

  

(Level 2)

  

(Level 3)

 
  

(in thousands)

 

Liabilities:

                

Derivative warrant liabilities

  12,887         12,887 

Total

 $12,887  $  $  $12,887 
      

Fair Value Measurements at June 30, 2023

 
  

Fair Value at June 30,

             
  

2023

  

(Level 1)

  

(Level 2)

  

(Level 3)

 
  

(in thousands)

 

Liabilities:

                

Derivative warrant liabilities

  6,403         6,403 

Total

 $6,403  $  $  $6,403 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
  

Derivative

 
  

Warrant Liabilities

 
  

(in thousands)

 

Balance as of June 30, 2023

 $6,403 

Included in earnings

  6,484 

Balance as of December 31, 2023

 $12,887 
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
  

June 2023 Warrants

  

Warrants

 
  

Tranche A & B

  

Other *

 
  

Monte Carlo Simulation

    
  

& Black-Scholes

  

Black-Scholes

 

Equivalent term (years)

 4.44  3.09-3.69 

Expected volatility

 

96.15%

  

96.15%

 

Risk-free rate

 

3.88%

  

3.95-4.01%

 

Dividend yield

 

0.00%

  

0.00%

 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 15 - Equity Incentive Plans (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
          

Weighted

 
          

Average

 
      

Weighted

  

Remaining

 
  

Number of

  

Average

  

Contractual

 
  

Options

  

Exercise Price

  

Life in Years

 

Outstanding June 30, 2023

  52,762  $18.37   9.06 

Granted

  112,000  $1.73   9.61 

Forfeited/cancelled

  (15,060) $2.94    

Expired

  (615) $184.80    

Outstanding at December 31, 2023

  149,087  $6.43   9.17 
             

Exercisable at December 31, 2023

  20,470  $30.18   8.02 
Nonvested Restricted Stock Shares Activity [Table Text Block]
      

Weighted

 
      

Average Grant

 
  

Number of

  

Date Fair

 
  

Shares

  

Value

 

Unvested at June 30, 2023

  38,075  $142.20 

Granted

  12,500  $1.77 

Vested

  (12,189) $130.45 

Forfeited/cancelled

  (457) $136.80 

Unvested at December 31, 2023

  37,929  $99.75 
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
      

Weighted

 
      

Average Grant

 
  

Number of

  

Date Fair

 
  

Shares

  

Value

 

Unvested at June 30, 2023

  4,963  $25.62 

Vested

  (1,126) $24.28 

Forfeited

  (939) $31.60 

Unvested at December 31, 2023

  2,898  $24.19 
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
  

Three Months Ended

  

Six Months Ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

  

2023

  

2022

 
  

(in thousands)

 

Cost of sales

 $1  $3  $1  $8 

Research and development

  2   14   3   23 

Selling and marketing

     3      6 

General and administrative

  817   3,047   1,746   4,207 

Total stock-based compensation expense

 $820  $3,067  $1,750  $4,244 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 16 - Warrants (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Warrant or Right Activity
          

Weighted

 
          

Average

 
      

Weighted

  

Remaining

 
  

Number of

  

Average

  

Contractual

 
  

Warrants

  

Exercise Price

  

Life in Years

 

Outstanding June 30, 2023

  6,538,052  $4.42   4.71 

Warrants exercised

  (37,004) $2.32    

Warrants expired

  (20,958) $300.00    

Outstanding December 31, 2023

  6,480,090  $3.48   4.22 
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 17 - Earnings Per Share (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
  

December 31,

 
  

2023

  

2022

 

Warrants to purchase common stock - liability classified

  6,498,980   1,642,235 

Warrant to purchase common stock - equity classified

  39,072   56,486 

Employee stock options

  149,087   52,861 

Employee unvested restricted stock

  40,017   48,280 

Employee unvested restricted stock units

  2,898   8,167 

Total

  6,730,054   1,808,029 
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 19 - Segment Reporting (Tables)
6 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Three Months Ended December 31, 2023

            
             

Product revenue, net

 $18,748  $4,186  $22,934 

Income (loss) from operations

 $3,146  $(782) $2,364 
             

Depreciation and amortization

 $1,510  $389  $1,899 

Stock-based compensation expense

 $707  $113  $820 
             

Three Months Ended December 31, 2022

            
             

Product revenue, net

 $18,029  $8,250  $26,279 

Loss from operations

 $(5,464) $(1,404) $(6,868)
             

Depreciation and amortization

 $1,572  $281  $1,853 

Impairment expense

 $2,600  $  $2,600 

Stock-based compensation expense

 $2,987  $80  $3,067 
  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Six Months Ended December 31, 2023

            
             

Product revenue, net

 $36,565  $8,468  $45,033 

Income (loss) from operations

 $2,280  $(1,420) $860 
             

Depreciation and amortization

 $3,064  $776  $3,840 

Stock-based compensation expense

 $1,432  $318  $1,750 
             

Six Months Ended December 31, 2022

            
             

Product revenue, net

 $36,681  $17,253  $53,934 

Loss from operations

 $(6,457) $(2,219) $(8,676)
             

Depreciation and amortization

 $3,146  $562  $3,708 

Impairment expense

 $2,600  $  $2,600 

Stock-based compensation expense

 $4,149  $95  $4,244 
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 1 - Nature of Business, Financial Condition, Basis of Presentation (Details Textual)
$ in Thousands
3 Months Ended 6 Months Ended
Jan. 06, 2023
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
Number of Operating Segments           2    
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents   $ 19,500       $ 19,500    
Accounts Receivable, after Allowance for Credit Loss, Current   29,403       29,403   $ 28,937
Net Income (Loss) Attributable to Parent   (220) $ (8,120) $ (6,693) $ (701) (8,340) $ (7,394)  
Retained Earnings (Accumulated Deficit)   (312,469)       (312,469)   $ (304,129)
Net Cash Provided by (Used in) Operating Activities           (346) $ (11,588)  
Avenue Note [Member]                
Debt Instrument, Face Amount   $ 15,000       $ 15,000    
Reverse Stock Split [Member]                
Stockholders' Equity Note, Stock Split, Conversion Ratio 20              
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 2 - Significant Accounting Policies (Details Textual)
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Effective Income Tax Rate Reconciliation, Percent 136.20% 0.00% 11.00% 0.00%
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 3 - Revenues From Contract With Customers - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Revenue $ 22,934 $ 26,279 $ 45,033 $ 53,934
Rx Segment [Member]        
Revenue 18,748 18,029 36,565 36,681
Rx Segment [Member] | ADHD Portfolio [Member]        
Revenue 16,572 11,120 31,700 22,705
Rx Segment [Member] | The Pediatric Portfolio [Member]        
Revenue 2,145 6,328 4,710 12,886
Rx Segment [Member] | Product and Service, Other [Member]        
Revenue 31 581 155 1,090
Consumer Health [Member]        
Revenue $ 4,186 $ 8,250 $ 8,468 $ 17,253
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Inventories (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Inventory Write-down $ 100 $ 0 $ 133 $ 82
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 4 - Inventories - Schedule of Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Raw materials $ 1,654 $ 1,301
Work in process 2,674 2,956
Finished goods 8,673 7,738
Inventories $ 13,001 $ 11,995
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Property and Equipment (Details Textual) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Depreciation $ 0.3 $ 0.4 $ 0.6 $ 0.7
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Property and equipment, gross $ 4,205 $ 5,496
Less: accumulated depreciation and amortization (3,078) (3,681)
Property and equipment, net 1,127 1,815
Manufacturing Equipment [Member]    
Property and equipment, gross 1,183 2,433
Office Equipment, Furniture and Other [Member]    
Property and equipment, gross 1,146 1,125
Leasehold Improvements [Member]    
Property and equipment, gross 999 999
Lab Equipment [Member]    
Property and equipment, gross 832 832
Asset under Construction [Member]    
Property and equipment, gross $ 45 $ 107
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Leases (Details Textual) - USD ($)
$ in Thousands
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Operating Lease, Right-of-Use Asset [1] $ 2,133   $ 2,054
Operating Lease, Liability $ 2,214   $ 2,090
Lease for Principal Office [Member]      
Lessee, Operating Lease, Term of Contract (Year)   5 years 6 months  
Operating Lease, Right-of-Use Asset   $ 700  
Operating Lease, Liability   $ 700  
Lessee, Operating Lease, Discount Rate   10.30%  
[1] Includes $0.2 million from the Consumer Health Segment as of December 31, 2023 and June 30, 2023.
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Leases - Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Total net lease cost $ 418 $ 399 $ 816 $ 802  
Operating lease assets (Year) 2 years 7 months 13 days   2 years 7 months 13 days   1 year 8 months 19 days
Finance lease assets (Year) 4 months 13 days   4 months 13 days   10 months 13 days
Operating lease assets 8.85%   8.85%   7.78%
Finance lease assets 6.54%   6.54%   6.54%
Operating cash flows from operating leases     $ 697 716  
Operating cash flows from finance leases     2 5  
Financing cash flows from finance leases     46 52  
Operating Expense [Member]          
Operating lease cost $ 381 359 741 716  
Short-term lease cost 21 19 44 44  
Cost of Sales [Member]          
Amortization of leased assets 15 19 29 37  
Other Expense [Member]          
Interest on lease liabilities $ 1 $ 2 $ 2 $ 5  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Leases - Lease Balance Sheet Information (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Operating lease right-of-use assets [1] $ 2,133 $ 2,054
Total lease assets 2,133 2,213
Total lease liabilities 2,253 2,175
Property and Equipment, Net [Member]    
Finance lease assets 0 159
Other Current Liabilities [Member]    
Operating leases 1,369 1,258
Current Portion of Debt [Member]    
Finance leases 39 85
Other Noncurrent Liabilities [Member]    
Operating leases $ 845 $ 832
[1] Includes $0.2 million from the Consumer Health Segment as of December 31, 2023 and June 30, 2023.
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Leases - Schedule of Lease Liability Maturity (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Operating lease, 2024 (remaining 6 months) $ 735  
Finance lease, 2024 (remaining 6 months) 40  
Operating lease, 2025 938  
Finance lease,2025 0  
Operating lease, 2026 282  
Finance lease,2026 0  
Operating lease, 2027 241  
Finance lease,2027 0  
Operating lease, 2028 199  
Finance lease,2028 0  
Operating lease, thereafter 151  
Finance lease, thereafter 0  
Total operating lease payments 2,546  
Total finance lease payments 40  
Operating lease, less: Imputed interest (332)  
Finance lease, less: Imputed interest (1)  
Operating lease liabilities 2,214 $ 2,090
Finance lease liabilities $ 39 $ 85
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Intangible Assets (Details Textual) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Amortization Expense of Intangible Assets $ 1.6   $ 1.5 $ 3.3 $ 3.0
Minimum [Member]          
Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)       1 year  
Maximum [Member]          
Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)       20 years  
Patented Technology [Member] | ADHD Portfolio [Member]          
Finite-Lived Intangible Asset, Useful Life (Year) 17 years     17 years  
Distribution Rights [Member] | Consumer Health [Member]          
Impairment of Intangible Assets, Finite-Lived   $ 3.0      
In Process Research and Development [Member] | Rx Segment [Member] | Neos Therapeutics, Inc. [Member]          
Impairment of Intangible Assets, Finite-Lived     $ 2.6    
Tris Karbinal Agreement [Member]          
Supply and Distribution Agreement, Extension Term (Year)       20 years  
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Finite-lived intangible assets, gross $ 77,874 $ 78,583
Finite-lived intangible assets, amortization (22,163) (19,613)
Finite-lived intangible assets, net $ 55,711 $ 58,970
Finite-lived intangible assets, remaining life (Year) 12 years 4 months 6 days 12 years 8 months 1 day
Technology-Based Intangible Assets [Member]    
Finite-lived intangible assets, gross $ 41,467 $ 42,176
Finite-lived intangible assets, amortization (11,777) (10,881)
Finite-lived intangible assets, net $ 29,690 $ 31,295
Finite-lived intangible assets, remaining life (Year) 11 years 14 days 11 years 5 months 26 days
Developed Technology Rights [Member]    
Finite-lived intangible assets, gross $ 30,200 $ 30,200
Finite-lived intangible assets, amortization (4,943) (4,054)
Finite-lived intangible assets, net $ 25,257 $ 26,146
Finite-lived intangible assets, remaining life (Year) 14 years 3 months 14 years 9 months
Distribution Rights [Member]    
Finite-lived intangible assets, gross $ 6,207 $ 6,207
Finite-lived intangible assets, amortization (5,443) (4,678)
Finite-lived intangible assets, net $ 764 $ 1,529
Finite-lived intangible assets, remaining life (Year) 6 months 1 year
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 7 - Intangible Assets - Future Amortization Expense (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
2024 (remaining 6 months) $ 3,259  
2025 4,989  
2026 4,989  
2027 4,989  
2028 4,988  
Thereafter 32,497  
Total future amortization expense $ 55,711 $ 58,970
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Accrued savings offers $ 14,852 $ 15,739
Accrued program liabilities 11,841 11,012
Accrued customer and product related fees 5,699 6,579
Return reserve 5,129 5,777
Accrued employee compensation 3,362 5,675
Other accrued liabilities 2,530 2,017
Total accrued liabilities $ 43,413 $ 46,799
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 9 - Other Liabilities (Details Textual)
3 Months Ended 6 Months Ended
May 12, 2022
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Fixed Payment Arrangements   $ 9,043,000 $ 9,043,000 $ 10,420,000
Employee Retention Credit   3,759,000 $ 3,759,000 $ 0
Employee Retention Credit, Vendor Fee   $ 400,000    
Tris Karbinal Agreement [Member]        
Supply and Distribution Commitment, Period (Year)     20 years  
Supply and Distribution Commitment, Royalty, Percentage of Net Sales     23.50%  
Supply and Distribution Agreement, Minimum Sales Per Year   70,000 70,000  
Supply and Distribution Agreement, Make-whole Payment Per Unit for Sales Under Minimum   $ 30 $ 30  
Supply and Distribution Agreement, Maximum Yearly Make-whole Payment   2,100,000 2,100,000  
Supply and Distribution Agreement, Maximum Milestone Obligations   3,000,000 3,000,000  
Supply and Distribution Agreement, First Milestone, Minimum Net Revenues     40,000,000  
Tris Karbinal Agreement [Member] | Other Current Liabilities [Member]        
Fixed Payment Arrangements   1,800,000 1,800,000  
Tris Karbinal Agreement [Member] | Other Noncurrent Liabilities [Member]        
Fixed Payment Arrangements   1,200,000 1,200,000  
Tris License Agreement [Member]        
Fixed Payment Arrangements $ 9,000,000      
Fixed Payment Arrangements, Liability, Reduction $ 8,000,000      
Tris License Agreement [Member] | Other Current Liabilities [Member]        
Fixed Payment Arrangements   $ 6,000,000 $ 6,000,000  
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Fixed payment arrangements $ 9,043 $ 10,420
Operating lease liabilities 2,214 2,090
Employee retention credit 3,759 0
Other 564 1,555
Total other liabilities 15,580 14,065
Less: current portion (9,236) (7,090)
Total other liabilities, non-current $ 6,344 $ 6,975
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 10 - Line of Credit (Details Textual) - Eclipse Business Capital LLC Loan Agreement [Member] - Secured Debt [Member] - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Mar. 24, 2023
Line of Credit Facility, Maximum Borrowing Capacity $ 14,000,000            
Line of Credit Facility, Maximum Borrowing Capacity, Portion Available for Short-term Swingline Loans $ 3,500,000            
Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Eligible Accounts Receivable 85.00%            
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.50%            
Interest Expense, Debt   $ 23,200 $ 176,700 $ 50,100 $ 274,000    
Long-Term Line of Credit   $ 1,000,000   $ 1,000,000   $ 1,600,000  
After January 26, 2023 But Before January 26, 2024 [Member]              
Line of Credit Facility, Termination, Fee, Percentage of Commitment             1.00%
After January 26, 2024 But Before January 26, 2025 [Member]              
Line of Credit Facility, Termination, Fee, Percentage of Commitment             0.50%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]              
Debt Instrument, Basis Spread on Variable Rate 4.50%            
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 11 - Long-term Debt (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jan. 26, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Oct. 25, 2022
Mar. 07, 2022
Debt Instrument, Final Payment   $ 638   $ 638   $ 638    
Avenue Capital Issuance [Member]                
Shares Issued, Price Per Share (in dollars per share)               $ 25
Avenue Capital Warrants [Member]                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 24.2           $ 8.6 $ 24.2
Warrants and Rights Outstanding $ 600              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)               43,388
Avenue Capital Loan [Member]                
Debt Instrument, Face Amount $ 15,000              
Debt Instrument, Interest Rate, Stated Percentage 3.25%              
Debt Instrument, Final Payment $ 600              
Loan Processing Fee $ 400              
Debt Instrument, Interest Rate, Effective Percentage   19.60%   19.60%        
Interest Expense, Debt   $ 700 $ 700 $ 1,500 $ 1,300      
Avenue Capital Loan [Member] | After January 26, 2023 But Before January 26, 2024 [Member]                
Debt Instrument, Prepayment Fee, Percentage 2.00%              
Avenue Capital Loan [Member] | After January 26, 2024 But Before January 26, 2025 [Member]                
Debt Instrument, Prepayment Fee, Percentage 1.00%              
Avenue Capital Loan [Member] | Prime Rate [Member]                
Debt Instrument, Basis Spread on Variable Rate 7.40%              
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Long-term debt, due on January 26, 2025 $ 15,000 $ 15,000
Long-term, final payment fee 638 638
Unamortized discount and issuance costs (660) (925)
Finance lease liabilities 39 85
Total debt 15,017 14,798
Less: current portion (39) (85)
Non-current portion of debt $ 14,978 $ 14,713
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 11 - Long-term Debt - Future Principal Payments (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
2024 (remaining 6 months) $ 39  
2025 15,638  
Future principal payments 15,677  
Less: unamortized discount and issuance costs (660)  
Less: current portion (39) $ (85)
Non-current portion of debt $ 14,978 $ 14,713
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Financial liabilities, fair value $ 12,887 $ 6,403
Fair Value, Inputs, Level 1 [Member]    
Financial liabilities, fair value 0 0
Fair Value, Inputs, Level 2 [Member]    
Financial liabilities, fair value 0 0
Fair Value, Inputs, Level 3 [Member]    
Financial liabilities, fair value 12,887 6,403
Derivative Financial Instruments, Liabilities [Member]    
Financial liabilities, fair value 12,887 6,403
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 1 [Member]    
Financial liabilities, fair value 0 0
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 2 [Member]    
Financial liabilities, fair value 0 0
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]    
Financial liabilities, fair value $ 12,887 $ 6,403
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) - Derivative Financial Instruments, Liabilities [Member] - Fair Value, Inputs, Level 3 [Member]
$ in Thousands
6 Months Ended
Dec. 31, 2023
USD ($)
Balance $ 6,403
Included in earnings 6,484
Balance $ 12,887
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Fair Value Considerations - Valuation Assumptions (Details)
Dec. 31, 2023
Measurement Input, Expected Term [Member] | June 2023 Warrants Tranche A & B [Member]  
Derivative liability, measurement input 4.44
Measurement Input, Expected Term [Member] | Other Warrants [Member] | Minimum [Member]  
Derivative liability, measurement input 3.09
Measurement Input, Expected Term [Member] | Other Warrants [Member] | Maximum [Member]  
Derivative liability, measurement input 3.69
Measurement Input, Price Volatility [Member] | June 2023 Warrants Tranche A & B [Member]  
Derivative liability, measurement input 0.9615
Measurement Input, Price Volatility [Member] | Other Warrants [Member]  
Derivative liability, measurement input 0.9615
Measurement Input, Risk Free Interest Rate [Member] | June 2023 Warrants Tranche A & B [Member]  
Derivative liability, measurement input 0.0388
Measurement Input, Risk Free Interest Rate [Member] | Other Warrants [Member] | Minimum [Member]  
Derivative liability, measurement input 0.0395
Measurement Input, Risk Free Interest Rate [Member] | Other Warrants [Member] | Maximum [Member]  
Derivative liability, measurement input 0.0401
Measurement Input, Expected Dividend Rate [Member] | June 2023 Warrants Tranche A & B [Member]  
Derivative liability, measurement input 0
Measurement Input, Expected Dividend Rate [Member] | Other Warrants [Member]  
Derivative liability, measurement input 0
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 13 - Commitments and Contingencies (Details Textual)
1 Months Ended 6 Months Ended
Apr. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
Feb. 22, 2023
shares
Apr. 12, 2021
USD ($)
Sabby Volatility Warrant Master Fund Ltd. [Member] | Sabby Litigation [Member]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares     312,908  
Sabby Volatility Warrant Master Fund Ltd. [Member] | Sabby Litigation [Member] | Sabby Litigation Warrants [Member]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares     575,000  
Walleye Opportunities Master Fund Ltd. [Member] | Sabby Litigation [Member]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares     54,146  
Walleye Opportunities Master Fund Ltd. [Member] | Sabby Litigation [Member] | Sabby Litigation Warrants [Member]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares     100,000  
Rumpus Acquisition [Member] | Earn Out Payments [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       $ 67,500,000
Payment for Contingent Consideration Liability, Operating Activities $ 600,000      
Rumpus Acquisition [Member] | Royalties [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       $ 101,700,000
License Agreement, Royalty Percentage       3.00%
License Agreement, Minimum Annual Royalty Payment       $ 20,000
Rumpus Acquisition [Member] | Milestone Payments [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       $ 1,600,000
Tris Karbinal Agreement [Member]        
Supply and Distribution Commitment, Period (Year)   20 years    
Supply and Distribution Commitment, Royalty, Percentage of Net Sales   23.50%    
Supply and Distribution Agreement, Minimum Sales Per Year   70,000    
Supply and Distribution Agreement, Make-whole Payment Per Unit for Sales Under Minimum   $ 30    
Supply and Distribution Agreement, Maximum Yearly Make-whole Payment   2,100,000    
Supply and Distribution Agreement, Maximum Milestone Obligations   3,000,000    
Supply and Distribution Agreement, First Milestone, Minimum Net Revenues   $ 40,000,000    
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 14 - Capital Structure (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 08, 2023
Aug. 11, 2022
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Sep. 28, 2021
Jun. 04, 2021
Jun. 08, 2020
Common Stock, Shares Authorized (in shares)     200,000,000   200,000,000      
Common Stock, Par or Stated Value Per Share (in dollars per share)     $ 0.0001   $ 0.0001      
Preferred Stock, Shares Authorized (in shares)     50,000,000   50,000,000      
Preferred Stock, Par or Stated Value Per Share (in dollars per share)     $ 0.0001   $ 0.0001      
Common Stock, Shares, Outstanding (in shares)     5,567,347   5,517,174      
Proceeds from Issuance or Sale of Equity     $ 86 $ 11,573        
Payments of Stock Issuance Costs     160 $ 1,000        
August 2022 Prefunded Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   87,500            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)   $ 0.02            
August 2022 Common Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   1,265,547            
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)   1            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)   $ 8.6   $ 3.3 $ 2.32      
Warrants and Rights Outstanding, Term (Year)   5 years            
August 2022 Common and Prefunded Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)   1            
Sale of Stock, Price Per Share (in dollars per share)   $ 8.58            
Warrants and Rights Outstanding, Term (Year)   5 years            
Warrants and Rights Outstanding   $ 6,000            
Pre-Funded Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 430,217              
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) 1              
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.0001              
Tranche A Common Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,173,912              
Warrants and Rights Outstanding, Term (Year) 5 years              
Tranche B Common Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,173,912              
Common Warrants [Member]                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 1.59              
Common Warrants Exchanged for PreFunded Warrants [Member]                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) 1.5899              
Tranche A Common Warrants at Double Exercise Price [Member]                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 3.18              
Securities Purchase Agreement Warrants [Member]                
Warrants and Rights Outstanding $ 5,000              
Payments of Stock Issuance Costs $ 600              
The 2020 Shelf [Member]                
Sale of Stock, Maximum Amount of Equity Issuable               $ 100,000
At-the-market Offering [Member]                
Sale of Stock, Maximum Amount of Equity Issuable             $ 30,000  
Stock Issued During Period, Shares, New Issues (in shares)         699,929      
Proceeds from Issuance or Sale of Equity         $ 2,900      
The 2021 Shelf [Member]                
Sale of Stock, Maximum Amount of Equity Issuable           $ 100,000    
Sale of Stock, Remaining Amount Available     $ 82,400          
The August 2022 Offering [Member]                
Stock Issued During Period, Shares, New Issues (in shares)   1,075,290            
Proceeds from Issuance or Sale of Equity   $ 10,000            
Sale of Stock, Price Per Share (in dollars per share)   $ 8.6            
Payment of Financing and Stock Issuance Costs   $ 900            
Securities Purchase Agreement [Member]                
Stock Issued During Period, Shares, New Issues (in shares) 1,743,695              
Proceeds from Issuance or Sale of Equity $ 4,000              
Payment of Financing and Stock Issuance Costs 3,400              
Class of Warrant or Right, Covenant, Adjusted EBITDA $ 12,000              
Restricted Stock [Member]                
Common Stock, Shares, Outstanding (in shares)     40,017          
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 15 - Equity Incentive Plans (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended 12 Months Ended
May 18, 2023
Apr. 19, 2021
Jun. 01, 2015
Dec. 31, 2023
Dec. 31, 2023
Jun. 30, 2023
Feb. 13, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)       149,087 149,087 52,762  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)       $ 1.73      
Share-Based Payment Arrangement, Option [Member]              
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount       $ 0.4 $ 0.4    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       1 year 10 months 6 days      
Restricted Stock [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)       37,929 37,929 38,075  
Restricted Stock Units (RSUs) [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)       2,898 2,898 4,963  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount       $ 0.1 $ 0.1    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)         1 year 2 months 12 days    
The 2023 Equity Incentive Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 200,000            
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) 87,129            
The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) 10 years            
The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 3 years            
The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 4 years            
The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Minimum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 3 years            
The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Maximum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 4 years            
The 2023 Equity Incentive Plan [Member] | Restricted Stock [Member]              
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount       $ 2.0 $ 2.0    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       1 year 10 months 24 days      
The 2015 Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)       179,732 179,732    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)     150,000       250,000
The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)     10 years        
The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)     3 years        
The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)     4 years        
The 2015 Plan [Member] | Restricted Stock [Member] | Minimum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)     4 years        
The 2015 Plan [Member] | Restricted Stock [Member] | Maximum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)     10 years        
The 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)     4 years        
Neos 2015 Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)   5,272          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)   3,486          
Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)   10 years          
Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)   1 year          
Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)   4 years          
Neos 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)   1,786          
Outside Equity Incentive Plan [Member] | Restricted Stock [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)       2,088 2,088    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount       $ 0.3 $ 0.3    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       1 year 1 month 6 days      
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 15 - Equity Incentive Plans - Stock Option Activity (Details) - $ / shares
6 Months Ended 12 Months Ended
Dec. 31, 2023
Jun. 30, 2023
Outstanding, options (in shares) 52,762  
Outstanding, options, weighted average exercise price (in dollars per share) $ 18.37  
Outstanding, options, weighted average remaining contractual life (Year) 9 years 2 months 1 day 9 years 21 days
Granted, options (in shares) 112,000  
Granted, options, weighted average exercise price (in dollars per share) $ 1.73  
Granted, options, weighted average remaining contractual life (Year) 9 years 7 months 9 days  
Forfeited/Cancelled, options (in shares) (15,060)  
Forfeited/Cancelled, options, weighted average exercise price (in dollars per share) $ 2.94  
Expired, options (in shares) (615)  
Expired, options, weighted average exercise price (in dollars per share) $ 184.8  
Outstanding, options (in shares) 149,087 52,762
Outstanding, options, weighted average exercise price (in dollars per share) $ 6.43 $ 18.37
Exercisable, options (in shares) 20,470  
Exercisable, options, weighted average exercise price (in dollars per share) $ 30.18  
Exercisable, options, weighted average remaining contractual life (Year) 8 years 7 days  
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) - Restricted Stock [Member]
6 Months Ended
Dec. 31, 2023
$ / shares
shares
Unvested, shares (in shares) | shares 38,075
Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 142.2
Granted, shares (in shares) | shares 12,500
Granted, weighted average grant date fair value (in dollars per share) | $ / shares $ 1.77
Vested, shares (in shares) | shares (12,189)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares $ 130.45
Forfeited/cancelled, shares (in shares) | shares (457)
Forfeited/cancelled, weighted average grant date fair value (in dollars per share) | $ / shares $ 136.8
Unvested, shares (in shares) | shares 37,929
Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 99.75
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]
6 Months Ended
Dec. 31, 2023
$ / shares
shares
Unvested, shares (in shares) | shares 4,963
Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 25.62
Vested, shares (in shares) | shares (1,126)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares $ 24.28
Forfeited, shares (in shares) | shares (939)
Forfeited, weighted average grant date fair value (in dollars per share) | $ / shares $ 31.6
Unvested, shares (in shares) | shares 2,898
Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 24.19
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Total stock-based compensation expense $ 820 $ 3,067 $ 1,750 $ 4,244
Cost of Sales [Member]        
Total stock-based compensation expense 1 3 1 8
Research and Development Expense [Member]        
Total stock-based compensation expense 2 14 3 23
Selling and Marketing Expense [Member]        
Total stock-based compensation expense 0 3 0 6
General and Administrative Expense [Member]        
Total stock-based compensation expense $ 817 $ 3,047 $ 1,746 $ 4,207
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 16 - Warrants (Details Textual)
$ / shares in Units, $ in Millions
Jun. 08, 2023
USD ($)
$ / shares
shares
Jan. 06, 2023
Jun. 30, 2023
$ / shares
Dec. 31, 2022
$ / shares
Aug. 11, 2022
$ / shares
shares
Reverse Stock Split [Member]          
Stockholders' Equity Note, Stock Split, Conversion Ratio   20      
Pre-Funded Warrants [Member]          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 430,217        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 0.0001        
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) 1        
Tranche A Common Warrants [Member]          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,173,912        
Warrants and Rights Outstanding, Term (Year) 5 years        
Tranche B Common Warrants [Member]          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,173,912        
Common Warrants [Member]          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 1.59        
Common Warrants Exchanged for PreFunded Warrants [Member]          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares 1.5899        
Tranche A Common Warrants at Double Exercise Price [Member]          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 3.18        
August 2022 Prefunded Warrants [Member]          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)         87,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares         $ 0.02
August 2022 Common Warrants [Member]          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)         1,265,547
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares     $ 2.32 $ 3.3 $ 8.6
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)         1
Warrants and Rights Outstanding, Term (Year)         5 years
August 2022 Common Warrants [Member] | Minimum [Member]          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares         $ 2.32
August 2022 Common Warrants [Member] | Maximum [Member]          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)         2,325,581
Securities Purchase Agreement [Member]          
Stock Issued During Period, Shares, New Issues (in shares) 1,743,695        
Class of Warrant or Right, Covenant, Adjusted EBITDA | $ $ 12        
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 16 - Warrants - Schedule of Warrants Outstanding (Details) - $ / shares
6 Months Ended 12 Months Ended
Dec. 31, 2023
Jun. 30, 2023
Warrants outstanding (in shares) 6,538,052  
Warrants, weighted average remaining contractual life (Year) 4 years 2 months 19 days 4 years 8 months 15 days
Warrants exercised (in shares) (37,004)  
Warrants expired, weighted average exercise price (in shares) (20,958)  
Warrants outstanding (in shares) 6,480,090 6,538,052
Weighted Average [Member]    
Warrants, weighted average exercise price (in dollars per share) $ 4.42  
Warrants exercised, weighted average exercise price (in dollars per share) 2.32  
Warrants expired (in dollars per share) 300  
Warrants, weighted average exercise price (in dollars per share) $ 3.48 $ 4.42
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) - shares
6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive securities (in shares) 6,730,054 1,808,029
Liability Warrants [Member]    
Antidilutive securities (in shares) 6,498,980 1,642,235
Equity Warrants [Member]    
Antidilutive securities (in shares) 39,072 56,486
Share-Based Payment Arrangement, Option [Member]    
Antidilutive securities (in shares) 149,087 52,861
Restricted Stock [Member]    
Antidilutive securities (in shares) 40,017 48,280
Restricted Stock Units (RSUs) [Member]    
Antidilutive securities (in shares) 2,898 8,167
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 19 - Segment Reporting (Details Textual)
6 Months Ended
Dec. 31, 2023
Number of Reportable Segments 2
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 19 - Segment Reporting - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Product revenue, net $ 22,934 $ 26,279 $ 45,033 $ 53,934
Income (loss) from operations 2,364 (6,868) 860 (8,676)
Depreciation and amortization 1,899 1,853 3,840 3,708
Stock-based compensation expense 820 3,067 1,750 4,244
Impairment expense 0 2,600 0 2,600
Rx Segment [Member]        
Product revenue, net 18,748 18,029 36,565 36,681
Income (loss) from operations 3,146 (5,464) 2,280 (6,457)
Depreciation and amortization 1,510 1,572 3,064 3,146
Stock-based compensation expense 707 2,987 1,432 4,149
Impairment expense   2,600   2,600
Consumer Health [Member]        
Product revenue, net 4,186 8,250 8,468 17,253
Income (loss) from operations (782) (1,404) (1,420) (2,219)
Depreciation and amortization 389 281 776 562
Stock-based compensation expense $ 113 80 $ 318 95
Impairment expense   $ 0   $ 0
EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 90 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 93 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 257 328 1 true 94 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://aytubio.com/20231231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Business, Financial Condition, Basis of Presentation Sheet http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation Note 1 - Nature of Business, Financial Condition, Basis of Presentation Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Significant Accounting Policies Sheet http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies Note 2 - Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Revenues From Contracts with Customers Sheet http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers Note 3 - Revenues From Contracts with Customers Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Inventories Sheet http://aytubio.com/20231231/role/statement-note-4-inventories Note 4 - Inventories Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Property and Equipment Sheet http://aytubio.com/20231231/role/statement-note-5-property-and-equipment Note 5 - Property and Equipment Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Leases Sheet http://aytubio.com/20231231/role/statement-note-6-leases Note 6 - Leases Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Intangible Assets Sheet http://aytubio.com/20231231/role/statement-note-7-intangible-assets Note 7 - Intangible Assets Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Accrued Liabilities Sheet http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities Note 8 - Accrued Liabilities Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Other Liabilities Sheet http://aytubio.com/20231231/role/statement-note-9-other-liabilities Note 9 - Other Liabilities Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Line of Credit Sheet http://aytubio.com/20231231/role/statement-note-10-line-of-credit Note 10 - Line of Credit Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Long-term Debt Sheet http://aytubio.com/20231231/role/statement-note-11-longterm-debt Note 11 - Long-term Debt Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Fair Value Considerations Sheet http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations Note 12 - Fair Value Considerations Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Commitments and Contingencies Sheet http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies Note 13 - Commitments and Contingencies Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Capital Structure Sheet http://aytubio.com/20231231/role/statement-note-14-capital-structure Note 14 - Capital Structure Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Equity Incentive Plans Sheet http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans Note 15 - Equity Incentive Plans Notes 21 false false R22.htm 021 - Disclosure - Note 16 - Warrants Sheet http://aytubio.com/20231231/role/statement-note-16-warrants Note 16 - Warrants Notes 22 false false R23.htm 022 - Disclosure - Note 17 - Earnings Per Share Sheet http://aytubio.com/20231231/role/statement-note-17-earnings-per-share Note 17 - Earnings Per Share Notes 23 false false R24.htm 023 - Disclosure - Note 18 - License Agreements Sheet http://aytubio.com/20231231/role/statement-note-18-license-agreements Note 18 - License Agreements Notes 24 false false R25.htm 024 - Disclosure - Note 19 - Segment Reporting Sheet http://aytubio.com/20231231/role/statement-note-19-segment-reporting Note 19 - Segment Reporting Notes 25 false false R26.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 26 false false R27.htm 995471 - Disclosure - Significant Accounting Policies (Policies) Sheet http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies 27 false false R28.htm 995472 - Disclosure - Note 3 - Revenues From Contracts with Customers (Tables) Sheet http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers-tables Note 3 - Revenues From Contracts with Customers (Tables) Tables http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers 28 false false R29.htm 995473 - Disclosure - Note 4 - Inventories (Tables) Sheet http://aytubio.com/20231231/role/statement-note-4-inventories-tables Note 4 - Inventories (Tables) Tables http://aytubio.com/20231231/role/statement-note-4-inventories 29 false false R30.htm 995474 - Disclosure - Note 5 - Property and Equipment (Tables) Sheet http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-tables Note 5 - Property and Equipment (Tables) Tables http://aytubio.com/20231231/role/statement-note-5-property-and-equipment 30 false false R31.htm 995475 - Disclosure - Note 6 - Leases (Tables) Sheet http://aytubio.com/20231231/role/statement-note-6-leases-tables Note 6 - Leases (Tables) Tables http://aytubio.com/20231231/role/statement-note-6-leases 31 false false R32.htm 995476 - Disclosure - Note 7 - Intangible Assets (Tables) Sheet http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables Note 7 - Intangible Assets (Tables) Tables http://aytubio.com/20231231/role/statement-note-7-intangible-assets 32 false false R33.htm 995477 - Disclosure - Note 8 - Accrued Liabilities (Tables) Sheet http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-tables Note 8 - Accrued Liabilities (Tables) Tables http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities 33 false false R34.htm 995478 - Disclosure - Note 9 - Other Liabilities (Tables) Sheet http://aytubio.com/20231231/role/statement-note-9-other-liabilities-tables Note 9 - Other Liabilities (Tables) Tables http://aytubio.com/20231231/role/statement-note-9-other-liabilities 34 false false R35.htm 995479 - Disclosure - Note 11 - Long-term Debt (Tables) Sheet http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables Note 11 - Long-term Debt (Tables) Tables http://aytubio.com/20231231/role/statement-note-11-longterm-debt 35 false false R36.htm 995480 - Disclosure - Note 12 - Fair Value Considerations (Tables) Sheet http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables Note 12 - Fair Value Considerations (Tables) Tables http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations 36 false false R37.htm 995481 - Disclosure - Note 15 - Equity Incentive Plans (Tables) Sheet http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables Note 15 - Equity Incentive Plans (Tables) Tables http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans 37 false false R38.htm 995482 - Disclosure - Note 16 - Warrants (Tables) Sheet http://aytubio.com/20231231/role/statement-note-16-warrants-tables Note 16 - Warrants (Tables) Tables http://aytubio.com/20231231/role/statement-note-16-warrants 38 false false R39.htm 995483 - Disclosure - Note 17 - Earnings Per Share (Tables) Sheet http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-tables Note 17 - Earnings Per Share (Tables) Tables http://aytubio.com/20231231/role/statement-note-17-earnings-per-share 39 false false R40.htm 995484 - Disclosure - Note 19 - Segment Reporting (Tables) Sheet http://aytubio.com/20231231/role/statement-note-19-segment-reporting-tables Note 19 - Segment Reporting (Tables) Tables http://aytubio.com/20231231/role/statement-note-19-segment-reporting 40 false false R41.htm 995485 - Disclosure - Note 1 - Nature of Business, Financial Condition, Basis of Presentation (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual Note 1 - Nature of Business, Financial Condition, Basis of Presentation (Details Textual) Details http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation 41 false false R42.htm 995486 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies-details-textual Note 2 - Significant Accounting Policies (Details Textual) Details 42 false false R43.htm 995487 - Disclosure - Note 3 - Revenues From Contract With Customers - Disaggregation of Revenue (Details) Sheet http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details Note 3 - Revenues From Contract With Customers - Disaggregation of Revenue (Details) Details 43 false false R44.htm 995488 - Disclosure - Note 4 - Inventories (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-4-inventories-details-textual Note 4 - Inventories (Details Textual) Details http://aytubio.com/20231231/role/statement-note-4-inventories-tables 44 false false R45.htm 995489 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details) Sheet http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details Note 4 - Inventories - Schedule of Inventories (Details) Details 45 false false R46.htm 995490 - Disclosure - Note 5 - Property and Equipment (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-details-textual Note 5 - Property and Equipment (Details Textual) Details http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-tables 46 false false R47.htm 995491 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) Details 47 false false R48.htm 995492 - Disclosure - Note 6 - Leases (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-6-leases-details-textual Note 6 - Leases (Details Textual) Details http://aytubio.com/20231231/role/statement-note-6-leases-tables 48 false false R49.htm 995493 - Disclosure - Note 6 - Leases - Lease Cost (Details) Sheet http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details Note 6 - Leases - Lease Cost (Details) Details 49 false false R50.htm 995494 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) Sheet http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details Note 6 - Leases - Lease Balance Sheet Information (Details) Details 50 false false R51.htm 995495 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details) Sheet http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details Note 6 - Leases - Schedule of Lease Liability Maturity (Details) Details 51 false false R52.htm 995496 - Disclosure - Note 7 - Intangible Assets (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual Note 7 - Intangible Assets (Details Textual) Details http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables 52 false false R53.htm 995497 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) Details 53 false false R54.htm 995498 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details) Sheet http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details Note 7 - Intangible Assets - Future Amortization Expense (Details) Details 54 false false R55.htm 995499 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 55 false false R56.htm 995500 - Disclosure - Note 9 - Other Liabilities (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual Note 9 - Other Liabilities (Details Textual) Details http://aytubio.com/20231231/role/statement-note-9-other-liabilities-tables 56 false false R57.htm 995501 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) Sheet http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) Details 57 false false R58.htm 995502 - Disclosure - Note 10 - Line of Credit (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual Note 10 - Line of Credit (Details Textual) Details http://aytubio.com/20231231/role/statement-note-10-line-of-credit 58 false false R59.htm 995503 - Disclosure - Note 11 - Long-term Debt (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual Note 11 - Long-term Debt (Details Textual) Details http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables 59 false false R60.htm 995504 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) Sheet http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) Details 60 false false R61.htm 995505 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details) Sheet http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details Note 11 - Long-term Debt - Future Principal Payments (Details) Details 61 false false R62.htm 995506 - Disclosure - Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details) Sheet http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details) Details 62 false false R63.htm 995507 - Disclosure - Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) Sheet http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) Details 63 false false R64.htm 995508 - Disclosure - Note 12 - Fair Value Considerations - Valuation Assumptions (Details) Sheet http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details Note 12 - Fair Value Considerations - Valuation Assumptions (Details) Details 64 false false R65.htm 995509 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual Note 13 - Commitments and Contingencies (Details Textual) Details http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies 65 false false R66.htm 995510 - Disclosure - Note 14 - Capital Structure (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual Note 14 - Capital Structure (Details Textual) Details http://aytubio.com/20231231/role/statement-note-14-capital-structure 66 false false R67.htm 995511 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual Note 15 - Equity Incentive Plans (Details Textual) Details http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables 67 false false R68.htm 995512 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details) Sheet http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details Note 15 - Equity Incentive Plans - Stock Option Activity (Details) Details 68 false false R69.htm 995513 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) Sheet http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) Details 69 false false R70.htm 995514 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) Sheet http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) Details 70 false false R71.htm 995515 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) Sheet http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) Details 71 false false R72.htm 995516 - Disclosure - Note 16 - Warrants (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual Note 16 - Warrants (Details Textual) Details http://aytubio.com/20231231/role/statement-note-16-warrants-tables 72 false false R73.htm 995517 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details) Sheet http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details Note 16 - Warrants - Schedule of Warrants Outstanding (Details) Details 73 false false R74.htm 995518 - Disclosure - Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) Sheet http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) Details 74 false false R75.htm 995519 - Disclosure - Note 19 - Segment Reporting (Details Textual) Sheet http://aytubio.com/20231231/role/statement-note-19-segment-reporting-details-textual Note 19 - Segment Reporting (Details Textual) Details http://aytubio.com/20231231/role/statement-note-19-segment-reporting-tables 75 false false R76.htm 995520 - Disclosure - Note 19 - Segment Reporting - Schedule of Segment Information (Details) Sheet http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details Note 19 - Segment Reporting - Schedule of Segment Information (Details) Details 76 false false All Reports Book All Reports aytu-20231231.xsd aytu-20231231_cal.xml aytu-20231231_def.xml aytu-20231231_lab.xml aytu-20231231_pre.xml aytu20231231_10q.htm aytu20231231_10qimg001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 96 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aytu20231231_10q.htm": { "nsprefix": "aytu", "nsuri": "http://aytubio.com/20231231", "dts": { "schema": { "local": [ "aytu-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "aytu-20231231_cal.xml" ] }, "definitionLink": { "local": [ "aytu-20231231_def.xml" ] }, "labelLink": { "local": [ "aytu-20231231_lab.xml" ] }, "presentationLink": { "local": [ "aytu-20231231_pre.xml" ] }, "inline": { "local": [ "aytu20231231_10q.htm" ] } }, "keyStandard": 280, "keyCustom": 48, "axisStandard": 28, "axisCustom": 0, "memberStandard": 36, "memberCustom": 53, "hidden": { "total": 44, "http://fasb.org/us-gaap/2023": 34, "http://aytubio.com/20231231": 1, "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 4 }, "contextCount": 257, "entityCount": 1, "segmentCount": 94, "elementCount": 538, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 811, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 5 }, "report": { "R1": { "role": "http://aytubio.com/20231231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited", "longName": "003 - Statement - Consolidated Statements of Operations (Unaudited)", "shortName": "Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R5": { "role": "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2022-07-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R6": { "role": "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "longName": "005 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R7": { "role": "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "longName": "006 - Disclosure - Note 1 - Nature of Business, Financial Condition, Basis of Presentation", "shortName": "Note 1 - Nature of Business, Financial Condition, Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies", "longName": "007 - Disclosure - Note 2 - Significant Accounting Policies", "shortName": "Note 2 - Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers", "longName": "008 - Disclosure - Note 3 - Revenues From Contracts with Customers", "shortName": "Note 3 - Revenues From Contracts with Customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://aytubio.com/20231231/role/statement-note-4-inventories", "longName": "009 - Disclosure - Note 4 - Inventories", "shortName": "Note 4 - Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment", "longName": "010 - Disclosure - Note 5 - Property and Equipment", "shortName": "Note 5 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://aytubio.com/20231231/role/statement-note-6-leases", "longName": "011 - Disclosure - Note 6 - Leases", "shortName": "Note 6 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:LeasesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:LeasesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "longName": "012 - Disclosure - Note 7 - Intangible Assets", "shortName": "Note 7 - Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities", "longName": "013 - Disclosure - Note 8 - Accrued Liabilities", "shortName": "Note 8 - Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:AccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:AccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "longName": "014 - Disclosure - Note 9 - Other Liabilities", "shortName": "Note 9 - Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "longName": "015 - Disclosure - Note 10 - Line of Credit", "shortName": "Note 10 - Line of Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "longName": "016 - Disclosure - Note 11 - Long-term Debt", "shortName": "Note 11 - Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations", "longName": "017 - Disclosure - Note 12 - Fair Value Considerations", "shortName": "Note 12 - Fair Value Considerations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "longName": "018 - Disclosure - Note 13 - Commitments and Contingencies", "shortName": "Note 13 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "longName": "019 - Disclosure - Note 14 - Capital Structure", "shortName": "Note 14 - Capital Structure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "longName": "020 - Disclosure - Note 15 - Equity Incentive Plans", "shortName": "Note 15 - Equity Incentive Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://aytubio.com/20231231/role/statement-note-16-warrants", "longName": "021 - Disclosure - Note 16 - Warrants", "shortName": "Note 16 - Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:WarrantsOrRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:WarrantsOrRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share", "longName": "022 - Disclosure - Note 17 - Earnings Per Share", "shortName": "Note 17 - Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://aytubio.com/20231231/role/statement-note-18-license-agreements", "longName": "023 - Disclosure - Note 18 - License Agreements", "shortName": "Note 18 - License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:LicensingAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:LicensingAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://aytubio.com/20231231/role/statement-note-19-segment-reporting", "longName": "024 - Disclosure - Note 19 - Segment Reporting", "shortName": "Note 19 - Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies", "longName": "995471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers-tables", "longName": "995472 - Disclosure - Note 3 - Revenues From Contracts with Customers (Tables)", "shortName": "Note 3 - Revenues From Contracts with Customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://aytubio.com/20231231/role/statement-note-4-inventories-tables", "longName": "995473 - Disclosure - Note 4 - Inventories (Tables)", "shortName": "Note 4 - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-tables", "longName": "995474 - Disclosure - Note 5 - Property and Equipment (Tables)", "shortName": "Note 5 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://aytubio.com/20231231/role/statement-note-6-leases-tables", "longName": "995475 - Disclosure - Note 6 - Leases (Tables)", "shortName": "Note 6 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables", "longName": "995476 - Disclosure - Note 7 - Intangible Assets (Tables)", "shortName": "Note 7 - Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-tables", "longName": "995477 - Disclosure - Note 8 - Accrued Liabilities (Tables)", "shortName": "Note 8 - Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-tables", "longName": "995478 - Disclosure - Note 9 - Other Liabilities (Tables)", "shortName": "Note 9 - Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables", "longName": "995479 - Disclosure - Note 11 - Long-term Debt (Tables)", "shortName": "Note 11 - Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables", "longName": "995480 - Disclosure - Note 12 - Fair Value Considerations (Tables)", "shortName": "Note 12 - Fair Value Considerations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables", "longName": "995481 - Disclosure - Note 15 - Equity Incentive Plans (Tables)", "shortName": "Note 15 - Equity Incentive Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://aytubio.com/20231231/role/statement-note-16-warrants-tables", "longName": "995482 - Disclosure - Note 16 - Warrants (Tables)", "shortName": "Note 16 - Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:ScheduleOfWarrantOrRightActivity", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:ScheduleOfWarrantOrRightActivity", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-tables", "longName": "995483 - Disclosure - Note 17 - Earnings Per Share (Tables)", "shortName": "Note 17 - Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-tables", "longName": "995484 - Disclosure - Note 19 - Segment Reporting (Tables)", "shortName": "Note 19 - Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "longName": "995485 - Disclosure - Note 1 - Nature of Business, Financial Condition, Basis of Presentation (Details Textual)", "shortName": "Note 1 - Nature of Business, Financial Condition, Basis of Presentation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies-details-textual", "longName": "995486 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "longName": "995487 - Disclosure - Note 3 - Revenues From Contract With Customers - Disaggregation of Revenue (Details)", "shortName": "Note 3 - Revenues From Contract With Customers - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-10-01_2023-12-31_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R44": { "role": "http://aytubio.com/20231231/role/statement-note-4-inventories-details-textual", "longName": "995488 - Disclosure - Note 4 - Inventories (Details Textual)", "shortName": "Note 4 - Inventories (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:InventoryWriteDown", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details", "longName": "995489 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details)", "shortName": "Note 4 - Inventories - Schedule of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "longName": "995490 - Disclosure - Note 5 - Property and Equipment (Details Textual)", "shortName": "Note 5 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "longName": "995491 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)", "shortName": "Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual", "longName": "995492 - Disclosure - Note 6 - Leases (Details Textual)", "shortName": "Note 6 - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-09-30_LeaseContractualTermAxis-LeaseForPrincipalOfficeMember", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R49": { "role": "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details", "longName": "995493 - Disclosure - Note 6 - Leases - Lease Cost (Details)", "shortName": "Note 6 - Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:LeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:LeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details", "longName": "995494 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details)", "shortName": "Note 6 - Leases - Lease Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "aytu:OperatingLeaseAndFinanceLeaseRightofuseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "aytu:ScheduleOfLeaseByBalanceSheetInformationTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R51": { "role": "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "longName": "995495 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details)", "shortName": "Note 6 - Leases - Schedule of Lease Liability Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "aytu:LesseeLiabilityMaturityTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "aytu:LesseeLiabilityMaturityTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual", "longName": "995496 - Disclosure - Note 7 - Intangible Assets (Details Textual)", "shortName": "Note 7 - Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "aytu:AmortizationExpenseOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "aytu:AmortizationExpenseOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "longName": "995497 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)", "shortName": "Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "longName": "995498 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details)", "shortName": "Note 7 - Intangible Assets - Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "longName": "995499 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "shortName": "Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "aytu:AccruedSavingOffers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "aytu:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "aytu:AccruedSavingOffers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "aytu:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual", "longName": "995500 - Disclosure - Note 9 - Other Liabilities (Details Textual)", "shortName": "Note 9 - Other Liabilities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "aytu:FixedPaymentArrangements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "aytu:EmployeeRetentionCreditVendorFee", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R57": { "role": "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "longName": "995501 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)", "shortName": "Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "aytu:FixedPaymentArrangements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OtherSundryLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R58": { "role": "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "longName": "995502 - Disclosure - Note 10 - Line of Credit (Details Textual)", "shortName": "Note 10 - Line of Credit (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "i_2021-03-31_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2021-03-31_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "longName": "995503 - Disclosure - Note 11 - Long-term Debt (Details Textual)", "shortName": "Note 11 - Long-term Debt (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "aytu:DebtInstrumentFinalPayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-03-07_SubsidiarySaleOfStockAxis-AvenueCapitalIssuanceMember", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R60": { "role": "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "longName": "995504 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)", "shortName": "Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details", "longName": "995505 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details)", "shortName": "Note 11 - Long-term Debt - Future Principal Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "longName": "995506 - Disclosure - Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details)", "shortName": "Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "longName": "995507 - Disclosure - Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details)", "shortName": "Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "longName": "995508 - Disclosure - Note 12 - Fair Value Considerations - Valuation Assumptions (Details)", "shortName": "Note 12 - Fair Value Considerations - Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "i_2023-12-31_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheABMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheABMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R65": { "role": "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "longName": "995509 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)", "shortName": "Note 13 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2023-02-22_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-02-22_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R66": { "role": "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "longName": "995510 - Disclosure - Note 14 - Capital Structure (Details Textual)", "shortName": "Note 14 - Capital Structure (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember", "name": "us-gaap:SaleOfStockPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R67": { "role": "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "longName": "995511 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual)", "shortName": "Note 15 - Equity Incentive Plans (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R68": { "role": "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "longName": "995512 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R69": { "role": "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "longName": "995513 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "i_2023-06-30_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-06-30_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R70": { "role": "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "longName": "995514 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R71": { "role": "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "longName": "995515 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)", "shortName": "Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R72": { "role": "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "longName": "995516 - Disclosure - Note 16 - Warrants (Details Textual)", "shortName": "Note 16 - Warrants (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MinimumMember", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R73": { "role": "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "longName": "995517 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details)", "shortName": "Note 16 - Warrants - Schedule of Warrants Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "aytu:ScheduleOfWarrantOrRightActivity", "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "aytu:ScheduleOfWarrantOrRightActivity", "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } }, "R74": { "role": "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "longName": "995518 - Disclosure - Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)", "shortName": "Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true, "unique": true } }, "R75": { "role": "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-details-textual", "longName": "995519 - Disclosure - Note 19 - Segment Reporting (Details Textual)", "shortName": "Note 19 - Segment Reporting (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": null, "uniqueAnchor": null }, "R76": { "role": "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "longName": "995520 - Disclosure - Note 19 - Segment Reporting - Schedule of Segment Information (Details)", "shortName": "Note 19 - Segment Reporting - Schedule of Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-10-01_2023-12-31", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20231231_10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20", "r592" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r235", "r236" ] }, "aytu_AccruedCustomerAndProductRelatedFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AccruedCustomerAndProductRelatedFeesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued customer and product related fees", "documentation": "Represents the amount of accrued customer and product related fees classified as current." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22" ] }, "aytu_AccruedLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AccruedLiabilitiesTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Text Block]", "documentation": "The entire disclosure regarding accrued liabilities." } } }, "auth_ref": [] }, "aytu_AccruedProgramRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AccruedProgramRelatedLiabilities", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued program liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities." } } }, "auth_ref": [] }, "aytu_AccruedSavingOffers": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AccruedSavingOffers", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued savings offers", "documentation": "Represents information related to accrued saving offers." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r50", "r147", "r452" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r87", "r592", "r693" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r367", "r368", "r369", "r488", "r627", "r628", "r629", "r672", "r694" ] }, "aytu_AdhdPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AdhdPortfolioMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "ADHD Portfolio [Member]", "documentation": "Relating to the ADHS Portfolio." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "auth_ref": [] }, "aytu_AfterJanuary262023ButBeforeJanuary262024Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AfterJanuary262023ButBeforeJanuary262024Member", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "After January 26, 2023 But Before January 26, 2024 [Member]", "documentation": "Relating to after January 26, 2023 but before January 26, 2024." } } }, "auth_ref": [] }, "aytu_AfterJanuary262024ButBeforeJanuary262025Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AfterJanuary262024ButBeforeJanuary262025Member", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "After January 26, 2024 But Before January 26, 2025 [Member]", "documentation": "Relating to after January 26, 2024 but before January 26, 2025." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r362", "r370" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "aytu_AmortizationExpenseOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AmortizationExpenseOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_AmortizationExpenseOfIntangibleAssets", "terseLabel": "Amortization Expense of Intangible Assets", "documentation": "The value of amortization expense of intangible assets." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Amortization of senior debt discount", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r293", "r413", "r569", "r570", "r623" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r6", "r43", "r47" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r197" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r34" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r385" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Impairment expense", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r6", "r48" ] }, "us-gaap_AssetUnderConstructionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetUnderConstructionMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Asset under Construction [Member]", "documentation": "Asset in process of being built." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r123", "r150", "r172", "r206", "r221", "r227", "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r386", "r388", "r406", "r445", "r511", "r592", "r605", "r638", "r639", "r679" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r143", "r156", "r172", "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r386", "r388", "r406", "r592", "r638", "r639", "r679" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r172", "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r386", "r388", "r406", "r638", "r639", "r679" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Non-current assets:" } } }, "auth_ref": [] }, "aytu_AtthemarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AtthemarketOfferingMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "At-the-market Offering [Member]", "documentation": "Represents the at-the-market offering." } } }, "auth_ref": [] }, "aytu_August2022CommonAndPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "August2022CommonAndPrefundedWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "August 2022 Common and Prefunded Warrants [Member]", "documentation": "Relating to the August 2022 Common and Prefunded Warrants." } } }, "auth_ref": [] }, "aytu_August2022CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "August2022CommonWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "August 2022 Common Warrants [Member]", "documentation": "Relating to the August 2022 Common Warrants." } } }, "auth_ref": [] }, "aytu_August2022PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "August2022PrefundedWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "August 2022 Prefunded Warrants [Member]", "documentation": "Relating to August 2022 prefunded warrants." } } }, "auth_ref": [] }, "aytu_AvenueCapitalIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AvenueCapitalIssuanceMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Avenue Capital Issuance [Member]", "documentation": "Relating to Avenue Capital Issuance." } } }, "auth_ref": [] }, "aytu_AvenueCapitalLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AvenueCapitalLoanMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Avenue Capital Loan [Member]", "documentation": "Relating to the Avenue Capital Loan." } } }, "auth_ref": [] }, "aytu_AvenueCapitalWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AvenueCapitalWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Avenue Capital Warrants [Member]", "documentation": "Relating to the Avenue Capital Warrants." } } }, "auth_ref": [] }, "aytu_AvenueNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "AvenueNoteMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Avenue Note [Member]", "documentation": "Relating to the Avenue Note." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r383", "r576", "r577" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r60", "r61", "r383", "r576", "r577" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 }, "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Loss from contingent consideration", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r384", "r622" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r63" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r32", "r145", "r553" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r32", "r103", "r169" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r32", "r103", "r169" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r103" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r54" ] }, "aytu_ClassOfWarrantOrRightCovenantAdjustedEbitda": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ClassOfWarrantOrRightCovenantAdjustedEbitda", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_ClassOfWarrantOrRightCovenantAdjustedEbitda", "terseLabel": "Class of Warrant or Right, Covenant, Adjusted EBITDA", "documentation": "Represents the amount of Earnings Before Income Tax, Depreciation, and Amortization needed satisfy a warrant or right covenant." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod": { "xbrltype": "perShareItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Warrants exercised, weighted average exercise price (in dollars per share)", "documentation": "Represents the exercise price of warrants or rights exercised during the period." } } }, "auth_ref": [] }, "aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod": { "xbrltype": "perShareItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Warrants expired (in dollars per share)", "documentation": "Represents the exercise price of warrants or rights expired during the period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "periodStartLabel": "Warrants, weighted average exercise price (in dollars per share)", "periodEndLabel": "Warrants, weighted average exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r312" ] }, "aytu_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "aytu_ClassOfWarrantOrRightExercisedDuringPeriod", "negatedLabel": "Warrants exercised (in shares)", "documentation": "The number of warrants or rights exercised during period." } } }, "auth_ref": [] }, "aytu_ClassOfWarrantOrRightExpiredDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ClassOfWarrantOrRightExpiredDuringPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "aytu_ClassOfWarrantOrRightExpiredDuringPeriod", "negatedLabel": "Warrants expired, weighted average exercise price (in shares)", "documentation": "Represents the number of warrants or rights expired during the period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r312" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodStartLabel": "Warrants outstanding (in shares)", "periodEndLabel": "Warrants outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "presentation": [ "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Warrants, weighted average remaining contractual life (Year)", "documentation": "The weighted average period of remaining contractual life of warrants or rights." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (note 13)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r28", "r73", "r447", "r498" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r113", "r263", "r264", "r549", "r635" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r595", "r596", "r597", "r599", "r600", "r601", "r602", "r627", "r628", "r672", "r691", "r694" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r86" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r86", "r499" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r86" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, outstanding (in shares)", "terseLabel": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r86", "r499", "r517", "r694", "r695" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,347 and 5,517,174 shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r86", "r449", "r592" ] }, "aytu_CommonWarrantsExchangedForPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "CommonWarrantsExchangedForPrefundedWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Warrants Exchanged for PreFunded Warrants [Member]", "documentation": "Relating to Common Warrants exchanged for Pre-Funded Warrants." } } }, "auth_ref": [] }, "aytu_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "CommonWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Warrants [Member]", "documentation": "Relating to the Common Warrants." } } }, "auth_ref": [] }, "aytu_ConsumerHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ConsumerHealthMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Consumer Health [Member]", "documentation": "Represents consumer health." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Cost of sales", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r99", "r438" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r173", "r174", "r281", "r301", "r432", "r559", "r561" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "aytu_CurrentPortionOfDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "CurrentPortionOfDebtMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Current Portion of Debt [Member]", "documentation": "Represents current portion of debt." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r17", "r81", "r82", "r124", "r126", "r175", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r414", "r566", "r567", "r568", "r569", "r570", "r624" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "Long-term debt, due on January 26, 2025", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r17", "r126", "r294" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r68", "r71", "r278", "r414", "r567", "r568" ] }, "aytu_DebtInstrumentFinalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "DebtInstrumentFinalPayment", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "Long-term, final payment fee", "terseLabel": "Debt Instrument, Final Payment", "documentation": "Represents the final payment of a debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r25", "r68", "r296", "r414" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r25", "r279" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r26", "r175", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r414", "r566", "r567", "r568", "r569", "r570", "r624" ] }, "aytu_DebtInstrumentPrepaymentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20231231", "localname": "DebtInstrumentPrepaymentFeePercentage", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_DebtInstrumentPrepaymentFeePercentage", "terseLabel": "Debt Instrument, Prepayment Fee, Percentage", "documentation": "Represents the percentage of loan that is payable as a prepayment fee." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "negatedLabel": "Less: unamortized discount and issuance costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r69", "r284", "r295", "r567", "r568" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet", "negatedLabel": "Unamortized discount and issuance costs", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r67", "r68", "r69", "r70", "r71", "r641" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r49" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r6", "r49" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Depreciation, amortization and accretion", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r6", "r211" ] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments, Liabilities [Member]", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": [] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "(Loss) gain on derivative warrant liabilities", "negatedLabel": "Loss (gain) on derivative warrant liabilities", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r670" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Derivative warrant liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r157" ] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Derivative liability, measurement input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": [ "r404" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r120" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers-tables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r642" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r334", "r335", "r363", "r364", "r366", "r579" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20231231/role/statement-note-18-license-agreements", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting", "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers", "http://aytubio.com/20231231/role/statement-note-4-inventories", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment", "http://aytubio.com/20231231/role/statement-note-6-leases", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DistributionRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributionRightsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Distribution Rights [Member]", "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r609" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r610" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "aytu_EarnOutPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "EarnOutPaymentsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Earn Out Payments [Member]", "documentation": "Relating to earn out payments." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per common share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r164", "r181", "r182", "r183", "r184", "r185", "r191", "r192", "r194", "r195", "r196", "r200", "r398", "r399", "r441", "r456", "r562" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r190", "r197", "r198", "r199" ] }, "aytu_EclipseBusinessCapitalLlcLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "EclipseBusinessCapitalLlcLoanAgreementMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "Eclipse Business Capital LLC Loan Agreement [Member]", "documentation": "Relating to Eclipse Business Capital LLC Loan Agreement." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r375" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued employee compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22" ] }, "aytu_EmployeeRetentionCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "EmployeeRetentionCredit", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Employee retention credit", "terseLabel": "Employee Retention Credit", "documentation": "Represents the amount of employee retention credit." } } }, "auth_ref": [] }, "aytu_EmployeeRetentionCreditVendorFee": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "EmployeeRetentionCreditVendorFee", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_EmployeeRetentionCreditVendorFee", "terseLabel": "Employee Retention Credit, Vendor Fee", "documentation": "Represents the amount of vendor fee from employee retention credit during the period." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r365" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r365" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r607" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited", "http://aytubio.com/20231231/role/statement-document-and-entity-information", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20231231/role/statement-note-16-warrants-tables", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20231231/role/statement-note-18-license-agreements", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-details-textual", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-tables", "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies", "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies-details-textual", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers-tables", "http://aytubio.com/20231231/role/statement-note-4-inventories", "http://aytubio.com/20231231/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20231231/role/statement-note-4-inventories-tables", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20231231/role/statement-note-6-leases", "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details", "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20231231/role/statement-note-6-leases-tables", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-tables", "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r607" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r607" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r613" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r607" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r607" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r607" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r607" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r140", "r161", "r162", "r163", "r176", "r177", "r178", "r180", "r186", "r188", "r201", "r238", "r239", "r313", "r367", "r368", "r369", "r380", "r381", "r390", "r391", "r392", "r393", "r394", "r395", "r397", "r407", "r408", "r409", "r410", "r411", "r412", "r431", "r476", "r477", "r478", "r488", "r537" ] }, "aytu_EquityWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "EquityWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Equity Warrants [Member]", "documentation": "Relating to Equity Warrants." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r10" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r286", "r326", "r327", "r328", "r329", "r330", "r331", "r402", "r433", "r434", "r435", "r567", "r568", "r573", "r574", "r575" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r66", "r122" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r400" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r286", "r326", "r331", "r402", "r433", "r573", "r574", "r575" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r286", "r326", "r331", "r402", "r434", "r567", "r568", "r573", "r574", "r575" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r286", "r326", "r327", "r328", "r329", "r330", "r331", "r402", "r435", "r567", "r568", "r573", "r574", "r575" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r11" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r11", "r66" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details" ], "lang": { "en-us": { "role": { "label": "Included in earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r405" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r11" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r286", "r326", "r327", "r328", "r329", "r330", "r331", "r433", "r434", "r435", "r567", "r568", "r573", "r574", "r575" ] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Interest on lease liabilities", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r417", "r422", "r583" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from finance leases", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r419", "r425" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Finance lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r416", "r428" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details": { "parentTag": "aytu_OperatingLeaseAndFinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Finance leases", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r416" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "totalLabel": "Total finance lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r428" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Finance lease,2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Finance lease,2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Finance lease,2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Finance lease,2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Finance lease, 2024 (remaining 6 months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r678" ] }, "aytu_FinanceLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Finance lease, thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Finance lease, less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r428" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Financing cash flows from finance leases", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r418", "r425" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details": { "parentTag": "aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Finance lease assets", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r415" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Amortization of leased assets", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r417", "r422", "r583" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Finance lease assets", "label": "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r427", "r583" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Finance lease assets (Year)", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r426", "r583" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, fair value", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Finite-lived intangible assets, amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r148", "r256" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details" ], "lang": { "en-us": { "role": { "label": "2024 (remaining 6 months)", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r439", "r440" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r109", "r440" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r44", "r46" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, net", "totalLabel": "Total future amortization expense", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r109", "r439" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, remaining life (Year)", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r439" ] }, "aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20231231", "localname": "FinitelivedIntangibleAssetUsefulLifeRenewablePeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod", "terseLabel": "Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)", "documentation": "Represents the renewable period for a finite-lived intangible asset." } } }, "auth_ref": [] }, "aytu_FixedPaymentArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "FixedPaymentArrangements", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Fixed payment arrangements", "terseLabel": "Fixed Payment Arrangements", "documentation": "Represents the amount of fixed payment arrangements." } } }, "auth_ref": [] }, "aytu_FixedPaymentArrangementsLiabilityReduction": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "FixedPaymentArrangementsLiabilityReduction", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_FixedPaymentArrangementsLiabilityReduction", "terseLabel": "Fixed Payment Arrangements, Liability, Reduction", "documentation": "Represents the amount of reduction of a fixed payment arrangement liability." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r100", "r521" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r97" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r98", "r172", "r206", "r220", "r226", "r229", "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r406", "r563", "r638" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ImpairmentOfIntangibleAssetsFinitelived", "terseLabel": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r623", "r633" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income (loss) before income tax", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r95", "r128", "r206", "r220", "r226", "r229", "r442", "r454", "r563" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r258", "r260", "r522" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r260", "r522" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r130", "r138", "r187", "r188", "r214", "r374", "r382", "r457" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r160", "r372", "r373", "r376", "r377", "r378", "r379", "r484" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r33" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet", "negatedLabel": "Other operating assets and liabilities, net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r611" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r253" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r42", "r45" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r101", "r291", "r297", "r569", "r570" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r165", "r167", "r168" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-4-inventories" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r240" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r108", "r556" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Inventories", "totalLabel": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r153", "r554", "r592" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r108", "r558" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r108", "r557" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-note-4-inventories-details-textual" ], "lang": { "en-us": { "role": { "label": "Inventory write-down", "terseLabel": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r241" ] }, "aytu_June2023WarrantsTrancheABMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "June2023WarrantsTrancheABMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "June 2023 Warrants Tranche A & B [Member]", "documentation": "Relating to the June 2023 Warrants Tranche A & B." } } }, "auth_ref": [] }, "aytu_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LabEquipmentMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Lab Equipment [Member]", "documentation": "Represents lab equipment." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases", "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases", "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total net lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r421", "r583" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r677" ] }, "aytu_LeaseForPrincipalOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LeaseForPrincipalOfficeMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases", "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease for Principal Office [Member]", "documentation": "Relating to the lease for principal office." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r112" ] }, "aytu_LeasesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LeasesDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases" ], "lang": { "en-us": { "role": { "label": "Leases Disclosure [Text Block]", "documentation": "The entire disclosure for leases." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited", "http://aytubio.com/20231231/role/statement-document-and-entity-information", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20231231/role/statement-note-16-warrants-tables", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20231231/role/statement-note-18-license-agreements", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-details-textual", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-tables", "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies", "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies-details-textual", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers-tables", "http://aytubio.com/20231231/role/statement-note-4-inventories", "http://aytubio.com/20231231/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20231231/role/statement-note-4-inventories-tables", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20231231/role/statement-note-6-leases", "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details", "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20231231/role/statement-note-6-leases-tables", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-tables", "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "aytu_LesseeLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LesseeLiabilityMaturityTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lessee, Liability, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r582" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total operating lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Operating lease, 2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Operating lease, 2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Operating lease, 2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Operating lease, 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Operating lease, 2024 (remaining 6 months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r678" ] }, "aytu_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Operating lease, thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Operating lease, less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r428" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r676" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r91", "r127", "r451", "r592", "r625", "r632", "r675" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r24", "r144", "r172", "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r387", "r388", "r389", "r406", "r592", "r638", "r679", "r680" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total non-current liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r17", "r77", "r78", "r79", "r83", "r172", "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r387", "r388", "r389", "r406", "r638", "r679", "r680" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities:" } } }, "auth_ref": [] }, "aytu_LiabilityWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LiabilityWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Liability Warrants [Member]", "documentation": "Represents liability warrants." } } }, "auth_ref": [] }, "aytu_LicenseAgreementMinimumAnnualRoyaltyPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LicenseAgreementMinimumAnnualRoyaltyPayment", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_LicenseAgreementMinimumAnnualRoyaltyPayment", "terseLabel": "License Agreement, Minimum Annual Royalty Payment", "documentation": "Represents the minimum annual royalty payment as part of a license agreement." } } }, "auth_ref": [] }, "aytu_LicenseAgreementRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LicenseAgreementRoyaltyPercentage", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_LicenseAgreementRoyaltyPercentage", "terseLabel": "License Agreement, Royalty Percentage", "documentation": "Represents the percentage of net sales that is paid as a royalty." } } }, "auth_ref": [] }, "aytu_LicensingAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LicensingAgreementsTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-18-license-agreements" ], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Text Block]", "documentation": "The entire disclosure for licensing agreements." } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCredit", "terseLabel": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r17", "r126", "r689" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r21", "r624" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r21", "r624" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r21" ] }, "aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Eligible Accounts Receivable", "documentation": "Represents the percentage of eligible accounts receivable on a line of credit facility." } } }, "auth_ref": [] }, "aytu_LineOfCreditFacilityMaximumBorrowingCapacityPortionAvailableForShortTermSwinglineLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LineOfCreditFacilityMaximumBorrowingCapacityPortionAvailableForShortTermSwinglineLoans", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_LineOfCreditFacilityMaximumBorrowingCapacityPortionAvailableForShortTermSwinglineLoans", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity, Portion Available for Short-term Swingline Loans", "documentation": "With regard to the maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility, this element represents the portion available for short-term swingline loans." } } }, "auth_ref": [] }, "aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LineOfCreditFacilityTerminationFeePercentageOfCommitment", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment", "terseLabel": "Line of Credit Facility, Termination, Fee, Percentage of Commitment", "documentation": "Represents the percentage of commitment used as a termination fee of a line of credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LoanProcessingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoanProcessingFee", "crdr": "debit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LoanProcessingFee", "terseLabel": "Loan Processing Fee", "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "Non-current portion of debt", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r17", "r446" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent", "negatedLabel": "Less: current portion", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": [ "r22" ] }, "aytu_LongTermDebtAndCapitalLeaseObligationsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "LongTermDebtAndCapitalLeaseObligationsGross", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details" ], "lang": { "en-us": { "role": { "label": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "totalLabel": "Future principal payments", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "totalLabel": "Total debt", "documentation": "Amount of long-term debt and lease obligation, including portion classified as current." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Current portion of debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r151" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details": { "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r175", "r289" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details": { "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "terseLabel": "2024 (remaining 6 months)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r626" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Debt, net of current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r152" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r114" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r26" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r26", "r51" ] }, "aytu_ManufacturingEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ManufacturingEquipmentMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Manufacturing Equipment [Member]", "documentation": "Represents manufacturing equipment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r332", "r437", "r475", "r490", "r491", "r542", "r543", "r544", "r545", "r546", "r550", "r551", "r564", "r571", "r578", "r594", "r640", "r681", "r682", "r683", "r684", "r685", "r686" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r673" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r673" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r673" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r673" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r403" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "aytu_MilestonePaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "MilestonePaymentsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Milestone Payments [Member]", "documentation": "Relating to milestone payments." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r332", "r437", "r475", "r490", "r491", "r542", "r543", "r544", "r545", "r546", "r550", "r551", "r564", "r571", "r578", "r594", "r640", "r681", "r682", "r683", "r684", "r685", "r686" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r612" ] }, "aytu_Neos2015PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "Neos2015PlanMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Neos 2015 Plan [Member]", "documentation": "Represents Neos 2015 plan." } } }, "auth_ref": [] }, "aytu_NeosTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "NeosTherapeuticsIncMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Neos Therapeutics, Inc. [Member]", "documentation": "Related to Neos Therapeutics, Inc." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r166" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r166" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r103", "r104", "r105" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Net loss", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r96", "r105", "r129", "r142", "r158", "r159", "r163", "r172", "r179", "r181", "r182", "r183", "r184", "r187", "r188", "r193", "r206", "r220", "r226", "r229", "r237", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r399", "r406", "r455", "r519", "r535", "r536", "r563", "r603", "r638" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r612" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r612" ] }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonmonetaryTransactionTypeAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]", "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r429", "r430", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ] }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonmonetaryTransactionTypeDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Domain]", "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r429", "r430", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r15" ] }, "aytu_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "aytu_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r631" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r631" ] }, "aytu_OfficeEquipmentFurnitureAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "OfficeEquipmentFurnitureAndOtherMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Office Equipment, Furniture and Other [Member]", "documentation": "Represents office equipment, furniture and other." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenseMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating Expense [Member]", "documentation": "Primary financial statement caption encompassing expenses associated with normal operations." } } }, "auth_ref": [ "r14" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Income (loss) from operations", "totalLabel": "Income (loss) from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r206", "r220", "r226", "r229", "r563" ] }, "aytu_OperatingLeaseAndFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "OperatingLeaseAndFinanceLeaseLiability", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "aytu_OperatingLeaseAndFinanceLeaseLiability", "totalLabel": "Total lease liabilities", "documentation": "Represents operating and finance lease liability." } } }, "auth_ref": [] }, "aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "OperatingLeaseAndFinanceLeaseRightofuseAsset", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset", "totalLabel": "Total lease assets", "documentation": "Represents right-of-use asset for operating lease and finance lease." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r423", "r583" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual", "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "terseLabel": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r416" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details": { "parentTag": "aytu_OperatingLeaseAndFinanceLeaseLiability", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Operating leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r416" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details": { "parentTag": "aytu_OperatingLeaseAndFinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseLiabilityNoncurrent", "terseLabel": "Operating leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r416" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r420", "r425" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details": { "parentTag": "aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset", "weight": 1.0, "order": 1.0 }, "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "terseLabel": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r415" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating lease assets", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r427", "r583" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating lease assets (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r426", "r583" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r76", "r121", "r481", "r482" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r22" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r155", "r592" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Other non-current assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r149" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherExpenseMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Other Expense [Member]", "documentation": "Primary financial statement caption encompassing other expense." } } }, "auth_ref": [ "r14" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherLiabilities", "totalLabel": "Total other liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r72", "r444", "r494", "r495", "r605", "r692" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "negatedLabel": "Less: current portion", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r22", "r592" ] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-9-other-liabilities" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r23" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total other liabilities, non-current", "label": "Other non-current liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_OtherLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Other Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherNoncashIncomeExpense", "negatedLabel": "Other noncash adjustments", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r105" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r102" ] }, "us-gaap_OtherSundryLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSundryLiabilities", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "The aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements." } } }, "auth_ref": [ "r82", "r84", "r125" ] }, "aytu_OtherWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "OtherWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Other Warrants [Member]", "documentation": "Relating to other warrants." } } }, "auth_ref": [] }, "aytu_OutsideEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "OutsideEquityIncentivePlanMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Outside Equity Incentive Plan [Member]", "documentation": "Relating to outside the equity incentive plan." } } }, "auth_ref": [] }, "us-gaap_PatentedTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentedTechnologyMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Patented Technology [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law." } } }, "auth_ref": [ "r62" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities", "negatedLabel": "Contingent consideration payment", "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability." } } }, "auth_ref": [ "r2" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities", "terseLabel": "Payment for Contingent Consideration Liability, Operating Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentOfFinancingAndStockIssuanceCosts", "terseLabel": "Payment of Financing and Stock Issuance Costs", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": [ "r30" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities", "negatedLabel": "Other investing activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r616", "r620" ] }, "aytu_PaymentsOfFixedPaymentArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "PaymentsOfFixedPaymentArrangements", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "aytu_PaymentsOfFixedPaymentArrangements", "negatedLabel": "Payment made to fixed payment arrangement", "documentation": "The cash outflow for fixed payments arrangements." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of stock issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r30" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r85", "r299" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, authorizzed (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r85", "r499" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, issued (in shares)", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r85", "r299" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r85", "r499", "r517", "r694", "r695" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r85", "r448", "r592" ] }, "aytu_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "PrefundedWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants [Member]", "documentation": "Relating to the Pre-Funded Warrants." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r154", "r242", "r243", "r555" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of stock and warrants", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r3", "r485" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Other financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r617", "r621" ] }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Net (payments made on) proceeds received from, short-term line of credit", "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)." } } }, "auth_ref": [] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r643" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r231", "r438", "r469", "r470", "r471", "r472", "r473", "r474", "r552", "r572", "r593", "r619", "r636", "r637", "r642", "r690" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r231", "r438", "r469", "r470", "r471", "r472", "r473", "r474", "r552", "r572", "r593", "r619", "r636", "r637", "r642", "r690" ] }, "aytu_PropertyAndEquipmentNetMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "PropertyAndEquipmentNetMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net [Member]", "documentation": "Relating to Property and Equipment, Net." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r111", "r133", "r136", "r137" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r112", "r146", "r453" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 }, "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r443", "r453", "r592" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r112" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r325", "r332", "r358", "r359", "r360", "r436", "r437", "r475", "r490", "r491", "r542", "r543", "r544", "r545", "r546", "r550", "r551", "r564", "r571", "r578", "r594", "r597", "r634", "r640", "r682", "r683", "r684", "r685", "r686" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r325", "r332", "r358", "r359", "r360", "r436", "r437", "r475", "r490", "r491", "r542", "r543", "r544", "r545", "r546", "r550", "r551", "r564", "r571", "r578", "r594", "r597", "r634", "r640", "r682", "r683", "r684", "r685", "r686" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Payments made to borrowings", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r31", "r486" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r173", "r174", "r281", "r301", "r432", "r560", "r561" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r75", "r371", "r687" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "aytu_RestrictedStockAndRestrictedStockUnitsRsusMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "RestrictedStockAndRestrictedStockUnitsRsusMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Restricted Stock and Restricted Stock Units (RSUs) [Member]", "documentation": "Share instruments in which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r34" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r88", "r118", "r450", "r479", "r480", "r487", "r500", "r592" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r140", "r176", "r177", "r178", "r180", "r186", "r188", "r238", "r239", "r367", "r368", "r369", "r380", "r381", "r390", "r392", "r393", "r395", "r397", "r476", "r478", "r488", "r694" ] }, "aytu_ReturnReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ReturnReserveCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Return reserve", "documentation": "Represents the amount of return reserve classified as current." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "Product revenue, net", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r207", "r208", "r219", "r224", "r225", "r231", "r233", "r234", "r322", "r323", "r438" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r139", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r324" ] }, "aytu_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ReverseStockSplitMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding." } } }, "auth_ref": [] }, "aytu_RoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "RoyaltiesMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Royalties [Member]", "documentation": "Relating to royalties." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r612" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r612" ] }, "aytu_RumpusAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "RumpusAcquisitionMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Rumpus Acquisition [Member]", "documentation": "Relating to the Rumpus Acquisition." } } }, "auth_ref": [] }, "aytu_RxSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "RxSegmentMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Rx Segment [Member]", "documentation": "Relating to the Rx Segment." } } }, "auth_ref": [] }, "aytu_SabbyLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SabbyLitigationMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Sabby Litigation [Member]", "documentation": "Relating to the Sabby Litigation." } } }, "auth_ref": [] }, "aytu_SabbyLitigationWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SabbyLitigationWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Sabby Litigation Warrants [Member]", "documentation": "Relating to warrants calculated by the claimant in the Sabby Litigation." } } }, "auth_ref": [] }, "aytu_SabbyVolatilityWarrantMasterFundLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SabbyVolatilityWarrantMasterFundLtdMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Sabby Volatility Warrant Master Fund Ltd. [Member]", "documentation": "Relating to Sabby Volatility Warrant master Fund Ltd." } } }, "auth_ref": [] }, "aytu_SaleOfStockMaximumAmountOfEquityIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SaleOfStockMaximumAmountOfEquityIssuable", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SaleOfStockMaximumAmountOfEquityIssuable", "terseLabel": "Sale of Stock, Maximum Amount of Equity Issuable", "documentation": "Represents the maximum monetary amount of equity issuable." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SaleOfStockPricePerShare", "terseLabel": "Sale of Stock, Price Per Share (in dollars per share)", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "aytu_SaleOfStockRemainingAmountAvailable": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SaleOfStockRemainingAmountAvailable", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SaleOfStockRemainingAmountAvailable", "terseLabel": "Sale of Stock, Remaining Amount Available", "documentation": "Represents the remaining amount of equity issuable." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r189", "r333", "r614", "r630" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r26", "r52", "r53", "r67", "r68", "r71", "r74", "r116", "r117", "r567", "r569", "r626" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r401", "r402" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r44", "r46" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-4-inventories-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r19", "r92", "r93", "r94" ] }, "aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ScheduleOfLeaseByBalanceSheetInformationTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Lease by Balance Sheet Information [Table Text Block]", "documentation": "Tabular disclosure of leases by balance sheet information." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r38", "r39", "r40", "r41" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r12", "r13", "r56" ] }, "aytu_ScheduleOfWarrantOrRightActivity": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ScheduleOfWarrantOrRightActivity", "presentation": [ "http://aytubio.com/20231231/role/statement-note-16-warrants-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrant or Right Activity", "documentation": "Tabular disclosure of warrant or right activity." } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r46" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r671" ] }, "aytu_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Relating to the Securities Purchase Agreement." } } }, "auth_ref": [] }, "aytu_SecuritiesPurchaseAgreementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SecuritiesPurchaseAgreementWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement Warrants [Member]", "documentation": "Relating to the Securities Purchase Agreement Warrants." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r606" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r608" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r203", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r234", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r261", "r262", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r565", "r619", "r690" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-19-segment-reporting" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r202", "r203", "r204", "r205", "r206", "r218", "r223", "r227", "r228", "r229", "r230", "r231", "r232", "r234" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Selling and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "label": "us-gaap_ShareBasedCompensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r579" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited, shares (in shares)", "negatedTerseLabel": "Forfeited/cancelled, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r352" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Forfeited/cancelled, weighted average grant date fair value (in dollars per share)", "label": "Forfeited, weighted average grant date fair value (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r352" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "Granted, shares (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r350" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" ], "lang": { "en-us": { "role": { "label": "Granted, weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r350" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)", "periodStartLabel": "Unvested, shares (in shares)", "periodEndLabel": "Unvested, shares (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r347", "r348" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Unvested, weighted average grant date fair value (in dollars per share)", "periodEndLabel": "Unvested, weighted average grant date fair value (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r347", "r348" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested, weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r581" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, options (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r341" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, options, weighted average exercise price (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r341" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Expired, options (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r346" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited/Cancelled, options (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Granted, options (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r343" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r353" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)", "periodStartLabel": "Outstanding, options (in shares)", "periodEndLabel": "Outstanding, options (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r339", "r340" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, options, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r339", "r340" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Expired, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r346" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Granted, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r343" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r580" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, options, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r55" ] }, "aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Granted, options, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards granted during the periof, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Outstanding, options, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r119" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balances (in shares)", "periodEndLabel": "Balances (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Short-term line of credit", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r80", "r124", "r592", "r688" ] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Text Block]", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": [ "r114" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r424", "r583" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r106", "r170" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r141", "r203", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r234", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r259", "r261", "r262", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r565", "r619", "r690" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r29", "r140", "r161", "r162", "r163", "r176", "r177", "r178", "r180", "r186", "r188", "r201", "r238", "r239", "r313", "r367", "r368", "r369", "r380", "r381", "r390", "r391", "r392", "r393", "r394", "r395", "r397", "r407", "r408", "r409", "r410", "r411", "r412", "r431", "r476", "r477", "r478", "r488", "r537" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20231231/role/statement-note-16-warrants-tables", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20231231/role/statement-note-18-license-agreements", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-details-textual", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-tables", "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies", "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies-details-textual", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers-tables", "http://aytubio.com/20231231/role/statement-note-4-inventories", "http://aytubio.com/20231231/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20231231/role/statement-note-4-inventories-tables", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20231231/role/statement-note-6-leases", "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details", "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20231231/role/statement-note-6-leases-tables", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-tables", "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r176", "r177", "r178", "r201", "r438", "r483", "r489", "r492", "r493", "r494", "r495", "r496", "r497", "r499", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r514", "r515", "r516", "r518", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r537", "r598" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r189", "r333", "r614", "r615", "r630" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation", "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20231231/role/statement-note-16-warrants-tables", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20231231/role/statement-note-18-license-agreements", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-details-textual", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-schedule-of-segment-information-details", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-tables", "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies", "http://aytubio.com/20231231/role/statement-note-2-significant-accounting-policies-details-textual", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers-tables", "http://aytubio.com/20231231/role/statement-note-4-inventories", "http://aytubio.com/20231231/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20231231/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20231231/role/statement-note-4-inventories-tables", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20231231/role/statement-note-6-leases", "http://aytubio.com/20231231/role/statement-note-6-leases-details-textual", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20231231/role/statement-note-6-leases-lease-cost-details", "http://aytubio.com/20231231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20231231/role/statement-note-6-leases-tables", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-tables", "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r176", "r177", "r178", "r201", "r438", "r483", "r489", "r492", "r493", "r494", "r495", "r496", "r497", "r499", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r514", "r515", "r516", "r518", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r537", "r598" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock with exercise of warrants (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r85", "r86", "r118", "r485", "r537", "r547" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r9", "r85", "r86", "r118" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock with exercise of warrants", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r85", "r86", "r118", "r488", "r537", "r547", "r604" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r58", "r85", "r86", "r118" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://aytubio.com/20231231/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r86", "r89", "r90", "r107", "r501", "r517", "r538", "r539", "r592", "r605", "r625", "r632", "r675", "r694" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r115", "r171", "r298", "r300", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r396", "r540", "r541", "r548" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://aytubio.com/20231231/role/statement-note-1-nature-of-business-financial-condition-basis-of-presentation-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r18" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SupplyAndDistributionAgreementExtensionTerm", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementExtensionTerm", "terseLabel": "Supply and Distribution Agreement, Extension Term (Year)", "documentation": "Represents the extension term of a supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues", "terseLabel": "Supply and Distribution Agreement, First Milestone, Minimum Net Revenues", "documentation": "The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementMakewholePaymentPerUnitForSalesUnderMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SupplyAndDistributionAgreementMakewholePaymentPerUnitForSalesUnderMinimum", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementMakewholePaymentPerUnitForSalesUnderMinimum", "terseLabel": "Supply and Distribution Agreement, Make-whole Payment Per Unit for Sales Under Minimum", "documentation": "The amount of make-whole payment per unit for sales under the minimum units for the supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SupplyAndDistributionAgreementMaximumMilestoneObligations", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations", "terseLabel": "Supply and Distribution Agreement, Maximum Milestone Obligations", "documentation": "The maximum amount of milestone obligations of the supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SupplyAndDistributionAgreementMaximumYearlyMakewholePayment", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment", "terseLabel": "Supply and Distribution Agreement, Maximum Yearly Make-whole Payment", "documentation": "The maximum amount of make-whole payment per year under supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementMinimumSalesPerYear": { "xbrltype": "decimalItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SupplyAndDistributionAgreementMinimumSalesPerYear", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementMinimumSalesPerYear", "terseLabel": "Supply and Distribution Agreement, Minimum Sales Per Year", "documentation": "Th minimum amount of units to be sold per year under supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SupplyAndDistributionCommitmentPeriod", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionCommitmentPeriod", "terseLabel": "Supply and Distribution Commitment, Period (Year)", "documentation": "Period covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20231231", "localname": "SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales", "terseLabel": "Supply and Distribution Commitment, Royalty, Percentage of Net Sales", "documentation": "The percentage of net sales to be paid for royalties under supply and distribution agreement." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20231231/role/statement-note-12-fair-value-considerations-tables", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20231231/role/statement-note-16-warrants-tables", "http://aytubio.com/20231231/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20231231/role/statement-note-19-segment-reporting-tables", "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contracts-with-customers-tables", "http://aytubio.com/20231231/role/statement-note-4-inventories-tables", "http://aytubio.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20231231/role/statement-note-6-leases-tables", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20231231/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r16" ] }, "aytu_The2015PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "The2015PlanMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2015 Plan [Member]", "documentation": "Represents the Aytu BioScience 2015 Stock Option and Incentive Plan (the \u201c2015 Plan\u201d)." } } }, "auth_ref": [] }, "aytu_The2020ShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "The2020ShelfMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2020 Shelf [Member]", "documentation": "Relating to the 2020 Shelf." } } }, "auth_ref": [] }, "aytu_The2021ShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "The2021ShelfMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2021 Shelf [Member]", "documentation": "Relating to the 2021 Shelf." } } }, "auth_ref": [] }, "aytu_The2023EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "The2023EquityIncentivePlanMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20231231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2023 Equity Incentive Plan [Member]", "documentation": "Relating to the 2023 Equity Incentive Plan." } } }, "auth_ref": [] }, "aytu_TheAugust2022OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "TheAugust2022OfferingMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "The August 2022 Offering [Member]", "documentation": "Relating to the August 2022 Offering." } } }, "auth_ref": [] }, "aytu_ThePediatricPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "ThePediatricPortfolioMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "The Pediatric Portfolio [Member]", "documentation": "Represents the Pediatric Portfolio." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://aytubio.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "aytu_TrancheACommonWarrantsAtDoubleExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "TrancheACommonWarrantsAtDoubleExercisePriceMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Tranche A Common Warrants at Double Exercise Price [Member]", "documentation": "Relating to Tranche A Common Warrants at double exercise price." } } }, "auth_ref": [] }, "aytu_TrancheACommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "TrancheACommonWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Tranche A Common Warrants [Member]", "documentation": "Relating to Tranche A Common Warrants." } } }, "auth_ref": [] }, "aytu_TrancheBCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "TrancheBCommonWarrantsMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Tranche B Common Warrants [Member]", "documentation": "Relating to the Tranche B Common Warrants." } } }, "auth_ref": [] }, "aytu_TrisKarbinalAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "TrisKarbinalAgreementMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets", "http://aytubio.com/20231231/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Tris Karbinal Agreement [Member]", "documentation": "Relating to Tris Karbinal Agreement." } } }, "auth_ref": [] }, "aytu_TrisLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "TrisLicenseAgreementMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Tris License Agreement [Member]", "documentation": "Represents the Tris License Agreement." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities", "http://aytubio.com/20231231/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r385" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r35", "r36", "r37", "r131", "r132", "r134", "r135" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://aytubio.com/20231231/role/statement-note-10-line-of-credit", "http://aytubio.com/20231231/role/statement-note-10-line-of-credit-details-textual", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt", "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "aytu_WalleyeOpportunitiesMasterFundLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20231231", "localname": "WalleyeOpportunitiesMasterFundLtdMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20231231/role/statement-note-13-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Walleye Opportunities Master Fund Ltd. [Member]", "documentation": "Relating to Walleye Opportunities Master Fund Ltd." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://aytubio.com/20231231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://aytubio.com/20231231/role/statement-note-14-capital-structure-details-textual", "http://aytubio.com/20231231/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r674" ] }, "aytu_WarrantsOrRightsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20231231", "localname": "WarrantsOrRightsDisclosureTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-note-16-warrants" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights Disclosure [Text Block]", "documentation": "The entire disclosure for warrants or rights." } } }, "auth_ref": [] }, "aytu_WarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20231231", "localname": "WarrantsPolicyTextBlock", "presentation": [ "http://aytubio.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Warrants [Policy Text Block]", "documentation": "Disclosure of the company's accounting policy regarding warrants." } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://aytubio.com/20231231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r550", "r551", "r681", "r683", "r686" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://aytubio.com/20231231/role/statement-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Basic and diluted weighted-average common shares outstanding (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r191", "r196" ] }, "aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-11-longterm-debt-future-principal-payments-details", "lang": { "en-us": { "role": { "label": "Note 11 - Long-term Debt - Future Principal Payments (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "lang": { "en-us": { "role": { "label": "Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-11-longterm-debt-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-11-longterm-debt-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Long-term Debt" } } }, "auth_ref": [] }, "aytu_statement-statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "lang": { "en-us": { "role": { "label": "Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-12-fair-value-considerations-summary-of-level-3-changes-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "lang": { "en-us": { "role": { "label": "Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-12-fair-value-considerations-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-12-fair-value-considerations-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Fair Value Considerations" } } }, "auth_ref": [] }, "aytu_statement-statement-note-12-fair-value-considerations-valuation-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 12 - Fair Value Considerations - Valuation Assumptions (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-15-equity-incentive-plans-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Stock Option Activity (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-15-equity-incentive-plans-tables", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans" } } }, "auth_ref": [] }, "aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 16 - Warrants - Schedule of Warrants Outstanding (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-16-warrants-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-16-warrants-tables", "lang": { "en-us": { "role": { "label": "Note 16 - Warrants" } } }, "auth_ref": [] }, "aytu_statement-statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-17-earnings-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-17-earnings-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 17 - Earnings Per Share" } } }, "auth_ref": [] }, "aytu_statement-statement-note-19-segment-reporting-schedule-of-segment-information-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-19-segment-reporting-schedule-of-segment-information-details", "lang": { "en-us": { "role": { "label": "Note 19 - Segment Reporting - Schedule of Segment Information (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-19-segment-reporting-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-19-segment-reporting-tables", "lang": { "en-us": { "role": { "label": "Note 19 - Segment Reporting" } } }, "auth_ref": [] }, "aytu_statement-statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-3-revenues-from-contract-with-customers-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Note 3 - Revenues From Contract With Customers - Disaggregation of Revenue (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-3-revenues-from-contracts-with-customers-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-3-revenues-from-contracts-with-customers-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Revenues From Contracts with Customers" } } }, "auth_ref": [] }, "aytu_statement-statement-note-4-inventories-schedule-of-inventories-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-4-inventories-schedule-of-inventories-details", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories - Schedule of Inventories (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-4-inventories-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-4-inventories-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories" } } }, "auth_ref": [] }, "aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-5-property-and-equipment-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-5-property-and-equipment-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment" } } }, "auth_ref": [] }, "aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-6-leases-lease-balance-sheet-information-details", "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Lease Balance Sheet Information (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-6-leases-lease-cost-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-6-leases-lease-cost-details", "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Lease Cost (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Schedule of Lease Liability Maturity (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-6-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-6-leases-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Leases" } } }, "auth_ref": [] }, "aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-7-intangible-assets-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "Note 7 - Intangible Assets - Future Amortization Expense (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-7-intangible-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-7-intangible-assets-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Intangible Assets" } } }, "auth_ref": [] }, "aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-8-accrued-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-8-accrued-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Accrued Liabilities" } } }, "auth_ref": [] }, "aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-9-other-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-note-9-other-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Other Liabilities" } } }, "auth_ref": [] }, "aytu_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20231231", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(ee)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "38", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482864/845-10-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482864/845-10-50-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-5" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r614": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r615": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 97 0001437749-24-004149-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-004149-xbrl.zip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�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�S!&W(WFUT'),YP+ M^VTT)40Y6=;$4,T09+7R:%@!4><*2)@>Z#&K'W#Q'=!U(3.)@)"4/UA&_V?E MKC]V,&;I4(046'W +$5D0'S#VP;ETG M!^3 !%\4/X/4:*(%0ML!70)$;8 ' MYS+T9BEN2AQ;53YME:Q!JK;O@/>(7G!@NTPXQ%CZAQL>(H/':DI<[S9C:2+2 M/! MA)V(",F4 ZL*;$].>?0XWC@@O6KU5E7$<6TVXHRK:=5:G'.TQ;:25([Q7--3 MENPTZ^J$TH;,B>GSB C*5\%?<]&4.\;3?.H=/8PM?4%EAM'>6Y%B> F" :U( M4%F4'>0\VMMN RX;H[X1Q8,RER\(C)W+NM_8W(B"955*6 MK!)=9I7(K))SRBJADIJOYG\"@Q4>XJ&,@8F_TQ6>EX^TUQS=A"%R[8W=4E_B@,[[?Y M@L*=RUVJ[SS2Y0"^Q8'7NI1 ;GI>$)GAE.,F%KK$T*H]0P(/II2N@!(.1-Q( MN F_@FE4K<4Y\D/%!+F49"*,M#)8"%<5'PS8@P]JO0^R"2-/:H+'R$#F"4*! MC:^ZP&U@"SF]]@X/J1!=T0?:N]=TWP*+9MW23D$@/H,+Z^-=ZJ\=/9'*[[*) M88)(,!X-TR*SAC,TKA4O(N I'B*VQA"6%SS\&Q,1 !J(!ZWZH=I*.\7#")TG MR]U7?]J6M: M(O?I P@5V^;9?,HW8T8?1T\"JR%'SW@.T\*2S'!32Y(@0R$ @N$:I))-^46? M2'GCSVY1Q%P(UK^[_G0;,GUBEW2IB=7N/@$6,YPHAP+L)G$A!+82"JW #M!& M(FT]9"2Z:G1,$5L T\[%2QSQ',6DX[2HB0&"))@LG(DG=23+C*V<$$_K4"&\_N]@ M_ADN(*A%\K!Y H*(W*U+-*8^6<[3Z7I6=''C8&2,B(JHQ!O#B;DE.<3#QU6G MZP?CWAX86GSG/(SSMU>U5PK&0T1KBNAO;VKTH[]YY 3,=PHU9(?6-@M/*4GX M*C7J@\$C$W&W"X5Z<<:+_\$,W&*T_%I#,93L)IXKFVJN$7?);>&RFY?!N0 1 M]M]>:8 &\''$'ZOCA&NO_(+FKKOCN\0QQ"GFQ/QXOZ0*[&$Q*I;#,B-DC M%1Z6O"[H H%G0GJORT%F^325;BN_-YH*[V:;S=]R^LNO?DWZ=C2[-QVVD"?G MBX(#F*K"X_=8UX&!60IC;M-;_J6!W&_:EZ 8L M/*D;=B5]]&9-BIZR8J?>+D3L2 2MSSZ=@Z#H==G=A8*5PC"ZUI1*81=4K79: M4BV4%C]@D;:ZQ5BD$DGK^W4-M=D\"):6:(?-9@XHE% *F3YUH6L-:,;1$*HT7UW#'E6BBG A[]06\-38O/U/C_O9*W-H^ M45OVY+@_J2692-#G]49VA7;$.QF$O5DHO2EJ;,]E*M7U11 M:NS27E:7'&/^(Z8&F09/6DJUDZ&V;V&-=[*&6^SQ!/)X\CN%K5W(:*]%3[X# MV&:\<4"J#1C/L@IXYQYZ3[KF$?<2ES/.#V] % 643Y9 :Q8)#L'<]>)BXJO) MU')F#+/CL(0&,7[)$\?#KI%ABY:X T%\KF2U]H4';T'!XOA,Z2H5T4S@:_P( M2A-,D!79<09UL>>,E9X(D=CNU,%R Z!;@@@S7)O2W2]"3DL\&G'/^M2\H@ ] M+J_FA,]S\+-8[K6L^BM+U5]=5OW)JK]E.#_%JK\7JB^=SU+:0'-I6MRVXF5: M*VI/0S498.$,HH:):B2KY]1:.$VH()5AQNG=F,V]7"7P8KOY[E3>P35%(4[% MQ8\PYG23B#E]B2XBSLW%$#G2O&?3XFT,)V;;P8YK5NAR4#<:P30;9%6?,7W% MI1KG1E^AX,Z*ZHJ&>.VHLF>PD7,S)]")AJ-ZWXDQH%9ER]M^G44_E @/JR+L MO$)1VQ(9>B8R?NU6M62]8]P*C@I[ U?I!2/P8WAM%%8B^3/%_?_;N];F-*ZD M_7U_Q91K4^6D ''1U7&\A24E)I$EK<#Q[J?4 (.8%6+(7"SQ_OJWG^YSFP$D M)(,E8U?MQ@+F3_LA' 7_;#@(5'2O;VPS5@I,@;$LM"TR3H8D(4# MR!>A/"4IYH[$D 8HW$I[%/9FH5,%UUQ#C@."?!0&L0+R1]6\:CN5% KR<,X^ M5-H5[S?4'8^97:FW3"(^=(S0J@?0E9,B!8:J5@Y5\XDNB\:]=E1XNL905HX] M1@KO!C0ZX!FA?+DFALVP]CGTX>. >Z[*'V@4%%E"I.&Z6MH1X2V_IT MD,4*!Q8P-+R+-N",S,?A0%5ZK>Z@5ULX; U?D0/2[L0D(P1"FT17KV(JSO&# MJ3@']35"-Z]#)_L_AM?0^-PEXL(&);Q$HW#1=[#6;@?& M!PM&'I @>KA!D@5#8PS.W4JU$ QRR3 "H]BPLPMMQ=(D]:4-2MK8M+OC7"C4D49AFPL M^4->!*M4[$@Y8)NY25IHQ3(>*\11%@L%[<)L'>[K(AOA(KN>T K^>7S4+GDG M)XWD0_#BX!(XW M(.WS#0]50@3\_65B87;OT%-D"EIZ^+EF6!QUT/@U;O]$LPO]WA#6FU*E/ACD MDSFZG:S543"./D7>VS":B!QGXBIRRH^6G$R!?@ ;0A_/ C(XQ(:O8?48+(;H MX*+@Y"S<# Q&N(H9-AZYD'!VILD2ZT&K9KU72U'C]VA(?.9=-+D"PM6'<0C3 M".)04^3W=Q\L.7CX#Q_Z,B.OY%0+>BM3SC9 ((TGO8D<J!Z7M[3TOH0TA;L 97+];Z?)84XK+12=A17"U5JU46 MXM, C($/]H(]U0MBMNB7VUMV'0JZSD<,8RZCX#XO; Q):SA&$UH9\P$C2+(N MM!T51:3_+%A_E0"&>..73WKZGNVQ*-MC^WNVQ_=LCV\IVT,<<<"I!%]K"KX> M1-!Q(OSOV?C;ODRP@!L DPC/I'\V9VN0^3Y-0N._'AA?%"G5*G4#U[EN;NOB MAE 059*E7OX!!K?4\:,#!34(QI+!HOJ+B=')SSD!:DM!E:;A,A Q%JPRDR8* (-L9&,/. M:8>*H<1AH.%?Z4?M[Y3\4]: )H[YRDLF(196^E@'])-H7$!2[85Q+[N&N.]A MHH50AZPGXV+C%QZZN&PD%&,)[7=A8/ 3_3B>ZE8@@4/J(F7L0.&>B0&&,F*' MAQ]S/PN.D4I'>P$QKR"'(6-'DHP0RFT_!$*N<58E[EZ0:$>D]ZO=A*&ED; &FH3B M$5J0#--T\FIKZ^;FII($OJ-9V&P>-+7^:9F7X%:J[C>IMK7I5&:;71D:5 MZ>EE8A1PK+\*;H>D'(-/<(X,H^#6JN4_($6^G5CSV6!0?BN>/ )DQW0=#(T MGB _9P$B,;1Q[DLN.8YR%=6/E# 6 ?YW!8YU(+"'RN@5\5VIG3XKV"+T(/X M E_;,A['/U*P5('1]F:DC#FK);=B9.[OAH='L-BO?O#\W33JO3[+3^//::IT?XXD1_ M/FJU#T_.VA\NCMM>\^W9AX[WOGGQQW''NVBU_W@NJMO*>=]'"7CZ7D+7CH+8 MZ;+7T\X-X,L/T%P=H8"+C"1WK=XMFV9+Q[=R%B 71=B)C:>(E7:_CEV@YOL]I.'W\Z@-?.1BPQYSX:D+P->U!4 M$5+GWVPX7/\&S3'D$&;*/<]L#S*UWTV/!72$MLGST,-$+=:,79LYCJZN]X . MJ_2"/C-X?WY\IN*]U6HX'Q,[F,?/CX4>C4,UEV=)N>0H53)T:DE0TBUQ)9"H M!,]-X%\Q<4(1H*%NQZ8>["'%RQ&;EN?D6T+/Z+J.?CM@U1GNQ%OG28@5Q)F* MW\*^0_^)N,\FFFT=P6VTZ?&YI34E#[.=N6E!P;40#;-IF,:89?Z(:& 7&S48 M13=X6S!F4AKRSC4BQ1.]G'G:Y)]HZH@ T7'S1=?1]I72>:25\)Q7(6+)!HT? MQ@I$'BY5O62JV6-2&*N4;*B>I_-L+O)?#6L_M$J?:3%X MZ.YI>]PN])Y^+DQ[]9G_X9MSTG+9_C_*N2/>ZUWUT6$$18(EW,IA/L4VM#<( M4>RC8D(53N(B1J/8KBKOHL.W4KN<#/-M:Y?7JP=LE__M+V.8VSY%C:ID21DS M_=];3:@NS!Q#S# G=K%FR,U;EDA"0$:=Q^O U*O)C&ZD+CS3(/>4,)S]/.8ONUIUZIXPFB1J1@(M)"(VFW\-XSR6,M_,]C/<] MC/[ M$4H:WI9X%_QN$L7=H-@K52IY\"S(-&,EZ@ADSTK\D9;EBB[7I+C8IHX+MTK% M:PWXV61WQA#L_9+R-@P0W!GWINHEJM@!ZLJ"EVC%AQWH.N4'+5CA$2@$ "QZ3-ZRC& MSAY;WS94+H3TYH]CLKEU"\2++@)I'(<-?S[RQQMK+IUQA2P@CZ0<)D6"9<)! M%E21\3ZT7$65[TOZ-,<^7+77'':D";[[T*7+^.WXT^2=2;?3M# MVS88[0!'EJD%XT\A*C_"C4,_LLJK(C0+7&5F,&AGFH8C"EBIU]R226XC_V3''!G51)&$X]:Q9J=L.9I9_"@ N<<_%MR6%D M8U'7: EC*#;3OL.]]PRCR^M168:2;W!B&\[>SRHV([@^-YZ />IN^L"_=@M4 M'^E/+]G:'ABZG.'S (\ZN(/V0("-!'$RRDX. :(WX^;"PV.M<.$<+)AGPR@C2 M6?;6=P9ICJ)X#3FU8"I:HG'ZAYON93/&PK&IY"^K=#*UD08^:=1337ZZJ4L/ MN>I'-V.^(NKU:&A=2]*$)9P<8,[8(/4[]:\" 3K@_'15T7.M^J0+KH#DGEC/ M78SD%#X64*79+H(H=%B'=O"Y(:9Q$+)K;IA=(VC)7(0XH]Y^1LTH8AS@RG$ M%[XUO[CV2[,YF)/K%)F>_O_^.J6EXTF TPOL%Z%W!GF\N='%\VPMHD;0% M/D]9)EFB%>628FKVQ!+_<#*FYL5VEWZ,]HSZQ=THW=;]'OK/S-GO(_SU^U[TYH M_,$7RJ9?QD7]^0?,9GQ!QJJ(2TUNEOSR8A;1WV M<]OO=J=D/&N7DHK8B_\!JCD[?@>.K5Z]:%#]'0SB;PC-#> M)E-!Z]Z,O8(/&/-_H_@*&6[RQC\CJ._LX53) MY[/X&I]RNQ(>\D[9OZ7+[! M((] /_R(),XI&:X3R)=L+#KOHOO5U;;&=QB-^L"X\9DL8%W^(+9 MKP^=6M\TSEC*0QF7:E[G'C,WE&O$ 9O*CG+OCFD@U1=.UBK]2W8I-!P,1B6G M%1^,UP)6Q>8/%*F0!,%5P@4>Q-=C*+)+F*X6T5">+\X3J&(1V\>LL>-+(5&K5XZJ.ZKQS@$(9ER]WOT5EOV M33O;I=KVKGH.VT06#H/1+(L /'.157B EX <8RUJQ(#%'("3>3N'8 ," "Z7 MCL/DRC!I^3"'1SRB08+Y0M @T6ER^'L2\E]B"9$V6YM> +*QEE)^F M4:;3@GIT* ;9B$OD;9C@FAE([-3!L"T%'F6&J*TJ%2O%Q,V45#E:E 3*X."S M9>K GG%T^8F=]'=(+Y.S@:=N-^,XP[=_!:J^@LI&ZCO;#>V#QHOO(#$ MVP2&1)P%VMQ:,X\!#]EA712JJ.$V_/5?_/U?\L,LYWD=7+MC>R4^.5[>'5K- MX/K-W4KNFN:67]@O6MS'E3)WD*56[>XP8;PMOR,.S3VU_U:L3! M]O;JM3U:S"6NJ^\N>=VRS]M_\0;>BM=;N/C-W']L@0G2)I7;.3#1JT@B5(GW MTBGA(MEW[\;<]9?=E_.+;\@6Z4<3[KT56S1$) 89Y*K5'8U4'0VG_E,9-'B[ M>B'Z27R9E\IN!,5%\&+Z$CIW5J %G_P=;]FN[LM[:($O!,('89=V^0_;I>(9 M85*S2 QN.=PRQ['UJ!38NUQC7R@)5K_MKI5"6V,LE!Z8XZU:Y+IZ8H_EY[HL M'[PPGY\L^U4X*I=:^]=;Q9/B'AU]J@K7\!=6XWRTKW-U>J)2W6UMJ_UB5C/< MK7C'_WG7>MOJ/(4YRKU"U6GZY47UA8<].4$=W_C2?"9IVM.?'TXX.21\-MW( MB9^ET<^YP E_HU5YV] 4'V*S<6QC51ET6?I:TQZV-%Z!3OB6%;>.XTJ9G47-(J]9Z#U'^[KIKL:@NROF2)'%AIV'D4^ MI^?YO.;FQ=FFT22_]K5JI?93B=63[464_>REN6L40G##PX/;OW;KN]7]_65< M X<6L3"/E-T.XD\AW#Y-"[I< ,JN-33*K7(,=H/T!@Z4YC3- (J8-X*GQ<7 MO/-'D8+X[C$J*_H;X%OXS#@Q6S0YW"NHI]>E#=_0K99+UCJ(>0Z]X995?K+[OZ^]-IKP_F: :3V5(<'8EM^*C9_BI3QL$)IM*K45 MF=^3^I?B2(-VUT=>G\H1EF?8 >GW59Z21V&=VH?O?GH>:]3Q;Z-Q=#VELYD" M#![.Q-XPN/8?3Z.56":URF'SY/G2Z-"F7WCP8:%VX+HC(X#U1X4![([8>>'8IC)&9L'9[7>BC^KX-&Z?/8_ M"1G<__**J]@^+=: M>]G]\66M^N-L;+BDFYVJ6DT 1JI3\))8"%MJTLX-Z<#(D/O1J=")5+LW/U$5 M+ZQKJ5G>6)K\5NI@IQ68JCM9LMZ&6Q5)+DL+[I MY]I!8[LT5UYDFI?W11)) K)J H)4;2F;@7>G&PS]T0"""0_BE#)U 81OAF( M?AQI),,HILE^<3S9KS&)@-@JD@1_>5%_L4"SAV(OKZWO+;8*'O2<[GW!W2N= MV)JL.3+;@E=:G=;%<;5M#LD_Q("=H>6:QOMV^NJN4>5S3R3M! DH6J.Y=Q'7 M-.RM9,O[/4J&F>]=5(##W"5=9U,/PCH"*M\,\0Z'?A@#'<2B&![-BX::]79MS#W!\U7V; #_9(RGR]Y5(#A5V^]^,K M[X^*=W85;N#";_;L%F00;.!,\WQK9L:;RK?6E>*2HZ;3G35/SA7%"=8)VW/2 M;'?*UB&W$'+^88ZP+P E?_! QQ/]^7J+B?Z/UUO#]'KTYO\!4$L#!!0 ( M +6 3EA=U7DXU/L>!_#?F&'LHE$(DWT9%(84FI!*RSBR+U'VY4QV#8DX(4H:V8ZN MINQ+R'[(EF4FD0ZCL8Q]#XT9-0MAKLYSEW_N'_?>]^?/S^?Y/,_K^3S?Y\L9 MX\P"ARY?L+@ @$ @X.9! 1P*8 ;P\O! >;AYH5 H'Q\OOR!,2%! 0%!2[+ ( M3$8*+BLC)2U]7%%+Y;B\AH*TM.HI-8V3VD@D$JYRVMA QTA+%ZGS X (&[07P'^$1 7 M&,+- ^7EXQ.2DA**2FKJ*JI(_7T3QF(Z\[/ 5$(MYPVCYB)%?16 M\&%YG3A>F"GN5]H*N8Q*U/5N.FTS$7T<\L,KT<],\$< MX!6KL+;V[K.V1QIN@VU0\Z&C/?::&'5\;=SOS[=!FXXM6:G*J:7&&;\]6#KV MHW]L5 N3EL30AD.M?L9ZYS MM5Z39U;_0FNOV"LH*K\T_D)0 ;\9)46KG?2I?U9RJNR[8Y6HZ>>;]6/3Y5*$ M,DS^*BLWC_(@?D(9U\?\RC!6W\.F$?"')OV=BO&S'S6R<_W$2VQ1D3ESASF M-RKAKLI#V6/LABA!E]Q6+XL@1,?2AH]9 M)I*AZ*M3J[BCN(SHX;)E,P9T>7?=LFOGXTP//.'9!,6M'U/E6)+AE6+ZVM,J M([! N",5B"KVK99GGUI 4%AMM.7F8,2:_L;P>5+CC6R#<$66]>Y>!2D\SXEB M.E3%N$*@!&(DD< MI?;2?N;R6=D&^DR/0MGZD?;C>'2]6..A#S]T1_WC5K5=.$ W7CA@6JYCQ/W/ MAKIB"RZUS&Z=[?MU'M0]E!.P4X*T?\%6>+>O3MNOTR,WS=N-5.9.X6YI?4W4 M$-Y\/@8?;+:,=Z)65@1,]$0]*0H/2Q;+<"S2@%&-5<$4/[6[]HG8I!N?9]D, MKQ+SLAM*CR8I".?7A7(0P=UZ$#7,RAS QM25?@JOG&J8Z0NJ%?=$=3^)+TMV M>/.+#O$^HH*=-S?_.G>IY6:P# &ZMS5#VJK2[2;8D^4,:VMBOD%Q1,M1\56C M\WY#X;+OV1-L=;P3$T/]%$!;SFA!I\$D]M:CM^!V>M:]$]=G_&)]S0?('$#G MQ>(=^"CM=0(=75B0E=Q>9GM[U[&\5ER(/_YD,)P].D >\'67G]\L8^8$,F^[ MHI.,3G+[8UWWYNCBK4=6!OS0XX=B[XSL(1Z_?;$PB).UFQ!!Q[?ISI$3F,8& M:Z'%RBWPM^^7/+YN,W8K!COG%-?*W#S6Z)_]B (#C.6QU5WS2@H[M)N5VT " MR;1ZQ;.\]\5E%V?M/\K*D(W,CJ9XT7\](]W2,)"F@&A%OZ^:>N=FTGL7VNLF MP"[I7>Y'#XMQD_+/>GY2?'>EPX28G[9RHR/QNV&@,#;FDT6#Q)/IDX4'"Y51 MUL_*-$/28X@'P6&MT!./O_M*=5[0,[PX8#X(+KBWI+*%2@"".F!A M%7@HEF));T_/2?&S&3B<\ U8A/NX[".C+]-Q])HA([VYT6]V'*#_A8MT]$>6 M59MV'^KR6@/"^=&)^-&(L_HVWRI?:BOBWDLWP]<>HJ9_%-"J F;M'YBU3JN] MO9HPQ9US:X8]&;N*R@.B!A->4K !77]^T7\9&61J\NN]9>I,*J: M XQ*<(#O^M61-R4O*1RGNT*#:1R *,M'MR44S-*T-(LG814JDRJ&,A),8^*7 M<[([4?;W=WG"DWJC/KT(ML^\)J+70\P5V7-&,@T31\%?E1 OE=!?#S"5*X"@21$4>/ C;MKJD7VISAY? MW3HPK[.)K74\KLJ/#;5%N'#;>7->3&\SE9VOD]K'@MF2JX% M/(/KOZF[1 CS4,<]GY+&?;%5<14*2YP6V5Z [VVI2V)>$G<>QBI3-Z])@V)+2@5NWHO*9 HOE%#J"&4ON2VN@^]Y<)*N)FHU.P[G\J' M2"_GB1JU<+.,BT]5'+5V8JQ,E)-?\M.B@_114\N*_(/N%*KQMW')^9 M;-C;RQDA^29YMB\4N?!/IF&<:G"_^@FSF/ M4=#]AWSN1(H/=B\A, 90=DOP1H#[ALA7C,&LI^3!;Q5-CL%!KI5.4Y-%J)U+ M%W<9N4]%KU6[5-5IUI^ I32I"0;QYOP.R]?&;'<2YF-G]62JDV^O'+$R+K4H MS+.S.SV^5-.5R4(5"YEY)N_%G9YH/FHW('P&KB6*[T]I"DDQTO5( OG+)0X M 35% 5]*_8^>#'QTL[_3JEE=F(0GX@OXU1/;8,&^.Y%/D*8 4!Y'&"*NHM15 MP9SQOP-02P,$% @ M8!.6!A<9&4>" (#0 T !E>%\V,3(Q,3#)X^Z3OA) Q@ M^M^?VIUV^U4#:_O-4(BU_ZK7V3M08+B#A$4S=IV5*@%SIG-@E]HX+EF==9KM MXV:GU3EF[4[W^*?NRPX;OF?U^J"?@^,LSKBQX$X.2I?67Q]4I8KG<'*0:I-S M5T_ 0>R$5@D/!=RUF7/OY3:]:Y%#I9]@ F[TCE7H;#'"IXD0HVZK"44:S7:0O58 M7!JK39?QTND>C5G<&*CJ=ZW#WM()[X/_.N9&<.6ZBN8G>PZFKLZE&*FN$:/, M]7)N1D)UT9[-_[[&MK@XT>!\FHE(.';4;K3[S6C0;Q:#I[?X\N.:,S_>QYOE MX#C@\[LO,)KBB!@ IA1PGCQ]@B'9S.W'-+^8RPHDB(+"6Y%1LM9IYY7W MTU6V)AXC)',X7-F5> ;)*) M.&.VI'^6[2=@H.J$)I +*U&U(?[81+@,)V@+3&,T.O5;H&LZP6DBPH*^7%F& M/*\N.=IAEP%*A$,=$B25N:T@Q-,=JLU(O5#B>D# 4*I9E@GTB-U9 6D-> M"4H?!4*;6$ELE7))NPKQ=FUH9'8BJ.,:6902#9!KNJ"3%I9:[T_,;<92J2=V M3D0#(V&=(47(J3#XC5[65OADY\YL>+NGU&.EU/'CI]3U#?P]_^%UI_VJ9RO2 M5$J< KT.YR6/S O@.(*8%;3IBE8$E B;D3F9Y9CD*-'1]T386&I;8CM* M?T;+0(;"Z!@2++;L$+&? )(I /Q\&F=:Y*B1;M(^X=[/3:+P_AA>^@ M_3)9+0N%@HY=*A"2QF*4BE9X&GA#?CUPT'3+H"D.2O-?9S+:D33M[MGY-7;. M_;R5(M^7Q?S%HV?Q&5CL%S'LE=O7R58C41GSTMZ_":F[") LU4A!+^H2-[[$ M##46UN<]M +E^Z'C^S)CKF9= Y)[]E6"<84U(HA5G]T5U9>6!*0/1]:K39_[ MM 4,C;[ZGIXZ3:-= MH^F]L]0&6^^?W^Y-6B3Z6"3$16ZU\B#D%GE,AT,B*#?)G%=(7\$C(86;D8+= M-BR%#D]!SZ[ ^ANF*X=+KQVFU82*TA1(;NL5=QPC#;P#_I@Y\H\L))(<:Z @ M(4PF>(0.1$8Q+PI,V7LJ[SJ5X\=/Y?,QEZ5_?D8XAS2E>_PQ(M1N.=8M9/4] MTFSXNOVDYYF+#?'0:L-Y,M*EN]V#^P@!OK &.BRG7[_"8='\&.Z#$8250']Z MU/F>?#M.ON3QD^\LX'J3'W2E6IW@?,U6$CX@>Y*$U7%<&F+!BK3N2'?5F$!/L2'D.PPUN:I$AGS&MSL\KC&-GEKX'IAEB5"X=>!'JFE*A MYSTD7B/XA:CR]XQ)\1ED=2>\9E_[TVNS<;.QY_DCX>_+?^JEDW_0E\RI7UNF M(L+L,L\%\Z!)^R69I%&W4QUB4#? M? >'R%-,KY;2-W[2J7@>5>!+*=!U'T%*Y=\+L"_V]T>[GE!WX/YH*/%(ACW[ M5V80?G0E&@M @F!O"-C%--2XH0]?2NML/6)T%["_A,8MP-7 M04-4JJG!+%)# H!/?$@A_W2]XEHMZ#VAQEJ.@42?XJ/J)0%3Y4K("ZEG@+63 M3(<$R6\0&9GWETCA79=[#WAK+<##LR?X4:>][WJX5 7^;<_N D"!3NLP6Z-5 MI)W3>=5[YZC1>;8!OK_RU;I^-#A#('796X@,'C!F81G;QS5&[_0NWAZ\A2-W M.=]NO'YV9PRX<^;MQM%FZPI-?W09_Y@K^WD\RGE\.TZZ=[[KO_&3%X/ R/.M!@;(Q251^8GV6?[=(2<28Q9);>W+PZ_#3=?UR M^.Z\?GIU/OR%?GVR4GOY[NWUU5I9EM81H)N%)&S8Y;L/O[]?CH86]!.:+1_H M19-^4H-+X7\9]']02P,$% @ M8!.6%G,L.\F" -C4 T !E>%\V M,3(Q,3@N:'1M[5M;I6 M_ 5=UFX5KL=\0\IS(2==]OQKJ5WO3.1@V2<8LU.=ZS@22+4>9>UA&*M M1ENH'HM+8[7I,EXZW:,UBRL+5?,N3=B;*^%U\%]'W BN7%>1?;+GX-+5N13G MJFO$>>9Z.3?G0G51GDW_OL&QN#G1X.@R$Y%P;*_=Z/2;T:#?+ 9/K]'EQ9(R M+^ZBS7QQ7/"YBFS1NVF-;[,WQL,$\^+D5 04Q6,O-A$1R?@$^0*LKT-1AFP=,;?YGY;0XBA.':;A7ZA0A%"]$^H6)8) MSHG86'#2&N)*4/HHT+4)E816*>>PJSS>+BV-R$X$35PCB5*B &)-%U1/8:OU M^L3<9BR5>FRG0#1P+JPSQ/LX-0:]40>JR0VG_\D#J[XG_/ M?WK3:;_NV0HT%>NF0*]#5>0]\YAQ QX#Z-."#AU]E8$E!Q V(W$2RS')4:*C M[XFPL=2VQ'&4_HR6 0R%T3$DV&S9+OI^ @BFX.!'EW'&U3GXRN:TE"C1WN-> MP4ZO_6H77OH)VJ^2Q;;0**BX4@&0M!:C5+2 TX ;TNN>BZ9K%DUQ4;)_&B/ E9JB1L#[OH10H/P^5ZO.,N9AU#4CNT5<1Q@74B$!6?797U%]: M(I ^'%G/-GWNTQ9P&8>Y%A4K.'E<*3EE;-35SSSGH3@@L-I%,H[_BX $,:GB M>$BV273381IM&DSOG*56T'KW_'9GT"+01R(A+'*KE7=";A''5!P20+E)IKA" M^ H>"2GG0%U%\172@N/7>XK PJ2E,@N*UGW'&,,/ *^#+S MW#^8D AR[(&"B#")8 D=@(QD7A28LK=0WG0HQX\?RDG27:_!78@ GTD#%L&N& M11IY,_4E G7S$^PB3C&]6DK?^$E5\32JP-=2H.H^@I3*/_VW+[?W1YN>4#?@ M_F@HL23#F?V+,>A^="4:"T" X&SHL+-KG#'P"V*8H4+S'-/7EOXAY?0YQ[U0 M5UW.A!OE-;F+)SC0PBQU78O0JB+%(0@U=--:H+F6["YSW$HTV,.WX@IKGPAM M*>R/@+@-N H:(E--#6:1&@( ?.)#"/FGZQ76:H'O"372<@1$^A0_KUX2,%6N MA+R0>@+8.\YT2)#\"I 1>?\(%=YTNG>/=].">WCT!#WJ=/9=[RY5@W^GLSMS MH "G93=;@E6DG=-Y-7MGK]%^MN)\_^0+=/UH\ X=J0V2PP)B$;6SOUQB] MN3M[1_ :C-RD?+OQR[,;8\"-EK<;>ZNC*V_ZN]OX]U39VO$H[7@X3!Q.5LCT MHFXAJM2#3EVKI4A8N[AD/[7\G]Y=MO'AE&_:YN(KL=?$XPWTO >-@5=V;#7D M;>ZNT9OL-[VXOO'VB<'N27BD@Z:M&(D$3_P 5CZ@[U_9O^'\.=G5#7P4I"X1 M(Q9+;NW!SO^&7\[J)\,/1_7#TZ/AK_2;G(7>DP_OSTZ7VK*T;O1XM9&((#OY M\.GWC_/54()^6+3F [5HT@^-<$O\[Z7^#U!+ P04 " "U@$Y8SDT-<<<$ M !Y( #0 &5X7S8Q,C$Q.2YH=&WM6FUOVD@0_IS\BCFJIHF$ 1O:2PQ! MUO8Y7L7>=]3H)]^MOUD!>FU[2:YH7$2DRWMUY>SR>>4;0 MBE02MUL1)4%[?:VEF(IIFY[__<&T3'.G@KNMZGP1=W\S#-BGG$JB: #>#*91 MS@,JNR*A,!)2D1@,L*IFHVK5K :8EMWXW6Y\ .4J M-+9+BU5.$KI;"H5,B#("JJBOF. E\ 57E.-I16.:1H+372Y*[?56=>YRRQ/! M##(UBPMQKHR,_4-M,&NI:D*Q$)*$Q3,;-DYRH9I3EM ,!O0,QB(A?+[8A)0$ M >-'-M08AUK%9+P)?BXS(6T@N1)-;3.]9FBA]X;"YJ43A0_%[2F1C'!E MO\.7=S><>7WKS]P!IV^<[#<^R]P'L7QT>%XF;]?:W\),XX$W"ZP]'4[<)3X[($8Z?V0:?3 M]*,+$V>\YPSN#^!4YGJG>L6LUZH:_5-0M]^$-D44Y@7($NRSPISLK@ M4ZE8."M#BJ4L1U%0 A8IHS-F7F7G&0,D Q*(5)?VJ\>7AS22(@0549@0Z1%. MLXTWVU9MISD\C^D,'%_I?8UG&4\15=;2R0R.N3B+:7!$RX7PEYQ(?&+Q#,8T MQ9X!J+N' 6')7NC[HO4X,Y7#'A,C;!<)*4.?^Q6LY[+0$;+,QUYS,E<%%)M0 M %WJT\3#V[I91C>L>AG"/$8[ODC2F"&Z9TQ%A;RD)SF3-,'8_OB1W09K;E3;P#A01$P,#YO8%J5;ER$9:BLUEY@0,GW-?K:"Y@A6'M#9[* MXWEH(M7M&C>RNU!]ZLS_R384\6(*GI!(3'9+-:00-(X7[?WB/DN)O[Q_^,MX MQ@(5X06TG\H*_!TN2I?CTQD1>ES!-* MB62AW:I7S+>%+(K\_(IQP3.L9<7L8HK9T*.>Q#R=S2$U&\6;U+@HD-J9J@H> M$HA9V7E[Y1D]3-@R*_7;TG@ML/Q!2'_,E54S/Y>SL\KC#'W MR!\?&#SBLA-_ [7;Y>[G8Z7$K M0IZ!Z!1DH1,Q&B*S09:CV"F%81@R)([SH%]ZL(^8**R].9(,Z5>*_.L6?%NM M*KLK:=;QJEG*:Z)=+WAP^DSD,7RJP/"8K4:FUW5CDIZ,>A>,X55-1M?GEUM!+N:7EQ[EKYK_'-\7 M.5=(D)[C !BP4_!CDF6[I0-G,C5&SKYK[(U=YY/^6OO*[FB_-QW?6(M"0XJS MVXN:%,)H?W#X^=(:GM#?S7_C@EY4]7?U"$GQDX-_ 5!+ P04 " "U@$Y8 MN],1FF6. "9.0, #0 &5X7S8R-C X."YH=&WLO6MSW$:6)OQY^E?@]4;/ M5,V"M*B++9L>15 D97-&HC@DU9Z.C8T-5"&+A(4"JG$AQ?[U[[GF!4!5D;)E MVF1MS+;%*A20R#QY\ER>\YP?+IMY_NJ'2Y.DK_[R+S\T69.;5^;3__OFZ3=/ M7K[1'5SD]//BV:KSOYIOH]VGBR:W8@^F"7S++_Y/OK7?[1ELWN>S4T='9OK MZ+2<)P5_N!LMDC3-BHOOHR=9$3W9WLF*W6C:5G59?1\E;5/NXC,7^J!Y4EUD M!5R\^!31@QKSJ=E*\NP"/JRRBTM]]F<-!N8$KPW>2G_W;YV?_%L"_>:O#K\=)E-L@8^V-[YX>O)JQ^^QJO@/XM7?[GM6^5F]@=ZJ7\M)O5B M=\E[^/?NW7K7W8O>@/Z\2JHL*9KO"Y2_?%'J^=W0<[;\_?G-T<'A\?K3W-CHZ?O/^]-W>^=%[^@(O.#R 3Z/S MGX[.>&5_YV$>O-__\ Y&%T?O]D[_"P;S^N_1__GW?__W_QM'/^V=1:\/#X^C M]^^.SL_QJ\/]O0]GA]'1>70$7[T__^E>ACPZ&D?'[\]AP.>'ISBK>\<'T>@( M/H51G?]T&)W__03^YZ>]<_KK]/#'H[/ST[UC^//T<._\?N89YO+D].AO,&0: MKB\5V^L&]*?= S^TK_;?OWMW>+J/R_1N[_C#F[W]\P^G1\<_1F>'IW\[VC\\ MB_9^/#T\1!'\X>OVU9]T*H(GG%]F=;1?SN>FFF9PH+Y+BG:63)NV@@,J.C/5 M53:%!^Q=5,;,8>*B48._^-?_]?+ITR>[*"OZ#F?G$5-'.LSB" _L9WLIX=SJT/SB $S^X'1S^20$V@&FNC2FBGY*\ MC$[@:)\G4],VV33)X^BHF&['41(=F#RY3BH#IWFU*,%X@*,]&KG'X(_]F\=T MZ[V;IHU>9R7?]?9WV\^SSKMO1X?)]!+?F(:)-^>+HGER Z\0569FJ@I,FJ:, M+DUEP ;(BC2[RM(VR?,;G*[$FY:3I&INO =$906#R7.>*[X^G$C\169J_,VV M_.A/**;K=^SIX?[1^=[;M3KR#_J"P1/VMOD9=_U?$:W4@"B4"S!BX*X?35.S M5-R4:%&5:3MMZNT_^YR]_LPYHWT)LP [#IX_=;?1W=0LJ5W\4X]SCTH#2F->\ M$=K)+Z P=('2B_/\OEMSI^='^V\-HYU[L M2#"I#@[?'!T?H0]Q]N__L=>OS.]LXVO/FRC0 S\F->UG52 MW>AT;$?G()$S.-'+:U0[TV21-3"M_T0+@03X,@&;",46S80IZ:.Y20JX&$3] M.FLNHXLJF<\35D T=)9M^"'=L01SHUZ@S,-?^M/O_[SK($]P-NALEN59:#32 M>^K\X.O+]D^B$U/598'Z!)0T3&LEG\ 4)Z"C0+5,F_PF1CL+)YS_A"^KLKT MNZXP^,V\K' ]<(%,FL$H4>V0MB]S^%=6ZQ\YQZ[P9G5$\2LZ<>!Q<@&/D!08 MCV,[>@-7T]'2@LU9&S*?R>Q.S2PK2''!.'",7\';RWWPW;]"91=[NL_[G@=B MKXK@FZ^6CHE0U*309AS=9.71:6I"%(IIEL^8F6H!U0)[/BR=_'>N[ M]89@G^H-E>3#U(W_>G_B(Z:W[4Z.>AN.)B=A-ZYG&8&KF.)9/JK';I6GEV9. MW\,$3K(R+R^R*5P;%0G882:.\JQ&C0<""LKS#*Y.V]Q$AZ@^02AA3RU24HFS MJIQ'#;P<'?+X7]@^=0NOH:>^:%-8DG(VICT@Y@/M4+%1X,G)%#1FFA13PWOS MC./#T;-M\%GAI<>@K5%JIGF+^P!_0/@'#*+D*(>=YD',6GW49)?)S?U;C2!O6*J[Z,";(Y@ M,+L@=?Q63Q>?=C$:A)FC__6$_A_\+IE^O("CLTBWPJ]Z$_#3P? $U ML<]2+\NS(7;5=N@L:9MT' MJ[LO3QB^MRBZ=K<5\M8 [G)'N4YX=% E>EF/*_"G0PV@J^I*4N,.4P 0,U M:6-RH#+QB:P;4&?P7DE%]W+6+KD$!>UNO$/=+JK$_3DSL*'I<]QI,1_A!<8F M\2%MT;!;.F\+<)L62?Z05@T3,&^2*3CR0RM'OKE&!V=R&;E:*6D2T02TP^A6 MO']AP^8EATS@]T^_>_XD.B;[[R+.3*LG MHX=#YW^B;U\\>?&$E=2;@SU4SKC9.0]4M)30>O9DY[MOO_GNQ;??/:#U>)TT MT\N!'<0Q")C/?Z M+):AZL>D]DQL.3O.0/UF,XQ;X8GVD&8(O+\"]>]!LD35 MI"!@YM/4+)KH#+U9^!N%K:#_BE)A98%7EGKH>!F)25)\="(,,XH#_WM9?8R] M?WTXVXLP12G*[)]\WJ";D%6R(X(3!<^$"1P)>8E'$QY&$WF5![0Z=$+VEV7: M5A4>_A=EF7;R/0L,'E'2 =3NO,TO5)^Q^5"Y 0\7N-R#VG_[Y?S M!?C-\%(#20$?/Q&30U:!6IS#PL&M<]VJ=EIBV; 4% ;9CMD<22@%H, 0TL\@ MA3#/)+NP5G^AY\H[ C+Z+Y]0,MV<+@W'%,.=]=! MU5Y$AP4(]92UTEZ*@4)KFFFTR)"7# M-HHG8U:HP;WX1TLJ%:]0Z1UEVV9;1)_S\"6,%A4:R#FNFG&-" M!.P;7"\!GHP?T#RO>4/%.7Y#\1,4>)R-,R@1/QY\MLL8#I M9%/O/^$K _]^\NUW+W?(YMN$8#G$@UL=X6_09$5#B\[RS?D=S"&Z!&2B8L83 M#F!X[<%X9IY31-%>NI!+:6+-?%*FV5S.=LI3QF)(DK^;-&S<\C^BA(57$@^P M$JE!7\W_]] U6$Q%)O7BAO0\HE\8 XEBCUB]"WLMXB4JBT[]6)376Y?E-24P MKE%O)?I*]O<4V[.1T_Y[ZB/Q.K+C[1 8>B%?P?52Y>69.: RRVE&YS#:XG&$ M$9.K)!=PBLH7NFE^/&4FZ!SS"8,T-?I_ B;BO0W?FXL29CB.X.4,IL%AS6OZ M(/!C-2;,,453L@%(=E3\-<&'QX)<+QPK/!2>SC,EZ8@YY:C=+ E2B3*^@4ZK-7T4./Z"U$$P19T517E%RP'K/<<0ON&L@H"TY0\\4T VP*2;@QB4<*:X_8 & M-9U)L!R79(S'.(L?:?(I!,4H)D]*,QV4RS7 MVB=8R8(UC^ 146S[).QX2@4 M #JLP-]MYR0^G7NPBB AH/(#V>L):8]ZW;B_:WYF@;! M1?#O7V +(L!KX-.9L1YU'(X=O2 $=TU!C0-(H42F,O+'AI0+KEE"*0;VE MP;B)OV3^L89"A$%WL.6L\66?B+=D% QC\N ]TK*R!B':('/8 1;+)$I_;E\) M[YZ7\)C<)"E''/4I7N#&3J7SD26 PZGWDZ,')#=OV7PX,%B^-:P2P7T"/Z@@ MRZVYD61>TB(T2J,+G),XA@OWY4**84I>"6:>?U2V>4KS:;%,5%/%1=R\OE=9 MW1+#4$22@MYO=E7999TF64SW' MW!B>\.NDJF#P-V$^4?&"WVT_&Z7C:*2#^EFN'D_;2HPQV,,"_K1[K*Z2#0W09K; M B\>TEPOVP\!(&&XPBY"6&4#!U\?OKR'>%/R>PAM7FL& .L_P66:5MF$S;,' MG4$_-?C&PX*<\$[''*L#9\/.K@R9S1'1A$2<;W$U">3?E%1TD-4UZ(($+%VP M+,"",15Y=?PGE<1X%J!+I,8*;!#C1E4,P;?0WL:H+!\:YY=9E?J&I6^"7)5Y MR_!:?$!:)=<(<7?WX\PE541@/M36*5"I\V#.^49>'Z8LMC?MWB=F4*#@E?@E MKXS,9ASZ '!HHO!B>!X\Y:J\\;5L*#ED\1,;E:5[Y\0+#"!C-H;*"#O,!NNW3C "$$BE-%O0E M1AS0U]:*;XJ*,6X"+KQL81JH/D+.F7-3P5CQM1S& S_W0SVU WG@5YK_\H!V MGALTJ,1L)IM^?[#',>##/88QVV#3@SKF%K#\&#]!73R4A^WD)6P]H[C;XGO" MA&65'E6HU;ELC6(A)?QD2F#PVT1.T)O&TXG"OTD#'Q;FIB9W?,8'*17:%&CJ M)];UO7A@6 /U78:S%2$X;.3%S3DX1UL6%A;L:3&!8=$0PXMYC$OZ2BZ:E@EO M<--,MT,I'Y.Y03M(RR]IJL%VJ1+*08$0\(^IC!U6"LOF70Y>2GTX*V*CMD$X MJP]$J=EJ0)06T9,X((G;N]:Q,Y]DO^ZE7#,/HJ%?/B1A"(SLVQ42\VPRB$NC MK'5P'U*T7-OK,$"XGV>9;+%9=M%*TFMUR1B[<*")T9O V!461M)EG.8@6AG, M6]8,W+"Q#I+7M*V,IDGP,%E@D3C:A8A.I; :^!P4QXI%O1-:K9W#1W@3PJSA M4Y+B@@M6M-J5B!50&^D-;(*$!N;<&5;P^#JI7Z 0QF=UA'Q,2?'"0\Z6GH$J MZ+N70^)&B&P6-O3QQ=VAOR=M_C$"=5((!BW-9B0,3>1.'L[^<"#,I72<#)>2 MU*)@W@(++QL)J!&4<3L:_9"]>D/9I 2.&",5Z"^>_!5OBV7Q-$#\PQL.!^P0 M;8S""QI187+$VP93"Z.\:"[=..2@@U?'0# *"#YA]6VZ=]G&(LIQ1%-+,@9C MHL&1Y(:H32QX3!/PXR8T>EQ#=HQR%E/GLE."P4HPE6B&8CPI<0C6'031QUD! M3=VIF-4"3IQ /N!KGZ $2UV=JIT9$\+JAR()#V@_6"/T-A@"A%RPAO(/:-2O MC=R&EF*.-BJZXI.DQK]=O*#VL\,4UZ*\$JJ_.CII307K<9I-RX>$67-ABR5> MBT^'D7'V0BQ4QF4X^U2(#?"K!S1!?S=)-:"1A^#^E._/*MC,-_"CH4.;B#! M1,O4A6I"ICM0);SM_53_@9DR6]ZS':NIDCGH/X0G@+ZBY^T.5@+@M>"PWWY( M_PF6+NX.>A()/_T\>-3@(.DH$C'@4GV+WC&?%EEE<5'=XG OO@?_XZLE7$0J74'7;O^M%,M6_[[ZH+.#?/-_^]LF+ MER^?/GOQ]+OG.T__NNOK$KPNT"3*"/XO?_F7?_FAL=NXO^FJB\GHZ;,G<:3_ M,Z:?X:]2^RMZO2W=:;B;Y2.ZX'O,#>Z A,) M5U2EORD7=A^_^&Y[YZ\ZA.%]MY(FO;?G@O6,9$&CH5WQW4(HZ+ &S)+.X3B^ M;M(EU/.:5)X%N[PJL^?;'_W5SMK\(U_&YHW^Z4<#]VO[W>:)+$^-%/P MW^H5B]X7F#B6$9T;/DS_/#,W$!+[707MCS?@DVZD:$[R) CT'[4DG.$ MX6^,WF"Z"(/J8"\L+C>2=/L95"[RC1AMQ.A7BU&$#L(0*'6K(Y MU#Y'AJ0HX=&+T-.-"-U5A)!4J]D81J^>81^MC=S<7FZ*&0-OB=N$N[R1;_NH MI6AG9WMGHX'N-&4'9H;LY,@ >%QBT=HC%Z%O-A)T5PG*:F)9JQZYY&R4S^>( MSJ)M'KO*V=D8/W>:KVX/O4N>QL#K@[2DY6S:/W.+A'+CC/P:+>*)T[BD[=*$0<@4N, M\WS44O1BXY?=58I*+,&N-T'IS;%UA^GBIN./6F(VWMAO(42;M'R8EM^80)\A M09NDO$O*;P3H+E/VEBKG'KO<;/! =YVRDVJ3/MWX6G>7FB'^T$3I465&2H#/SIYY#($EL_&?;^+\"@?\";RS)'GS3EVEQGK\=<\<@GZ M=OOE1GQN/UVG8/TL-J4]&Q399XD.#.VQF\S?;C_;",U=A.87)M.WY->/6GH0 M]CS=:)T[S-A9NUCDU%J22.0>>^#GVTVX\(XSQJP=CUIH7FX\]#M)C".UB_;S M)'OLXK,Z1_$7^"^R'6T(U3:$:@^&4.VWWE'A*$2BB"UI[_3\:/_M8?34\B7] M=AQOWC/ED<&V@JV<-E]V[@*K= M,3$)N=U]S\X7$DR9I.CIMS0.T/8KIFBO(N9N#CZVK[:C(VJ#B$S(CJ:SPU.\ M2&Z(SD_[FAH8/O;7(I9YQ]3,/.!"$TB4SP6S8FFWT9!]=("VOD^W;]GGI?^: MZS-12(.;!F[";H;708Y?8%O;!'O'U$T/]N=ZI>!_8:'<^NZ/M3DFJS;' M?EF K:>$ZOVV"+QCSAQ%=R-=$@9I^CT!G]*-FX%;,GOYB6O,LJ;#Y79T7O)' MIDA_3U;,^UBT%\]YT;*5&NWDZ&[K(EL.F[IK5T+J8T"-*)G+F#^]X8[.FS12 M:2"B6EQ>R=,JMK&U=&+H9:O@WOMC5'#S18.4_TP"S8U6KWA*8:X+H?1/P?*- MDEE#C:W]%^_I\I'VQN 31"BIL2=>0DT]I96&TZF]D8UC9"?'V5%]BGI)%5ANIU(J&$Q$6[#3\*FWC"H0SAKZ)VNC/:2+FDCV%%VGH!- M(:C]WJ+)YM@T@C.VO7RMY,TJ;&> 1D(NY.0D107(_X0: MWM38,KO$]@[8:D&ZC>IUR91:^)7S3)O]T7Z#9_TXID96^ CJJL ];ZZPSP-U M4!1S0IC'?QH/B@UNJ6FVH,X"W"3>T7LF,+'@NF)KVE;4JT-+2\ XFVF?8"3@3[0W$+:DJ-M)W=AED*D5 MNF0:7;"R?!J1,%H[ \4P%AVEK2C\GC"HQ1-4?^4UKXCM8<,K*"3V!X=[U$^! M>EO2(."^M.6]5\'AND8B,MM^3UT9 #]$GHQ4T^WJ!F!?VGK9>?D'.PE7'H6_ M@:5BC63\PV_C7??.A[!3DO2KBF9M15H\Z%ZJ!^1S/"#!V %)9[W-8L3=MVN_ M3^HR31]VKI0>+$VYO)%0_2Y$P2.L]K3/\/3H;10H MZ6RK0&TOA@PQCYO-$&R&E;MA&6KTM]@935GFTM.MJ-LYJEGMJ@7ZFNT8?;Z> MO[R"V(EIB_LX]OI?B5[T6IH7!EO,(5;1/UI\?]EZR*->L^+>F]M6)J&!BDW/ MJ9E<5;87E\Y_IC>E@/H6!]1YGW( P!X&.B_DHP?]MM&+I^9FL.D6>8L'&)N& M23K'YGA-18T0\7Y_.+G>1*HWD>H_:Z2ZIR>O5JG)0SC=%BX>Z&L\L9R[1B/I M!:,_4]MWB5Z*_99F?5VKEH&BV:_&:/7&D>M!TF^4%$>CG3%]CLVUYV; GEX: MP$/GA[MCSI./Z*S<0MM:Q>_< /?V,VIRI/0XTD679TY';U6T>[C3L:-LVVQ3 MVSW\;1)=P&T*.BIHPD,?QM[)_GY,(<*G8^H6!P-*M=5GIQ7+R&Q?;'/+)WT- M;MI5@-C)Y-"]$CP.B@NCR]6Q\D9)35X(=I=-Q)S7-<3"%C..1N=F>EE0>Y=] MNE4]'NN"5X>/=!.S;$& M,4Q&1@$&@U2@:/)HN#08.H73H6/X\\]5CB"_]I_)S8)!KCQ'#%O*8A ]XWU, M8SHX.(E&1\6TY W[],G3)^..;=R+;%@5\5AR+=-5FI7[8!ZWV+^MIUSA^(*S M(C()7,(7)E%;9. %2P?*@GX'>P752+#^_O?X97U3PW[$WDU9^"5O ^RBBC&6 M@O2VBS%24W&)+5(K.'28IFT.U]* -FD#M\[IJG56AW"?HS/]VX[.-UR;2]/MNL=IM$2I4H# KTD3>X#'F% L/;Z*J5CK3\^:6F)H5NOX MT=Q;#+XH:A*U^!YSBX-&V-6NYH!BH]MZF7L:=)%_P/&HCQNT*;V0\ MZ(K#O%XD>% M*[0)^(!T:&]G?C@W<@2S*IM)BJ-VBY2;P'YR;?EHDU()[@Z88 MRCTZ.;4I7)2D<]=UF$\#[\*%?^$4LPEXF9J)(/G:[SRPW\D2]<*:LK5LEBKQ MFBXNS4_N/-_^)AH=%DV&62>7UMM3QZ'>C7Y.2%^-E\3(T"IF-(=KU2X&#=XD MHJ@06)(\EJX3$K:,U=[5]1CWY!E?NI89_.W^N$$+(NHSJ%UKD?./WQ7*K57\L( M7E2( )(TZM.2.I BW "TT'Y0E+-,>)KBD_&_7IASL.N>'^,\O\U^X<&SF+ Q M5<-!!*#DM\YJ.S<1FV\8QQT<7R0WW$;VQYSUN M>#ZPX?"A^RWP""VLQVZB@5<2Q(28O,/G!NHH.=LK0LCUF+29*:@Z\ZJ:W\R; MNPGP_K91B!,,$[U+JH^&-.I9DXB'=\ZFO!@H S:[&.KD@ YL5\6<]."C%B2Z M6K=T$7)T*"QPM',[VMJ.UL*7"GN #%@ZI/W 3YJ;:HK&/0Y1+W?WLKK[-F?0 MO5L(7]@#>+;& T"PQ]\SDZ?+FH2+^4<87 E9AS IO(-UL'%%%DG&6!E[.&Y' M/[/#76>?$!'V#;C<'H",CC\\/6<<,$/&WH<.?KR5 W)DD06G%'^HER9Q@LA" MX4$2.' 1>[:"/]/3)#<8?(D(NA1SNB,1#- E2$47,2$1D.[]7:P)%YFQ2]B9 M*V>3B\-&R]3%/JL+>PL+-R+'WF*RK>KJ!@3JLJU 0RSRI"!XU.C=Z7'&4;^R&].3@!WCF- M11H\H+ZZ.,,C6[]58V".AXF%1\%%P?>@ @A BC%1QJZ@6G)8R^82OQT]&T<" MN'2'E8Y)@]$2[^V%N26X'<262;3X0 +O3O+#!'B$A^#A)X,$V\<3XVS ]&'T M# :(\/S$"9!Q;4>Z%M2#;DD@F3Q"JL99J,..\'+_ZF% M'F+D2\+Q+L.BPDTFJVYR"8?,Q, [T,FAL78\$63J M\K*XH/,^P4DP.;S,:.>I74=,9D[Y 8,M:>![PK7SL^"[P8>YL\E_'%@>8'?8 M1W%5$X)_P4G&-+.'$S"?%DR, ;.Z!/QKSQ*W#>RI=2OL[WWKK]^_BO+9?551 M[K\].CP^C]Z_?GOTX][YT?OCQU%/^6QM/>4I;&_44"J4+OB/N4X16574%#F# MB;8U)H-5-Z%1:E-MH$]4O3&4@78A;BF&C\LA[_ ^9(,&NL5B&1QX/Y,J'TF) MV=TI!8,I6WIT*WX>/281L'ZTQ1]*/6!9RL*<58+3+> MBW:B!N8"CPE6:!B)N^,@1CM/FDORB9:8YI3?CRI9L> %0/%D6O(PZ1;PV.H! M/3*#3*5)\)3E+&V:P MU4ID+\#K=R3';VCM9,?5T4Z2G (:=C0)!NNV9$QQ=%&"-((1!P/"F @F,KN" MER?P>PKT,?K-E=%*75FP(G H!R56>X@# 5,%C+OW?(]_3>:+WMMX^F+U M:U*[!>27C<-;\WCP^!R:U7L_Y+ZP?EV77 VQ=4ZYGH#"J53*NI%[6>E+?^Y] M/;H TPLS%YA)FY:+&]6='2 ?IAY %@3_(\*KN "T>9*F2=!HQ:]] W:/O3X[ M1AD/RAS>#)&BO-="LM2U)P 8PS"Q%!$PG\RT127I$ &SC"*/ R4G/;Q])5FL MS/7\]HTWB6N:P"3LYJC\)!?Y3F2D#P\"RY0R6"2RWVQ9E+\,W5^LFMGX%G!* M/^1&T3AQ2^P<8QR3H9-#2]]+J@68QO6/WZ1I-FF:!Y6F^<+'P"TB[)YA[6G) M?KTFJ3QT/XL:=JV$9?QZ[EM"=S.!-7LF#"G3AC]N:$*6)D?JDKXK(\.8+K6K M\6?.I@NQ[V2>HAU3M;68I'$T:9NP@APM8/C &];(4TU8:DJUH:@"6ZQ]SB1W M7H-JJVU,T+K6+MKCE0/T3--AT[!SJZ&J5F=3P\1AO$/OLO /\%KT>TIQ+=R: M5.LOL#F\0J&)BLK3&ENM+FYK+.S_(7NE!_X/7V>O8C*Z,2I>MGD:\A;@0LP0 MM4 #(&>HUM1JI-#(3-S4>)08 ^W6+_% 2!^(29#8 ACAC/=YHK5M,!4B^G$ MO[CD&M98A(!6F!8WO2)S%H&2=B;"6/L(S]P29 $E.R5?:!Q"C)BL(:NG;2WE MX.!GT#$%3W &\78/V>KC&&4SR?;A&!P8&I4Z-PZ!!)=@S@(NP"ITS([@M7"< M(SB:2M:Y(AH^9;@#81-S(6'Q,)AA(BS$1$AF3#8MG.-9DQN&<<#$9O5'O$(K M_76+R\G/-3B\34&NL;2>[!8?:N+S7(#1WXH_*0P,@YP$@R+FA74[$SKSJ CZ M?!(D0FDOPOHF 5'RX]&5F9'X866A#4VS$(FC3CP*$N%=B$2@V=62^D$]6"\R MV$Z>9R2R@O9.S( RD!@$RQ2DG^!GH!C="'_;W2,167@F:#^I>2%3A%X-C#51 ML_#$Y(8)#J8H4'D>Y- =J"AR[6X]I[L;C,<*JFCD+JVUS%-1MG=P^SN\""Y& M(>@=+HK)^=D/W8];EVSI% " IYS,3',S?*ASA(-.] [D7I,8FIOP@@JRLQ@8 M(?PE%=RI2"G< Z+>E',/6+:B2NL;3-KLZP^."M14&5KUJ]Q.XFBAO6T_]@\P M3U)7%*'%>N!.P[>KEZ)>7?8_',XX'IC2(6\8"Q6+JZPJ14/'8#TG.47B4C : M<)4Z?J*KB5&F&.L;._"?!8_++2@/75\:@PC:%4H4C/.BO(8#\$)+V>0U;#%; M6L$["YU++7F'0.'&M/W\,9>65D7=]ZP.XFKR#%%S^%I>>J+J!RT'U,1@&40< M>O$X+HYNUAQD[>+V^8TG!LP@D),KT/4H,0]=>;Q8HSQTBQ_ B06/RHK6YM8' ME =:90[?1.$,6UH!>Q,A('X-9<M6$XIJF;F$(H=#B 0G*S#]2S6>M>F)1E!Z_V(LI)(^M9ETCUVF=3)*HXDLCD*=/35I$75Y+@W M28,$.0EA_;EA-TRNX )6<0*=$33Q"4)AF)V*DAJ,Z^*BN13O4:I@P=(@#QMC M2,[=QEF/1DT/6]^/D^,[R@T(#&.#O7B+VDY*%SF+M=;J4I"Q9+%S=+,N78S) M)3X1%,(8Y[BYZ$K*='1T X^KT$[4")^")7H>)4RG(WB.8M4574I2WN"/($WJMZ3(H4^K0U>"39:H[EPV/RF4)[ 3QGD->7,FM M.M.;W=+E_]9U>FU@->@_\M;? MV?IU-\7,"'P^I",[*GC8,.N$RX*@!&D0IUE$!,/;;A(SF\3,@TK,_!' SUX\ MS<,[4T@-Z77Q6R\\QKBD3N8[-%)L/,&2]VI29]JS&>*04W<9"P&%4[5TGZ.B M 07I,BW2(R#OCMQ#EM9E/R@8!'9E-FP(DW&MX>E-U1^:'G($-TA- IN[8-Z: M[@QX5 6"))DS."H)N(9-4L'M*%*+02]%D5YBR4'64*G_YTW#=O0>N60)$[WR MC?DF6UE=MXA\[:A\YB0BGF/^0"(A)$(#)IL3O 'F/DS&*5$3V:]#TJ/!6B]Z M+.*41/_[ZRTW>?!QD9;7_(K+<,:/Q95:64VW'\3IJ^B=5XV.T^UI"R=6K#<< M9LIC[>^BISP !\HZ^U!LE:6X]P:6$Q-G@5AR]E&7$3=[IUB#Z9NM8&F.H3;1)A7TMU_-*+./R@; MLW=P$B=@@^H>ULN+T6+MZARV-2IJW-:A[, 5#[W"\26']$9[2V?Q;)$3'[NR M-Y$S>IUP8B3)06FEB*[+,^N3^YO+0XYXFX*RN(G\BF\[$S)ZRWU('ZRK7[[/ MJ=N2P^H/LX:OEZ[AJ8]#Q#DG)6@A+[BXTO> ."I=6";V8C*[O@V-&I,*S&05 MQTS6V%E_*Q\2+$KU\F6"L5G]SU[]_>4[&$O#LJ9MN.T26YS=P*$-V3&BP3\B M)]L,*I$(&J!%U@/CE\==/\>;GBS-I]E9/OUQK:+ MJ,U-H'$3:-P$&C^K8P7XSLM49\U "SB@V*O.A!^8XH.TGPDYY0ZO9()FT A\ MTICZ!((I+?]XK?_8E\HR^N-@O#1;28K/=U9C5H',]CD/PAR5JO7LGW(I8A@M M!BQ&->T:_GB-TS1*>CNX=#][NAP5.4)DE*A'&QQ$/1X>'EEQA3#0E!/!'#'$ M,K4ES\37FI<2MQU\,&A\6- NCIW20*M>DB \,-=JGW092,SR%Q++V7^7E;<. MH=82$>SC]N0D%=:\=>-SO#]TD,-UM,[E=-I6"DBC&>1@.>HK3K-BHS1$7]<> M\MZBZ>PI3F#RBKUBK>X?AXEQ?ZX MYHE$Z$HXJ;W(4+RDAVBLQ("]\,+:X&(V"V-- DA]XF@?:V/@L##AT_RJBI=]"4SQ&&-@:W)P5*=A6OT)2W= M^N40G@:"3:\-;[/Q0'9;Y4\Z9*SOE-J)P=T"-BGU!G[-]W"1MV4&:8E:A34\ M9H#L''5+JSH!OU^1E6.N-%S<287F@>85EY2_4Q4+D35HG8O'KLT=,"I;$V,[ ME 29"(O>HLI1Z@AE*W-0>WBJ&&&C%5?QXJ.&9R^ ,7339 XMS=)=.^(45BPD MM-H8F2R@>]<85E!N MP#@@;]%L?FI&4A0BNF*B,AK(> ]V>W3437BR![81>#3EM:$^O *'83)L,D ? M^N*NJP[UVB5N0*W!*2J]$$ Q.#*6SV@$3?J.>DQ($6RO2,,A/BH$P)4AHTGL M:WV\@1]282S^5#&<'E?5<+,I";R0VB\GN32J\ \G2]$F[1W",V^/SD30](@S M5'A%"\=%1?A IFSEAL9UO\.5-[S?L+[6G8[K2VJIT B5E%0<"/G..I+6/J)N+>=PXZ!59721HK-@6GH6(?Z@AO:Y2H'[,5S[78M9;S2G:LG$>$![LG' MQ-Q0"SA_KMRV4'(;+7P4P](WD<1V*.0^%+G%O)%46-5-.?WHS!-B MI2<7_LHH_5#@+0JXI@[R ?I2PUNL"QT-*:L-C\8FBKJ)HO[6<,TA7D@R"QZXS;0>G@23\S9C+KVEDP2* M:TG2^X",_1%%1%E+]X]<;E*?KWB(9T\Q9%&3@98QP=?3\(\:CPB?ED@;A8+O M-W+W'0^1.*$-%= M!(0DWEDR6 KESF?%YJWMUZ60NX4[M6L^M2GN"K];/B?2 M\8;/8UM&2^!55^J[%)(@JQ,2S0T^K&]1A"QT,(\?C5G@]S:TIV;>4G*_00K3 M57;Q<)_9@#3KEJ,/ =)+NITDMI&H@N!<6,UK2S+$[V5Y^93ZU^-PU)L1[PD/ M@&A/.(9.^V#-BE%F9XEQ.OBVVK&-JZS$_%HN5=P@AK-*SNJA8""L#%+WND;S M,):OR\J%MCS+:6E\(* .E +S?L?P1Z-[5RK?]Q,,S3?#R\7:M]/*,)M/0 -* M$@6UF9;3&^Y=RV (]B^5D<>Q\RS90GX1?JE#F@5A/$OAZM6!>>IRKQCT5;KY M('OS1 FXZ^^I_RW%DK C/8\EI<("$54,.B^RRB8:*[.%;R2E *0/D;1?V6CL M,\0GSQ.ZUB:XF !5":RE2ZXEE5!-A81$=&$8G_;8F.R1=$T)N20UPOWTNOCN4TI0/"\YUOJ>ZVH^.R005/X1D-=%N/EIW[M=HOG/L^]Y'FM[0E=!P$ M?/BWEO-F2/(IQ(#ADF3*Q3S9+'91:V94,[66C];Q\CM-D8B\\6B_+$GE0!=P MO^&UJ@SD]%Q^^X#\/%''E_#\$H%5.'_'AQ6+RV_UDF##; ='IVF"\0X]EH?E M7B9VI@7>Q%\?>&\VFQ0VF-K$OQ\N\G^""NG&:4ON^-D&8K[T5:@?R54)LYFN M:ISX GZ7@I"_Y^PT!XG&TLN&^[RM_/7S:'0B8,1SC$8^^#RH#WA9Q7S8IMDR M7R'Z&]D.0R?C U9TJ:99:6C)@Y"*#!L=(MA4O=%OZ\>U*H?ZESKMSS$?<"W MY=$,U&9,#(Q_IEK5TX=ARXC!3GP/7&)N57UU@ 5)_1Y'4L6$"6X5!^(J1W8U MV)=#% G94+UD.2'U&082,X_44(#J[DR6LQ?YME.?<)N$(;A'QZD*E9*V4O-. M8-;/=9C*<"8\\A)ZW'6]L+33[D$#S]C.CD!LW!C52%K6V>/7S3V[. MWB;7N@2> 42-[>K&.OBW25]86BO?=%+V:.1J$\)H>SZ%H^C$M7VR/9[>$1KH M2<[H*.UTD(Z[R^/*= 5$UNT?+)DM?ZQ-TF-$E5<>$3 7CJEIB+V;9@6@>CC=:QIQH5'T_A-TBDP)%Y M\D*UC9B&@QZJ-;J"[._%?9']G9P>[1\=_RAL?R=[?W\T9'\OUI+]<<$ZRO:[ M('KI=[#?(*9DLO;]1LV?!952M>DU/VQ*(3[?:@OP>>LDIZ(_617+M;;,MQ5: M.&DU4"=SH^"_)/VE58SH$-[\EDWI.SDQ$IB 3^7^5^T/(STK$^M'0J(C,TB, M)MR$#1=[]0)[S85OS2M-R"P+K$$'%CUN"AAV6+'K:;DP_:6G=#0X?QF&H"MR M&5W-R:P%0<8VTM1$U#4,]]@5;6/9W%QA$GH5\$Y+5LTGK5+7JX-"3ZEO)F?Y MRN3E@M_-[3/AQ^-A2Y,U*YASQ>@;QLHX8YM]M MJQZFB@8GY%)8&K22*+U%HM86JG4Z"9 Q>(TC8S;.1@,?(?9Q!._;)UL<"*,X M2!S# \IXZ"5#44A/E\N]Q-S@6U4X1;'Y94AFM*=%S&: MKL\DK.\6(=Q;G_M$&R.Q.EECJ>$>.3!3'L^S'1K/<[SS@P]8WRK\B&0&& 0& MD235POTG;!4,:^T$S>L]_(&P5O3WCDY$@JA"X3F,.I M:1OJ!792F452"3CY9/_#LZ@%Y/6?A"=825]#<^H8\XR+AJC)+X]I G-)")%D\K8K"C;$*5MYTFM MV$#_X%SC#W:=EO'3Z=S;#)_I9>,HQVZ['2V2FG:L\_4Y'A%*$SU+5GJ7PZLR!1PS.J#*93JIV@,P)$KH]PIW/8W0LCX!/3 M7!O-<%)\%GXNF1MI'*ZXGLXV<>9$MW$GU@(L0,5V%(I(Q>_ MD;:_@-%A\F),.1PJ1*>>/)X3*H'&\PZU/,+JY&W0.*;6] O47V6+5)#VQ890 MK_@R4W !UEH@8^Z3M7(>J%9W^'QB @'&[_ITX Y9(RDA]\2P1E!:'O-R@5M6 MD;'KVQT\STG35-FD%4LF3)E%UMG'XFZ854JTUWF7]>:>!D6815*GW^6E42HK(4:#:085&7>[6O2Y M5+2'F?/@@X)TZ8+'J%Y%+6;H9HL!CL75D73!5(I3H)EHPAF& M>&/+"YUJM$+JW!-7U1Z68)'@:J6D.S;"%ALPWH12TS-CZL&P12Q7VJ#/TH@H M):D4&D+= CG%HE,BP9L;:>YX- O>&=&:1F(BHM9X4H_@"J?.SKM%Z-NG$)K*@RJ2;+HNY[7#N ]$Y^R$4)O26VVE MWM[I$")U4G*\EVQS7^VB&),C'W(MV,9J1PK;C(,TZ759?02ELD7R5*-6Q7?H M@*\3[5NBJ^%-J= H=+#F-E8DN.;R@HTB&WSG0[R<:1Y6$Y>*!;EW_?V%\U+K M&!G.$&%BI"LL:._J8I.+"L^VY),]S["3+?X9@TEM3P0!<$D]-KAE3.,X85Z1 M/2YEACTW =%/Q ,7PS7_!?I @M#"Z8"6+L9-D@@^BQ;*V5 MB;J]HF@I0LO'Q"D973W,+-5&!,F?*:FI(+3)=UI8E@+]1&' MG-MO$1]_:M"U>?C(^%LE&DZ-E'%YR[:D2T"P:#-2=6&#=MN)_ H_9O<0.]YHM7,L?OWV6H?H",;! *<[ 6D5#9PX&D(V!XH?:M52_ _,,.O1ZT() [$!/^;! M#_+/;[VESZ*+C!:4U:>?4GT'GMW^N6K1*;4.QOH!]GC\AXP%M)_@@%.7DY>6 M\]PS@P( @MD.)F"@(_V7G 0J6\$,?VX4B!-BCWC4:$ P5>X4'#P.SICP8F/A M:HKBX8?*$*0'<8_@+.0UU*[$3(?,?]4N(E,D<]/M)AMKGL&BJSD:X$JC"4 I M\ $E0^FR)P:JA'O:VM[+/@<)00-TX?SZ*\KY\!M/RRO#!,ZM=_%C4=^KN[O9 M;."I7T[<4^8#$IOT:I!A:;Q-"WL'18S:'?/&"(N2H]%0'3NUMBF6EBE9E!TE M$PFI+R@[CCUH: #/ F'2PQP=MZ##KP;K,)Q,A6DQS\?OL -*LHQ#IXJ#D<"O M-R6W@98$%8:2T!):(#GQA(9@2C!CE&.?(0>3LU6J>>5^=:.79.BFQ_SLV8I4 M&97H>2P1^)RVP+F/L3,&_%OF-O;Y".P\^ Z1Q[8; A[#?*BRXTW+"J8Y:;2; M"=,YI$/41Q;CY_+%KE3?6Q&_F'D*8\X:7Z:]]?3&+Q;'8U$8*W$. 2' K=0$ MIL7I1Y2#ZO 4>'AB10(/+.Z2<*3#QOIM'.IN5\JA",QS(M6*1GY?@S&E#CA/ MA'THJH)*G#$G5;6H.=#]IY>PP5DJ"]6H$3$AN52ALBPX?"H#L86LQ6+:Y)CF M[$-P1E>&6D!A2])PKFA_Z@&>>7H*[9N&S&NL,$Z(H%J;&\HIW#!@X=Z%^0M[ M<^OJ\P)V"E>DURO[\*3:A:"#N(ZG8!._IA@;/V 7L(#Y;-([7IWJ,M".:H,%9"32ATS:#6%H225 MS2HCXJBE9S$!EZW:]TYG&2^9S7@XV/$%5>\N2@__S21_P PU2Z.T,3>(E[:@ M$MW7A/7<4#PO*$#/DVO!+J$IT-SP.8.3YH-[; FA3=YS'/[[")E], .>%8H@ M9\KY56PG+[>?$B'0:[IRO!NA9JE;;/N1:K21?@7SB-XM*D2P.O#U;;:GDD2& MB C<8SK64*>S3HAK7IJ@X@N4;6-Y@NIV+G[PI;%3"T-!.(^TM")9$4JWF^B7 M-KW@JI'$=FQ!9G0"$E,SEFQ&=.F<=)\GGX@138['H"XA+! =RXOZ+\3S]-FJ8$!7U3B^?B"7[95@)NBZ4/@ D+8FS! M#0.9Y4DPY^E834@OB;.HS!9J@IE/'J$LCI:$2F1[5TGE1F;LMZO6+<'HBL$# M<&4KZJ"E>FE'2;*$[0*]MK:>=DC2*W43!URD[6A=[Q7K%3J""\]D''P+BZ!J MF$\C=9A'L<W#PA1M=3 9:ZN?CW#F;F+8FQCV)H9]:ZOGQ=KJ8;/U-U=I M)RVPEI@_ Z13/EJ6CD6."W&^U ,4=2H%K>K2[I4AV[SG3'ME@)Y*Z\2H*!)4 M,_C-CYTY\AO0QJ?FHH6#!'G?% Y@D02VO7* AG+F ![GMH$J%N7T %"HII*H MGB:YV6H7:A.%D3J%*+$GCQ-D&Y$,=HD9Q\SVD[%U(IV:P;AA#AECFD&"!6=5 M!(^/(S\K6L-$)/ R#MIYX:Q%NQY6/L$4@-Q>.R-M_0NO13S0/VG"X-0='7-9B?$6WFC M'LJ*1VOL:&I-)>;CLF$ >KO8!7'7:YI?]W ;T0J4F\/L=)B@L'$L>P!&\ 0U M-AUD"Z8"^P?Q@<@5M7XX]^YC__Z<(=_<'V?(^X,/^^?1_MN]HW=GT=[Q071Z MN+_W]NW9HR .^>86Q"%\2.[G23;?0#/]J3DNBZW]DF+J'I%!0,-YF?2( VPC M0L]0(=#>0#+*4@V"3W1AH8O#S[6=#,$'$FM('*@*T^-D86FRP64L/RPH%V!+ M3(R?^K-#&JX "!0CG Y< I85'/'W[+S$!31H0&IAV$-XN*:"&NUX#C7?H6-M M8I-#.91"'UBF=8IRJT5EMB7LDBDD*P\+HXD505CO>.[SFV4_&BGJ&^GS'>W$ M@>'$SQ1_V'3(5,)8WKJZ']>V-:+XBM2'45D:$BZ\3X@;7J+4N@5'1.X1]:MX1!G=!(K)*YM65!03\/Y:HL*JV"_,"*)>K/E M083= [K,Z5SV$>1_'XEB6MW:!11 ZY$7*2P!EIUJ0NJELQ[$5&EKJ;W5VUS, MM2EWG&MBO2-W',-5DZ?W.!S:;>2U4P/W;W7XX$+&WJV&F@EBB)N@,3>!EJUZ MZDE2(ID+4O>E<:G.&"PM:AO6A<(91YB"U&!@%\>7(X$#NYAE)1S,^'!0<+7K M$:X56Q2*-KRBQ@[?)RCA./ *E=8H3:DJQ0*NGE6+"'OE%K9$MZ(@='&7BNE8J%]&TO^VVYY[A'4*767! M50VY-@->$G:01LS>-I@H@83Z%>&;VZ[Q\"L-[7\C5!L)S9)GR=6;JJ=[$NB]^DRL7[:D,D;>3&NC^1MM">G3OHDO$U&,GR$5O MD5-=?C--\FG+L3'QE;AY%KXS7A:$?-G<; M]5]&XDFUNTT]_-MNM077B, 'DW1SDHLT-]LL/C<+]YQ53(2.0T@8"$4$ ]8 MS)T/RS=Q>V !I->"_6;@#@0FM$>:'I8&O+]2:Z%=;@&KG+M1\+1%%[536=B& MV#7I6=RI=(X]T.\MZJ3O76Z^&*M/ZVJK[^:)1/D/? MM8B5[Y^BKQY+ ](L@*&^N$2LQT@,65[#T.T9.]8R!Z2T_:\RUTLWN>:R5LQ1 M4.0GL0T I$]O;/L@47Z N7$25_SJTX7X_>:F99NG/L!T8J1!I%+=40$[]>+@ MR>(>>[*E^-9X YOETFX+BLWE7SG#T36YB'T>"YY?))5QLAX[UXN!DN66%RTG MET7NGM3^.PS4P,687&+L!N)4R8N#WW6;0*PA7$@]^,;H?5L:D=3T$N7=@SMSA,&JITE$&.*FKB9!*JB M,*D!(*2[)>H=!.<$JY%Q9@(GI,S1 >O60U#.RV:\IH2(&LIT68P&Q:9\XT'? MP4-X]GQ\!>G$@K!A@F -H%^?LM$8S7U@?%. &G_R%&2.-+#P$LR\.YA>8!/D1[: M7KX$ H"WH8JAFZ%V#?W1Q3;#$.B&196A-I"#$C4A@3=$#\B?0;%"6WBZ'^]Y M:7(X3ZAO#QXL-"XAB:.6/6QLQVJ QY93@JB.4YIE&]L:W@STMKRKG*%>LV[/ M+9F9/<@1,5FDS!M5@\^)>Y(S">NA\"[KC^<4!=DM-4E M<./UD.)&F_J;GEG;VX;XZF!BN<_%BJ*9575 <:D@WYY5H'BYJ567VJCWKM)X MR7I:#WWGKX.)[[=U Y9@!5.*OD&V%"QE<F5Q2R"KL7 MQ%&MB\Z).I5!U'QP7<)/L>RM52?Q2?-I9)/B:MP0/\K8=2P>H6+:6<+$D".[R M_G8H#S^J'NLZP25Q#_]A)WS9\CWT[;(.7^A,)6^?K$,9^SNH\#D=P^K@RM7^ M9#-I*2#IA(R,07>C)#9>@560R M@KF=7*.=3 2B6@O8.8D].!R8:\A5YKHM8:NB&&]J441\8K%"&/(H!QW*P)0H MIV !,VKPVE'H\P62%ZH=AUD7.-P5U4<72=$,0_HW&:)-ANA!98B^\!GYS3JF1#00*4-T M8Z&)!,2C_V)'$^ILPG]2S,]Z]6"83T%%*[X!=RDHGRG<[QOGU*-2T>0/J *X M2MZ-#20N@\?AH"\6#F-*J3H.0+9!3U8X-6'Q+7;8M/G$$%!B MNCF*9+$H,^+I-4H-RTDG8[1 ,+%Q"6HG"=.37)@JZL+=>C@9#YLS^[;V_'[$K\(E?V:#8#%#6HH==:L+<3YD42>0-0L$3VRJ!CBE &C[6-17N#:&;=P+Y7M* @_IZ MYD8,Q8&FL/SR!5[U&DB5$#-ECI(ZOK0;NB&W_20-ACD>.5 M&+YWAB)9]5H1)OMJ!':)PKX#& K1=7M)+NGE$'8$&7-C#=521"3$Q1L8[:(T M_ZQB5BO",B4*LN?:7\V=00H4PI3K7F T#?@$Y IQZ(. MEKU0=XZV(YE'N,X4::(GG;04[4#D0SP.P\(Q3#7-%HS;XLY3J9EK>L.FR+W M:Z&-B&K!@ _L[DR[2T2:V*T5J*@'I9W$_K4XMM/D.GJG@XMP1:V;;VWTH[>%'F0LDX*O#7VVI*U=ZC M[&HL21@^N&EWF]3>:R3?6]",=\OEQ>L8'^^$C0EF?B5O:R.X#7H<;*/@J&05Q(*3&?EZF8W#-F\:L1 MM)4CIY,I]/?\,9VN> S?NTWRA?WO=1"D4W%"V'1L$F0EH?)6+]'J)5/)B?$[ M\S&CL-%%:*L!S\:SLBU[2*S4(=)7W(/;#YR] ^VC8)_IPU,I?+!?Z%$ET-0. M^ZIDW]N\J2V4@R!)GB+GKYC!2$C'$P,217QE!CPO*=OG>-(U<)1R )X:X M3[#QH/97$%=9CTGV.&EF.]0V*V%9MF&8O[;LK 0#\_8L?BYYQ,3RV\[4ZP^B M#5K5J^]$!;\,N<)R"$-5>S8CVB-QVXY>,VE<@'Z2=?.1P;!:T\;#592SF:W[ M9(0VL?N G]W<6#(^:\*0UUX2G:: ZQ2PR3/2 X*@?GKHNF =*$DZQ[B-+X'L M ,-#"&J?*3MQT.G<-!00)"1F:E//C0]K,X8# M#S&O3B=^'$*!BP%& 42/^#T[:^I01D.4=L$VAW0)+FI-\/@$AZ/"_X:CLS>N MUD P01YPQJ=GBQGWB/] C<'4S&2.<#K&&L^'XI3+ M4W^$\KDPW:$2(Y?]PR\MQ^0G5R/ 7&5S[%V79G75+A3Z[B<)FG =7;!U@E@# M>'6^DQHG%8B:_1L45R<;D5"HU=Y /L6GX"<-;5.1,"'DU3?8[BMC_YXN">EL M,7_@[F=MCDC8 -:+VWE>H#SAZUV6.?Q/4LTI!F;+>% :)-A1:AE2'Y'5'14( M?4YYC0X*W\ M_@ QV"^L&->A9+SC9T@YWO?L_!&RCD=>L/0,I-(6X*ZII5Q= M1*FE=3E8)\I_3S3)GL*V^,H5EI;M6B%D4E@ Q7VR+?VP/3]LUM!!Q3&&Z-KR MJ7M:<&F>UV5DUN9@_N4U!S \=N+&*N#N>%,Q("7W)WI_B;VC452MH?+53MB^ MPS73"8EPRIE/>X/3A>GBZ/G+9PS$)-,.;%D*H%I,+,%0X=.TLNKJ@GTD$+%'%_7K4[.);B,8*Z&#&/7/9O,4^/PMO@+.V%: M5Y!4TD'5OA8;*1XUOVV:(JSQ-EH!I@/W1.\ZZPMI."FYR$ZOE%DX/])?W6W! M[>AM]M%@2F15^W 6"5O+J1&:B&#F5'A@['S>SH&SCQ)MB_"?;_+J ++]A//3BZ M9]Z2@OA:])%WR-GCV37D2:@%@I)K=\HKAHK44U9-T2]@KM=IQE\-E3D\I=/LW]W%G7B-H#%-61EV=GH992O[3/<1Y M"PDWD76P=>\0(?,0O,P^4$ECCO'Z80EV7D\]<&L\D,'LE'V.8/) M '0',0_/J;:Z%!9>";'0/?W8NQ&0P?3&L4KH_86;"%L]-F)Z6BL(;[3EW@1? M+&A]I43C,$T6QI#?V,*X.@Q2N!P 4JLXJ(!RZ0Y"WH+?<29/ B!A5XU>9%X@ ME:NF/;'>M% O6]JJ!*:VH$" 1V\5$LO+W*^28W!A M=Z2_--KU)FPGV0W!>4W4DDEY9;B5FL7[^-0%\?+PI3)[$,G9+L:24Z2:2Y"&B 5P[0-,T"B3$'RKB"ZQC$$F46]=+ M2BIXFG**>LECP>Z4)UCU/5"Q84U0I@1Q59.HGD%4/,+<@9EP +'ELT$8%RI) M6M'U(O/()GK0*KH%;4PBADB%H;1TR55DW+!SM35):B+\MMP;2^LVHCWF XPM MH7I_:([!R^MSQ+D?N[WP*"K(71@PZ_&V045,133TO2(9TU\0%[UIN NQ /1# M)HOA<5,DI0-B52[TX,=+*H!"R(K+53#3B;"4#:0N?/.CV_'U_YQ+JU@AJ_F_ MD?2 I;O:JIXGT>B(\\@T"VS\'A6R \8^\7QA,B\7YSE:B4?\/[7D..LFS7Q" MN"0'\=;]/K1GCAAZQ&U#R!;&C A(<6.A/-Y)Q5W%AB?0;M?^\+J%SWH)2Q:J#K>D7#P7(L]+YQ!56?TQ[I S+-N PQ,QT(!59F"3:]GD M6C:YEE_#\_'ROG@^0,C>R5&!_SPZ?CR4'R_74G[@N>L;K@,:D/F:IU1B* H^ MM%H]VX"P\4:;X\RR&79 ?_%#W=IW!VW:()1%EJTI%[M8=KXE6WSG*>SWKUXU MES]\#3]ZA>=_@0!W@A9H?(4\, 6O:%\%;(.02F@%*SC?9-4\>H\JQ=9:VG[T M:622"GY7K>E&'XT\NV2\9'Z2MBG176)\#L6E4V4EQ3 (3I,6F=(P<+JXWC2P M42X(S-9%$75B2/VN4_C&+I!G7[%W[-K%P^')/QOL$JO,)?A3MM9=/831A28 MZH!)![?E-QYN=!MTX'B)'3B$N=VMQ%U6(&9_8&8J:2X@]>[.%V%YMN['PW92 M7ZXE&_$F;Y/$\^:%O0L!^?F;$,/B2_<0(;P[.U!<('_+2MMI_R.,FF+O-6U) M0+1@B4,M+76[@CB1JTOR<7"]$1$U=A#'E=MG ?5'BD50N=*+@'F,/9P1U.:! M!Y%87>\[T%.'W;?'(E$KLS.OD^(CPKNG-W>5JFR.I'0=DX+11E M]XO6!L,2MC6V]KW4%*EVD:, --+JDYJE2" 3;DYDL!P+F);P-.X9,%\8RJ7Z M@!/)%C*?-=XM4<@*5PIP,U4*$O%QL:2JSFMOA^DFE"Q$P!4-'NWP7,L*/[%3 M28<#>8$K1[C+P8_.;'#F)K.\/3 ;>?:/UG5E[\%M_"=SCF"7"$,SYCX(5XWX M<#E0-Y$$D[_C-< S@:-SEO'@81VRIEQ#@?7(4IYKVG_9N/.^-!1QG,B=J(3= M%B@P7B(G^4B!SA#Q"^KNBD+LVGT#(^W9G/)$F!\'A:C_%!"F9'NP$4$ OB81 MS8G,&(N[U;*"@[?*M*$E2:<7,U/U^6S[A6.T.:"N(?#,5FT=&1MUS&2^"GN) M&1A(T ( !3JMDNO:NX!>DK-UQ/ZQ9N1!JGB571GB@CFNZ^*T7NXMG!@Z39>7 M2>%M?^],V";TL@F]_+E90C1H>MI[3EK=A'^_TC ML557>C\_8^(8#L\3QFE(L\%>*38=/-V"3%DF/&B#TO%>/R9.3V>%HD%BB=?T M>B<-'(P@Q=2*4+L7QO84G5(1/4F%;0K05$E1S[0%=.>QF!PLM31>$1V41G"U MTVXL(J LD0X^C3=#V'02)7/0=HT"_I0M#DW*76YWAV4KPR#*5Z5C:^'V. M' X,#R_L?(NE[,LQ3*BRW(>4^YI TW09_!0_PLES'@G,G^(9*$E(@(:AX!5U M8UXIO@]HBZQTY[S.5!U4;TB[(=T#I;UJK+BDDXI:I%N/R(,K,6S3,KEPVTNZ MF]'AIA(OPOE8EFRELW"D['(#BZ:55'&O$RWU:QJ%H&+,Z2Z0HOGNB04ULL>!Y3F9WV39U3[B=ZB,@]CV^$>,:K]B9@3'%1$MS;-J!2XB8;'D+6D8:YE.42E0F[A1^,B7GO&8//]\'Y M"7L4E/:K&^WD=5H;7/V@FY7!,E@R0RRRYAE2[\\;./9F451%TEQ98 M6M:!9ZWVV)W&GW7)"EI\&^('#A-3*R5BL,NQ5VQ)].3BQW._X1&,6UZ=+ V^ MO0K0#%N(Q5V:_LZ[:_22X[AC"@;#%RV]+U4Y=>CP/'R::Y/6[P/DN:!AK0S3 M9^@2"YF?(*;1KHM],@U!3M#[,(572DTR'B$+W\NU+'QG;76%]3XN_G1<-KAY M"-&LY QW"/)8FY:SG<-MGUVOYZ$R0>,E6SV4H'#MTX"-(EY9XSMG;YC1(ZM\ M)GR"S'ZOTE:#XX!]ZH3 +^ZUK7N!2 CBB:47A(VY?PDK0+QC+[:?(2SVJLRF MW##P!?[X)+FAJ<#X'E[U+5XEQ@G]^3(:]2"8\,5+O&YYC)"NP+')FC% ][OM M9[!KI<$W;*:?N2O>C2!R!;];#Q#XLYGDVN^NA_CN[$2C_9!3!#]]BK]K#!&7 M(LD./ <+P^F[X68 -+0=>)=W64V>2F'*]O=MT;W)-VSR#0\0ZOG=?4$]3P]/ M3@_/#H_/">)Y)MKCY[W3T[WC\Z/#LTC39L>]C(]C.K/T>GPZ2H?3 M.D0Z<;8=C,"LH1 EG9@MQB9P^W(.V.7@L3M90VC+7L$G][=EJ)'V-+/GOM#I M!O0GR)U8722%;:4K5+G^1;6S2!%ZP2W3:NY'RW$^,W7M>?U@[I)BA4Y-CEA] M(<, %N*P^9"6%$*T)1+<+9EK1<'K:_ @2K" ,,&FOE2 3"5.@G4IB*^1;A7K M1TTEY'%>4V<=""V;U+ZD-)?"*.V\$)R@3JB F>&5S+/[,O=-.'4?VV8=F%*\ M@9]MR]]>!WO;_]?K%"RQ5W\;L1,!.VB3C42ES98XIO\"MM@@C%]>%Y1!OJ0* M+# \L]13-4PN0:X6>EPH[1WF6?0(N.NDAU+QW#MN22YML/-R^":Z='VWN39# M@#+7.5$+"S=AU%OFWYQ0#%KU$I^CB/; U]'(GE(=5MAA'V&H*-Q?[%NO+P4! M WD"UU_;C#,F\U:WD3K&,?)#8),!A%EQ: [#)Z3UAU_<44+@H8$]5)55H'OL MTDWPQ=(2;DDI+VKH*C6M63%#A@,31U=9F5-M,C*]9#5M,(?JN#1Y)T&4;<3\ MUCE+/ZVV0M")$X.R:D6YZ+Y;9DI19)!NT_6%U$\PAX5$E7Z+)>I?,F,H=$<'L6<4(S7&5CG; M6I131#<3L(/(B$O,:="BX0,8Z@UW(86Q%4(:A#F#>(8R:P-LEO26^=,/M=\I MR6D'VR/'0ED<+$&WJU,6-N6#1YPVJ8C)C(K1/F^J;-+23@5K)V6-X)#O< %W M9<1*$H+?4],4N.?,:^(\H'GZ/O+F7 C7_F+5VA^#)J66Q=F4%_ZX]#N0)%JD M><'72(%FE%;MA6W<,S+;%]LQE0O*1Q=): MZFAGZYSLV/+^VKXIFF_ *%IEX#:(2C MHV9)7%%"J0-)M=NDH%AX-$HJHG#"#8Y3'(&VLVNQ;P'&(O@N3W>B#]MGV_O; M8(7N?//M[K-G+S!YB>#+R7B7>02]$3-1G#_L2TK/H8.(?5GAZ5C]'F%\M;PQ MQA_&]247;5"T8UH6,-2&O9$DFIF\A"L=R"C'"EW9M*%%.^-TH?2S#&D*A679 M [8%5K2[/;YS],9@V33V_BE!(Z-!++5/93T'VWH:[4V9R"69TY1M1/Z6D3#U M;L)HV%% _^^HDOLTR5W6>#]^IJ%1ZQ2OQWZ/.J&RL6LC>[M'T+#C;EC-9L=# M#&@7H6:C;7<.LGU.C"WZ(7NE[_+#U]DKZ M=)H-4,H$;XCQ)&VH+1D7"BN-\,H/@@6 BE#7$FQ .A!(%0E%VWY3;6?&+#G$O>L0"TZR:MO-:^H5+ M>9)CC6$XK_)<.P;&4&2^0;H#@@BR;(PWFN:6H=+C,GH+FU7L/*IY]D$K=GO; M71W4)^ A9&X&"EY10\4,N<'O.-C",I@U3!?, !.Y?XQ-<07VFB.R6TX?4X!P M3 B@61.+1LU-X1+9)'K=0&M/"J]NPFRW#[%JVPP7-;?]CL#JX$7NMC@F9:@E M1S$R_@CE&S:\,UAPDF?U)=E7H!0QP&I5X:KTW9?U*J3K UYZ<+BWW&U L]$Z M"OK\SM&H&LL[6[J8,A+T09YS:4EUWW&)+QSG60?2[T*[/;#^X='Y3X>GT MZ?G?HW=[_W5X%NT=_ST*P9BQPC#_'KT_C7[\L(?_/CR,WK^AB__KZ/@@CN1. MA_^#OSS#"X_>G;P].H2O7O\]>K.W?XZ?O=W[.8[>TY7G/^T=P_^\/SO4'[W] M>W1V>!Z]>7]Z_E-TA%\>P7 4F+H=_;3W]KUW[<'1V?[;O:-W9W#AH3[-&^J; MZ,W1^3$.!NX8[=%+'NU_>+L'[_OA] 0?O'=\0*_@_^C=X>D^#.U\[_71VR/X MZ&=X,9B0LY-#>(7S]_2PD]/W!Q_VS\_H!F>'IW\[VC\\VX2G-^'I!Q6>_OW1 MYSM/[@M^#CKL\-WQ$2+-M7#E^.P#*(7]PT>!/-]YLA9Z[LQ_/'3?9EZ][1^" MG/0+S<^S;VX1]07&CU^ ?RI<#8\GTQ,&G M*E+N%=2G=/BLKR[HG M-9+4S%3^G9?,&PS&W2SC--"5*5I4.:[ ':W6)IMF"XK-U@FV-X<+N&?5I*TS M9A^NR%4A8U:KIEW?.NMTXN]PVF)&@&"4CLM.U3;\F&&TSRO;[L8RS0Z]&:1/1Z'*OB,[CP MY&@<2_QA_9XA9WGB]5GQHC4LP94L#0X&[OW0%VAEJ/]=\BF;M_-0>V^'T:FY M7-.-!:TLU/479B1^6G)Q@1M)6.;#?NU,QE4C^Q)330X0F&@#K[$7DL.J>8G( M7I 32I$,U&(/VM73Q5T9U#[$4%[MZB_.@U@ISVJ-E5]\#29 MHLPB&"G1IU)PL-LA"0QJV%_NW*&H)*CX69MC5%A3(*KP;W5/=W+9SD$#1<,/ M=9FM+;:NGDGJK#56O['!D,:;H^P]PAZ,V1?4PISG3,*IEV4._Y-4(-&H>NQ)KN ^JDQ M[)VTHR1_6,8$YP8B@Q%Z4%5?(8X,I MVROIJ Z*X9WII0"T)$?YO MKI1H*WR62A*Y6K+?>WOV<_:IBM]OO%-I/W;J#VXGV[%L1TF$218$9L-<4"7, M(/!I*>YI&-[D]>G4E%OPEV9T_?)(R5]/K!'>11(N,$ @?NLM:BF%J_=*0P(" MUR0K;?Z"?A^U1:\S'6L^W,(Z@QA+Z.I2.IC/Q>SH4%K#;%TTN=KK?1BG6 M)MT,.)5S$T\4&_ZCS'GO%/*(RK/0=8I&2_!(A/;)DQLA))J/E<:U%P,FB6C:K=CD@0**(J5A6'VLD(NR[L* 4VH.B@V6RW8&;L=BATZ/EAS =H14PY5[*X^-[<3(D3*V%[E=@>&\^,] MPP.)$J:7R$QP3[$ LN,[-!6VT08UNQ*V(#%6,FNG^,P1=!]/AAPR.YUG%NYW M7<'E*87YQ*=V=XO=;QC?Q:%Q&]P->GM$H^M+0P:FZ[[LYXS&45ET1TN]FEM6 M&-COT@1K@]Y%%UMX:]%9(J&>1/,4RC2P:>S-EA4P7=R'ZHS:P.&ZFB]+Q^A M0 <=R%DB/5 [[4M))2:S!IFMC*,FBRN@8XE*UBA24:Y<>UHL,,X6& MW=X/NR^EU>0#^=<$[&WPV^@$1ZL'@]-3:Q^X$5.CK,Z/K?2B4)J'SB$+,KD. MGW;J[(R]H"O\:59_]#L<6R;8*,%E3X.E-?.6I27GVH%KYZJ_#8I1ELI";9+IM,A48\PRNPE_I;.I(VU4YE4 M'<37,W>A)31,A]A0D)2^ES,[D%]404!_P(#Q?G,*^G'!.0KO-X+ND(C%J>>X M71$=*_CTZBI,#*(,XDB*?(0M4)FJ"=:92B$$AJ- FQN\/I-^=-*;F">$U#O& M TR:M>*M4DQ!QU!6=$)0C4VJ_88Q]J]N+2A\F4Y_S76-X>?R[0D9K0:[)FN3 M^^B-'.7)59FE6D^;ENVDX;H)9)N/EHF2R^VS+<#8! M\DV ?!,@_VU2OT=%B,9:NH?9-8%Q@GV-%JA%8K'S.J+H:6V2BOH I6H_,TNC M]7=W/<*E19Y@EM3";ZDJS%QDFCMVN-P%MGAN"[D#**RC; MZL76H@5G?HJGADMB+BQ_+)\'6-=V64I;K0J))FL#;AV!7*3EO%L"A)O9_#K] M)$C.^OG?:;F@3T <,+F*TMO.8>IUP%(K5R3Y3JN+ MI5RZ?%(_74M4U'V!;B^58**3;@CLA&D)0VD\+#9#=P=AW&59+E?-D"D;;A!:-.H$98PS1!YN+<5-PU><_S8 M%8,4[,M6:J^BLVZ[0..-E-Z3@@M=.]9[!XQW7^*@)C=N4%ZXC#K@Z&;,Y+Y7 MO'5N^Q*".O53 /Y[A1S]MYCW6XY9@1499_^(X:3 J(6+AMQ]_^O *S,S%6UG M&!NA)D"3D2G)=NXRX;WEZ%<;J6ML4^%12%&GI-)02TED6(VG)4:+Q2SGJ!;* M3J<%F.-H048L3H/"04)Q-"Q@G]H9U$;1E!*=@V=BMT!W>TJ\9W L7#U/SW1P M&CNDAZH;;9A@;4.%SL[ <^08CN8/M9=9.*(\3YTAB8T-G-*>12MEN50Z^6<9 M0O6R5,S*(J<&SJM:8G#2$Q/;M7XM8*S!T@;'4XS2:]L*+!V"DFZPA'IJ//&9 M-CB%/$CI3ON\UK8K_V311==7,GI6WVQ[<\.M[6XQ-KAI;9;JD,N20NC,FQ05 MAGCB@B2HEED/E%&8>ABJ:^B)?E % M:,7 %M]T4;PK[NV1T?0GK2,5#UZ]K4N3GF$;(TSJ(.UP4GDZK;M N'? PFLP MD[-T$]ID1)W,C9=_F2:5WE?)],;;YNAB2B< I[3;!H\%_)B;$R( M6/N=X]YD5-6\Y/K,6[](!&EZ]J 0;"!,A9%>"05LR P]>!ZU+B^^CMY@CK]J!G:(A/70' M.\#"""W8:=(CW.&^\L1PF'&?ZUJ4(9: M[E@[A,]3VV)M)C0X!"#*KH@YX.9 M?@@/A3@/!F;XIS99_4%U YW*^&0FB;= */<3U+BD*X?QB1>4;[![#WXZ;ZDG M>\9Q_,SK V>GP?-:(_5_$P&)&F94Z MUYNGG%2HP8?.$U0[X!H)VG4()\F.GO=025]P8V9^<^+^ZP?\!6+BH_Z<_4,^ M/.,3O&&C"XDFM7"Z6@&R35'GF, 9Z6/;C3]DB,P M,ZGCP.3_5!A5/#L?!DBYH&6LNQTKDI_$"H(B013_8KK23MR;GDOWQG8Q#5HH MMO=O0-(;D\$6/DB53833F!ORZ=9Y/$P?3FX@-IFI54LP Z56)>"6A\N*C H4 MJ57PE;%X2=R"2#6RD( 8S0@,^)K:(=#BB%7#YIX;M>1E?2-(5LQ;H55^8I1A MQ)S,Z5(Z+TBOA6CD"AWE/7U2S/$ *R;[R"M'!]9>BU8X_A@V1HMF9.ED79#S M=A8GI40[;!DQ#0MO>)7D^(P+!%D7%-6;E.E-D%+L5W/V0TP8>F@1&81&R5:[ MH*6JII<<#%YH.5FMX%M.M*Z2BGA8JD@RY=<6* O&0DE$\:R?4 _3LS'M#N,Q M*8[(#M&F;;J5&');;LB!$YZD&=YKB@GN3.'#^C7%VZ1W-/)GIS9N9V70Q8I! M])+Z_V_ORIK;MM+L<_I7H%)3U585K,A+CV-GVM6T1"=**9)&R[BZIOH!!$$) M-@FPL4CAO^]OO0L60D[BT*;YD,BB0"P7]W[WV\XY>G&D!^9-I7<^\=/".5WJ M')\>F\ [F4&J09S!XV.P< TK6<-5YCJ;^=8S'@#J&J8*3N_]F,9? ^U[LO\$ MI^DC6TO=_JWLQ5!BT<;!&&QCC,^U.M-_6F.+9?V:&Y)A:BH_;VD3A9C5)F/+ MG[TB"]M MO?72S3;U=MIV&*7Q\4EB>R&%+I![WMM&?:\R/4%5D,W!3ZS]&"# M?<7TG>01[9_-(S@Y@_O;E"A+&E5!]_(=5V51[$12Q:PR5K[&F(TKCF:!.J$ADG""P1,'W%OY%G:O] M^WX7@<8E!24Q<[2S8)[_NX;Y M"OLUP4_0I04?NAE@P[%X1]6<_3/*"Z9V$ E"/G-K$1AS]#"M! X#>VZ8V>V( M2!#]\.+HVKJ!&B)]I_=1JLA7=C@5W4P5R1P;#!/RZ?*RXH9D6? KS5Q&5M61 M!EF2L3@"6[^P7@XLK',R=RZQKLNFZ3A7S_%=M4L$>T@%ZQ+)DDG&Z=Z'0\RP M*"EO1HPMY;1_K3R8//4Q*,;73E3MG+'I'L;#6:R=&X532WL19:7*"WA:][CI M3%9>A9%F(H.O6R!,E*DPO:RPD*N,(^8^,K+X%L(J5"=FFML:_%Q]8BWV%X%' M)11ZB.VNP9/^#JDO-,*K4,R'XI2]EJ@Z!G6S$4.&X*8B @?<33@OSOY M(&CEM-OOTG)-B2=4D+@12@B=J@^[&T,U'1.-FYH.-TSQBW%*.*E^ SF W(-L M:\\#2"<$7TP]:*HF*[M$8T;8(&@1ZG["U8]*K!0G1AMSN3V+;0=C6=;"8 5K M02>B/7)7 -D50'8%D(^!(!X,!E''+QV)R4],U$.T_2PL0+Z_/# MZ(18LL6.1&E__4+Z2"VMNI1ZV?+.N:+NR/X)/L'%)#"LP^F>V?,S-O:,*A,T MXX9!R4U)-K9]+2Y=E_RI0*L?"7\* ;@I>FJU^:';*@DOK5O[?8WBN4>_V0G? MN)>W :3ST\UI6UR-3T[&AU?7HQ.4KCD?7WPM>.>G@WAG!Y/9K]?,1N@M^0F4 MN.V RW 6#E=M3[WP7M"IRH[F%SO=#I@>V2X;2$HNUIS2NE4_:)M*SUU(59)I M489NA&[614H(+QKI2S9N)G3JFYVUZLZ;-:VXO3?,O?OD2E(RD? >9,^F=GO"^'EI,'[RUFW%OD3T9=M#;<4?>%0R3$]&BEVQ,GI>0N53,CFP1HMY8\I9'=#*8E?OZ0W[?'2&-7T1K0P+%C5R8 H& MHB>J")@&Z,8[-'G-B&R?.TE)C8" :+Z=LE^F?AU[=;WAL>WR?=&Z+0J]VVAE3[#U'6:=; (VLZ_ID05DX"6W(2# MGBDV2\%K+JEM25K(B$DQR11-QS.(S7![-I6! E):Z0@Z.2X=>_^[Q.4N<;E+ M7'Y$T#*$&CSAX'H7LN!@7.6.')/34@3A,O5LE[KCF<8--P5"#47&:P.S&*78 MHA<&1;Z*YM7J,5D!Z)Z6UNKG"4ZF?F1;DG7=LL M><1MVTTA=ND-;_D*73D+AVVTY4#OZ6[04:1T&3RW?>ZLC66NU)UT_,W6W#$. M9V.J?,2<:/8E#40)IY?HTY*7=$6:QM9KBTTV'<6D]\="MV.BTM9 ]1HU(FUP=V]E"U'?]R9.JORZT@? M3 <'[2?;^?[-CCF$<358)X+31%5DL^UC'M@F7,89OJ>D*]M8BWN-RSB:-P!6[:BY8CD26%#( M#1"(7!B")ZS@6UV)4%BGI^,WACF4.>9$TX1K]LR=TJ3V5COPW_M/R R,[Z)Y MS9K2P:/(*;(<\>E\\<@%=4.MW.3HHDSF! BT, M?CF*$L.Q,%0"JB#>"6^#P012B92QD8-"EYOS&'KW@W>.Y!%<%S'GINT(,Q5B MK/3+2GW14F6(ELL\S2J#LPH5&57X8$CC?**,1[#,[XG!<*I\1)7WKMTK>P/] M-D)9[PII'+W,*4T?YX\ZAQ:)=CZD95R75/>$20+[9B1B-T7OA>%0\ /B#UQO ME (@>G?[P3&2A1V9MS2G>,*88/;2JB2^15# 7$3VRJ;]YQ;CCILFJEUE\<.9 M,9T6JD9CS^KW,6,#&3?R$K[09G96S&I,<*WLAH0M,I<>#NGN\X)Y,5EP+RDJ MT;9)2\HX+J3%/BUT&)GE_A9>XAWB 1C&OZRM_%#G2;U\XB1E'!_2&SI36,:V MH;.#Q>#YRIEKSJC1ZI^A &RY3%DRBD0KFRU^'<---07&6-'KGSIO]=Y;'[J5 MKUT:S97(RYNKX'%>,T.-?;/O(?HKIVG<2M$:]X.DZG]V#F-F:8LF622P> A2 MI\/983J\?DHUL7A_U">_<9?@4V]&0U7@'PESB&-W$MTWN\':97F'!!L[/M'S MB[MW#Z(W0:R'KOM*)@\^ZS_SXH-I>G>/NLZ(E)<.+EW82,79W]!A9%1)$*8L MRF9P*)L9[-):%FD6I\LY@F?1.EZ?8H.98?/)\#>FES6)8HQ("L.5="GEV!_S M?%HZBQ?O:=5&]FW]1!K*S+D+M=NO02S(7@:,N0^X_30YJNQ/4%EF,$FGE M*P>^UIY$CE"8#0)@U=PD!2) MC3X-RI<5V";,]Y(K)+:DN>3=CVX2?/:0L1ZE4*.^3\Q-\]*@MGSXBMQCYG^7 M<%3V^ZS^;;5>91 =-"'M?C$MA%2Z,NN%^X1A(\[VHNLY=K8CVD@ .'=@9,'# M*5)5DJ1""B\@K)/QG1GJ0=X+*M8B7N&H&+B*O)-0EC6U3XI)8/0Y_(NVTYDM M J([4\+.RO:''EA.LX\J1\$TCVLKM&Y=R%YI99T8QMK)K!O#TZ8E;NO930T^ MQ*ZJLZOJ[*HZ'[%W/-]?LW'\/^T6*;71>N;CC T/;R;IZ_U_;7J+W4#ZYOFF MTC>_'%\>CD].1J?CL^O+KR-S\WPP<_-66!5'I:@/ECV07/9NF& M(C'!E"^T;2E;8TK.M=VS<"LF;.!<( 1**Q!3VS\&UZ*&9@1E39.*C?,Q9FJH M.48%?BZ8.V7*L!OX5P?&?CX8)UVH X-.@H[6)>F@.FSERS'=R%@S M"8QQ/Y3C%9U5N@"C[[A0@E$+.#^AUK3 9P37%Q[AL33]A<'H_#@D*AEI,+TP M]"K18CEG8AJ9/-3X-TD0V*(\M#;7GF)?MI(A"R0PTK8:D4^4P[T4@3+]4!2N M'562A#-7"-VVMK:V[U1&5AUDOE.C;.CB0:E2^$B XSSUL4<\P9D+HW83X4IB ME[@ GZ^K5Q;C57!>M[;MT,SLH<#M+8;PP2_1^\1C/SWMJ-U9JFR-F3%')926 M0DK>8B/O[/-/Y1WK]Q'>%<=12:!<1D4P@8"H#1#I=XPO>I6K)AC=V5\]DE*1 M" ^;PF*8;RZ3A&O5MG4 N8@_N(N#$G>DQ5D7$V'IG>?Q!\0R0&R2YOCCWW6$ M%7+$1(>6_63"[9*,=JTKA&U]*-T^A66$(LMI+%SYRY1_V\,($#F9(TV2)D61 M0[RX"(,9PLG@QQQS$,@.#.-;AER4+6K3]ZD09HI7L"R/S9+2^SB'G<<4"90I MQ:[M69W :%$^.C24(*4*O,/+R"HFHVVQ>F"XJC2K#AY.C);!/1/B VT"6POR MR4VW'\1I,K],IVAD[0'$\T3OY++=.Y/)Y EABELY82*#"PW!B!JH4"FCFWAF MQT)+;&EAS"E9<&?0=(IKYLI/0E,N# :1%E) 7,Q(+( ,LO0DIAT2YTZ=..C" MOJ^;8TNAX*,MWC?>VQ[D/9@ZQ_9D()ZH3 M:>A%1GO]&[& 5B'C[GD;:-I,=ZK1R^:^>,:I"K5WD;PSN*DKJ@ZHM0+H:5# H<@RQ?83E'%^V!T MZ-9WF8Q=)F.7R?@(9VJHV^:47%XG+$2"02U&JY?A,*:YK-\LL-,K8.-F)77+ MXDB2D))(RF[RQIX.+9*Y+^E"K!&&-)D%;'S# ESWB@=S1%Z//:V$GMNJV0;W.%, MGM*9KQCH^#K/]U[]B4:;WS.;L+]_>_!M@+9A":,!HV1^+V%?TM^[C+J[DF!I M_0H7^N]RI?TE%X$'+DWA?1$HQ;42>M2SR#*\@= MV;/#]\SPK#4J8H0>D.$;,E[?OK[*>>PXTN37A'?R734UC^+??%17^;K[-?^] M_-3W/EI5=? FS<_)D0C!%8K%.?#N[5.F0[V'_?;UBY<'!\$8=9^N,YS[(RJ! MA>!18Y_#RZ<'F[V]HR2C[H_#L^#[@Z?/7FSV;D:59,Y?!2=4+SM"VKUJ00W> MF[RQ,9K/5US$^T<$DVR2YONP 387!_PL7K--^,W+7BW7T'+SC_O]5PZZK9? M,UY][/K_$]\.A2'O;M/E$D*KS4Z49P?!*6VL/R<0N1)-[,5TPR9(1R8X_3DX M>/'R^R?!]>7HLUGH_W<>!C_^\L8C"IHT6<;W;6 M_ VVTLO[9$J0,#"L%82EKN MP\V&VM5),2E7)Z76@!'2A$YF<"6&>(,[8"$BPV0I]KE2WL\$UA'=7ME,8U)' M*/VI$7<+OR;B4[C1'OTJG[2TDYBT$\KDP".4MW1:;_T'X;0%HGVZQD5Y(G"QP$VMN!/3(DQ%G"VR;X)^G8LZ MXP33G!43DM*'/%J&:Y;8]R#:-FU@?!,X'0SO5,?'YA'-B>HLK5J\ ,-)[LXY MR<0MV2PIK+J14/\)E;1,U2ZE8K?_&/F E=! JPG4MDU58&QA')R_VUZV'%(L M&M.\LZ_HAV $/Z;4//%#\ Y;#XM>&X-=CC=<(309E_^M67K8%ZFN&BSIWA&A MTUK)11Q>#::5XH9XU:R28Q=5D"<)2\VP/K,)SA*JJF&- =-UM(US-2>Y2_.Z M-"N6X (CDAN8.TJOS*F&U,*!;'*:$0E0X\EFE)M5O:"VB2;G0F]-\=ISD4^ M-:DVN)"^#5[OR^6<1Z"MB;*HRZHCKXG3G!.A$UA%9K18&S%1VKX>>*@M_CA M4:<(>KNXAO MFJ)[LLA")0#TGCFM?+P:. MHXB=^.:9$@SNBM>"YLAY4T+I!Z8-+YI2ZZ[I$443%R3+RY@JA_X4\SNS":\G MZ\/"=?4&J<% O0J:@:T1#OTA7D>^KHW9O1N MR&"_1USK8^R6@>T$>^%$::0T^K)&Q]O>0BC[!!:9A;I-Z Y+Q^F;(M!IJLH; M:M8[>YA,1RK#L_'2+CH;LQ$M_T^BVI):IW!#X\%D,)=NNZ'9@T1$-R7AD?YH M?Y+ #2FPO^\@C"%E^ZJL*)C!G2LR4@)1516[59W%]D-N^SI+27I3I\;V M\*-:J+CT6!,LW!L[T] FD1HO>Y/=HOZ])4IK=@M%;/LL7$O8=(F, M(-PW/P M>#885,(O#I$']TZOQ]O+JX&P!-P'5!":4WU6<@""ZJ;.#X%G2A(@5"UD5^K# M[BS8H)BR3=')E 1T"6KNH6NH%)*Y"#?72ES":AQ"9ZRA&.<8V-31FK"#D9:* MR)TFX)^),"]2!9'J7$5\''=*4B9,&#!5MY\7;"UWZU$J8VOMW#3MGU\9C*GH MCL#>++U()(DR*&+\ X0C)M2_\F+J^C3- MNCZE#('\0=)R[(J)2T,KE!ZY([-'\G%<.VET<=L9@A>I\CWFB\N-VX(>8!K7 M>*6'O0(S;%8VSY@)R5)N^9)/UM,U-WCKW]TF&9I&SC&UIG\8U,VU8Z:RU6$Q MHIW1 L%4O*)E9M!9V>BRT)(L-5H:,L/^2V<6O#3Y:)K/X:67^@=TET*E"9G5 MX%O514%0H"[&$-9FP8_OP?724YJIIR=]1,E:=*ANBFB!39K8-$]#+PRB>-FR M]7U36)O#(A"$C9ZS=2S6UG!"T[&T,9GUA?D^A.=1?E;6$VR>>0%1/;:[Z@.8 M.Z"L?7NL3-*PL=IM.(!G+9OQ2)-UB-:<0E9)?8:;3PN'-BG-7/8CKV;AYO<2 M2REH!5LL#9/R-*PM;L(83-LOT<+W\ %YF(5+:U[MQ^!X M-YZVR^:L('A/<)Q(U3B@B$85Q93I+7<%?.CQDT&7H<&>0 M)J/BPN#Z0HZ/;Y$?A AQ1&?H9J]CK=,V"-T[0NX&%TM\I(0T$@C*?,J^)_5[("+2VI&IR;LLYP3<^ MS2KY,PL@6*=X< '$2^=_@16,KG+$;D&LO<+Q:?#N^.IT?'D9O/MI?#$^>\L> M)X03*U.03:8-3L]6,55(R,06MT.A3L7!C5NLWSMX*.HT.CD+SG\:7?PR.AQ? M7QT?CD["X/CT<#_X'$ACOH1!?+,*^GR!]?\'3^&[\KM@-(T6P4_Y<@FQ.GT> M?((?.@SUQE_I[QWN4_!!7OF/Z(S@E_YT5PC#?]7Y(L_!?E$GVZ:?\4L81^3A M^N?5=?#F^(R-&QNUG4W[A2G/;:16V=OW!_:\Z81%_QCDD]7,*JWU6+^^C]02P$"% ,4 " "U M@$Y82)\7=S,7 #\,@$ $0 @ $ 87ET=2TR,#(S,3(S M,2YX&UL4$L! A0#% @ M8!.6/!Z MR\?(7 6VP( !4 ( !'"< &%Y='4M,C R,S$R,S%?9&5F M+GAM;%!+ 0(4 Q0 ( +6 3EBC8>:'OG( )V'!@ 5 " M 1>$ !A>71U+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4 " "U@$Y8JUKW MZ\)@ !4"@D %0 @ $(]P 87ET=2TR,#(S,3(S,5]P&UL4$L! A0#% @ M8!.6.$YK8"#8@$ F;D3 !0 ( ! M_5" (#0 T M ( !:\0" &5X7S8Q,C$Q-RYH=&U02P$"% ,4 " "U@$Y86%\V,3(Q,3DN M:'1M4$L! A0#% @ M8!.6+O3$9IEC@ F3D# T ( ! G]]D" &5X7S8R-C X."YH=&U02P4& L "P#! @ AV@# end XML 98 aytu20231231_10q_htm.xml IDEA: XBRL DOCUMENT 0001385818 2023-07-01 2023-12-31 0001385818 2024-02-01 0001385818 2023-12-31 0001385818 2023-06-30 0001385818 2023-10-01 2023-12-31 0001385818 2022-10-01 2022-12-31 0001385818 2022-07-01 2022-12-31 0001385818 us-gaap:CommonStockMember 2023-06-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001385818 us-gaap:RetainedEarningsMember 2023-06-30 0001385818 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001385818 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001385818 2023-07-01 2023-09-30 0001385818 us-gaap:CommonStockMember 2023-09-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001385818 us-gaap:RetainedEarningsMember 2023-09-30 0001385818 2023-09-30 0001385818 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001385818 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001385818 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001385818 us-gaap:CommonStockMember 2023-12-31 0001385818 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001385818 us-gaap:RetainedEarningsMember 2023-12-31 0001385818 us-gaap:CommonStockMember 2022-06-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001385818 us-gaap:RetainedEarningsMember 2022-06-30 0001385818 2022-06-30 0001385818 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001385818 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001385818 2022-07-01 2022-09-30 0001385818 us-gaap:CommonStockMember 2022-09-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001385818 us-gaap:RetainedEarningsMember 2022-09-30 0001385818 2022-09-30 0001385818 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001385818 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001385818 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001385818 us-gaap:CommonStockMember 2022-12-31 0001385818 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001385818 us-gaap:RetainedEarningsMember 2022-12-31 0001385818 2022-12-31 0001385818 aytu:ReverseStockSplitMember 2023-01-06 2023-01-06 0001385818 aytu:AvenueNoteMember 2023-12-31 0001385818 aytu:RxSegmentMember 2023-10-01 2023-12-31 0001385818 aytu:RxSegmentMember 2022-10-01 2022-12-31 0001385818 aytu:RxSegmentMember 2023-07-01 2023-12-31 0001385818 aytu:RxSegmentMember 2022-07-01 2022-12-31 0001385818 aytu:ConsumerHealthMember 2023-10-01 2023-12-31 0001385818 aytu:ConsumerHealthMember 2022-10-01 2022-12-31 0001385818 aytu:ConsumerHealthMember 2023-07-01 2023-12-31 0001385818 aytu:ConsumerHealthMember 2022-07-01 2022-12-31 0001385818 aytu:AdhdPortfolioMember aytu:RxSegmentMember 2023-10-01 2023-12-31 0001385818 aytu:AdhdPortfolioMember aytu:RxSegmentMember 2022-10-01 2022-12-31 0001385818 aytu:AdhdPortfolioMember aytu:RxSegmentMember 2023-07-01 2023-12-31 0001385818 aytu:AdhdPortfolioMember aytu:RxSegmentMember 2022-07-01 2022-12-31 0001385818 aytu:ThePediatricPortfolioMember aytu:RxSegmentMember 2023-10-01 2023-12-31 0001385818 aytu:ThePediatricPortfolioMember aytu:RxSegmentMember 2022-10-01 2022-12-31 0001385818 aytu:ThePediatricPortfolioMember aytu:RxSegmentMember 2023-07-01 2023-12-31 0001385818 aytu:ThePediatricPortfolioMember aytu:RxSegmentMember 2022-07-01 2022-12-31 0001385818 us-gaap:ProductAndServiceOtherMember aytu:RxSegmentMember 2023-10-01 2023-12-31 0001385818 us-gaap:ProductAndServiceOtherMember aytu:RxSegmentMember 2022-10-01 2022-12-31 0001385818 us-gaap:ProductAndServiceOtherMember aytu:RxSegmentMember 2023-07-01 2023-12-31 0001385818 us-gaap:ProductAndServiceOtherMember aytu:RxSegmentMember 2022-07-01 2022-12-31 0001385818 aytu:ManufacturingEquipmentMember 2023-12-31 0001385818 aytu:ManufacturingEquipmentMember 2023-06-30 0001385818 aytu:OfficeEquipmentFurnitureAndOtherMember 2023-12-31 0001385818 aytu:OfficeEquipmentFurnitureAndOtherMember 2023-06-30 0001385818 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001385818 us-gaap:LeaseholdImprovementsMember 2023-06-30 0001385818 aytu:LabEquipmentMember 2023-12-31 0001385818 aytu:LabEquipmentMember 2023-06-30 0001385818 us-gaap:AssetUnderConstructionMember 2023-12-31 0001385818 us-gaap:AssetUnderConstructionMember 2023-06-30 0001385818 aytu:LeaseForPrincipalOfficeMember 2023-09-30 0001385818 us-gaap:OperatingExpenseMember 2023-10-01 2023-12-31 0001385818 us-gaap:OperatingExpenseMember 2022-10-01 2022-12-31 0001385818 us-gaap:OperatingExpenseMember 2023-07-01 2023-12-31 0001385818 us-gaap:OperatingExpenseMember 2022-07-01 2022-12-31 0001385818 us-gaap:CostOfSalesMember 2023-10-01 2023-12-31 0001385818 us-gaap:CostOfSalesMember 2022-10-01 2022-12-31 0001385818 us-gaap:CostOfSalesMember 2023-07-01 2023-12-31 0001385818 us-gaap:CostOfSalesMember 2022-07-01 2022-12-31 0001385818 us-gaap:OtherExpenseMember 2023-10-01 2023-12-31 0001385818 us-gaap:OtherExpenseMember 2022-10-01 2022-12-31 0001385818 us-gaap:OtherExpenseMember 2023-07-01 2023-12-31 0001385818 us-gaap:OtherExpenseMember 2022-07-01 2022-12-31 0001385818 aytu:PropertyAndEquipmentNetMember 2023-12-31 0001385818 aytu:PropertyAndEquipmentNetMember 2023-06-30 0001385818 us-gaap:OtherCurrentLiabilitiesMember 2023-12-31 0001385818 us-gaap:OtherCurrentLiabilitiesMember 2023-06-30 0001385818 aytu:CurrentPortionOfDebtMember 2023-12-31 0001385818 aytu:CurrentPortionOfDebtMember 2023-06-30 0001385818 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0001385818 us-gaap:OtherNoncurrentLiabilitiesMember 2023-06-30 0001385818 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0001385818 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001385818 us-gaap:DistributionRightsMember 2023-12-31 0001385818 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-06-30 0001385818 us-gaap:DevelopedTechnologyRightsMember 2023-06-30 0001385818 us-gaap:DistributionRightsMember 2023-06-30 0001385818 aytu:TrisKarbinalAgreementMember 2023-07-01 2023-12-31 0001385818 us-gaap:PatentedTechnologyMember aytu:AdhdPortfolioMember 2023-12-31 0001385818 us-gaap:DistributionRightsMember aytu:ConsumerHealthMember 2023-04-01 2023-06-30 0001385818 aytu:NeosTherapeuticsIncMember us-gaap:InProcessResearchAndDevelopmentMember aytu:RxSegmentMember 2022-10-01 2022-12-31 0001385818 srt:MinimumMember 2023-07-01 2023-12-31 0001385818 srt:MaximumMember 2023-07-01 2023-12-31 0001385818 aytu:TrisKarbinalAgreementMember 2023-07-01 2023-12-31 0001385818 aytu:TrisKarbinalAgreementMember 2023-12-31 0001385818 us-gaap:OtherCurrentLiabilitiesMember aytu:TrisKarbinalAgreementMember 2023-12-31 0001385818 us-gaap:OtherNoncurrentLiabilitiesMember aytu:TrisKarbinalAgreementMember 2023-12-31 0001385818 aytu:TrisLicenseAgreementMember 2022-05-12 0001385818 aytu:TrisLicenseAgreementMember 2022-05-12 2022-05-12 0001385818 us-gaap:OtherCurrentLiabilitiesMember aytu:TrisLicenseAgreementMember 2023-12-31 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2021-03-31 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2021-03-01 2021-03-31 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2021-03-01 2021-03-31 0001385818 aytu:AfterJanuary262023ButBeforeJanuary262024Member aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2023-03-24 0001385818 aytu:AfterJanuary262024ButBeforeJanuary262025Member aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2023-03-24 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2023-10-01 2023-12-31 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2022-10-01 2022-12-31 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2023-07-01 2023-12-31 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2022-07-01 2022-12-31 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2023-12-31 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMember us-gaap:SecuredDebtMember 2023-06-30 0001385818 aytu:AvenueCapitalLoanMember 2022-01-26 0001385818 aytu:AvenueCapitalLoanMember us-gaap:PrimeRateMember 2022-01-26 2022-01-26 0001385818 aytu:AfterJanuary262023ButBeforeJanuary262024Member aytu:AvenueCapitalLoanMember 2022-01-26 0001385818 aytu:AfterJanuary262024ButBeforeJanuary262025Member aytu:AvenueCapitalLoanMember 2022-01-26 0001385818 aytu:AvenueCapitalWarrantsMember 2022-01-26 0001385818 aytu:AvenueCapitalIssuanceMember 2022-03-07 0001385818 aytu:AvenueCapitalWarrantsMember 2022-03-07 0001385818 aytu:AvenueCapitalWarrantsMember 2022-10-25 0001385818 aytu:AvenueCapitalLoanMember 2022-01-26 2022-01-26 0001385818 aytu:AvenueCapitalLoanMember 2023-12-31 0001385818 aytu:AvenueCapitalLoanMember 2023-10-01 2023-12-31 0001385818 aytu:AvenueCapitalLoanMember 2022-10-01 2022-12-31 0001385818 aytu:AvenueCapitalLoanMember 2023-07-01 2023-12-31 0001385818 aytu:AvenueCapitalLoanMember 2022-07-01 2022-12-31 0001385818 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0001385818 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0001385818 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0001385818 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0001385818 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001385818 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001385818 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001385818 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-06-30 0001385818 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-06-30 0001385818 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-06-30 0001385818 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-06-30 0001385818 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001385818 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001385818 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001385818 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-07-01 2023-12-31 0001385818 aytu:June2023WarrantsTrancheABMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001385818 srt:MinimumMember aytu:OtherWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001385818 srt:MaximumMember aytu:OtherWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001385818 aytu:June2023WarrantsTrancheABMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001385818 aytu:OtherWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001385818 aytu:June2023WarrantsTrancheABMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001385818 srt:MinimumMember aytu:OtherWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001385818 srt:MaximumMember aytu:OtherWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001385818 aytu:June2023WarrantsTrancheABMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001385818 aytu:OtherWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001385818 aytu:RumpusAcquisitionMember aytu:EarnOutPaymentsMember 2021-04-12 0001385818 aytu:RumpusAcquisitionMember aytu:EarnOutPaymentsMember 2022-04-01 2022-04-30 0001385818 aytu:RumpusAcquisitionMember aytu:RoyaltiesMember 2021-04-12 0001385818 aytu:RumpusAcquisitionMember aytu:MilestonePaymentsMember 2021-04-12 0001385818 aytu:SabbyVolatilityWarrantMasterFundLtdMember aytu:SabbyLitigationMember aytu:SabbyLitigationWarrantsMember 2023-02-22 0001385818 aytu:SabbyVolatilityWarrantMasterFundLtdMember aytu:SabbyLitigationMember 2023-02-22 0001385818 aytu:WalleyeOpportunitiesMasterFundLtdMember aytu:SabbyLitigationMember aytu:SabbyLitigationWarrantsMember 2023-02-22 0001385818 aytu:WalleyeOpportunitiesMasterFundLtdMember aytu:SabbyLitigationMember 2023-02-22 0001385818 us-gaap:RestrictedStockMember 2023-12-31 0001385818 aytu:The2020ShelfMember 2020-06-08 0001385818 aytu:AtthemarketOfferingMember 2021-06-04 0001385818 aytu:AtthemarketOfferingMember 2022-07-01 2023-06-30 0001385818 aytu:The2021ShelfMember 2021-09-28 0001385818 aytu:The2021ShelfMember 2023-12-31 0001385818 aytu:TheAugust2022OfferingMember 2022-08-11 2022-08-11 0001385818 aytu:August2022PrefundedWarrantsMember 2022-08-11 0001385818 aytu:August2022CommonWarrantsMember 2022-08-11 0001385818 aytu:August2022CommonAndPrefundedWarrantsMember 2022-08-11 0001385818 aytu:TheAugust2022OfferingMember 2022-08-11 0001385818 aytu:SecuritiesPurchaseAgreementMember 2023-06-08 2023-06-08 0001385818 aytu:PrefundedWarrantsMember 2023-06-08 0001385818 aytu:TrancheACommonWarrantsMember 2023-06-08 0001385818 aytu:TrancheBCommonWarrantsMember 2023-06-08 0001385818 aytu:CommonWarrantsMember 2023-06-08 0001385818 aytu:CommonWarrantsExchangedForPrefundedWarrantsMember 2023-06-08 0001385818 aytu:TrancheACommonWarrantsAtDoubleExercisePriceMember 2023-06-08 0001385818 aytu:SecuritiesPurchaseAgreementMember 2023-06-08 0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-08 0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-08 2023-06-08 0001385818 aytu:The2023EquityIncentivePlanMember 2023-05-18 2023-05-18 0001385818 aytu:The2023EquityIncentivePlanMember 2023-05-18 0001385818 us-gaap:EmployeeStockOptionMember aytu:The2023EquityIncentivePlanMember 2023-05-18 2023-05-18 0001385818 srt:MinimumMember us-gaap:EmployeeStockOptionMember aytu:The2023EquityIncentivePlanMember 2023-05-18 2023-05-18 0001385818 srt:MaximumMember us-gaap:EmployeeStockOptionMember aytu:The2023EquityIncentivePlanMember 2023-05-18 2023-05-18 0001385818 srt:MinimumMember aytu:RestrictedStockAndRestrictedStockUnitsRsusMember aytu:The2023EquityIncentivePlanMember 2023-05-18 2023-05-18 0001385818 srt:MaximumMember aytu:RestrictedStockAndRestrictedStockUnitsRsusMember aytu:The2023EquityIncentivePlanMember 2023-05-18 2023-05-18 0001385818 aytu:The2015PlanMember 2023-12-31 0001385818 aytu:The2015PlanMember 2015-06-01 0001385818 aytu:The2015PlanMember 2020-02-13 0001385818 us-gaap:EmployeeStockOptionMember aytu:The2015PlanMember 2015-06-01 2015-06-01 0001385818 srt:MinimumMember us-gaap:EmployeeStockOptionMember aytu:The2015PlanMember 2015-06-01 2015-06-01 0001385818 srt:MaximumMember us-gaap:EmployeeStockOptionMember aytu:The2015PlanMember 2015-06-01 2015-06-01 0001385818 srt:MinimumMember us-gaap:RestrictedStockMember aytu:The2015PlanMember 2015-06-01 2015-06-01 0001385818 srt:MaximumMember us-gaap:RestrictedStockMember aytu:The2015PlanMember 2015-06-01 2015-06-01 0001385818 us-gaap:RestrictedStockUnitsRSUMember aytu:The2015PlanMember 2015-06-01 2015-06-01 0001385818 aytu:Neos2015PlanMember 2021-04-19 0001385818 us-gaap:RestrictedStockUnitsRSUMember aytu:Neos2015PlanMember 2021-04-19 0001385818 us-gaap:EmployeeStockOptionMember aytu:Neos2015PlanMember 2021-04-19 2021-04-19 0001385818 srt:MinimumMember us-gaap:EmployeeStockOptionMember aytu:Neos2015PlanMember 2021-04-19 2021-04-19 0001385818 srt:MaximumMember us-gaap:EmployeeStockOptionMember aytu:Neos2015PlanMember 2021-04-19 2021-04-19 0001385818 2022-07-01 2023-06-30 0001385818 us-gaap:EmployeeStockOptionMember 2023-12-31 0001385818 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-12-31 0001385818 us-gaap:RestrictedStockMember 2023-06-30 0001385818 us-gaap:RestrictedStockMember 2023-07-01 2023-12-31 0001385818 us-gaap:RestrictedStockMember aytu:The2023EquityIncentivePlanMember 2023-12-31 0001385818 us-gaap:RestrictedStockMember aytu:The2023EquityIncentivePlanMember 2023-07-01 2023-12-31 0001385818 us-gaap:RestrictedStockMember aytu:OutsideEquityIncentivePlanMember 2023-12-31 0001385818 us-gaap:RestrictedStockMember aytu:OutsideEquityIncentivePlanMember 2023-07-01 2023-12-31 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-12-31 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001385818 us-gaap:ResearchAndDevelopmentExpenseMember 2023-10-01 2023-12-31 0001385818 us-gaap:ResearchAndDevelopmentExpenseMember 2022-10-01 2022-12-31 0001385818 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-12-31 0001385818 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-12-31 0001385818 us-gaap:SellingAndMarketingExpenseMember 2023-10-01 2023-12-31 0001385818 us-gaap:SellingAndMarketingExpenseMember 2022-10-01 2022-12-31 0001385818 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-12-31 0001385818 us-gaap:SellingAndMarketingExpenseMember 2022-07-01 2022-12-31 0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2023-10-01 2023-12-31 0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2022-10-01 2022-12-31 0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-12-31 0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-12-31 0001385818 srt:MinimumMember aytu:August2022CommonWarrantsMember 2022-08-11 0001385818 srt:MaximumMember aytu:August2022CommonWarrantsMember 2022-08-11 0001385818 aytu:August2022CommonWarrantsMember 2022-12-31 0001385818 aytu:August2022CommonWarrantsMember 2023-06-30 0001385818 srt:WeightedAverageMember 2023-06-30 0001385818 srt:WeightedAverageMember 2023-07-01 2023-12-31 0001385818 srt:WeightedAverageMember 2023-12-31 0001385818 aytu:LiabilityWarrantsMember 2023-07-01 2023-12-31 0001385818 aytu:LiabilityWarrantsMember 2022-07-01 2022-12-31 0001385818 aytu:EquityWarrantsMember 2023-07-01 2023-12-31 0001385818 aytu:EquityWarrantsMember 2022-07-01 2022-12-31 0001385818 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-12-31 0001385818 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-12-31 0001385818 us-gaap:RestrictedStockMember 2023-07-01 2023-12-31 0001385818 us-gaap:RestrictedStockMember 2022-07-01 2022-12-31 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-12-31 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-12-31 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y 0001385818 false --06-30 Q2 2024 0.0001 0.0001 50000000 50000000 0 0 0 0 0.0001 0.0001 200000000 200000000 5567347 5567347 5517174 5517174 2 20 -300000 0 100000 P5Y6M 700000 70000 1 P5Y 1 P5Y 1 P5Y 1 P5Y 2 false false false false 10-Q true 2023-12-31 false 001-38247 AYTU BIOPHARMA, INC. DE 47-0883144 7900 East Union Avenue, Suite 920 Denver CO 80237 720 437-6580 Common Stock, $0.0001 par value AYTU NASDAQ Yes Yes Non-accelerated Filer true false false 5567597 19529000 22985000 29403000 28937000 13001000 11995000 8105000 8047000 1333000 868000 71371000 72832000 1127000 1815000 2133000 2054000 55711000 58970000 907000 792000 59878000 63631000 131249000 136463000 10473000 13478000 43413000 46799000 1026000 1563000 39000 85000 9236000 7090000 64187000 69015000 14978000 14713000 12887000 6403000 6344000 6975000 34209000 28091000 0 0 1000 1000 345321000 343485000 -312469000 -304129000 32853000 39357000 131249000 136463000 22934000 26279000 45033000 53934000 6731000 8986000 14046000 18609000 16203000 17293000 30987000 35325000 6576000 10560000 13998000 20662000 5439000 8018000 12395000 15340000 524000 1710000 1128000 2774000 1300000 1198000 2606000 2395000 0 2600000 0 2600000 0 75000 0 230000 13839000 24161000 30127000 44001000 2364000 -6868000 860000 -8676000 -1179000 -1228000 -1888000 -2312000 -577000 1403000 -6484000 3594000 608000 -6693000 -7512000 -7394000 828000 0 828000 0 -220000 -6693000 -8340000 -7394000 5517670 3110304 5499951 2817979 -0.04 -2.15 -1.52 -2.62 5517174 1000 343485000 -304129000 39357000 13061 0 930000 0 930000 0 -8120000 -8120000 5530235 1000 344415000 -312249000 32167000 108 0 820000 0 820000 37004 0 86000 0 86000 0 -220000 -220000 5567347 1000 345321000 -312469000 32853000 1928941 0 331386000 -287078000 44308000 -1666 0 1177000 0 1177000 1194196 0 3564000 0 3564000 0 -701000 -701000 3121471 0 336127000 -287779000 48348000 -19228 0 3067000 0 3067000 280902 0 1095000 0 1095000 0 -6693000 -6693000 3383145 0 340289000 -294472000 45817000 -8340000 -7394000 4409000 4507000 1750000 4244000 -6484000 3594000 302000 315000 133000 82000 0 2600000 0 230000 50000 33000 466000 3834000 1140000 2183000 321000 4606000 -3032000 -838000 -3927000 -1008000 -3852000 76000 -346000 -11588000 -0 5000 250000 -42000 -250000 37000 86000 11573000 -537000 3616000 2204000 2433000 160000 1000000 45000 -0 0 -64000 -2860000 11692000 -3456000 141000 22985000 19360000 19529000 19501000 2170000 2021000 432000 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> - Nature of Business, Financial Condition, Basis of Presentation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Aytu BioPharma, Inc. (“Aytu”, or the “Company”), is a pharmaceutical company focused on commercializing novel therapeutics. The Company operates through <span style="-sec-ix-hidden:c106376035">two</span> business segments (i) the Rx Segment, consisting of prescription pharmaceutical products sold primarily through <em style="font: inherit;">third</em> party wholesalers and (ii) the Consumer Health Segment, which consists of various consumer healthcare products sold directly to consumers (the “Consumer Health Portfolio”). The Company was originally incorporated as Rosewind Corporation on <em style="font: inherit;"> August 9, 2002, </em>in the State of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on <em style="font: inherit;"> June 8, 2015. </em>Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in <em style="font: inherit;"> March 2021, (</em>the “Neos Acquisition”) the Company changed its name to Aytu BioPharma, Inc.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> January 6, 2023, </em>the Company effected a reverse stock split in which each common stockholder received <em style="font: inherit;">one</em> share of common stock for every <span style="-sec-ix-hidden:c106376038">twenty</span> shares held (the “Reverse Stock Split”). All share and per share amounts in this quarterly report have been adjusted to reflect the effect of the Reverse Stock Split.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Rx Segment primarily consists of <em style="font: inherit;">two</em> product portfolios. First the ADHD Portfolio, which consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”). Second the Pediatric Portfolio, which consists of Poly-Vi-Flor and Tri-Vi-Flor, <em style="font: inherit;">two</em> complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Consumer Health Segment consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health and general wellness, commercialized through direct mail and e-commerce marketing channels. To date, the Consumer Health Segment has generated negative cash flows. In fiscal <em style="font: inherit;">2023,</em> the Company announced it would wind down the Consumer Health Segment in fiscal <em style="font: inherit;">2024.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company’s strategy is to continue building its portfolio of revenue-generating prescription pharmaceutical products, leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. As a result of focusing on building the portfolio of revenue-generating products and generating profitability, in fiscal <em style="font: inherit;">2023,</em> the Company indefinitely suspended active development of its clinical development programs including <em style="font: inherit;">AR101</em> (enzastaurin) and terminated the license agreements relating to Healight and <em style="font: inherit;">NT0502</em> (N-desethyloxybutynin).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023</em>, the Company had $19.5 million of cash and cash equivalents and $29.4 million of accounts receivable. The Company’s operations have historically consumed cash and <em style="font: inherit;"> may </em>continue to consume cash in the future. The Company had a net loss of $0.2 million and $8.3 million during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023, </em>respectively. The Company had an accumulated deficit of $312.5 million and $304.1 million as of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;"> June 30, 2023</em>, respectively. Cash used in operations was <span style="-sec-ix-hidden:c106376054">$0.4</span> million and $11.6 million during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, the Company has non-operating liabilities that are scheduled to, or <em style="font: inherit;"> may </em>become, current in the <em style="font: inherit;">twelve</em> months following the filing of this Form <em style="font: inherit;">10</em>-Q, most notably the maturity of the $15 million Avenue Capital term note (the “Avenue Note”) as discussed further in <i>Note <em style="font: inherit;">11</em> - Long-term Debt</i>. The Company expects to refinance the Avenue Note, however, there are <em style="font: inherit;">no</em> assurances the Company will be able to refinance the Avenue Note. As a result of this, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do <em style="font: inherit;">not</em> include adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on (i) improving cash flows from operations, (ii) winding down the Consumer Health Segment, (iii) refinancing its $15 million Avenue Note to extend its maturity date, and, (iv), if necessary, raising additional capital through public or private equity offerings, debt offerings, or monetizing additional assets in order to meet its obligations. Management believes that the Company has adequate access to capital resources. However, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets, or obtain new financing on commercially acceptable terms. If the Company is unable to support its operations and obligations, it <em style="font: inherit;"> may </em>be required to curtail its operations, or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses <em style="font: inherit;"> may </em>adversely impact its ability to sustain revenue-generating activities or otherwise operate its business. As a result, there can be <em style="font: inherit;">no</em> assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Basis of Presentation.</i></b> The unaudited consolidated financial statements contained in this Form <em style="font: inherit;">10</em>-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted pursuant to such rules and regulations. The unaudited consolidated financial statements should be read in conjunction with the Company’s <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1385818/000155837023016393/aytu-20230630x10k.htm" style="-sec-extract:exhibit;"><em style="font: inherit;">2023</em> Form <em style="font: inherit;">10</em>-K</a>, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of <em style="font: inherit;"> June 30, 2023</em>, was derived from the audited annual financial statements but does <em style="font: inherit;">not</em> contain all of the footnote disclosure from the annual financial statements. The results of operations for the period ended <em style="font: inherit;"> December 31, 2023</em> are <em style="font: inherit;">not</em> necessarily indicative of expected operating results for the full year or any future period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Prior Period Reclassification</i></b>. Certain prior year amounts in the consolidated statements of operations have been reclassified to conform to the current year presentation, including a reclassification of the fair value adjustment from contingent consideration. Net gain or loss from the fair value of contingent consideration was previously included in other expense, net, and is currently recorded in operating expenses on the consolidated statements of operations. This reclassification did <em style="font: inherit;">not</em> impact net loss or cash flows for the <em style="font: inherit;">three</em> or <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> or the Company’s financial position as of <em style="font: inherit;"> December 31, 2023</em> or <em style="font: inherit;"> June 30, 2023</em>.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> 19500000 29400000 -200000 -8300000 -312500000 -304100000 -11600000 15000000 15000000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">2</em> - Significant Accounting Policies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but <em style="font: inherit;">not</em> limited to, stock-based compensation, revenue recognition, allowance for credit losses, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of warrants and derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results <em style="font: inherit;"> may </em>differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Warrants</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (“ASC <em style="font: inherit;">480”</em>) and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging (“ASC <em style="font: inherit;">815”</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been <em style="font: inherit;">no</em> changes in tax law affecting the tax provision during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023</em>. The effective tax rate was 136.2% and negative 11.0% for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023</em>, respectively, primarily driven by the limitations on losses as a result of Section <em style="font: inherit;">382</em> of the Internal Revenue Code changes in ownership coupled with existing valuation allowances. The effective tax rate was 0% for both the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2022, </em>respectively, reflecting the full valuation allowance and <em style="font: inherit;">no</em> impact of Section <em style="font: inherit;">382</em> of the Internal Revenue Code.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">An ownership change could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section <em style="font: inherit;">382</em> of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation <em style="font: inherit;"> may </em>offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past <em style="font: inherit;">five</em> years have caused a significant limitation on the Company's ability to use the pre-acquisition net operating loss carryovers. The ownership changes could result in increased future tax liability and are a driver of the change from a <em style="font: inherit;">zero</em> percent effective tax rate.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employee Retention Credit</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> March 27, 2020, </em>the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) to provide certain relief as a result of the COVID-<em style="font: inherit;">19</em> pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to <em style="font: inherit;">70%</em> of the qualified wages paid to employees after <em style="font: inherit;"> December 31, 2020 </em>through <em style="font: inherit;"> September 30, 2021. </em>The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As there is <em style="font: inherit;">no</em> authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (“IAS”) <em style="font: inherit;">20,</em> Accounting for Government Grants and Disclosure of Government Assistance (“IAS <em style="font: inherit;">20”</em>). In accordance with IAS <em style="font: inherit;">20,</em> when management determines reasonable assurance that the Company had substantially met all eligibility requirements of the ERC, the ERC benefit shall be recognized as other income in the consolidated statement of operations (see <i>Note - <em style="font: inherit;">9</em> Other Liabilities</i>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recently Adopted Accounting Pronouncements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Financial Instruments</i></b> –<b><i> Credit Losses.</i></b> In <em style="font: inherit;"> June </em><em style="font: inherit;">2016,</em> the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em><i>, </i><i>Financial Instruments</i> –<i> Credit Losses</i> (“ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13”</em>) requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after <em style="font: inherit;"> December </em><em style="font: inherit;">15,</em> <em style="font: inherit;">2019.</em> However, in <em style="font: inherit;"> October </em><em style="font: inherit;">2019,</em> the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after <em style="font: inherit;"> December </em><em style="font: inherit;">15,</em> <em style="font: inherit;">2022.</em> The effective dates for the amendments in ASU <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> align with those of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> and ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05</em> on <em style="font: inherit;"> July 1, 2023. </em>The Company evaluated the impact of adoption of ASUs <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> and <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> and concluded that the application of the new standards did <em style="font: inherit;">not</em> have a material impact on the Company’s consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><i style="font-weight: bold;">Debt</i> - <b><i>Debt with Conversion and Other Options.</i></b> In <em style="font: inherit;"> August 2020, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em><i> Debt</i>—<i>Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging</i>—<i> Contracts in Entity</i>’<i>s Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>)</i>—<i> </i><i>Accounting for Convertible Instruments and Contracts in an Entity</i>’<i>s Own Equity</i>, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with <em style="font: inherit;">no</em> separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on <em style="font: inherit;"> July 1, 2024 </em>and does <em style="font: inherit;">not</em> expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><i><b>Segment Reporting - Improvements to Reportable Segment Disclosures.</b> </i>In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> <i>Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures</i> (“ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07”</em>). ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods in fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company’s consolidated financial statements and disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For a complete set of the Company’s significant accounting policies, refer to the Company's <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1385818/000155837023016393/aytu-20230630x10k.htm" style="-sec-extract:exhibit;"><em style="font: inherit;">2023</em> Form <em style="font: inherit;">10</em>-K</a>. Other than the application of IAS <em style="font: inherit;">20</em> for the ERC, there have been <em style="font: inherit;">no</em> significant changes to the Company’s significant accounting policies during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023</em>. </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but <em style="font: inherit;">not</em> limited to, stock-based compensation, revenue recognition, allowance for credit losses, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of warrants and derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results <em style="font: inherit;"> may </em>differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Warrants</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (“ASC <em style="font: inherit;">480”</em>) and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging (“ASC <em style="font: inherit;">815”</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been <em style="font: inherit;">no</em> changes in tax law affecting the tax provision during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023</em>. The effective tax rate was 136.2% and negative 11.0% for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023</em>, respectively, primarily driven by the limitations on losses as a result of Section <em style="font: inherit;">382</em> of the Internal Revenue Code changes in ownership coupled with existing valuation allowances. The effective tax rate was 0% for both the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2022, </em>respectively, reflecting the full valuation allowance and <em style="font: inherit;">no</em> impact of Section <em style="font: inherit;">382</em> of the Internal Revenue Code.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">An ownership change could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section <em style="font: inherit;">382</em> of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation <em style="font: inherit;"> may </em>offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past <em style="font: inherit;">five</em> years have caused a significant limitation on the Company's ability to use the pre-acquisition net operating loss carryovers. The ownership changes could result in increased future tax liability and are a driver of the change from a <em style="font: inherit;">zero</em> percent effective tax rate.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employee Retention Credit</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> March 27, 2020, </em>the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) to provide certain relief as a result of the COVID-<em style="font: inherit;">19</em> pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to <em style="font: inherit;">70%</em> of the qualified wages paid to employees after <em style="font: inherit;"> December 31, 2020 </em>through <em style="font: inherit;"> September 30, 2021. </em>The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As there is <em style="font: inherit;">no</em> authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (“IAS”) <em style="font: inherit;">20,</em> Accounting for Government Grants and Disclosure of Government Assistance (“IAS <em style="font: inherit;">20”</em>). In accordance with IAS <em style="font: inherit;">20,</em> when management determines reasonable assurance that the Company had substantially met all eligibility requirements of the ERC, the ERC benefit shall be recognized as other income in the consolidated statement of operations (see <i>Note - <em style="font: inherit;">9</em> Other Liabilities</i>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p> 1.362 0.11 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recently Adopted Accounting Pronouncements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Financial Instruments</i></b> –<b><i> Credit Losses.</i></b> In <em style="font: inherit;"> June </em><em style="font: inherit;">2016,</em> the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em><i>, </i><i>Financial Instruments</i> –<i> Credit Losses</i> (“ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13”</em>) requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after <em style="font: inherit;"> December </em><em style="font: inherit;">15,</em> <em style="font: inherit;">2019.</em> However, in <em style="font: inherit;"> October </em><em style="font: inherit;">2019,</em> the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after <em style="font: inherit;"> December </em><em style="font: inherit;">15,</em> <em style="font: inherit;">2022.</em> The effective dates for the amendments in ASU <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> align with those of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> and ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05</em> on <em style="font: inherit;"> July 1, 2023. </em>The Company evaluated the impact of adoption of ASUs <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> and <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> and concluded that the application of the new standards did <em style="font: inherit;">not</em> have a material impact on the Company’s consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><i style="font-weight: bold;">Debt</i> - <b><i>Debt with Conversion and Other Options.</i></b> In <em style="font: inherit;"> August 2020, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em><i> Debt</i>—<i>Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging</i>—<i> Contracts in Entity</i>’<i>s Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>)</i>—<i> </i><i>Accounting for Convertible Instruments and Contracts in an Entity</i>’<i>s Own Equity</i>, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with <em style="font: inherit;">no</em> separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on <em style="font: inherit;"> July 1, 2024 </em>and does <em style="font: inherit;">not</em> expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><i><b>Segment Reporting - Improvements to Reportable Segment Disclosures.</b> </i>In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> <i>Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures</i> (“ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07”</em>). ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods in fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company’s consolidated financial statements and disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For a complete set of the Company’s significant accounting policies, refer to the Company's <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1385818/000155837023016393/aytu-20230630x10k.htm" style="-sec-extract:exhibit;"><em style="font: inherit;">2023</em> Form <em style="font: inherit;">10</em>-K</a>. Other than the application of IAS <em style="font: inherit;">20</em> for the ERC, there have been <em style="font: inherit;">no</em> significant changes to the Company’s significant accounting policies during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023</em>. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">3</em> - Revenues from Contracts with Customers</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Net product revenue in the Rx Segment consists of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net product revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally “free-on-board” destination when shipped domestically within the United States, consistent with contractual terms.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Company generates Consumer Health Segment revenue from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized “free-on-board” shipping point, consistent with contractual terms and aligning with the transfer of control of the products. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from customers are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost, and are included in cost of sales.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which <em style="font: inherit;"> may </em>vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> follow historical trends. The Company’s periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate reporting and settlement of deductions. The Company continually monitors these provisions and does <em style="font: inherit;">not</em> believe variances between actual and estimated amounts have been or will be material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Revenues by Segment.</i></b><b> </b>Net product revenue disaggregated by segment for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Consolidated net revenue:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Rx Segment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Consumer Health Segment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,186</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,250</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total consolidated net revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,934</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,279</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,033</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">53,934</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Revenues by Product Portfolio.</i></b><b> </b>Net product revenue disaggregated by significant product portfolio in the Rx Segment for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Rx Segment net revenue:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">ADHD Portfolio</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Pediatric Portfolio</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,710</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,886</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">581</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">155</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Rx Segment net revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Other includes discontinued products in the Rx Segment. The Consumer Health Segment is comprised of <em style="font: inherit;">one</em> product portfolio, the Consumer Health Portfolio.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Revenues by Geographic location.</i></b> The Company’s revenues are predominately within the United States, with insignificant sales internationally.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Consolidated net revenue:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Rx Segment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Consumer Health Segment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,186</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,250</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total consolidated net revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,934</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,279</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,033</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">53,934</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Rx Segment net revenue:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">ADHD Portfolio</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Pediatric Portfolio</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,710</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,886</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">581</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">155</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Rx Segment net revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 18748000 18029000 36565000 36681000 4186000 8250000 8468000 17253000 22934000 26279000 45033000 53934000 16572000 11120000 31700000 22705000 2145000 6328000 4710000 12886000 31000 581000 155000 1090000 18748000 18029000 36565000 36681000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4</em> - Inventories</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Inventories consist of raw materials, work in process and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are <em style="font: inherit;">no</em> alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period <em style="font: inherit;">first</em> recognized. The Company incurred inventory write-downs of $0.1 million and zero for each of the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectfully, and $0.1 million for each of the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Inventory balances consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,654</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,301</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,674</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,956</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,673</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,738</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,995</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 100000 0 100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,654</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,301</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,674</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,956</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,673</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,738</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,995</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1654000 1301000 2674000 2956000 8673000 7738000 13001000 11995000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5</em> - Property and Equipment</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assets’ estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Property and equipment consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,183</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,433</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Office equipment, furniture and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,146</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lab equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets under construction</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, gross</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,205</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,815</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Depreciation and amortization expense from property and equipment was $0.3 million and $0.4 million for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectfully, and $0.6 million and $0.7 million for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,183</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,433</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Office equipment, furniture and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,146</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lab equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets under construction</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, gross</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,205</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,815</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1183000 2433000 1146000 1125000 999000 999000 832000 832000 45000 107000 4205000 5496000 3078000 3681000 1127000 1815000 300000 400000 600000 700000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">6</em> - Leases</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between fiscal <em style="font: inherit;">2024</em> and fiscal <em style="font: inherit;">2029.</em> Most leases include <em style="font: inherit;">one</em> or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain leases also include options to purchase the leased property. The Company’s lease agreements generally do <em style="font: inherit;">not</em> contain any material residual value guarantees or material restrictive covenants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In <em style="font: inherit;"> May 2023, </em>the Company entered into a lease agreement to relocate its principal office. The space was made available to the Company in <em style="font: inherit;"> September 2023 (</em>lease commencement) with an initial term of <span style="-sec-ix-hidden:c106376307">five</span> and a half years. The Company recorded an operating lease right-of-use (“ROU”) asset of $0.7 million and a lease liability of $0.7 million at lease commencement. The ROU asset and lease liability were recorded at present value using an incremental borrowing rate of 10.3%. The Company utilized the practical expedient to <em style="font: inherit;">not</em> separate lease and non-lease components upon recognition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The components of lease expenses are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Statement of Operations Classification</em></b></p> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 37%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease cost:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">381</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">359</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">716</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease cost:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of leased assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Cost of sales</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Other expense, net</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total net lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">418</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">399</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">816</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">802</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Supplemental balance sheet information related to leases is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 34%;"><em style="font: inherit;"> </em></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">2023</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">2023</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><b><em style="font: inherit;">Balance Sheet Classification</em></b></p> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Operating lease right-of-use assets</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">159</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Property and equipment, net</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,213</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"><em style="font: inherit;"> </em></td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,369</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,258</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Other current liabilities</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Current portion of debt</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">845</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Other non-current liabilities</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"><em style="font: inherit;"> </em></td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Remaining lease term and discount rate used are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Weighted-average remaining lease term (years):</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.87</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Weighted-average discount rate:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Supplemental cash flow information related to lease is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flow classification of lease payments:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">697</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">716</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Financing cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023</em>, the maturities of the Company’s future minimum lease payments were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Operating</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Finance</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024 (remaining 6 months)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">938</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">282</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">241</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">151</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,546</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 700000 700000 0.103 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Statement of Operations Classification</em></b></p> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 37%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease cost:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">381</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">359</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">716</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease cost:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of leased assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Cost of sales</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Other expense, net</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total net lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">418</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">399</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">816</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">802</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Weighted-average remaining lease term (years):</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.87</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Weighted-average discount rate:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flow classification of lease payments:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">697</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">716</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Financing cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 381000 359000 741000 716000 21000 19000 44000 44000 15000 19000 29000 37000 1000 2000 2000 5000 418000 399000 816000 802000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 34%;"><em style="font: inherit;"> </em></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">2023</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">2023</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><b><em style="font: inherit;">Balance Sheet Classification</em></b></p> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Operating lease right-of-use assets</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">159</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Property and equipment, net</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,213</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"><em style="font: inherit;"> </em></td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,369</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,258</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Other current liabilities</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Current portion of debt</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">845</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Other non-current liabilities</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"><em style="font: inherit;"> </em></td></tr> </tbody></table> 2133000 2054000 0 159000 2133000 2213000 1369000 1258000 39000 85000 845000 832000 2253000 2175000 P2Y7M13D P1Y8M19D P0Y4M13D P0Y10M13D 0.0885 0.0778 0.0654 0.0654 697000 716000 2000 5000 46000 52000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Operating</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Finance</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024 (remaining 6 months)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">938</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">282</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">241</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">151</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,546</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 735000 40000 938000 0 282000 0 241000 0 199000 0 151000 0 2546000 40000 332000 1000 2214000 39000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">7</em> - Intangible Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table provides the summary of the Company’s intangible assets as of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;"> June 30, 2023</em>, respectively. Carrying amounts are net of any impairment charges from prior periods. An intangible asset with <em style="font: inherit;">zero</em> net carrying amount at the end of a reporting period is <em style="font: inherit;">not</em> presented in the table of a future reporting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>December 31, 2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted-</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b><em style="font: inherit;"> </em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b><em style="font: inherit;"> </em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Net</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amortization</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Definite-lived intangibles:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">41,467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(11,777</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">29,690</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired technology right</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">30,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,943</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired product distribution rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,443</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(22,163</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">June 30, 2023</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Net</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amortization</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Definite-lived intangibles:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,176</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,881</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">31,295</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.49</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired technology right</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">30,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">26,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14.75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired product distribution rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">78,583</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19,613</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table summarizes the estimated future amortization expense to be recognized over the next <em style="font: inherit;">five</em> fiscal years and periods thereafter:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 0pt; margin-left: 0pt; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024 (remaining 6 months)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,988</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total future amortization expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Acquired Product Technology Rights</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in <em style="font: inherit;"> November 2019 </em>and the Neos Acquisition in <em style="font: inherit;"> March 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Karbinal ER.</i> The Company acquired and assumed all rights and obligations pursuant to the Supply and Distribution Agreement, as Amended, with Tris Pharma, Inc. (“Tris”) for the exclusive rights to commercialize Karbinal ER in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in <em style="font: inherit;"> August </em>of <em style="font: inherit;">2033,</em> with an optional additional 20-year extension.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Poly-Vi-Flor</i> <i>and Tri-Vi-Flor.</i> The Company acquired and assumed all rights and obligations pursuant to a Supply and License Agreement and various assignment and release agreements, including a previously agreed to Settlement and License Agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>ADHD Portfolio.</i> As part of the Neos Acquisition, the Company acquired product technology for the production and sale of Adzenys XR-ODT and Cotempla XR-ODT. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 17 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Acquired Technology Right</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>TRRP Technology.</i> As part of the Neos Acquisition, the Company acquired Time Release Resin Particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlies the ADHD portfolio and can potentially be used in future product development initiatives as well.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Acquired Product Distribution Rights (and customer list)</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In connection with the Innovus Acquisition, the Company obtained <em style="font: inherit;">35</em> products with a combination of over <em style="font: inherit;">300</em> registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. During the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2023,</em> the acquired product distribution rights incurred an impairment charge of $3.0 million due to the discontinuation of products in the Consumer Health Segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Acquired In-Process R&amp;D</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>IPR&amp;D </i>–<i> <em style="font: inherit;">NT0502.</em> </i>As part of the Neos Acquisition, the Company acquired in-process research and development associated with <em style="font: inherit;">NT0502,</em> a new chemical entity being developed for the treatment of sialorrhea, which is excessive salivation or drooling. As this is an indefinite-lived intangible asset, this acquired asset remains an indefinite-lived asset until the completion or abandonment of the associated research and development efforts. If a product using this technology is eventually approved for commercial sale, at that time, the IPR&amp;D will begin amortizing on a straight-line basis over the life of the product. During fiscal <em style="font: inherit;">2023,</em> the Company terminated its development program of <em style="font: inherit;">NT0502.</em> As a result, the Company fully impaired the IPR&amp;D of <em style="font: inherit;">NT0502,</em> recording impairment expense of $2.6 million to its Rx Segment during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.6 million and $1.5 million for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively, and $3.3 million and $3.0 million for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>December 31, 2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted-</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b><em style="font: inherit;"> </em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b><em style="font: inherit;"> </em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Net</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amortization</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Definite-lived intangibles:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">41,467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(11,777</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">29,690</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired technology right</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">30,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,943</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25,257</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired product distribution rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,443</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(22,163</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">June 30, 2023</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Net</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amortization</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Definite-lived intangibles:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,176</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,881</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">31,295</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.49</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired technology right</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">30,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">26,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14.75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Acquired product distribution rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">78,583</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19,613</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 41467000 11777000 29690000 P11Y14D 30200000 4943000 25257000 P14Y3M 6207000 5443000 764000 P0Y6M 77874000 22163000 55711000 P12Y4M6D 42176000 10881000 31295000 P11Y5M26D 30200000 4054000 26146000 P14Y9M 6207000 4678000 1529000 P1Y 78583000 19613000 58970000 P12Y8M1D <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 0pt; margin-left: 0pt; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024 (remaining 6 months)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,988</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total future amortization expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 3259000 4989000 4989000 4989000 4988000 32497000 55711000 P20Y P17Y 3000000 2600000 P1Y P20Y 1600000 1500000 3300000 3000000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">8</em> - Accrued Liabilities</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Accrued liabilities consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued savings offers</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,852</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,739</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued program liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,841</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,012</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued customer and product related fees</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,699</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,579</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Return reserve</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,777</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued employee compensation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,362</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,675</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other accrued liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,530</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,017</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,413</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,799</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Accrued savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. The return reserve represents the Company’s accrual for estimated product returns. Other accrued liabilities consist of various other accruals, <em style="font: inherit;">none</em> of which individually or in the aggregate represent greater than <em style="font: inherit;">five</em> percent of total liabilities.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued savings offers</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,852</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,739</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued program liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,841</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,012</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued customer and product related fees</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,699</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,579</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Return reserve</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,777</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued employee compensation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,362</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,675</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other accrued liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,530</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,017</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,413</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,799</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 14852000 15739000 11841000 11012000 5699000 6579000 5129000 5777000 3362000 5675000 2530000 2017000 43413000 46799000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">9</em> - Other Liabilities</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Fixed payment arrangements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,043</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee retention credit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,555</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total other liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,580</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,065</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,236</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total other liabilities, non-current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,975</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Fixed Payment Arrangements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in <em style="font: inherit;">2019,</em> including fixed and variable payments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from <em style="font: inherit;"> August </em><em style="font: inherit;">1</em> through <em style="font: inherit;"> July </em><em style="font: inherit;">31,</em> of 70,000 units annually through <em style="font: inherit;">2025.</em> The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through <em style="font: inherit;">2025.</em> The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in <em style="font: inherit;"> August </em>of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the <em style="font: inherit;">first</em> of which is triggered at $40.0 million of net revenues. As of <em style="font: inherit;"> December 31, 2023</em>, the fixed payment arrangement balance was $1.8 million in other current liabilities, and $1.2 million in other non-current liabilities on the consolidated balance sheet.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> May 12, 2022, </em>the Company entered into an agreement with Tris to terminate the Tuzistra XR License, Development, Manufacturing and Supply Agreement dated <em style="font: inherit;"> November 2, 2018 (</em>the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $9.0 million, which reduced its total liability for minimum payments by approximately $8.0 million from the original License Agreement. As of <em style="font: inherit;"> December 31, 2023</em>, the balance was $6.0 million in other current liabilities on the consolidated balance sheet.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Operating Lease Liabilities</i></b> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to <i>Note <em style="font: inherit;">6</em> - Leases</i> for further detail.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Employee Retention Credit</i></b> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The $3.8 million ERC accrual in other non-current liabilities as of <em style="font: inherit;"> December 31, 2023</em>, represents the proceeds the Company received from the ERC program during the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em> The ERC is a refundable payroll tax credit from the CARES Act enacted by the U.S. government to provide certain relief from the COVID-<em style="font: inherit;">19</em> pandemic. The refundable payroll tax credit shall be recognized in the consolidated statement of operations following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Service (see <i>Note <em style="font: inherit;">2</em> – Significant Accounting Policies</i>). The associated vendor fee of $0.4 million was expensed as incurred in the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Other</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Other consists of taxes payable and deferred cost related to the Company’s technology transfer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Fixed payment arrangements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,043</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee retention credit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,555</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total other liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,580</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,065</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,236</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total other liabilities, non-current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,975</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 9043000 10420000 2214000 2090000 3759000 0 564000 1555000 15580000 14065000 9236000 7090000 6344000 6975000 P20Y 0.235 70000 30 70000 2100000 3000000 40000000 1800000 1200000 9000000 8000000 6000000 3800000 400000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">10</em> - Line of Credit</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Company has entered into a secured credit agreement, as amended, with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $14.0 million, less a $3.5 million availability block, in secured revolving loans (the “Revolving Loans”), against 85% of eligible accounts receivable. The Revolving Loans thereunder, accrue at variable interest through maturity at the <em style="font: inherit;">one</em>-month Secure Overnight Financing Rate (“SOFR”), plus 4.50%. The Eclipse Loan Agreement includes an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The maturity date under the Eclipse Loan Agreement is <em style="font: inherit;"> January 26, 2025.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 1.0% of the Revolving Loans commitment if such event occurs after <em style="font: inherit;"> January 26, 2023 </em>but on or before <em style="font: inherit;"> January 26, 2024, </em>and (ii) 0.5% of the Revolving Loans commitment if such event occurs after <em style="font: inherit;"> January 26, 2024 </em>but on or before <em style="font: inherit;"> January 26, 2025. </em>The Company <em style="font: inherit;"> may </em>permanently terminate the Eclipse Loan Agreement at any time with at least <em style="font: inherit;">five</em> business days prior notice to Eclipse.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of <em style="font: inherit;"> December 31, 2023</em>, the Company was in compliance with the covenants under the Eclipse Loan Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with a <em style="font: inherit;">first</em> priority lien in favor of Eclipse on the ABL Priority Collateral, and a <em style="font: inherit;">second</em> priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Total interest expense on the Revolving Loans, including amortization of deferred financing costs, was $23.2 thousand and $176.7 thousand for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively and $50.1 thousand and $274.0 thousand for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively. As of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;"> June 30, 2023</em>, the outstanding Revolving Loans under the Eclipse Loan Agreement, as amended, were $1.0 million and $1.6 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 14000000 3500000 0.85 0.045 0.005 0.01 0.005 23200 176700 50100 274000 1000000 1600000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">11</em> - Long-term Debt</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Avenue Capital Loan</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> January 26, 2022 (</em>“Closing Date”), the Company entered into a Loan and Security Agreement (the “Avenue Capital Agreement”) with Avenue Venture Opportunities Fund, L.P. (“Avenue”) and Avenue Venture Opportunities Fund II, L.P. (Avenue <em style="font: inherit;">2”</em>) as lenders (the “Avenue Capital Lenders”), and Avenue Capital Management II, L.P. as administrative agent (the “Avenue Capital Agent”, and collectively with the Avenue Capital Lenders, “Avenue Capital”), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan is the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan is <em style="font: inherit;"> January 26, 2025. </em>The proceeds from the Avenue Capital Agreement were used to repay the senior secured term credit facility with Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P., which the Company assumed through the Neos Acquisition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Pursuant to the Avenue Capital Agreement, the Company made interest only payments for the <em style="font: inherit;">first</em> <em style="font: inherit;">18</em> months following the Closing Date (“Interest-only Period”). In <em style="font: inherit;"> June 2023, </em>the Company achieved certain defined milestones extending the Interest-Only Period through the maturity date.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 2.0% of the loan if such event occurs after <em style="font: inherit;"> January 26, 2023 </em>but on or before <em style="font: inherit;"> January 26, 2024, </em>and (ii) 1.0% of the loan if such event occurs after <em style="font: inherit;"> January 26, 2024 </em>but before <em style="font: inherit;"> January 26, 2025. </em>In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with a <em style="font: inherit;">first</em> priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a <em style="font: inherit;">second</em> priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of <em style="font: inherit;"> December 31, 2023</em>, the Company was in compliance with the covenants under the Avenue Capital Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> January 26, 2022 (</em>“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to <em style="font: inherit;"> June 30, 2022, </em>the exercise price would be adjusted to the effective price of such equity offering, and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants are immediately exercisable and expire on <em style="font: inherit;"> January 31, 2027. </em>The Company accounted for the Avenue Capital Warrants as a liability as the number of warrants was <em style="font: inherit;">not</em> fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> March 7, 2022, </em>the Company closed on an equity offering of shares of common stock and warrants at an offering price of $25.00 per share. As the Avenue Capital Agreement precluded the Company from pursuing any equity financing prior to <em style="font: inherit;"> July 7, 2022, </em>and the effective price of the <em style="font: inherit;"> March 7, 2022 </em>offering was more than the exercise price of the Avenue Capital Warrants, the number of shares of common stock issuable upon exercise of the Avenue Capital Warrants were set to 43,388 at an exercise price of $24.20.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> October 25, 2022, </em>the Company entered into an agreement with Avenue to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in <em style="font: inherit;"> January 2022, </em>extends the interest-only period to <em style="font: inherit;"> January </em>of <em style="font: inherit;">2024.</em> In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company’s <em style="font: inherit;"> August 2022 </em>equity financing.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition to the debt discount discussed above, the Company incurred $0.4 million in loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 19.6%. Total interest expense, including debt discount amortization, was $0.7 million for both the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, and $1.5 million and $1.3 million for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Long-term debt consists of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt, due on January 26, 2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term, final payment fee</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unamortized discount and issuance costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(660</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(925</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing leases, maturing through May 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,798</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current portion of debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,978</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Future principal payments of long-term debt, including financing leases, are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2024 (remaining 6 months)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Future principal payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,677</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: unamortized discount and issuance costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(660</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current portion of debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,978</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 15000000 0.0325 0.074 0.02 0.01 600000 24.2 24.2 600000 25 43388 24.2 8.6 400000 0.196 700000 1500000 1300000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt, due on January 26, 2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term, final payment fee</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unamortized discount and issuance costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(660</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(925</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing leases, maturing through May 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,798</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current portion of debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,978</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 15000000 15000000 638000 638000 660000 925000 39000 85000 15017000 14798000 39000 85000 14978000 14713000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2024 (remaining 6 months)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Future principal payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,677</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: unamortized discount and issuance costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(660</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current portion of debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,978</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 39000 15638000 15677000 660000 39000 14978000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">12</em> - Fair Value Considerations</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes <em style="font: inherit;">three</em> levels of inputs that <em style="font: inherit;"> may </em>be used to determine fair value as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1:</em> Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2:</em> Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3:</em> Unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, fixed payment arrangements, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on the unaudited consolidated balance sheets. The remaining financial instruments and derivative warrant liabilities are reported on the unaudited consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were <em style="font: inherit;">no</em> transfers between Level <em style="font: inherit;">1,</em> Level <em style="font: inherit;">2,</em> and Level <em style="font: inherit;">3</em> in the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recurring Fair Value Measurements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;"> June 30, 2023</em>, by level within the fair value hierarchy.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 19%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at December 31, 2023</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value at December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 19%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 19%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 19%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 19%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at June 30, 2023</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value at June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 19%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 19%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 19%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Summary of Level <em style="font: inherit;">3</em> Input Changes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table sets forth a summary of changes to those fair value measures using Level <em style="font: inherit;">3</em> inputs for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023</em>.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Derivative</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Warrant Liabilities</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 79%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Included in earnings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,484</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Significant Assumptions</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table presents the valuation methodologies and key assumptions used for the marked to market fair value measurements of derivative warrant liabilities as of <em style="font: inherit;"> December 31, 2023</em>.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 2023 Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Tranche A &amp; B</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Other *</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i><em style="font: inherit;">Monte Carlo Simulation</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><i> </i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i><em style="font: inherit;">&amp; Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i><em style="font: inherit;">Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equivalent term (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3.09-3.69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">96.15%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">96.15%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3.88%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3.95-4.01%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">0.00%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">0.00%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td colspan="7" style="width: 51.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>* Includes <em style="font: inherit;"> August 2022 </em>Warrants, <em style="font: inherit;"> March 2022 </em>Warrants, and Avenue Capital Warrants.</i></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Black-Scholes option pricing model is used to value all warrants with significant Level <em style="font: inherit;">3</em> inputs. The Monte Carlo Simulation is used to simulate the exit price and EBITDA forecast; average warrant value per share is from <em style="font: inherit;">100,000</em> Monte Carlo simulations. The Monte Carlo is based on significant inputs including financial projections provided by the Company’s management used primarily to forecast future results <em style="font: inherit;">not</em> observable in the market, and thus, represents a Level <em style="font: inherit;">3</em> measure.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 19%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at December 31, 2023</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value at December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 19%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 19%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 19%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 19%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at June 30, 2023</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value at June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 19%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 19%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 42%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 19%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 12887000 0 0 12887000 12887000 0 0 12887000 6403000 0 0 6403000 6403000 0 0 6403000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Derivative</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Warrant Liabilities</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 79%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Included in earnings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,484</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 6403000 6484000 12887000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 2023 Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Tranche A &amp; B</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Other *</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i><em style="font: inherit;">Monte Carlo Simulation</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><i> </i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i><em style="font: inherit;">&amp; Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i><em style="font: inherit;">Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equivalent term (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3.09-3.69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">96.15%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">96.15%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3.88%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3.95-4.01%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">0.00%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">0.00%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 4.44 3.09 3.69 0.9615 0.9615 0.0388 0.0395 0.0401 0 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">13</em> - Commitments and Contingencies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Pediatric Portfolio Fixed Payments and Product Milestone</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell Karbinal ER in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from <em style="font: inherit;"> August </em><em style="font: inherit;">1</em> through <em style="font: inherit;"> July </em><em style="font: inherit;">31,</em> of 70,000 units annually through <em style="font: inherit;">2025.</em> The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the <span style="-sec-ix-hidden:c106376795">70,000‑unit</span> annual minimum sales commitment through <em style="font: inherit;">2025.</em> The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in <em style="font: inherit;"> August </em>of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the <em style="font: inherit;">first</em> of which is triggered at $40.0 million of product net revenues.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Rumpus Earn Out Payments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> April 12, 2021, </em>the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating to <em style="font: inherit;">AR101.</em> Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, the Company made a payment of $0.6 million for a license fee in <em style="font: inherit;"> April 2022. </em>In addition, upon the achievement of regulatory and commercial milestones, the Company <em style="font: inherit;"> may </em>be required to pay up to $101.7 million and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for royalties of 3.0% of net product sales, with a minimum of $20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. In <em style="font: inherit;"> October 2022, </em>the Company announced the indefinite suspension of its development of <em style="font: inherit;">AR101.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Legal Matters</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Witmer Class-Action Securities Litigation. </i>A stockholder derivative suit filed on <em style="font: inherit;"> September 12, 2022, </em>in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, and later amended, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice’s Chief Investment Officer and Managing Partner, and a former director of Aytu) (collectively “Armistice”), and certain other current and former directors of Aytu, Joshua Disbrow, Gary Cantrell, John Donofrio, Jr, Carl Dockery and Ketan B. Mehta. The amended complaint alleges that (i) Armistice facilitated the sale of assets of Cerecor, Inc., in <em style="font: inherit;">2019</em> and Innovus Pharmaceuticals, Inc., in <em style="font: inherit;">2020</em> to Aytu in exchange for convertible securities, which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants’ breaches of fiduciary duties, in connection with these acquisitions. The amended complaint seeks unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys’ fees. While the Company believes that this lawsuit is without merit and has vigorously defended against it, the Company has agreed to settle the matter, as against it and the director defendants other than Mr. Boyd, for various corporate governance modifications and the payment of plaintiff’s attorneys’ fees. That settlement is subject to court approval, the hearing on which has <em style="font: inherit;">not</em> yet been scheduled.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Sabby Litigation.</i> A complaint was filed on <em style="font: inherit;"> February 22, 2023, </em>in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund Ltd (“Sabby”) and Walleye Opportunities Master Fund Ltd (“Walleye”), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrant holders <em style="font: inherit;"> may </em>receive, and that the Company failed to provide prompt notice to the warrant holders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. In <em style="font: inherit;"> October 2023, </em>the Company entered into a settlement agreement and general release with Sabby and Walleye.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Stein Litigation.</i> Cielo Stein (“Stein”), a former sales specialist, filed a complaint on <em style="font: inherit;"> February 1, 2023, </em>in Jefferson County Circuit Court in Kentucky against the Company and its wholly owned subsidiary Neos Therapeutics. The complaint alleges that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleges that the Company’s response to Stein’s subsequent complaint to human resources was inadequate. The complaint seeks an award of unspecified compensatory damages, emotional-distress damages, and attorneys’ fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky and filed a motion to dismiss the complaint, which was denied. The case has been referred to a magistrate judge for, among other things, the entry of a scheduling order and to conduct a settlement conference. Due to the early stage of litigation, and while the Company believes that this lawsuit is without merit, the Company is <em style="font: inherit;">not</em> able to predict at this time whether this proceeding will have a material impact on its financial condition or results of operations and intend to vigorously defend this case in the event it is <em style="font: inherit;">not</em> dismissed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> P20Y 0.235 70000 30 2100000 3000000 40000000 67500000 600000 101700000 0.03 20000 1600000 575000 312908 100000 54146 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">14</em> - Capital Structure</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. Included in the common stock outstanding are 40,017 shares of unvested restricted stock issued to executives, directors and employees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> June 8, 2020, </em>the Company filed a shelf registration statement on Form S-<em style="font: inherit;">3,</em> which was declared effective by the SEC on <em style="font: inherit;"> June 17, 2020. </em>This shelf registration statement covered the offering, issuance, and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the <em style="font: inherit;">“2020</em> Shelf”). On <em style="font: inherit;"> June 4, 2021, </em>the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the <em style="font: inherit;">2020</em> Shelf (the “ATM Sales Agreement”). During the year ended <em style="font: inherit;"> June 30, 2023</em>, the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of approximately $2.9 million. The <em style="font: inherit;">2020</em> Shelf expired in <em style="font: inherit;"> June 2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> September 28, 2021, </em>the Company filed a shelf registration statement on Form S-<em style="font: inherit;">3,</em> which was declared effective by the SEC on <em style="font: inherit;"> October 7, 2021. </em>This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the <em style="font: inherit;">“2021</em> Shelf”). As of <em style="font: inherit;"> December 31, 2023</em>, approximately $82.4 million remained available under the <em style="font: inherit;">2021</em> Shelf. This availability is subject to SEC <em style="font: inherit;">1.B.6</em> limitation to the Form S-<em style="font: inherit;">3.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> August 11, 2022, </em>the Company closed on an underwritten public offering (the <em style="font: inherit;"> “August 2022 </em>Offering”) utilizing the <em style="font: inherit;">2021</em> Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock, and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with <span style="-sec-ix-hidden:c106376845">one</span> common warrant to purchase <em style="font: inherit;">one</em> share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in <em style="font: inherit;"> August 2022. </em>The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of <span style="-sec-ix-hidden:c106376851">five</span> years from issuance. The Company raised $10.0 million in gross proceeds through the <em style="font: inherit;"> August 2022 </em>Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants have a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders’ equity in the Company’s consolidated financial statements (See <i>Note <em style="font: inherit;">16</em> – Warrants</i>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> June 8, 2023, </em>using a placement agency, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the “Pre-Funded Warrants”), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the “Common Warrants”). The Common Warrants <em style="font: inherit;"> may </em>be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the “Exchange Warrants”). Each Pre-Funded Warrant is exercisable for <span style="-sec-ix-hidden:c106376861">one</span> share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) <span style="-sec-ix-hidden:c106376865">five</span> years after the date of issuance, and (ii) <em style="font: inherit;">30</em> days following the closing price of the Company’s common stock equaling <em style="font: inherit;">200%</em> of the exercise price ($3.18 per share) for at least <em style="font: inherit;">40</em> consecutive trading days. The Tranche B Warrants will expire upon the earlier of (<em style="font: inherit;">x</em>) <em style="font: inherit;">five</em> years after the date of issuance, and (y) <em style="font: inherit;">30</em> days following the Company’s achievement of consolidated trailing <em style="font: inherit;">twelve</em>-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million. The Company raised $4.0 million in gross proceeds and net proceeds were approximately $3.4 million after deducting offering expenses. The warrants have a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in other expense along with the issuance costs of $0.6 million in the consolidated financial statement of operations (See <i>Note <em style="font: inherit;">16</em> – Warrants</i>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 200000000 0.0001 50000000 0.0001 40017 100000000 30000000 699929 2900000 100000000 82400000 1075290 87500 1265547 8.6 8.58 0.02 8.6 10000000 900000 6000000 1743695 430217 2173912 2173912 0.0001 0.0001 1.59 1.5899 3.18 12000000 4000000 3400000 5000000 600000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">15</em> - Equity Incentive Plans</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i><em style="font: inherit;">2023</em> Equity Incentive Plan.</i> On <em style="font: inherit;"> May 18, 2023, </em>the Company’s stockholders approved the Aytu BioPharma, Inc. <em style="font: inherit;">2023</em> Equity Incentive Plan (the <em style="font: inherit;">“2023</em> Equity Incentive Plan”). Prior to the Company’s adoption of the <em style="font: inherit;">2023</em> Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. <em style="font: inherit;">2015</em> Stock Option and Incentive Plan (the “Aytu <em style="font: inherit;">2015</em> Plan”) and the Neos Therapeutics, Inc. <em style="font: inherit;">2015</em> Stock Options and Incentive Plan (the “Neos <em style="font: inherit;">2015</em> Plan”, and collectively with the Aytu <em style="font: inherit;">2015</em> Plan, the <em style="font: inherit;">“2015</em> Plans”). For the <em style="font: inherit;">2023</em> Equity Incentive Plan, the stockholders approved (a) 200,000 new shares, (b) 87,129 shares available for grant under the <em style="font: inherit;">2015</em> Plans be “rolled over” to the <em style="font: inherit;">2023</em> Equity Incentive Plan and (c) any shares that are returned to the company under the <em style="font: inherit;">2015</em> Plans be added to the <em style="font: inherit;">2023</em> Equity Incentive Plan. With the approval of the <em style="font: inherit;">2023</em> Equity Incentive Plan, <em style="font: inherit;">no</em> additional awards will be granted under the <em style="font: inherit;">2015</em> Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the <em style="font: inherit;">2023</em> Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of <em style="font: inherit;"> December 31, 2023</em>, the Company had 179,732 shares that are available for grant under the <em style="font: inherit;">2023</em> Equity Incentive Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Aytu <em style="font: inherit;">2015</em> Plan.</i> On <em style="font: inherit;"> June </em><em style="font: inherit;">1,</em> <em style="font: inherit;">2015,</em> the Company’s stockholders approved the Aytu <em style="font: inherit;">2015</em> Plan, which, as amended in <em style="font: inherit;"> July </em><em style="font: inherit;">2017,</em> provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 150,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu <em style="font: inherit;">2015</em> Plan will be added back to the shares of common stock available for issuance under the <em style="font: inherit;">2023</em> Equity Incentive Plan. On <em style="font: inherit;"> February </em><em style="font: inherit;">13,</em> <em style="font: inherit;">2020,</em> the Company’s stockholders approved an increase to 250,000 total shares of common stock in the Aytu <em style="font: inherit;">2015</em> Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, whereas the restricted stock units have a vesting period of 4 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Neos <em style="font: inherit;">2015</em> Plan.</i> Pursuant to the Neos Merger, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos <em style="font: inherit;">2015</em> Plan. Accordingly, on <em style="font: inherit;"> April </em><em style="font: inherit;">19,</em> <em style="font: inherit;">2021,</em> the Company registered 5,272 shares of its common stock under the Neos <em style="font: inherit;">2015</em> Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos <em style="font: inherit;">2015</em> Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stock Options</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Stock option activity is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52,762</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.06</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">112,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1.73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">9.61</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(15,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2.94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">184.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">149,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.43</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The weighted-average grant date fair value of options granted during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> December 31, 2023</em> was $1.73. As of <em style="font: inherit;"> December 31, 2023</em>, there was $0.4 million total unrecognized compensation costs related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.85 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Restricted Stock</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Restricted stock activity is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,075</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">142.20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.77</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(12,189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">136.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,929</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99.75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023</em>, there was $2.0 million total unrecognized compensation costs related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.9 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023</em>, there was $0.3 million total unrecognized costs related to non-vested restricted stock outside of the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.1 years. As of <em style="font: inherit;"> December 31, 2023</em>, 2,088 shares of restricted stock remain unvested.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Restricted Stock Units</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Restricted stock units (“RSU” or “RSUs”) activity is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,126</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.19</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023</em>, there was $0.1 million total unrecognized compensation costs related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.2 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling and marketing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">817</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,047</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,746</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 200000 87129 P10Y P3Y P4Y P3Y P4Y 179732 150000 250000 P10Y P3Y P4Y P4Y P10Y P4Y 3486 1786 5272 P10Y P1Y P4Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52,762</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.06</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">112,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1.73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">9.61</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(15,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2.94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">184.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">149,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.43</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 52762 18.37 P9Y21D 112000 1.73 P9Y7M9D 15060 2.94 615 184.8 149087 6.43 P9Y2M1D 20470 30.18 P8Y7D 1.73 400000 P1Y10M6D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,075</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">142.20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.77</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(12,189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">136.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,929</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99.75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 38075 142.2 12500 1.77 12189 130.45 457 136.8 37929 99.75 2000000 P1Y10M24D 300000 P1Y1M6D 2088 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,126</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.19</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 4963 25.62 1126 24.28 939 31.6 2898 24.19 100000 P1Y2M12D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling and marketing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">817</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,047</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,746</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1000 3000 1000 8000 2000 14000 3000 23000 0 3000 0 6000 817000 3047000 1746000 4207000 820000 3067000 1750000 4244000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">16</em> - Warrants</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Liability Classified Warrants </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> June 8, 2023, </em>the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock, (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering. The Tranche A Warrants and Tranche B Warrants <em style="font: inherit;"> may </em>be exercised for either shares of common stock or pre-funded exchange warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the pre-funded warrant. Each pre-funded warrant is exercisable for <span style="-sec-ix-hidden:c106377059">one</span> share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the pre-funded warrants are exercised in full. The Tranche A Warrants and Tranche B Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per pre-funded exchange warrant). The Tranche A Warrants will expire upon the earlier of (i) <span style="-sec-ix-hidden:c106377063">five</span> years after the date of issuance, and (ii) <em style="font: inherit;">30</em> days following the closing price of the Company’s common stock equaling <em style="font: inherit;">200%</em> of the exercise price ($3.18 per share) for at least <em style="font: inherit;">40</em> consecutive trading days. The Tranche B Warrants will expire upon the earlier of (<em style="font: inherit;">x</em>) <em style="font: inherit;">five</em> years after the date of issuance, and (y) <em style="font: inherit;">30</em> days following the Company’s achievement of consolidated trailing <em style="font: inherit;">twelve</em>-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million (see <i>Note <em style="font: inherit;">14</em> – Capital Structure</i>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> August 11, 2022, </em>the Company closed an offering (the <em style="font: inherit;"> “August 2022 </em>Offering”), pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which <em style="font: inherit;">one</em> common warrant to purchase <span style="-sec-ix-hidden:c106377077">one</span> share of common stock for each share of common stock or each pre-funded warrant was sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in <em style="font: inherit;"> August 2022. </em>The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of <span style="-sec-ix-hidden:c106377080">five</span> years from issuance. The common warrants provide that if there occurs any stock split, stock dividend stock recapitalization, or similar event (a “Stock Combination Event”), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (<em style="font: inherit;">x</em>) the sum of the VWAP of the common stock for each of the <em style="font: inherit;">five</em> lowest trading days during the <em style="font: inherit;">20</em> consecutive trading day period ending immediately preceding the <em style="font: inherit;">16th</em> trading day after such Stock Combination Event, divided by (y) five; or $2.32, and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the <em style="font: inherit;">second</em> anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see <i>Note <em style="font: inherit;">14</em> – Capital Structure</i>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In <em style="font: inherit;"> November 2022 </em>and throughout the quarter ended <em style="font: inherit;"> December 31, 2022, </em>the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the <em style="font: inherit;"> August 2022 </em>Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $8.60. As a result, the common warrants exercise price was adjusted to $3.30. On <em style="font: inherit;"> January 6, 2023, </em>the Company consummated a 20 to <em style="font: inherit;">1</em> reverse stock split. Pursuant to the warrant agreement described above, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest <em style="font: inherit;">five</em> trading days during the <em style="font: inherit;">twenty</em>-day consecutive trading day period beginning on <em style="font: inherit;"> December 30, 2022. </em>Subsequently, as a result of the Securities Purchase Agreement in <em style="font: inherit;"> June 2023, </em>the common warrants from the <em style="font: inherit;"> August 2022 </em>Offering had an adjusted exercise price of $2.32.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Certain outstanding warrants are classified as derivative warrant liabilities in the consolidated balance sheets and are marked to market at each reporting period (see <i>Note <em style="font: inherit;">12</em> – Fair Value Considerations</i>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A summary of warrants is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,538,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.71</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Warrants exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(37,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2.32</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Warrants expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(20,958</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">300.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,480,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.22</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1743695 430217 2173912 2173912 0.0001 0.0001 1.59 1.5899 3.18 12000000 87500 1265547 0.02 8.6 2.32 2325581 2.32 8.6 3.3 20 2.32 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,538,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.71</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Warrants exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(37,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2.32</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Warrants expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(20,958</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">300.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,480,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.22</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 6538052 4.42 P4Y8M15D 37004 2.32 20958 300 6480090 3.48 P4Y2M19D <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">17</em> - Earnings Per Share</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Basic loss per common share is calculated by dividing the net loss available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table sets forth securities that are considered anti-dilutive, and therefore excluded from the calculation of diluted earnings per share.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants to purchase common stock - liability classified</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,498,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,642,235</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrant to purchase common stock - equity classified</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">56,486</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52,861</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee unvested restricted stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,280</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee unvested restricted stock units</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,167</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,730,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,808,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants to purchase common stock - liability classified</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,498,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,642,235</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrant to purchase common stock - equity classified</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">56,486</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52,861</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee unvested restricted stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,280</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee unvested restricted stock units</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,167</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,730,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,808,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 6498980 1642235 39072 56486 149087 52861 40017 48280 2898 8167 6730054 1808029 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">18</em> - License Agreements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Teva</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> December 21, 2018, </em>Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on <em style="font: inherit;"> July 1, 2026, </em>or earlier under certain circumstances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Actavis</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> October 17, 2017, </em>Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis (now Teva, following Teva’s acquisition of Actavis’ generic products) has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on <em style="font: inherit;"> September 1, 2025, </em>or earlier under certain circumstances.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">19</em> - Segment Reporting</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on the Company’s financial information. The CODM reviews financial information presented for each reportable segment for the purpose of making operating decisions and assessing financial performance.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company manages and aggregates its operational and financial information in accordance with <span style="-sec-ix-hidden:c106377146">two</span> reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company’s prescription products. The Consumer Health Segment contains the Company’s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does <em style="font: inherit;">not</em> regularly review asset information by segment, accordingly, asset information is <em style="font: inherit;">not</em> provided by segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Select financial information for these segments is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Rx</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Consumer Health</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Consolidated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Three Months Ended December 31, 2023</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Product revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">18,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,186</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">22,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Income (loss) from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(782</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">389</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,899</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">820</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Three Months Ended December 31, 2022</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Product revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">18,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">8,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">26,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(5,464</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,404</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(6,868</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,853</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Impairment expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,987</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Rx</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Consumer Health</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Consolidated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Six Months Ended December 31, 2023</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Product revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">36,565</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">8,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">45,033</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Income (loss) from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,420</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,064</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">776</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,840</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Six Months Ended December 31, 2022</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Product revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">36,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">17,253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">53,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(6,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(8,676</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,708</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Impairment expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">95</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Rx</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Consumer Health</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Consolidated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Three Months Ended December 31, 2023</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Product revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">18,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,186</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">22,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Income (loss) from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(782</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">389</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,899</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">820</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Three Months Ended December 31, 2022</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Product revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">18,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">8,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">26,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(5,464</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,404</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(6,868</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,853</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Impairment expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,987</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Rx</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Consumer Health</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Consolidated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Six Months Ended December 31, 2023</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Product revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">36,565</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">8,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">45,033</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Income (loss) from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,420</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,064</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">776</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,840</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Six Months Ended December 31, 2022</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b> </b></i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Product revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">36,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">17,253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">53,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(6,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(8,676</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,708</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Impairment expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">95</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 18748000 4186000 22934000 3146000 -782000 2364000 1510000 389000 1899000 707000 113000 820000 18029000 8250000 26279000 -5464000 -1404000 -6868000 1572000 281000 1853000 2600000 0 2600000 2987000 80000 3067000 36565000 8468000 45033000 2280000 -1420000 860000 3064000 776000 3840000 1432000 318000 1750000 36681000 17253000 53934000 -6457000 -2219000 -8676000 3146000 562000 3708000 2600000 0 2600000 4149000 95000 4244000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a href="#" id="ITEM5OTHERINFO" title="ITEM5_OTHER_INFO"></a>ITEM <em style="font: inherit;">5.</em> OTHER INFORMATION</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> Trading Plans</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">During the fiscal quarter ended <em style="font: inherit;"> December 31, 2023</em>, <span style="-sec-ix-hidden:c106377217"><span style="-sec-ix-hidden:c106377226"><span style="-sec-ix-hidden:c106377227"><span style="-sec-ix-hidden:c106377228">none</span></span></span></span> of our directors or executive officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em> under the Exchange Act) adopted or terminated a “Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement” or “non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement” (as those terms are defined in Item <em style="font: inherit;">408</em> of Regulation S-K).</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> Includes $0.2 million from the Consumer Health Segment as of December 31, 2023 and June 30, 2023.